






Access to Electronic Thesis 
 
 
Author:  Sari Sabban 
Thesis title:    Development of  an in vitro model system for studying the interaction of 




This electronic thesis is protected by the Copyright, Designs and Patents Act 1988.  
No reproduction is permitted without consent of the author.  It is also protected by 




If this electronic thesis has been edited by the author it will be indicated as such on the 






Development of an in vitro model 
system for studying the interaction 
of Equus caballus IgE with its high-
affinity FcεRI receptor
By Sari Sabban
Thesis submitted in part fulfillment of the requirement
for the degree of Doctorate of Philosophy
September 2011
Department of Molecular Biology and Biotechnology
The University of Sheffield
1
Abstract
Allergy is a serious life altering disease that  is increasingly affecting people in the 
industrialized countries. Allergic manifestations are not restricted to humans, but are 
also observed, example, in inbred dogs and horses. Race horses are commonly  afflicted 
by horse allergies and we have developed a cell culture model system for studying horse 
allergies. We created a genetically engineered rat basophil (RBL-2H3.1) cell line that 
expresses the ligand binding domain of the horse IgE high-affinity Fc receptor (FcεRI) 
and complemented this with a mouse B (J558L) cell line that expresses the heavy  chain 
of horse IgE antibody. This allowed assessment of mediator release when the horse IgE 
binds to the transfected cell surface receptor and initiates downstream signaling upon 
antigenic challenge. To complement these studies a soluble form of the FcεRI 
(sFcεRIαD1&2) was expressed which facilitate the measurement of the binding kinetics 
between the horse IgE and FcεRI receptor. These developments formed the basis for the 
design of an allergy vaccine strategy, where rats were primed with an IgE-derived 
peptide followed by  subsequent challenge with a chimeric IgE antibody displaying 
canine self IgE epitopes. The immunization strategy resulted in large polyclonal 
antibody titer found in the serum of immunized rat. Analysis of the immune response 
clearly  indicated that antibodies were generated which aggregated human, horse and 
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IgE    Immunoglobulin E.
FcεRI    High-affinity IgE Fc receptor.
FcεRII    Low-affinity IgE Fc receptor.
FcγR    IgG Fc receptor.
FcεRIα   High-affinity IgE Fc receptor’s α chain.
sFcεRIαD1&2  Soluble High-affinity IgE Fc receptor’s
    domain 1 and 2 of the α chain.
Cε    IgE constant domain.
Th1 Cell   T helper cell type 1.
Th2 Cell   T helper cell type 2.
IL-4    Interleukin 4.
IFN-γ    Interferon gamma.
B Cell    B lymphocyte.
T Cell    T lymphocyte.
mg ml-1   Milli grams per milliliter.
µg ml-1   Micro grams per milliliter.
ng ml-1   Nano grams per milliliter.
kDa    Kilo Daltons.
4
ka    Rate constant of association.
kd    Rate constant of dissociation.
KA    Equilibrium constant of association (binding affinity).
KD    Equilibrium constant of dissociation.
APC    Antigen presenting cells.
E237G   Mutation at position 237 replacing amino acid E
    (Glutamic acid) by G (Glycine).
TNF-α    Tumor necrosis factor α.
HHoH    Human-Horse-Human IgE chimera.
DHD    Dog-Human-Dog IgE chimera.
HDH    Human-Dog-Human IgE chimera.
Equine IgE anti NIP-HSA Equine immunoglobulin E that has a variable 
    region binding to NIP-HSA antigen.
NIP-HSA   4-Hydroxy-5-iodo-3-nitrophenylacetic acid
    conjugated to Human Serum Albumin.
DNP-HSA   2,4-Dinitrophenol conjugated to Human Serum Albumin.
β-hexosaminidase Substrate  4-nitrophenyl N-acetyl β-d-glucosaminide.
Hε    Antibody heavy chain.
FCS    Fetal Calf Serum.
SPR    Surface Plasmon Resonance.
BSA    Bovine Serum Albumin.
5
BLAST   Basic Local Alignment Search Tool.
2Fcε2-3   Peptide used for immunizations.
6
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 Figure 4: Structure of the high-affinity










Membrane Anchor  Figure 5: Crystal structure of IgE binding to the FcεRI
































 Figure 6: Summary of the IgE/FcεRI
  mediated downward signaling.    43











 Figure 7: Representation of
  the novel anti-IgE immunotherapy.    48
 Figure 8: Representation of The
  Original Antigenic Sin hypothesis.    54


















Phosphoribosyltransferase  Figure 9: Mycophenolic acid selection.   76
NIP-ε-Aminocaproyl-OSu
NIP-CAP-OSu
6-(2-Hydroxy-3-nitro-5-iodophenyl)acetamido)hexanoic acid succinimidyl ester















Used complex IgE on the surface of RBL cells to
cause them to release during release assays
NP-OH
4-Hydroxy-3-nitrophenylacetic  acid













































































































The measurement of 
t h e a n g l e s h i f t 
between the reference 
c h a n n e l a n d t h e 
sample channel gives 
the resonance units 













































The measurement of 
t h e a n g l e s h i f t 
between the reference 
c h a n n e l a n d t h e 
sample channel gives 
the resonance units 
that are plotted in the 
top graph
1           2  Figure 12: Diagram explaining Surface
















































































 Figure 13: Diagram explaining
  Fluorescence-Activated Cell Sorting (FACS).          97-98
              1kb DNA   pUC57-   pSV-VNP
               Ladder        Hε    HεF424
                                             7000bp pSV-VNP
6000bp
3000bp                                   3000bp HεF424
                                          2710bp pUC57
                                                                         1302bp Hε
1000bp                                  
A
                              pSV-VNP                                                   pSV-VNP
              1kb DNA  CD23 α                                         1kb DNA CD23 α
                 Ladder  Control  1       2        3       4        5   Ladder Control  1 2       3       4        5       6 
   pSV-VNP        
6000bp                                                                              Right
                                                                              Orientation
3000bp
          Hε                   
                   
1000bp
B  Figure 14: Restriction digestion of
  pUC57-Hε and pSV-VNPF424.    118
BamHI
A                    B Figure 15: The structure of the pSV-VNP
  plasmid before and after the insertion
  of the Hε gene:      118
A! ! !     B! ! !    C
D! ! !     E! ! !    F
G  Figure 16: J558L cell morphology during selection. 120
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 Figure 17: SPR results of J558L selection for





 Figure 18: BB3 well SPR curve.    122
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 Figure 19: SPR results of the level of IgE
  against expression time.     123
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 Figure 20: SPR results of the level
  of IgE after media concentration.    124
! 10kDa!         Non-Reduced! !         Reduces
! Protein!         Equine! ! !         Equine














Chain  Fig e 21: SDS-PAGE of the equine






 Figure 22: Equine IgE anti
  NIP-HSA viability test.     127
TGT GCA GTACGTTCCCACCTGCTCTAGAAGATGAGGGCCAAGGCACGCCCTCATGCAGCCTCTCACTCGAGCACACTGCAG GAG AGC
 C   A                                    Intron                                     E   S
TGT GCA GAG AGC
 C   A   E   S
GTACGTTCCCACCTGCTCTAGAAGATGAGGGCCAAGGCACGCCCTCATGCAGCCTCTCACTCGAGCACACTGCAG
TGT GCA GGTACGTTCCCACCTGCTCTAGAAGATGAGGGCCAAGGCACGCCCTCATGCAGCCTCTCACTCGAGCACACTGCAG GAG AGC
 C   A                                    Intron                                      E   S
TGT GCA GGA GAG C
 C   A   G   E  .... Early Stop Codon
GTACGTTCCCACCTGCTCTAGAAGATGAGGGCCAAGGCACGCCCTCATGCAGCCTCTCACTCGAGCACACTGCAG
TGT GCA GGTACGTTCCCACCTGCTCTAGAAGATGAGGGCCAAGGCACGCCCTCATGCAGCCTCTCACTCGAGCACACTGCA GAG AGC
 C   A                                    Intron                                     E   S
TGT GCA GAG AGC







Fixed Normal Intron 
According To The Wild Type 
Human IgE Gene  Figure 23: Intron problem and how it was solved.  130
                   1kb DNA             pUC57-                pEE6-
                    Ladder               FcεR1α#          CD23α
6000bp ##  #                                                           6583bp pEE6
3000bp ## #                                                            2710bp pUC57
                                                 
                                                                                                 1200 CD23α
1000bp ## #
                                                          780bp FcεR1α
pEE6
                                  pEE6-
                  1kb DNA  CD23 α
                   Ladder    Control        1            2            3           4            5             6
    6000bp # # # # #                                                              pEE6
    3000bp
CD23α
    1000bp # # # #                                                           
                                                                                                                                          FcεR1α
A B  Figure 24: Restriction digestion of 
  pUC57-FcεRIα and pEE6-CD23α.    134
A                          B  Figure 25: The structure of the pEE6 plasmid
  before and after the insertion of the FcεRIα gene.  134
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A B
C  Figure 26: FACS results of RBL-2H3.1 cells
  transfected with pEE6-FcεRIα.    137
 Figure 27: Flow cytometry test of RBL-2H3.1
  cells expressing equine FcεRIα.    139
DC
BA
 Figure 28: Confocal image of RBL-2H3.1
  cells expressing equine FcεRIα.    140



























1 2 3 4 5 6 7 8 9 10 11 12
1.633 1.749 1.787 1.773 1.830 1.858 0.074 0.078 0.088 0.124 0.100 0.102
1.709 1.896 1.909 1.887 1.920 1.868 0.070 0.072 0.069 0.101 0.091 0.084
1.737 1.865 1.891 1.904 1.989 1.966 0.076 0.077 0.072 0.073 0.076 0.080
1.809 1.897 1.927 1.993 1.984 1.963 0.065 0.064 0.066 0.070 0.079 0.073
1.793 2.020 2.023 2.005 1.953 2.107 0.085 0.086 0.083 0.088 0.086 0.086
1.719 1.910 1.967 2.028 1.952 2.010 0.089 0.080 0.085 0.081 0.080 0.086
1.736 1.854 1.963 1.994 1.994 1.970 0.088 0.096 0.092 0.091 0.098 0.096
0.542 0.688 0.642 0.723 0.742 0.907 0.941 1.220 0.747 1.247 1.207 0.819
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.781 1.905 1.963 2.021 2.03 2.062 8.310 8.189 8.966 12.271 9.852 9.893
1.849 2.04 2.047 2.089 2.102 2.036 7.572 7.059 6.742 9.670 8.658 8.251
1.889 2.019 2.035 2.05 2.141 2.126 8.047 7.628 7.076 7.122 7.099 7.526
1.939 2.025 2.059 2.133 2.142 2.109 6.704 6.321 6.411 6.564 7.376 6.923
1.963 2.192 2.189 2.181 2.125 2.279 8.660 7.847 7.583 8.070 8.094 7.547
1.897 2.07 2.137 2.19 2.112 2.182 9.383 7.729 7.955 7.397 7.576 7.883
1.912 2.046 2.147 2.176 2.19 2.162 9.205 9.384 8.570 8.364 8.950 8.881




































1 2 3 4 5 6 7 8 9 10 11 12
1.558 1.607 1.635 1.633 1.530 1.566 0.081 0.089 0.093 0.088 0.085 0.089
1.538 1.668 1.661 1.829 1.563 1.637 0.068 0.067 0.067 0.070 0.068 0.070
1.549 1.720 1.748 1.749 1.629 0.992 0.073 0.072 0.075 0.071 0.070 0.078
1.741 1.656 1.748 1.843 1.824 1.869 0.066 0.064 0.066 0.065 0.071 0.065
1.742 1.798 1.776 1.870 1.754 1.760 0.087 0.086 0.087 0.086 0.086 0.089
1.766 1.832 1.762 1.758 1.766 1.796 0.083 0.078 0.087 0.079 0.080 0.077
1.722 1.780 1.711 1.794 1.738 1.799 0.100 0.084 0.090 0.091 0.093 0.090
0.391 0.365 0.290 0.656 0.436 0.615 1.072 0.812 1.109 0.881 0.996 0.623
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.72 1.785 1.821 1.809 1.7 1.744 9.419 9.972 10.214 9.729 10.000 10.206
1.674 1.802 1.795 1.969 1.699 1.777 8.124 7.436 7.465 7.110 8.005 7.878
1.695 1.864 1.898 1.891 1.769 1.148 8.614 7.725 7.903 7.509 7.914 13.589
1.873 1.784 1.88 1.973 1.966 1.999 7.048 7.175 7.021 6.589 7.223 6.503
1.916 1.97 1.95 2.042 1.926 1.938 9.081 8.731 8.923 8.423 8.930 9.185
1.932 1.988 1.936 1.916 1.926 1.95 8.592 7.847 8.988 8.246 8.307 7.897
1.922 1.948 1.891 1.976 1.924 1.979 10.406 8.624 9.519 9.211 9.667 9.096




















































































1 2 3 4 5 6 7 8 9 10 11 12
1.803 1.779 1.797 1.959 1.730 1.239 0.036 0.064 0.044 0.048 0.054 0.018
1.910 1.851 1.874 1.936 1.804 1.682 0.032 0.041 0.036 0.043 0.038 0.019
1.641 1.733 1.789 1.842 1.744 1.555 0.131 0.157 0.178 0.160 0.185 0.124
1.275 1.361 1.350 1.367 1.307 1.175 0.314 0.428 0.554 0.551 0.609 0.510
1.349 1.236 1.166 1.080 1.025 0.936 0.433 0.537 0.726 0.704 0.707 0.517
1.173 1.236 1.192 1.156 1.081 1.374 0.385 0.669 0.695 0.716 0.584 0.517
1.284 1.189 1.277 1.492 1.113 1.177 0.414 0.652 0.472 0.574 0.323 0.324
1.094 0.964 0.888 0.969 1.037 0.933 0.351 0.413 0.463 0.517 0.494 0.410
2.165 2.283 2.206 2.189 2.244 2.257 0.039 0.037 0.050 0.036 0.036 0.028
2.215 2.233 2.221 2.218 2.169 2.265 0.053 0.048 0.051 0.045 0.054 0.033
2.133 2.170 2.114 2.049 1.909 1.983 0.168 0.166 0.142 0.161 0.148 0.153
1.651 1.693 1.743 1.722 1.747 1.713 0.680 0.586 0.469 0.514 0.435 0.513
1.296 1.260 1.356 1.303 1.301 1.283 0.906 0.689 0.699 0.710 0.767 0.774
1.288 1.306 1.285 1.334 1.248 1.285 0.779 0.553 0.672 0.992 0.718 0.545
1.336 1.296 1.459 1.332 1.392 1.416 0.842 0.433 0.641 0.727 0.552 0.697
0.636 0.653 0.603 0.668 0.658 0.422 1.060 0.713 0.966 0.858 0.680 0.397
2.730 2.660 2.686 2.649 2.646 2.674 0.036 0.052 0.044 0.038 0.037 0.038
2.790 2.668 2.708 2.829 2.667 2.623 0.074 0.063 0.066 0.060 0.056 0.064
2.696 2.719 2.698 2.565 2.611 2.540 0.175 0.165 0.168 0.167 0.123 0.162
2.339 2.392 2.264 2.295 2.247 2.281 0.653 0.596 0.598 0.585 0.542 0.530
1.902 1.917 1.858 1.890 1.824 1.883 0.947 0.849 0.888 0.874 0.870 0.823
2.099 2.062 1.920 1.938 1.911 1.881 0.902 0.879 0.916 0.821 0.793 0.804
2.052 2.091 1.934 2.049 1.856 1.958 0.830 0.777 0.894 0.849 0.784 0.806
0.356 0.141 0.182 0.173 0.207 0.158 1.940 1.679 1.847 1.482 1.300 1.689
2.458 2.438 2.560 2.387 2.265 2.278 0.062 0.045 0.046 0.032 0.047 0.033
2.584 2.681 2.702 2.686 2.249 2.587 0.076 0.058 0.071 0.043 0.065 0.051
2.591 2.600 2.544 2.543 2.434 2.263 0.255 0.212 0.287 0.257 0.208 0.214
2.187 2.159 2.254 2.154 1.940 1.915 0.737 0.747 0.713 0.613 0.582 0.529
1.875 1.704 1.772 1.839 1.519 1.505 1.024 1.195 1.154 0.745 0.906 0.791
1.929 1.686 1.742 1.720 1.590 1.804 1.001 1.019 1.152 0.791 0.835 0.714
1.936 1.795 1.756 1.768 1.411 1.713 1.036 1.045 1.096 0.871 0.884 0.710
1.170 0.300 0.250 0.247 0.237 0.198 0.981 1.384 1.601 1.321 1.385 1.538
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.875 1.907 1.885 2.055 1.838 1.275 3.840 6.712 4.668 4.672 5.876 2.824
1.974 1.933 1.946 2.022 1.88 1.72 3.242 4.242 3.700 4.253 4.043 2.209
1.903 2.047 2.145 2.162 2.114 1.803 13.768 15.340 16.597 14.801 17.502 13.755
1.903 2.217 2.458 2.469 2.525 2.195 33.001 38.611 45.077 44.633 48.238 46.469
2.215 2.31 2.618 2.488 2.439 1.97 39.097 46.494 55.462 56.592 57.975 52.487
1.943 2.574 2.582 2.588 2.249 2.408 39.629 51.981 53.834 55.332 51.934 42.940
2.112 2.493 2.221 2.64 1.759 1.825 39.205 52.306 42.503 43.485 36.725 35.507
1.796 1.79 1.814 2.003 2.025 1.753 39.087 46.145 51.047 51.623 48.790 46.777
2.243 2.357 2.306 2.261 2.316 2.313 3.477 3.140 4.337 3.184 3.109 2.421
2.321 2.329 2.323 2.308 2.277 2.331 4.567 4.122 4.391 3.899 4.743 2.831
2.469 2.502 2.398 2.371 2.205 2.289 13.609 13.269 11.843 13.581 13.424 13.368
3.011 2.865 2.681 2.75 2.617 2.739 45.168 40.908 34.987 37.382 33.244 37.459
3.108 2.638 2.754 2.723 2.835 2.831 58.301 52.237 50.763 52.148 54.109 54.680
2.846 2.412 2.629 3.318 2.684 2.375 54.743 45.854 51.122 59.795 53.502 45.895
3.02 2.162 2.741 2.786 2.496 2.81 55.762 40.056 46.771 52.190 44.231 49.609
2.756 2.079 2.535 2.384 2.018 1.216 76.923 68.591 76.213 71.980 67.393 65.296
2.802 2.764 2.774 2.725 2.72 2.75 2.570 3.763 3.172 2.789 2.721 2.764
2.938 2.794 2.84 2.949 2.779 2.751 5.037 4.510 4.648 4.069 4.030 4.653
3.046 3.049 3.034 2.899 2.857 2.864 11.490 10.823 11.074 11.521 8.610 11.313
3.645 3.584 3.46 3.465 3.331 3.341 35.830 33.259 34.566 33.766 32.543 31.727
3.796 3.615 3.634 3.638 3.564 3.529 49.895 46.971 48.872 48.048 48.822 46.642
3.903 3.82 3.752 3.58 3.497 3.489 46.221 46.021 48.827 45.866 45.353 46.088
3.712 3.645 3.722 3.747 3.424 3.57 44.720 42.634 48.039 45.316 45.794 45.154
4.236 3.499 3.876 3.137 2.807 3.536 91.596 95.970 95.304 94.485 92.626 95.532
2.582 2.528 2.652 2.451 2.359 2.344 4.802 3.560 3.469 2.611 3.985 2.816
2.736 2.797 2.844 2.772 2.379 2.689 5.556 4.147 4.993 3.102 5.464 3.793
3.101 3.024 3.118 3.057 2.85 2.691 16.446 14.021 18.409 16.814 14.596 15.905
3.661 3.653 3.68 3.38 3.104 2.973 40.262 40.898 38.750 36.272 37.500 35.587
3.923 4.094 4.08 3.329 3.331 3.087 52.205 58.378 56.569 44.758 54.398 51.247
3.931 3.724 4.046 3.302 3.26 3.232 50.929 54.726 56.945 47.910 51.227 44.183
4.008 3.885 3.948 3.51 3.179 3.133 51.697 53.797 55.522 49.630 55.615 45.324




































































1 2 3 4 5 6 7 8 9 10 11 12
2.143 2.239 2.136 2.131 2.056 2.069 0.015 0.016 0.011 0.015 0.015 0.009
2.124 2.222 2.143 2.179 2.147 2.093 0.029 0.021 0.028 0.022 0.019 0.027
2.119 2.219 2.166 2.208 2.168 2.095 0.096 0.058 0.077 0.061 0.091 0.088
1.730 1.943 1.821 1.913 1.869 1.777 0.453 0.260 0.362 0.228 0.394 0.383
1.368 1.518 1.508 1.538 1.492 1.417 0.730 0.510 0.692 0.488 0.765 0.778
1.514 1.680 1.551 1.682 1.552 1.519 0.697 0.504 0.635 0.362 0.661 0.396
1.515 1.597 1.566 1.357 1.583 1.564 0.575 0.475 0.577 0.485 0.647 0.609
0.075 0.278 0.216 0.259 0.255 0.244 1.323 1.628 1.392 1.108 1.451 1.686
2.050 2.132 2.115 2.131 2.145 2.138 0.021 0.023 0.011 0.008 0.010 0.036
2.052 2.201 2.241 2.245 2.201 2.123 0.028 0.038 0.041 0.023 0.003 0.030
1.967 2.173 2.201 2.252 2.177 2.091 0.121 0.093 0.106 0.114 0.156 0.175
1.592 1.898 1.873 1.856 1.896 1.716 0.398 0.268 0.314 0.469 0.435 0.547
1.387 1.525 1.521 1.498 1.508 1.399 0.605 0.374 0.487 0.743 0.765 0.799
1.479 1.606 1.594 1.583 1.629 1.543 0.572 0.303 0.354 0.619 0.435 0.679
1.467 1.622 1.591 1.570 1.638 1.539 0.507 0.283 0.360 0.485 0.462 0.582
0.455 0.336 0.445 0.430 0.350 0.225 1.443 0.925 0.711 1.188 0.787 0.930
2.032 2.082 2.010 2.123 2.078 2.081 0.016 0.020 0.014 0.025 0.022 0.013
2.048 2.152 2.124 2.210 2.116 2.058 0.038 0.037 0.029 0.032 0.022 0.037
2.010 2.180 2.194 2.158 2.175 2.079 0.094 0.052 0.061 0.056 0.062 0.083
1.807 1.919 1.947 2.008 2.021 1.893 0.310 0.228 0.306 0.259 0.261 0.293
1.301 1.454 1.438 1.427 1.413 1.433 0.629 0.454 0.654 0.592 0.593 0.664
1.361 1.469 1.455 1.454 1.525 1.487 0.598 0.475 0.593 0.600 0.570 0.538
1.429 1.520 1.529 1.510 1.582 1.531 0.496 0.371 0.618 0.481 0.397 0.538
0.080 0.940 0.116 0.096 0.185 0.186 1.419 1.351 1.714 1.532 0.905 0.806
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.173 2.271 2.158 2.161 2.086 2.087 1.381 1.409 1.019 1.388 1.438 0.862
2.182 2.264 2.199 2.223 2.185 2.147 2.658 1.855 2.547 1.979 1.739 2.515
2.311 2.335 2.32 2.33 2.35 2.271 8.308 4.968 6.638 5.236 7.745 7.750
2.636 2.463 2.545 2.369 2.657 2.543 34.370 21.112 28.448 19.249 29.658 30.122
2.828 2.538 2.892 2.514 3.022 2.973 51.627 40.189 47.856 38.823 50.629 52.338
2.908 2.688 2.821 2.406 2.874 2.311 47.937 37.500 45.019 30.091 45.999 34.271
2.665 2.547 2.72 2.327 2.877 2.782 43.152 37.299 42.426 41.685 44.977 43.781
2.721 3.534 3 2.475 3.157 3.616 97.244 92.134 92.800 89.535 91.923 93.252
2.092 2.178 2.137 2.147 2.165 2.21 2.008 2.112 1.029 0.745 0.924 3.258
2.108 2.277 2.323 2.291 2.207 2.183 2.657 3.338 3.530 2.008 0.272 2.749
2.209 2.359 2.413 2.48 2.489 2.441 10.955 7.885 8.786 9.194 12.535 14.338
2.388 2.434 2.501 2.794 2.766 2.81 33.333 22.021 25.110 33.572 31.453 38.932
2.597 2.273 2.495 2.984 3.038 2.997 46.592 32.908 39.038 49.799 50.362 53.320
2.623 2.212 2.302 2.821 2.499 2.901 43.614 27.396 30.756 43.885 34.814 46.811
2.481 2.188 2.311 2.54 2.562 2.703 40.871 25.868 31.155 38.189 36.066 43.063
3.341 2.186 1.867 2.806 1.924 2.085 86.381 84.629 76.165 84.676 81.809 89.209
2.064 2.122 2.038 2.173 2.122 2.107 1.550 1.885 1.374 2.301 2.074 1.234
2.124 2.226 2.182 2.274 2.16 2.132 3.578 3.324 2.658 2.814 2.037 3.471
2.198 2.284 2.316 2.27 2.299 2.245 8.553 4.553 5.268 4.934 5.394 7.394
2.427 2.375 2.559 2.526 2.543 2.479 25.546 19.200 23.916 20.507 20.527 23.639
2.559 2.362 2.746 2.611 2.599 2.761 49.160 38.442 47.633 45.347 45.633 48.099
2.557 2.419 2.641 2.654 2.665 2.563 46.774 39.272 44.907 45.215 42.777 41.982
2.421 2.262 2.765 2.472 2.376 2.607 40.975 32.803 44.702 38.916 33.418 41.273




































































1 2 3 4 5 6 7 8 9 10 11 12
2.022 2.211 2.063 2.021 2.043 2.018 0.012 0.015 0.015 0.012 0.017 0.017
2.064 2.197 2.147 2.055 2.002 1.951 0.040 0.021 0.040 0.022 0.033 0.048
1.978 2.176 2.055 2.092 2.129 2.058 0.110 0.075 0.082 0.059 0.094 0.096
1.697 1.839 1.832 1.799 1.846 1.678 0.382 0.145 0.369 0.248 0.268 0.377
1.581 1.811 1.661 1.749 1.711 1.699 0.382 0.229 0.316 0.268 0.391 0.409
1.659 1.876 1.738 1.733 1.776 1.733 0.259 0.148 0.364 0.245 0.332 0.416
1.624 1.761 1.693 1.675 1.802 1.614 0.244 0.123 0.305 0.244 0.424 0.391
0.680 0.560 0.709 0.674 0.657 0.639 1.130 0.500 0.806 0.628 0.907 0.828
1.903 1.950 0.194 1.925 2.039 1.963 0.012 0.013 0.011 0.013 0.010 0.013
1.889 1.930 1.948 1.890 1.875 1.921 0.034 0.035 0.042 0.032 0.038 0.033
1.739 1.828 1.876 1.879 1.902 1.920 0.159 0.126 0.129 0.159 0.159 0.157
1.464 1.548 1.583 1.640 1.650 1.639 0.422 0.406 0.376 0.404 0.363 0.320
1.412 1.461 1.502 1.421 1.527 1.482 0.355 0.267 0.283 0.443 0.507 0.461
1.472 1.493 1.673 1.469 1.553 1.491 0.344 0.260 0.352 0.421 0.457 0.447
1.432 1.409 1.470 1.406 1.505 1.448 0.327 0.325 0.340 0.334 0.442 0.474
0.347 0.315 0.375 0.324 0.279 0.365 1.208 1.045 1.180 1.106 1.023 1.028
1.987 2.134 2.167 2.127 2.052 2.016 0.022 0.020 0.019 0.023 0.022 0.017
2.073 2.170 2.175 2.192 2.114 2.058 0.043 0.028 0.033 0.032 0.021 0.047
2.066 2.142 2.147 2.190 2.180 2.147 0.110 0.085 0.081 0.082 0.086 0.105
1.632 1.753 1.746 1.779 1.784 1.700 0.431 0.310 0.426 0.506 0.488 0.447
1.660 1.639 1.651 1.637 1.688 1.528 0.422 0.317 0.351 0.455 0.542 0.464
1.524 1.638 1.664 1.676 1.750 1.577 0.431 0.357 0.289 0.504 0.510 0.505
1.529 1.620 1.649 1.606 1.674 1.454 0.445 0.350 0.403 0.373 0.467 0.465
0.383 0.701 0.507 0.469 0.530 0.507 1.269 1.391 1.412 1.061 1.253 1.180
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.046 2.241 2.093 2.045 2.077 2.052 1.173 1.339 1.433 1.174 1.637 1.657
2.144 2.239 2.227 2.099 2.068 2.047 3.731 1.876 3.592 2.096 3.191 4.690
2.198 2.326 2.219 2.21 2.317 2.25 10.009 6.449 7.391 5.339 8.114 8.533
2.461 2.129 2.57 2.295 2.382 2.432 31.044 13.621 28.716 21.612 22.502 31.003
2.345 2.269 2.293 2.285 2.493 2.517 32.580 20.185 27.562 23.457 31.368 32.499
2.177 2.172 2.466 2.223 2.44 2.565 23.794 13.628 29.521 22.042 27.213 32.437
2.112 2.007 2.303 2.163 2.65 2.396 23.106 12.257 26.487 22.561 32.000 32.638
2.94 1.56 2.321 1.93 2.471 2.295 76.871 64.103 69.453 65.078 73.412 72.157
1.927 1.976 0.216 1.951 2.059 1.989 1.245 1.316 10.185 1.333 0.971 1.307
1.957 2 2.032 1.954 1.951 1.987 3.475 3.500 4.134 3.275 3.895 3.322
2.057 2.08 2.134 2.197 2.22 2.234 15.459 12.115 12.090 14.474 14.324 14.056
2.308 2.36 2.335 2.448 2.376 2.279 36.568 34.407 32.206 33.007 30.556 28.082
2.122 1.995 2.068 2.307 2.541 2.404 33.459 26.767 27.369 38.405 39.906 38.353
2.16 2.013 2.377 2.311 2.467 2.385 31.852 25.832 29.617 36.434 37.049 37.484
2.086 2.059 2.15 2.074 2.389 2.396 31.352 31.569 31.628 32.208 37.003 39.566
2.763 2.405 2.735 2.536 2.325 2.421 87.441 86.902 86.289 87.224 88.000 84.924
2.031 2.174 2.205 2.173 2.096 2.05 2.166 1.840 1.723 2.117 2.099 1.659
2.159 2.226 2.241 2.256 2.156 2.152 3.983 2.516 2.945 2.837 1.948 4.368
2.286 2.312 2.309 2.354 2.352 2.357 9.624 7.353 7.016 6.967 7.313 8.910
2.494 2.373 2.598 2.791 2.76 2.594 34.563 26.127 32.794 36.259 35.362 34.464
2.504 2.273 2.353 2.547 2.772 2.456 33.706 27.893 29.834 35.728 39.105 37.785
2.386 2.352 2.242 2.684 2.77 2.587 36.127 30.357 25.781 37.556 36.823 39.041
2.419 2.32 2.455 2.352 2.608 2.384 36.792 30.172 32.831 31.718 35.813 39.010


































1 2 3 4 5 6 7 8 9 10 11 12
1.165 1.115 1.113 1.14 1.132 1.153 0.079 0.074 0.082 0.073 0.073 0.072
1.149 1.106 1.16 1.149 1.177 1.12 0.073 0.082 0.07 0.078 0.083 0.09
1.178 1.178 1.196 1.176 1.176 1.257 0.07 0.069 0.065 0.069 0.07 0.068
1.191 1.154 1.201 1.199 1.19 1.188 0.066 0.063 0.06 0.066 0.067 0.069
1.167 1.16 1.203 1.239 1.169 1.16 0.076 0.074 0.073 0.08 0.077 0.081
1.177 1.203 1.242 1.236 1.245 1.167 0.077 0.073 0.077 0.081 0.077 0.08
1.171 1.142 1.205 1.189 1.162 1.094 0.078 0.079 0.069 0.081 0.079 0.089
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.323 1.263 1.277 1.286 1.278 1.297 11.943 11.718 12.843 11.353 11.424 11.103
1.295 1.27 1.3 1.305 1.343 1.3 11.274 12.913 10.769 11.954 12.360 13.846
1.318 1.316 1.326 1.314 1.316 1.393 10.622 10.486 9.804 10.502 10.638 9.763
1.323 1.28 1.321 1.331 1.324 1.326 9.977 9.844 9.084 9.917 10.121 10.407
1.319 1.308 1.349 1.399 1.323 1.322 11.524 11.315 10.823 11.437 11.640 12.254
1.331 1.349 1.396 1.398 1.399 1.327 11.570 10.823 11.032 11.588 11.008 12.057




































1 2 3 4 5 6 7 8 9 10 11 12
1.229 1.183 1.196 1.178 1.143 1.103 0.088 0.074 0.076 0.076 0.069 0.084
1.206 1.207 1.209 1.189 1.173 1.12 0.083 0.082 0.079 0.08 0.073 0.08
1.234 1.232 1.248 1.228 1.201 1.151 0.068 0.068 0.069 0.071 0.068 0.07
1.228 1.252 1.242 1.171 1.218 1.141 0.065 0.071 0.068 0.074 0.067 0.069
1.24 1.252 1.274 1.155 1.248 1.19 0.076 0.078 0.083 0.09 0.08 0.085
1.153 1.329 1.278 1.254 1.3 1.191 0.075 0.076 0.075 0.082 0.077 0.074
1.245 1.273 1.252 1.211 1.237 1.236 0.073 0.079 0.079 0.088 0.078 0.075
0.215 0.204 0.233 0.233 0.284 0.222 0.473 0.74 0.693 0.689 0.535 0.474
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.405 1.331 1.348 1.33 1.281 1.271 12.527 11.119 11.276 11.429 10.773 13.218
1.372 1.371 1.367 1.349 1.319 1.28 12.099 11.962 11.558 11.861 11.069 12.500
1.37 1.368 1.386 1.37 1.337 1.291 9.927 9.942 9.957 10.365 10.172 10.844
1.358 1.394 1.378 1.319 1.352 1.279 9.573 10.187 9.869 11.221 9.911 10.790
1.392 1.408 1.44 1.335 1.408 1.36 10.920 11.080 11.528 13.483 11.364 12.500
1.303 1.481 1.428 1.418 1.454 1.339 11.512 10.263 10.504 11.566 10.591 11.053
1.391 1.431 1.41 1.387 1.393 1.386 10.496 11.041 11.206 12.689 11.199 10.823




















































































1 2 3 4 5 6 7 8 9 10 11 12
1.734 1.65 1.614 1.587 1.616 1.564 0.068 0.077 0.051 0.068 0.063 0.067
1.767 1.739 1.695 1.632 1.663 1.556 0.066 0.065 0.07 0.069 0.069 0.074
1.733 1.713 1.697 1.617 1.663 1.523 0.088 0.087 0.086 0.087 0.089 0.106
1.441 1.441 1.429 1.401 1.411 1.272 0.245 0.292 0.305 0.35 0.401 0.404
1.438 1.426 1.392 1.364 1.364 1.304 0.26 0.337 0.376 0.434 0.405 0.488
1.433 1.457 1.43 1.393 1.379 1.302 0.256 0.346 0.401 0.413 0.454 0.466
1.442 1.411 1.389 1.34 1.35 1.237 0.293 0.346 0.393 0.399 0.452 0.428
0.696 0.675 0.666 0.6 0.687 0.594 0.761 0.763 0.886 0.738 0.769 0.776
1.747 1.781 1.722 1.662 1.632 1.484 0.07 0.069 0.071 0.073 0.076 0.073
1.69 1.763 1.746 1.66 1.543 1.599 0.072 0.082 0.069 0.07 0.083 0.082
1.693 1.72 1.694 1.7 1.641 1.613 0.101 0.097 0.096 0.095 0.097 0.107
1.477 1.454 1.471 1.425 1.401 1.295 0.355 0.327 0.407 0.386 0.415 0.447
1.391 1.374 1.357 1.357 1.326 1.266 0.367 0.45 0.486 0.462 0.534 0.548
1.408 1.396 1.374 1.302 1.335 1.325 0.381 0.402 0.475 0.416 0.5 0.502
1.413 1.357 1.371 1.335 1.375 1.311 0.416 0.421 0.465 0.432 0.541 0.578
0.672 0.627 0.601 0.63 0.55 0.57 0.877 0.763 0.79 0.504 0.652 0.752
1.682 1.719 1.653 1.674 1.684 1.915 0.063 0.062 0.063 0.063 0.061 0.064
1.725 1.737 1.701 1.658 1.696 1.577 0.061 0.061 0.059 0.057 0.058 0.059
1.712 1.704 1.695 1.679 1.707 1.597 0.075 0.079 0.079 0.069 0.066 0.088
1.369 1.371 1.455 1.377 1.392 1.357 0.215 0.231 0.338 0.271 0.268 0.335
1.349 1.36 1.364 1.317 1.317 1.382 0.32 0.34 0.418 0.319 0.377 0.478
1.321 1.345 1.365 1.334 1.277 1.214 0.303 0.334 0.458 0.334 0.369 0.458
1.316 1.288 1.333 1.218 1.206 1.161 0.353 0.304 0.351 0.303 0.332 0.475
0.596 0.695 0.607 0.628 0.563 0.651 0.611 0.391 0.675 0.329 0.489 0.542
1.696 1.696 1.688 1.69 1.662 1.622 0.063 0.067 0.067 0.067 0.066 0.064
1.659 1.665 1.643 1.618 1.662 1.585 0.063 0.063 0.061 0.069 0.066 0.068
1.675 1.695 1.657 1.614 1.654 1.57 0.075 0.073 0.071 0.079 0.084 0.08
1.402 1.465 1.409 1.354 1.567 1.301 0.295 0.287 0.296 0.308 0.361 0.327
1.351 1.379 1.369 1.349 1.39 1.269 0.309 0.321 0.296 0.401 0.442 0.377
1.4 1.401 1.419 1.362 1.418 1.463 0.261 0.308 0.305 0.373 0.436 0.394
1.355 1.362 1.349 1.319 1.357 1.223 0.291 0.364 0.336 0.421 0.45 0.443
0.589 0.639 0.568 0.582 0.665 0.577 0.607 0.672 0.708 0.795 0.71 0.787
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.87 1.804 1.716 1.723 1.742 1.698 7.273 8.537 5.944 7.893 7.233 7.892
1.899 1.869 1.835 1.77 1.801 1.704 6.951 6.956 7.629 7.797 7.662 8.685
1.909 1.887 1.869 1.791 1.841 1.735 9.219 9.221 9.203 9.715 9.669 12.219
1.931 2.025 2.039 2.101 2.213 2.08 25.375 28.840 29.917 33.317 36.240 38.846
1.958 2.1 2.144 2.232 2.174 2.28 26.558 32.095 35.075 38.889 37.259 42.807
1.945 2.149 2.232 2.219 2.287 2.234 26.324 32.201 35.932 37.224 39.703 41.719
2.028 2.103 2.175 2.138 2.254 2.093 28.895 32.905 36.138 37.325 40.106 40.898
2.218 2.201 2.438 2.076 2.225 2.146 68.620 69.332 72.683 71.098 69.124 72.321
1.887 1.919 1.864 1.808 1.784 1.63 7.419 7.191 7.618 8.075 8.520 8.957
1.834 1.927 1.884 1.8 1.709 1.763 7.852 8.511 7.325 7.778 9.713 9.302
1.895 1.914 1.886 1.89 1.835 1.827 10.660 10.136 10.180 10.053 10.572 11.713
2.187 2.108 2.285 2.197 2.231 2.189 32.465 31.025 35.624 35.139 37.203 40.841
2.125 2.274 2.329 2.281 2.394 2.362 34.541 39.578 41.735 40.509 44.612 46.401
2.17 2.2 2.324 2.134 2.335 2.329 35.115 36.545 40.878 38.988 42.827 43.109
2.245 2.199 2.301 2.199 2.457 2.467 37.060 38.290 40.417 39.291 44.037 46.859
2.426 2.153 2.181 1.638 1.854 2.074 72.300 70.878 72.444 61.538 70.334 72.517
1.808 1.843 1.779 1.8 1.806 2.043 6.969 6.728 7.083 7.000 6.755 6.265
1.847 1.859 1.819 1.772 1.812 1.695 6.605 6.563 6.487 6.433 6.402 6.962
1.862 1.862 1.853 1.817 1.839 1.773 8.056 8.485 8.527 7.595 7.178 9.927
1.799 1.833 2.131 1.919 1.928 2.027 23.902 25.205 31.722 28.244 27.801 33.054
1.989 2.04 2.2 1.955 2.071 2.338 32.177 33.333 38.000 32.634 36.408 40.890
1.927 2.013 2.281 2.002 2.015 2.13 31.448 33.184 40.158 33.367 36.625 43.005
2.022 1.896 2.035 1.824 1.87 2.111 34.916 32.068 34.496 33.224 35.508 45.002
1.818 1.477 1.957 1.286 1.541 1.735 67.217 52.945 68.983 51.166 63.465 62.478
1.822 1.83 1.822 1.824 1.794 1.75 6.915 7.322 7.355 7.346 7.358 7.314
1.785 1.791 1.765 1.756 1.794 1.721 7.059 7.035 6.912 7.859 7.358 7.902
1.825 1.841 1.799 1.772 1.822 1.73 8.219 7.930 7.893 8.916 9.221 9.249
1.992 2.039 2.001 1.97 2.289 1.955 29.618 28.151 29.585 31.269 31.542 33.453
1.969 2.021 1.961 2.151 2.274 2.023 31.386 31.766 30.189 37.285 38.874 37.271
1.922 2.017 2.029 2.108 2.29 2.251 27.159 30.540 30.064 35.389 38.079 35.007
1.937 2.09 2.021 2.161 2.257 2.109 30.046 34.833 33.251 38.963 39.876 42.010










Horse / Horse! ! 100%
Horse / Human! ! 56%
Horse / Mouse! ! 49% ! Mouse/Horse!  21%
Horse / Rat! ! 52%
Horse / Dog! ! 66%
FceRIa Identity:
Horse / Horse! ! 100%
Horse / Human! ! 63%!! Human/Dog! 53%
Horse / Mouse! ! 45%
Horse / Rat! ! 43%
Horse / Dog! ! 54%
Comparison of Peak Release Between Different IgE Types Bound To Parental RBL Cells 
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-1  Figure 29: β-hexosaminidase release assays of
  RBL- H3.1 cells expressing equine FcεRIα   143



























1 2 3 4 5 6 7 8 9 10 11 12
1.633 1.749 1.787 1.773 1.830 1.858 0.074 0.078 0.088 0.124 0.100 0.102
1.709 1.896 1.909 1.887 1.920 1.868 0.070 0.072 0.069 0.101 0.091 0.084
1.737 1.865 1.891 1.904 1.989 1.966 0.076 0.077 0.072 0.073 0.076 0.080
1.809 1.897 1.927 1.993 1.984 1.963 0.065 0.064 0.066 0.070 0.079 0.073
1.793 2.020 2.023 2.005 1.953 2.107 0.085 0.086 0.083 0.088 0.086 0.086
1.719 1.910 1.967 2.028 1.952 2.010 0.089 0.080 0.085 0.081 0.080 0.086
1.736 1.854 1.963 1.994 1.994 1.970 0.088 0.096 0.092 0.091 0.098 0.096
0.542 0.688 0.642 0.723 0.742 0.907 0.941 1.220 0.747 1.247 1.207 0.819
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.781 1.905 1.963 2.021 2.03 2.062 8.310 8.189 8.966 12.271 9.852 9.893
1.849 2.04 2.047 2.089 2.102 2.036 7.572 7.059 6.742 9.670 8.658 8.251
1.889 2.019 2.035 2.05 2.141 2.126 8.047 7.628 7.076 7.122 7.099 7.526
1.939 2.025 2.059 2.133 2.142 2.109 6.704 6.321 6.411 6.564 7.376 6.923
1.963 2.192 2.189 2.181 2.125 2.279 8.660 7.847 7.583 8.070 8.094 7.547
1.897 2.07 2.137 2.19 2.112 2.182 9.383 7.729 7.955 7.397 7.576 7.883
1.912 2.046 2.147 2.176 2.19 2.162 9.205 9.384 8.570 8.364 8.950 8.881




































1 2 3 4 5 6 7 8 9 10 11 12
1.558 1.607 1.635 1.633 1.530 1.566 0.081 0.089 0.093 0.088 0.085 0.089
1.538 1.668 1.661 1.829 1.563 1.637 0.068 0.067 0.067 0.070 0.068 0.070
1.549 1.720 1.748 1.749 1.629 0.992 0.073 0.072 0.075 0.071 0.070 0.078
1.741 1.656 1.748 1.843 1.824 1.869 0.066 0.064 0.066 0.065 0.071 0.065
1.742 1.798 1.776 1.870 1.754 1.760 0.087 0.086 0.087 0.086 0.086 0.089
1.766 1.832 1.762 1.758 1.766 1.796 0.083 0.078 0.087 0.079 0.080 0.077
1.722 1.780 1.711 1.794 1.738 1.799 0.100 0.084 0.090 0.091 0.093 0.090
0.391 0.365 0.290 0.656 0.436 0.615 1.072 0.812 1.109 0.881 0.996 0.623
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.72 1.785 1.821 1.809 1.7 1.744 9.419 9.972 10.214 9.729 10.000 10.206
1.674 1.802 1.795 1.969 1.699 1.777 8.124 7.436 7.465 7.110 8.005 7.878
1.695 1.864 1.898 1.891 1.769 1.148 8.614 7.725 7.903 7.509 7.914 13.589
1.873 1.784 1.88 1.973 1.966 1.999 7.048 7.175 7.021 6.589 7.223 6.503
1.916 1.97 1.95 2.042 1.926 1.938 9.081 8.731 8.923 8.423 8.930 9.185
1.932 1.988 1.936 1.916 1.926 1.95 8.592 7.847 8.988 8.246 8.307 7.897
1.922 1.948 1.891 1.976 1.924 1.979 10.406 8.624 9.519 9.211 9.667 9.096




















































































1 2 3 4 5 6 7 8 9 10 11 12
1.803 1.779 1.797 1.959 1.730 1.239 0.036 0.064 0.044 0.048 0.054 0.018
1.910 1.851 1.874 1.936 1.804 1.682 0.032 0.041 0.036 0.043 0.038 0.019
1.641 1.733 1.789 1.842 1.744 1.555 0.131 0.157 0.178 0.160 0.185 0.124
1.275 1.361 1.350 1.367 1.307 1.175 0.314 0.428 0.554 0.551 0.609 0.510
1.349 1.236 1.166 1.080 1.025 0.936 0.433 0.537 0.726 0.704 0.707 0.517
1.173 1.236 1.192 1.156 1.081 1.374 0.385 0.669 0.695 0.716 0.584 0.517
1.284 1.189 1.277 1.492 1.113 1.177 0.414 0.652 0.472 0.574 0.323 0.324
1.094 0.964 0.888 0.969 1.037 0.933 0.351 0.413 0.463 0.517 0.494 0.410
2.165 2.283 2.206 2.189 2.244 2.257 0.039 0.037 0.050 0.036 0.036 0.028
2.215 2.233 2.221 2.218 2.169 2.265 0.053 0.048 0.051 0.045 0.054 0.033
2.133 2.170 2.114 2.049 1.909 1.983 0.168 0.166 0.142 0.161 0.148 0.153
1.651 1.693 1.743 1.722 1.747 1.713 0.680 0.586 0.469 0.514 0.435 0.513
1.296 1.260 1.356 1.303 1.301 1.283 0.906 0.689 0.699 0.710 0.767 0.774
1.288 1.306 1.285 1.334 1.248 1.285 0.779 0.553 0.672 0.992 0.718 0.545
1.336 1.296 1.459 1.332 1.392 1.416 0.842 0.433 0.641 0.727 0.552 0.697
0.636 0.653 0.603 0.668 0.658 0.422 1.060 0.713 0.966 0.858 0.680 0.397
2.730 2.660 2.686 2.649 2.646 2.674 0.036 0.052 0.044 0.038 0.037 0.038
2.790 2.668 2.708 2.829 2.667 2.623 0.074 0.063 0.066 0.060 0.056 0.064
2.696 2.719 2.698 2.565 2.611 2.540 0.175 0.165 0.168 0.167 0.123 0.162
2.339 2.392 2.264 2.295 2.247 2.281 0.653 0.596 0.598 0.585 0.542 0.530
1.902 1.917 1.858 1.890 1.824 1.883 0.947 0.849 0.888 0.874 0.870 0.823
2.099 2.062 1.920 1.938 1.911 1.881 0.902 0.879 0.916 0.821 0.793 0.804
2.052 2.091 1.934 2.049 1.856 1.958 0.830 0.777 0.894 0.849 0.784 0.806
0.356 0.141 0.182 0.173 0.207 0.158 1.940 1.679 1.847 1.482 1.300 1.689
2.458 2.438 2.560 2.387 2.265 2.278 0.062 0.045 0.046 0.032 0.047 0.033
2.584 2.681 2.702 2.686 2.249 2.587 0.076 0.058 0.071 0.043 0.065 0.051
2.591 2.600 2.544 2.543 2.434 2.263 0.255 0.212 0.287 0.257 0.208 0.214
2.187 2.159 2.254 2.154 1.940 1.915 0.737 0.747 0.713 0.613 0.582 0.529
1.875 1.704 1.772 1.839 1.519 1.505 1.024 1.195 1.154 0.745 0.906 0.791
1.929 1.686 1.742 1.720 1.590 1.804 1.001 1.019 1.152 0.791 0.835 0.714
1.936 1.795 1.756 1.768 1.411 1.713 1.036 1.045 1.096 0.871 0.884 0.710
1.170 0.300 0.250 0.247 0.237 0.198 0.981 1.384 1.601 1.321 1.385 1.538
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.875 1.907 1.885 2.055 1.838 1.275 3.840 6.712 4.668 4.672 5.876 2.824
1.974 1.933 1.946 2.022 1.88 1.72 3.242 4.242 3.700 4.253 4.043 2.209
1.903 2.047 2.145 2.162 2.114 1.803 13.768 15.340 16.597 14.801 17.502 13.755
1.903 2.217 2.458 2.469 2.525 2.195 33.001 38.611 45.077 44.633 48.238 46.469
2.215 2.31 2.618 2.488 2.439 1.97 39.097 46.494 55.462 56.592 57.975 52.487
1.943 2.574 2.582 2.588 2.249 2.408 39.629 51.981 53.834 55.332 51.934 42.940
2.112 2.493 2.221 2.64 1.759 1.825 39.205 52.306 42.503 43.485 36.725 35.507
1.796 1.79 1.814 2.003 2.025 1.753 39.087 46.145 51.047 51.623 48.790 46.777
2.243 2.357 2.306 2.261 2.316 2.313 3.477 3.140 4.337 3.184 3.109 2.421
2.321 2.329 2.323 2.308 2.277 2.331 4.567 4.122 4.391 3.899 4.743 2.831
2.469 2.502 2.398 2.371 2.205 2.289 13.609 13.269 11.843 13.581 13.424 13.368
3.011 2.865 2.681 2.75 2.617 2.739 45.168 40.908 34.987 37.382 33.244 37.459
3.108 2.638 2.754 2.723 2.835 2.831 58.301 52.237 50.763 52.148 54.109 54.680
2.846 2.412 2.629 3.318 2.684 2.375 54.743 45.854 51.122 59.795 53.502 45.895
3.02 2.162 2.741 2.786 2.496 2.81 55.762 40.056 46.771 52.190 44.231 49.609
2.756 2.079 2.535 2.384 2.018 1.216 76.923 68.591 76.213 71.980 67.393 65.296
2.802 2.764 2.774 2.725 2.72 2.75 2.570 3.763 3.172 2.789 2.721 2.764
2.938 2.794 2.84 2.949 2.779 2.751 5.037 4.510 4.648 4.069 4.030 4.653
3.046 3.049 3.034 2.899 2.857 2.864 11.490 10.823 11.074 11.521 8.610 11.313
3.645 3.584 3.46 3.465 3.331 3.341 35.830 33.259 34.566 33.766 32.543 31.727
3.796 3.615 3.634 3.638 3.564 3.529 49.895 46.971 48.872 48.048 48.822 46.642
3.903 3.82 3.752 3.58 3.497 3.489 46.221 46.021 48.827 45.866 45.353 46.088
3.712 3.645 3.722 3.747 3.424 3.57 44.720 42.634 48.039 45.316 45.794 45.154
4.236 3.499 3.876 3.137 2.807 3.536 91.596 95.970 95.304 94.485 92.626 95.532
2.582 2.528 2.652 2.451 2.359 2.344 4.802 3.560 3.469 2.611 3.985 2.816
2.736 2.797 2.844 2.772 2.379 2.689 5.556 4.147 4.993 3.102 5.464 3.793
3.101 3.024 3.118 3.057 2.85 2.691 16.446 14.021 18.409 16.814 14.596 15.905
3.661 3.653 3.68 3.38 3.104 2.973 40.262 40.898 38.750 36.272 37.500 35.587
3.923 4.094 4.08 3.329 3.331 3.087 52.205 58.378 56.569 44.758 54.398 51.247
3.931 3.724 4.046 3.302 3.26 3.232 50.929 54.726 56.945 47.910 51.227 44.183
4.008 3.885 3.948 3.51 3.179 3.133 51.697 53.797 55.522 49.630 55.615 45.324




































































1 2 3 4 5 6 7 8 9 10 11 12
2.143 2.239 2.136 2.131 2.056 2.069 0.015 0.016 0.011 0.015 0.015 0.009
2.124 2.222 2.143 2.179 2.147 2.093 0.029 0.021 0.028 0.022 0.019 0.027
2.119 2.219 2.166 2.208 2.168 2.095 0.096 0.058 0.077 0.061 0.091 0.088
1.730 1.943 1.821 1.913 1.869 1.777 0.453 0.260 0.362 0.228 0.394 0.383
1.368 1.518 1.508 1.538 1.492 1.417 0.730 0.510 0.692 0.488 0.765 0.778
1.514 1.680 1.551 1.682 1.552 1.519 0.697 0.504 0.635 0.362 0.661 0.396
1.515 1.597 1.566 1.357 1.583 1.564 0.575 0.475 0.577 0.485 0.647 0.609
0.075 0.278 0.216 0.259 0.255 0.244 1.323 1.628 1.392 1.108 1.451 1.686
2.050 2.132 2.115 2.131 2.145 2.138 0.021 0.023 0.011 0.008 0.010 0.036
2.052 2.201 2.241 2.245 2.201 2.123 0.028 0.038 0.041 0.023 0.003 0.030
1.967 2.173 2.201 2.252 2.177 2.091 0.121 0.093 0.106 0.114 0.156 0.175
1.592 1.898 1.873 1.856 1.896 1.716 0.398 0.268 0.314 0.469 0.435 0.547
1.387 1.525 1.521 1.498 1.508 1.399 0.605 0.374 0.487 0.743 0.765 0.799
1.479 1.606 1.594 1.583 1.629 1.543 0.572 0.303 0.354 0.619 0.435 0.679
1.467 1.622 1.591 1.570 1.638 1.539 0.507 0.283 0.360 0.485 0.462 0.582
0.455 0.336 0.445 0.430 0.350 0.225 1.443 0.925 0.711 1.188 0.787 0.930
2.032 2.082 2.010 2.123 2.078 2.081 0.016 0.020 0.014 0.025 0.022 0.013
2.048 2.152 2.124 2.210 2.116 2.058 0.038 0.037 0.029 0.032 0.022 0.037
2.010 2.180 2.194 2.158 2.175 2.079 0.094 0.052 0.061 0.056 0.062 0.083
1.807 1.919 1.947 2.008 2.021 1.893 0.310 0.228 0.306 0.259 0.261 0.293
1.301 1.454 1.438 1.427 1.413 1.433 0.629 0.454 0.654 0.592 0.593 0.664
1.361 1.469 1.455 1.454 1.525 1.487 0.598 0.475 0.593 0.600 0.570 0.538
1.429 1.520 1.529 1.510 1.582 1.531 0.496 0.371 0.618 0.481 0.397 0.538
0.080 0.940 0.116 0.096 0.185 0.186 1.419 1.351 1.714 1.532 0.905 0.806
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.173 2.271 2.158 2.161 2.086 2.087 1.381 1.409 1.019 1.388 1.438 0.862
2.182 2.264 2.199 2.223 2.185 2.147 2.658 1.855 2.547 1.979 1.739 2.515
2.311 2.335 2.32 2.33 2.35 2.271 8.308 4.968 6.638 5.236 7.745 7.750
2.636 2.463 2.545 2.369 2.657 2.543 34.370 21.112 28.448 19.249 29.658 30.122
2.828 2.538 2.892 2.514 3.022 2.973 51.627 40.189 47.856 38.823 50.629 52.338
2.908 2.688 2.821 2.406 2.874 2.311 47.937 37.500 45.019 30.091 45.999 34.271
2.665 2.547 2.72 2.327 2.877 2.782 43.152 37.299 42.426 41.685 44.977 43.781
2.721 3.534 3 2.475 3.157 3.616 97.244 92.134 92.800 89.535 91.923 93.252
2.092 2.178 2.137 2.147 2.165 2.21 2.008 2.112 1.029 0.745 0.924 3.258
2.108 2.277 2.323 2.291 2.207 2.183 2.657 3.338 3.530 2.008 0.272 2.749
2.209 2.359 2.413 2.48 2.489 2.441 10.955 7.885 8.786 9.194 12.535 14.338
2.388 2.434 2.501 2.794 2.766 2.81 33.333 22.021 25.110 33.572 31.453 38.932
2.597 2.273 2.495 2.984 3.038 2.997 46.592 32.908 39.038 49.799 50.362 53.320
2.623 2.212 2.302 2.821 2.499 2.901 43.614 27.396 30.756 43.885 34.814 46.811
2.481 2.188 2.311 2.54 2.562 2.703 40.871 25.868 31.155 38.189 36.066 43.063
3.341 2.186 1.867 2.806 1.924 2.085 86.381 84.629 76.165 84.676 81.809 89.209
2.064 2.122 2.038 2.173 2.122 2.107 1.550 1.885 1.374 2.301 2.074 1.234
2.124 2.226 2.182 2.274 2.16 2.132 3.578 3.324 2.658 2.814 2.037 3.471
2.198 2.284 2.316 2.27 2.299 2.245 8.553 4.553 5.268 4.934 5.394 7.394
2.427 2.375 2.559 2.526 2.543 2.479 25.546 19.200 23.916 20.507 20.527 23.639
2.559 2.362 2.746 2.611 2.599 2.761 49.160 38.442 47.633 45.347 45.633 48.099
2.557 2.419 2.641 2.654 2.665 2.563 46.774 39.272 44.907 45.215 42.777 41.982
2.421 2.262 2.765 2.472 2.376 2.607 40.975 32.803 44.702 38.916 33.418 41.273




































































1 2 3 4 5 6 7 8 9 10 11 12
2.022 2.211 2.063 2.021 2.043 2.018 0.012 0.015 0.015 0.012 0.017 0.017
2.064 2.197 2.147 2.055 2.002 1.951 0.040 0.021 0.040 0.022 0.033 0.048
1.978 2.176 2.055 2.092 2.129 2.058 0.110 0.075 0.082 0.059 0.094 0.096
1.697 1.839 1.832 1.799 1.846 1.678 0.382 0.145 0.369 0.248 0.268 0.377
1.581 1.811 1.661 1.749 1.711 1.699 0.382 0.229 0.316 0.268 0.391 0.409
1.659 1.876 1.738 1.733 1.776 1.733 0.259 0.148 0.364 0.245 0.332 0.416
1.624 1.761 1.693 1.675 1.802 1.614 0.244 0.123 0.305 0.244 0.424 0.391
0.680 0.560 0.709 0.674 0.657 0.639 1.130 0.500 0.806 0.628 0.907 0.828
1.903 1.950 0.194 1.925 2.039 1.963 0.012 0.013 0.011 0.013 0.010 0.013
1.889 1.930 1.948 1.890 1.875 1.921 0.034 0.035 0.042 0.032 0.038 0.033
1.739 1.828 1.876 1.879 1.902 1.920 0.159 0.126 0.129 0.159 0.159 0.157
1.464 1.548 1.583 1.640 1.650 1.639 0.422 0.406 0.376 0.404 0.363 0.320
1.412 1.461 1.502 1.421 1.527 1.482 0.355 0.267 0.283 0.443 0.507 0.461
1.472 1.493 1.673 1.469 1.553 1.491 0.344 0.260 0.352 0.421 0.457 0.447
1.432 1.409 1.470 1.406 1.505 1.448 0.327 0.325 0.340 0.334 0.442 0.474
0.347 0.315 0.375 0.324 0.279 0.365 1.208 1.045 1.180 1.106 1.023 1.028
1.987 2.134 2.167 2.127 2.052 2.016 0.022 0.020 0.019 0.023 0.022 0.017
2.073 2.170 2.175 2.192 2.114 2.058 0.043 0.028 0.033 0.032 0.021 0.047
2.066 2.142 2.147 2.190 2.180 2.147 0.110 0.085 0.081 0.082 0.086 0.105
1.632 1.753 1.746 1.779 1.784 1.700 0.431 0.310 0.426 0.506 0.488 0.447
1.660 1.639 1.651 1.637 1.688 1.528 0.422 0.317 0.351 0.455 0.542 0.464
1.524 1.638 1.664 1.676 1.750 1.577 0.431 0.357 0.289 0.504 0.510 0.505
1.529 1.620 1.649 1.606 1.674 1.454 0.445 0.350 0.403 0.373 0.467 0.465
0.383 0.701 0.507 0.469 0.530 0.507 1.269 1.391 1.412 1.061 1.253 1.180
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.046 2.241 2.093 2.045 2.077 2.052 1.173 1.339 1.433 1.174 1.637 1.657
2.144 2.239 2.227 2.099 2.068 2.047 3.731 1.876 3.592 2.096 3.191 4.690
2.198 2.326 2.219 2.21 2.317 2.25 10.009 6.449 7.391 5.339 8.114 8.533
2.461 2.129 2.57 2.295 2.382 2.432 31.044 13.621 28.716 21.612 22.502 31.003
2.345 2.269 2.293 2.285 2.493 2.517 32.580 20.185 27.562 23.457 31.368 32.499
2.177 2.172 2.466 2.223 2.44 2.565 23.794 13.628 29.521 22.042 27.213 32.437
2.112 2.007 2.303 2.163 2.65 2.396 23.106 12.257 26.487 22.561 32.000 32.638
2.94 1.56 2.321 1.93 2.471 2.295 76.871 64.103 69.453 65.078 73.412 72.157
1.927 1.976 0.216 1.951 2.059 1.989 1.245 1.316 10.185 1.333 0.971 1.307
1.957 2 2.032 1.954 1.951 1.987 3.475 3.500 4.134 3.275 3.895 3.322
2.057 2.08 2.134 2.197 2.22 2.234 15.459 12.115 12.090 14.474 14.324 14.056
2.308 2.36 2.335 2.448 2.376 2.279 36.568 34.407 32.206 33.007 30.556 28.082
2.122 1.995 2.068 2.307 2.541 2.404 33.459 26.767 27.369 38.405 39.906 38.353
2.16 2.013 2.377 2.311 2.467 2.385 31.852 25.832 29.617 36.434 37.049 37.484
2.086 2.059 2.15 2.074 2.389 2.396 31.352 31.569 31.628 32.208 37.003 39.566
2.763 2.405 2.735 2.536 2.325 2.421 87.441 86.902 86.289 87.224 88.000 84.924
2.031 2.174 2.205 2.173 2.096 2.05 2.166 1.840 1.723 2.117 2.099 1.659
2.159 2.226 2.241 2.256 2.156 2.152 3.983 2.516 2.945 2.837 1.948 4.368
2.286 2.312 2.309 2.354 2.352 2.357 9.624 7.353 7.016 6.967 7.313 8.910
2.494 2.373 2.598 2.791 2.76 2.594 34.563 26.127 32.794 36.259 35.362 34.464
2.504 2.273 2.353 2.547 2.772 2.456 33.706 27.893 29.834 35.728 39.105 37.785
2.386 2.352 2.242 2.684 2.77 2.587 36.127 30.357 25.781 37.556 36.823 39.041
2.419 2.32 2.455 2.352 2.608 2.384 36.792 30.172 32.831 31.718 35.813 39.010


































1 2 3 4 5 6 7 8 9 10 11 12
1.165 1.115 1.113 1.14 1.132 1.153 0.079 0.074 0.082 0.073 0.073 0.072
1.149 1.106 1.16 1.149 1.177 1.12 0.073 0.082 0.07 0.078 0.083 0.09
1.178 1.178 1.196 1.176 1.176 1.257 0.07 0.069 0.065 0.069 0.07 0.068
1.191 1.154 1.201 1.199 1.19 1.188 0.066 0.063 0.06 0.066 0.067 0.069
1.167 1.16 1.203 1.239 1.169 1.16 0.076 0.074 0.073 0.08 0.077 0.081
1.177 1.203 1.242 1.236 1.245 1.167 0.077 0.073 0.077 0.081 0.077 0.08
1.171 1.142 1.205 1.189 1.162 1.094 0.078 0.079 0.069 0.081 0.079 0.089
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.323 1.263 1.277 1.286 1.278 1.297 11.943 11.718 12.843 11.353 11.424 11.103
1.295 1.27 1.3 1.305 1.343 1.3 11.274 12.913 10.769 11.954 12.360 13.846
1.318 1.316 1.326 1.314 1.316 1.393 10.622 10.486 9.804 10.502 10.638 9.763
1.323 1.28 1.321 1.331 1.324 1.326 9.977 9.844 9.084 9.917 10.121 10.407
1.319 1.308 1.349 1.399 1.323 1.322 11.524 11.315 10.823 11.437 11.640 12.254
1.331 1.349 1.396 1.398 1.399 1.327 11.570 10.823 11.032 11.588 11.008 12.057




































1 2 3 4 5 6 7 8 9 10 11 12
1.229 1.183 1.196 1.178 1.143 1.103 0.088 0.074 0.076 0.076 0.069 0.084
1.206 1.207 1.209 1.189 1.173 1.12 0.083 0.082 0.079 0.08 0.073 0.08
1.234 1.232 1.248 1.228 1.201 1.151 0.068 0.068 0.069 0.071 0.068 0.07
1.228 1.252 1.242 1.171 1.218 1.141 0.065 0.071 0.068 0.074 0.067 0.069
1.24 1.252 1.274 1.155 1.248 1.19 0.076 0.078 0.083 0.09 0.08 0.085
1.153 1.329 1.278 1.254 1.3 1.191 0.075 0.076 0.075 0.082 0.077 0.074
1.245 1.273 1.252 1.211 1.237 1.236 0.073 0.079 0.079 0.088 0.078 0.075
0.215 0.204 0.233 0.233 0.284 0.222 0.473 0.74 0.693 0.689 0.535 0.474
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.405 1.331 1.348 1.33 1.281 1.271 12.527 11.119 11.276 11.429 10.773 13.218
1.372 1.371 1.367 1.349 1.319 1.28 12.099 11.962 11.558 11.861 11.069 12.500
1.37 1.368 1.386 1.37 1.337 1.291 9.927 9.942 9.957 10.365 10.172 10.844
1.358 1.394 1.378 1.319 1.352 1.279 9.573 10.187 9.869 11.221 9.911 10.790
1.392 1.408 1.44 1.335 1.408 1.36 10.920 11.080 11.528 13.483 11.364 12.500
1.303 1.481 1.428 1.418 1.454 1.339 11.512 10.263 10.504 11.566 10.591 11.053
1.391 1.431 1.41 1.387 1.393 1.386 10.496 11.041 11.206 12.689 11.199 10.823




















































































1 2 3 4 5 6 7 8 9 10 11 12
1.734 1.65 1.614 1.587 1.616 1.564 0.068 0.077 0.051 0.068 0.063 0.067
1.767 1.739 1.695 1.632 1.663 1.556 0.066 0.065 0.07 0.069 0.069 0.074
1.733 1.713 1.697 1.617 1.663 1.523 0.088 0.087 0.086 0.087 0.089 0.106
1.441 1.441 1.429 1.401 1.411 1.272 0.245 0.292 0.305 0.35 0.401 0.404
1.438 1.426 1.392 1.364 1.364 1.304 0.26 0.337 0.376 0.434 0.405 0.488
1.433 1.457 1.43 1.393 1.379 1.302 0.256 0.346 0.401 0.413 0.454 0.466
1.442 1.411 1.389 1.34 1.35 1.237 0.293 0.346 0.393 0.399 0.452 0.428
0.696 0.675 0.666 0.6 0.687 0.594 0.761 0.763 0.886 0.738 0.769 0.776
1.747 1.781 1.722 1.662 1.632 1.484 0.07 0.069 0.071 0.073 0.076 0.073
1.69 1.763 1.746 1.66 1.543 1.599 0.072 0.082 0.069 0.07 0.083 0.082
1.693 1.72 1.694 1.7 1.641 1.613 0.101 0.097 0.096 0.095 0.097 0.107
1.477 1.454 1.471 1.425 1.401 1.295 0.355 0.327 0.407 0.386 0.415 0.447
1.391 1.374 1.357 1.357 1.326 1.266 0.367 0.45 0.486 0.462 0.534 0.548
1.408 1.396 1.374 1.302 1.335 1.325 0.381 0.402 0.475 0.416 0.5 0.502
1.413 1.357 1.371 1.335 1.375 1.311 0.416 0.421 0.465 0.432 0.541 0.578
0.672 0.627 0.601 0.63 0.55 0.57 0.877 0.763 0.79 0.504 0.652 0.752
1.682 1.719 1.653 1.674 1.684 1.915 0.063 0.062 0.063 0.063 0.061 0.064
1.725 1.737 1.701 1.658 1.696 1.577 0.061 0.061 0.059 0.057 0.058 0.059
1.712 1.704 1.695 1.679 1.707 1.597 0.075 0.079 0.079 0.069 0.066 0.088
1.369 1.371 1.455 1.377 1.392 1.357 0.215 0.231 0.338 0.271 0.268 0.335
1.349 1.36 1.364 1.317 1.317 1.382 0.32 0.34 0.418 0.319 0.377 0.478
1.321 1.345 1.365 1.334 1.277 1.214 0.303 0.334 0.458 0.334 0.369 0.458
1.316 1.288 1.333 1.218 1.206 1.161 0.353 0.304 0.351 0.303 0.332 0.475
0.596 0.695 0.607 0.628 0.563 0.651 0.611 0.391 0.675 0.329 0.489 0.542
1.696 1.696 1.688 1.69 1.662 1.622 0.063 0.067 0.067 0.067 0.066 0.064
1.659 1.665 1.643 1.618 1.662 1.585 0.063 0.063 0.061 0.069 0.066 0.068
1.675 1.695 1.657 1.614 1.654 1.57 0.075 0.073 0.071 0.079 0.084 0.08
1.402 1.465 1.409 1.354 1.567 1.301 0.295 0.287 0.296 0.308 0.361 0.327
1.351 1.379 1.369 1.349 1.39 1.269 0.309 0.321 0.296 0.401 0.442 0.377
1.4 1.401 1.419 1.362 1.418 1.463 0.261 0.308 0.305 0.373 0.436 0.394
1.355 1.362 1.349 1.319 1.357 1.223 0.291 0.364 0.336 0.421 0.45 0.443
0.589 0.639 0.568 0.582 0.665 0.577 0.607 0.672 0.708 0.795 0.71 0.787
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.87 1.804 1.716 1.723 1.742 1.698 7.273 8.537 5.944 7.893 7.233 7.892
1.899 1.869 1.835 1.77 1.801 1.704 6.951 6.956 7.629 7.797 7.662 8.685
1.909 1.887 1.869 1.791 1.841 1.735 9.219 9.221 9.203 9.715 9.669 12.219
1.931 2.025 2.039 2.101 2.213 2.08 25.375 28.840 29.917 33.317 36.240 38.846
1.958 2.1 2.144 2.232 2.174 2.28 26.558 32.095 35.075 38.889 37.259 42.807
1.945 2.149 2.232 2.219 2.287 2.234 26.324 32.201 35.932 37.224 39.703 41.719
2.028 2.103 2.175 2.138 2.254 2.093 28.895 32.905 36.138 37.325 40.106 40.898
2.218 2.201 2.438 2.076 2.225 2.146 68.620 69.332 72.683 71.098 69.124 72.321
1.887 1.919 1.864 1.808 1.784 1.63 7.419 7.191 7.618 8.075 8.520 8.957
1.834 1.927 1.884 1.8 1.709 1.763 7.852 8.511 7.325 7.778 9.713 9.302
1.895 1.914 1.886 1.89 1.835 1.827 10.660 10.136 10.180 10.053 10.572 11.713
2.187 2.108 2.285 2.197 2.231 2.189 32.465 31.025 35.624 35.139 37.203 40.841
2.125 2.274 2.329 2.281 2.394 2.362 34.541 39.578 41.735 40.509 44.612 46.401
2.17 2.2 2.324 2.134 2.335 2.329 35.115 36.545 40.878 38.988 42.827 43.109
2.245 2.199 2.301 2.199 2.457 2.467 37.060 38.290 40.417 39.291 44.037 46.859
2.426 2.153 2.181 1.638 1.854 2.074 72.300 70.878 72.444 61.538 70.334 72.517
1.808 1.843 1.779 1.8 1.806 2.043 6.969 6.728 7.083 7.000 6.755 6.265
1.847 1.859 1.819 1.772 1.812 1.695 6.605 6.563 6.487 6.433 6.402 6.962
1.862 1.862 1.853 1.817 1.839 1.773 8.056 8.485 8.527 7.595 7.178 9.927
1.799 1.833 2.131 1.919 1.928 2.027 23.902 25.205 31.722 28.244 27.801 33.054
1.989 2.04 2.2 1.955 2.071 2.338 32.177 33.333 38.000 32.634 36.408 40.890
1.927 2.013 2.281 2.002 2.015 2.13 31.448 33.184 40.158 33.367 36.625 43.005
2.022 1.896 2.035 1.824 1.87 2.111 34.916 32.068 34.496 33.224 35.508 45.002
1.818 1.477 1.957 1.286 1.541 1.735 67.217 52.945 68.983 51.166 63.465 62.478
1.822 1.83 1.822 1.824 1.794 1.75 6.915 7.322 7.355 7.346 7.358 7.314
1.785 1.791 1.765 1.756 1.794 1.721 7.059 7.035 6.912 7.859 7.358 7.902
1.825 1.841 1.799 1.772 1.822 1.73 8.219 7.930 7.893 8.916 9.221 9.249
1.992 2.039 2.001 1.97 2.289 1.955 29.618 28.151 29.585 31.269 31.542 33.453
1.969 2.021 1.961 2.151 2.274 2.023 31.386 31.766 30.189 37.285 38.874 37.271
1.922 2.017 2.029 2.108 2.29 2.251 27.159 30.540 30.064 35.389 38.079 35.007
1.937 2.09 2.021 2.161 2.257 2.109 30.046 34.833 33.251 38.963 39.876 42.010










Horse / Horse! ! 100%
Horse / Human! ! 56%
Horse / Mouse! ! 49% ! Mouse/Horse!  21%
Horse / Rat! ! 52%
Horse / Dog! ! 66%
FceRIa Identity:
Horse / Horse! ! 100%
Horse / Human! ! 63%!! Human/Dog! 53%
Horse / Mouse! ! 45%
Horse / Rat! ! 43%
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Comparison of Peak Release Between Different IgE Types Bound To Parental 






























RBL-Parent Cells Bound With Human IgE
RBL-pEE6 Cells Bound With Human IgE
RBL-Parent Cells Bound With Mouse IgE
RBL-pEE6 Cells Bound With Mouse IgE
RBL-Parent Cells Bound With Dog IgE
RBL-pEE6 Cells Bound With Dog IgE
RBL-Parent Cells Bound With Horse IgE
RBL-pEE6 Cells Bound With Horse IgE
Antigen Concentration of 100 (ng ml-1)  Figure : Summary graph of Figure 2 ’s peak
  release at 1 ng ml-1 of antigen    144
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x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.793 1.988 2.019 2.038 2.015 2.06 11.824 10.664 10.104 9.617 9.628 11.165
1.789 1.966 2.011 2.028 2.028 2.09 11.738 9.461 9.448 10.059 10.651 10.622
2.011 2.086 2.111 2.157 2.144 2.19 15.017 13.231 13.169 13.908 14.272 15.708
2.039 2.087 2.224 2.382 2.361 2.331 25.895 17.537 20.863 22.838 24.989 23.681
2.061 2.142 2.445 2.836 2.911 2.754 44.153 33.613 37.301 45.628 46.994 46.841
2.228 2.117 2.511 2.667 2.731 2.74 46.499 39.490 43.090 46.944 51.263 50.073
2.234 2.053 2.2 2.261 2.262 2.388 46.285 39.454 37.182 39.275 39.788 44.137




















































1 2 3 4 5 6 7 8 9 10 11 12
2.565 2.893 2.495 1.992 2.228 1.839 0.068 0.073 0.072 0.073 0.068 0.074
2.471 2.602 2.565 2.068 1.893 1.731 0.115 0.098 0.092 0.094 0.11 0.118
1.726 1.749 1.698 1.67 1.671 1.531 0.395 0.338 0.381 0.464 0.524 0.472
1.881 1.461 1.463 1.399 1.307 1.254 0.587 0.447 0.591 0.771 0.875 0.765
1.502 1.509 1.434 1.35 1.353 1.185 0.693 0.488 0.61 0.822 0.952 0.657
1.484 1.56 1.472 1.428 1.418 1.204 0.623 0.542 0.713 0.791 0.837 0.607
1.982 1.479 1.393 1.369 1.4 1.219 0.642 0.52 0.707 0.786 0.896 0.706
1.312 0.751 0.753 0.781 0.823 0.807 1.024 1.062 0.938 0.986 0.922 0.843
1.632 1.713 1.812 1.764 1.698 1.654 0.096 0.094 0.096 0.105 0.095 0.111
1.684 1.8 1.835 1.756 1.738 1.724 0.102 0.1 0.097 0.103 0.102 0.107
1.661 1.693 1.776 1.776 1.779 1.74 0.179 0.174 0.164 0.17 0.185 0.227
1.272 1.471 1.521 1.538 1.546 1.481 0.319 0.265 0.332 0.439 0.447 0.47
1.271 1.399 1.477 1.451 1.473 1.396 0.368 0.307 0.321 0.465 0.534 0.552
1.183 1.43 1.506 1.444 1.543 1.426 0.32 0.313 0.337 0.344 0.475 0.531
1.132 1.376 1.443 1.42 1.443 1.398 0.352 0.334 0.374 0.365 0.398 0.544
0.548 0.748 0.838 0.78 0.896 0.799 0.651 0.75 0.919 0.875 0.867 0.858
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.701 3.039 2.639 2.138 2.364 1.987 5.035 4.804 5.457 6.829 5.753 7.448
2.701 2.798 2.749 2.256 2.113 1.967 8.515 7.005 6.693 8.333 10.412 11.998
2.516 2.425 2.46 2.598 2.719 2.475 31.399 27.876 30.976 35.720 38.544 38.141
3.055 2.355 2.645 2.941 3.057 2.784 38.429 37.962 44.688 52.431 57.246 54.957
2.888 2.485 2.654 2.994 3.257 2.499 47.992 39.276 45.968 54.910 58.459 52.581
2.73 2.644 2.898 3.01 3.092 2.418 45.641 40.998 49.206 52.558 54.140 50.207
3.266 2.519 2.807 2.941 3.192 2.631 39.314 41.286 50.374 53.451 56.140 53.668
3.36 2.875 2.629 2.753 2.667 2.493 60.952 73.878 71.358 71.631 69.141 67.629
1.824 1.901 2.004 1.974 1.888 1.876 10.526 9.890 9.581 10.638 10.064 11.834
1.888 2 2.029 1.962 1.942 1.938 10.805 10.000 9.561 10.499 10.505 11.042
2.019 2.041 2.104 2.116 2.149 2.194 17.732 17.050 15.589 16.068 17.217 20.693
1.91 2.001 2.185 2.416 2.44 2.421 33.403 26.487 30.389 36.341 36.639 38.827
2.007 2.013 2.119 2.381 2.541 2.5 36.672 30.502 30.297 39.059 42.031 44.160
1.823 2.056 2.18 2.132 2.493 2.488 35.107 30.447 30.917 32.270 38.107 42.685
1.836 2.044 2.191 2.15 2.239 2.486 38.344 32.681 34.140 33.953 35.552 43.765




































































1 2 3 4 5 6 7 8 9 10 11 12
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1.693 1.807 1.804 1.812 1.809 1.833 0.091 0.091 0.088 0.085 0.087 0.078
1.744 1.779 1.801 1.744 1.772 1.789 0.091 0.096 0.096 0.09 0.091 0.085
1.707 1.793 1.803 1.774 1.793 1.783 0.111 0.124 0.121 0.12 0.123 0.112
1.721 1.719 1.737 1.752 1.796 1.747 0.094 0.086 0.092 0.091 0.087 0.08
1.695 1.762 1.772 1.774 1.796 1.801 0.097 0.095 0.093 0.094 0.092 0.087
1.677 1.636 1.713 1.737 1.695 1.728 0.105 0.105 0.107 0.119 0.116 0.126
1.739 1.746 1.777 1.795 1.756 1.786 0.093 0.091 0.092 0.094 0.091 0.085
0.753 0.826 0.842 0.808 0.814 0.781 0.748 0.774 0.804 0.715 0.603 0.791
1.631 1.553 1.46 1.58 1.674 1.838 0.086 0.094 0.084 0.085 0.084 0.086
1.485 1.651 1.623 1.738 1.74 1.848 0.086 0.089 0.088 0.088 0.089 0.089
1.609 1.57 1.609 1.736 1.772 1.774 0.104 0.118 0.106 0.108 0.113 0.124
1.557 1.654 1.725 1.843 1.727 1.756 0.083 0.081 0.082 0.086 0.086 0.084
1.578 1.673 1.68 1.626 1.645 1.657 0.145 0.137 0.149 0.155 0.172 0.189
1.654 1.595 1.603 1.603 1.625 1.629 0.137 0.129 0.137 0.141 0.152 0.159
1.684 1.696 1.605 1.698 1.716 1.718 0.091 0.093 0.094 0.092 0.092 0.089
0.816 0.707 0.857 0.844 0.748 0.865 0.746 0.639 0.695 0.694 0.733 0.805
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.193 2.256 2.241 2.228 2.238 2.184 8.208 9.043 8.568 8.438 8.490 8.425
2.268 2.28 2.197 2.252 2.232 2.23 7.760 8.246 8.375 8.171 8.333 8.700
2.332 2.295 2.257 2.342 2.29 2.319 11.664 11.678 11.786 12.212 12.751 14.661
2.39 2.314 2.32 2.346 2.326 2.368 17.322 14.088 15.690 18.414 17.713 20.439
2.322 2.229 2.34 2.263 2.322 2.347 17.313 14.177 15.641 16.350 17.916 19.344
2.231 2.22 2.248 2.231 2.176 2.214 11.833 11.081 12.633 12.371 12.868 14.815
2.228 2.222 2.205 2.178 2.188 2.131 8.348 8.281 8.345 8.448 8.501 8.259
2.59 2.732 2.808 2.619 2.713 2.469 67.645 67.204 67.949 67.736 68.264 67.396
1.875 1.989 1.98 1.982 1.983 1.989 9.707 9.150 8.889 8.577 8.775 7.843
1.926 1.971 1.993 1.924 1.954 1.959 9.450 9.741 9.634 9.356 9.314 8.678
1.929 2.041 2.045 2.014 2.039 2.007 11.509 12.151 11.834 11.917 12.065 11.161
1.909 1.891 1.921 1.934 1.97 1.907 9.848 9.096 9.578 9.411 8.832 8.390
1.889 1.952 1.958 1.962 1.98 1.975 10.270 9.734 9.499 9.582 9.293 8.810
1.887 1.846 1.927 1.975 1.927 1.98 11.129 11.376 11.105 12.051 12.039 12.727
1.925 1.928 1.961 1.983 1.938 1.956 9.662 9.440 9.383 9.481 9.391 8.691
2.249 2.374 2.45 2.238 2.02 2.363 66.518 65.206 65.633 63.896 59.703 66.949
1.803 1.741 1.628 1.75 1.842 2.01 9.540 10.798 10.319 9.714 9.121 8.557
1.657 1.829 1.799 1.914 1.918 2.026 10.380 9.732 9.783 9.195 9.281 8.786
1.817 1.806 1.821 1.952 1.998 2.022 11.447 13.068 11.642 11.066 11.311 12.265
1.723 1.816 1.889 2.015 1.899 1.924 9.634 8.921 8.682 8.536 9.057 8.732
1.868 1.947 1.978 1.936 1.989 2.035 15.525 14.073 15.066 16.012 17.295 18.575
1.928 1.853 1.877 1.885 1.929 1.947 14.212 13.923 14.598 14.960 15.759 16.333
1.866 1.882 1.793 1.882 1.9 1.896 9.753 9.883 10.485 9.777 9.684 9.388
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1.679 1.733 1.74 1.805 1.754 1.747 0.096 0.094 0.1 0.094 0.089 0.091
1.746 1.822 1.769 1.833 1.807 1.728 0.091 0.094 0.097 0.093 0.097 0.097
1.681 1.796 1.758 1.728 1.714 1.651 0.106 0.117 0.117 0.115 0.12 0.114
1.621 1.788 1.777 1.724 1.716 1.688 0.096 0.083 0.089 0.09 0.082 0.084
1.706 1.776 1.756 1.739 1.761 1.688 0.095 0.094 0.095 0.099 0.1 0.09
1.605 1.616 1.668 1.687 1.685 1.632 0.166 0.143 0.14 0.16 0.182 0.176
1.645 1.706 1.739 1.726 1.739 1.635 0.164 0.151 0.162 0.16 0.177 0.176
0.697 0.763 0.759 0.83 0.871 0.6 0.784 0.78 0.814 0.886 0.858 0.8
1.843 1.921 1.873 1.932 1.896 1.812 0.084 0.084 0.084 0.082 0.084 0.092
1.834 1.837 1.823 1.823 1.795 1.733 0.09 0.099 0.094 0.087 0.096 0.097
1.831 1.872 1.805 1.825 1.783 1.723 0.107 0.124 0.115 0.109 0.119 0.12
1.797 1.778 1.772 1.796 1.765 1.696 0.087 0.084 0.084 0.083 0.086 0.088
1.77 1.722 1.712 1.697 1.703 1.667 0.141 0.118 0.117 0.116 0.13 0.134
1.683 1.62 1.641 1.649 1.662 1.588 0.199 0.18 0.175 0.172 0.199 0.236
1.773 1.664 1.739 1.694 1.745 1.694 0.173 0.154 0.157 0.149 0.156 0.189
0.792 0.814 0.821 0.762 0.836 0.605 0.801 0.735 0.737 0.668 0.641 0.941
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.091 1.963 1.923 2.02 2.065 2.031 8.800 9.068 9.152 9.010 8.814 8.567
2.073 1.969 1.91 2.053 2.058 2.046 8.683 9.243 9.424 9.255 9.038 8.602
2.131 2.008 2.094 2.16 2.21 2.279 10.230 12.251 11.175 11.111 11.131 11.057
2.116 1.998 2.023 2.025 2.154 2.194 12.665 13.113 13.347 12.247 12.535 12.306
2.197 2.198 2.131 2.225 2.355 2.295 19.208 22.020 21.586 22.831 22.166 22.309
2.262 2.266 2.153 2.314 2.39 2.336 21.574 23.124 19.415 20.311 23.264 22.945
2.222 2.208 2.15 2.241 2.162 2.14 18.812 18.569 16.744 17.492 18.316 19.533
2.349 2.317 2.425 2.354 2.372 2.253 70.924 71.644 69.031 66.525 68.212 67.466
1.871 1.921 1.94 1.993 1.932 1.929 10.262 9.787 10.309 9.433 9.213 9.435
1.928 2.01 1.963 2.019 2.001 1.922 9.440 9.353 9.883 9.212 9.695 10.094
1.893 2.03 1.992 1.958 1.954 1.879 11.199 11.527 11.747 11.747 12.282 12.134
1.813 1.954 1.955 1.904 1.88 1.856 10.590 8.495 9.105 9.454 8.723 9.052
1.896 1.964 1.946 1.937 1.961 1.868 10.021 9.572 9.764 10.222 10.199 9.636
1.937 1.902 1.948 2.007 2.049 1.984 17.140 15.037 14.374 15.944 17.765 17.742
1.973 2.008 2.063 2.046 2.093 1.987 16.624 15.040 15.705 15.640 16.914 17.715
2.265 2.323 2.387 2.602 2.587 2.2 69.227 67.155 68.203 68.101 66.332 72.727
2.011 2.089 2.041 2.096 2.064 1.996 8.354 8.042 8.231 7.824 8.140 9.218
2.014 2.035 2.011 1.997 1.987 1.927 8.937 9.730 9.349 8.713 9.663 10.067
2.045 2.12 2.035 2.043 2.021 1.963 10.465 11.698 11.302 10.671 11.776 12.226
1.971 1.946 1.94 1.962 1.937 1.872 8.828 8.633 8.660 8.461 8.880 9.402
2.052 1.958 1.946 1.929 1.963 1.935 13.743 12.053 12.025 12.027 13.245 13.850
2.081 1.98 1.991 1.993 2.06 2.06 19.125 18.182 17.579 17.260 19.320 22.913
2.119 1.972 2.053 1.992 2.057 2.072 16.328 15.619 15.295 14.960 15.168 18.243
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1.712 1.839 1.818 1.868 1.818 1.79 0.097 0.086 0.086 0.086 0.088 0.086
1.959 1.86 1.827 1.883 1.904 1.807 0.091 0.09 0.09 0.087 0.091 0.093
1.932 1.887 1.887 1.863 1.833 1.798 0.107 0.113 0.11 0.107 0.117 0.122
1.816 1.809 1.809 1.832 1.814 1.76 0.089 0.082 0.087 0.089 0.093 0.079
1.666 1.747 1.715 1.738 1.728 1.709 0.173 0.136 0.142 0.164 0.186 0.162
1.662 1.711 1.702 1.783 1.746 1.7 0.164 0.137 0.134 0.141 0.164 0.16
1.703 1.795 1.731 1.79 1.812 1.8 0.099 0.094 0.091 0.095 0.092 0.086
0.807 0.88 0.964 0.933 0.978 0.919 0.718 0.807 0.693 0.775 0.729 0.713
1.793 1.854 1.818 1.781 1.854 1.783 0.093 0.098 0.088 0.096 0.086 0.099
1.839 1.86 1.84 1.821 1.86 1.805 0.089 0.097 0.098 0.091 0.093 0.095
1.771 1.783 1.746 1.842 1.853 1.75 0.109 0.127 0.121 0.116 0.125 0.133
1.874 1.879 1.849 1.865 1.862 1.798 0.085 0.081 0.085 0.085 0.081 0.09
1.881 1.863 1.843 1.81 1.857 1.81 0.096 0.091 0.089 0.089 0.09 0.096
1.801 1.794 1.777 1.803 1.803 1.745 0.112 0.113 0.114 0.111 0.127 0.124
1.807 1.841 1.776 1.783 1.788 1.742 0.097 0.097 0.099 0.092 0.094 0.1
0.743 0.8 0.822 0.824 0.824 0.716 0.846 0.782 0.789 0.673 0.707 0.79
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.136 2.208 2.187 2.225 2.196 2.216 9.551 9.420 9.145 8.899 8.925 8.935
2.272 2.308 2.293 2.265 2.274 2.268 8.627 8.406 8.548 8.124 8.004 7.760
2.298 2.302 2.307 2.32 2.285 2.322 10.531 10.686 10.230 10.345 10.241 11.025
2.289 2.296 2.315 2.362 2.349 2.368 15.378 12.631 13.650 15.411 15.241 17.399
2.377 2.341 2.368 2.373 2.392 2.363 16.912 12.815 14.611 15.929 16.304 17.435
2.225 2.229 2.245 2.199 2.246 2.232 12.135 10.857 10.512 11.824 12.110 13.530
2.186 2.21 2.212 2.179 2.24 2.175 8.783 8.688 8.409 9.913 8.214 8.460
2.813 2.957 3.116 3.09 2.924 2.881 68.539 70.071 69.769 66.731 65.253 70.045
1.906 2.011 1.99 2.04 1.994 1.962 10.178 8.553 8.643 8.431 8.826 8.767
2.141 2.04 2.007 2.057 2.086 1.993 8.501 8.824 8.969 8.459 8.725 9.333
2.146 2.113 2.107 2.077 2.067 2.042 9.972 10.696 10.441 10.303 11.321 11.949
1.994 1.973 1.983 2.01 2 1.918 8.927 8.312 8.775 8.856 9.300 8.238
2.012 2.019 1.999 2.066 2.1 2.033 17.197 13.472 14.207 15.876 17.714 15.937
1.99 1.985 1.97 2.065 2.074 2.02 16.482 13.804 13.604 13.656 15.815 15.842
1.901 1.983 1.913 1.98 1.996 1.972 10.416 9.481 9.514 9.596 9.218 8.722
2.243 2.494 2.35 2.483 2.436 2.345 64.021 64.715 58.979 62.424 59.852 60.810
1.979 2.05 1.994 1.973 2.026 1.981 9.399 9.561 8.826 9.731 8.490 9.995
2.017 2.054 2.036 2.003 2.046 1.995 8.825 9.445 9.627 9.086 9.091 9.524
1.989 2.037 1.988 2.074 2.103 2.016 10.960 12.469 12.173 11.186 11.888 13.194
2.044 2.041 2.019 2.035 2.024 1.978 8.317 7.937 8.420 8.354 8.004 9.100
2.073 2.045 2.021 1.988 2.037 2.002 9.262 8.900 8.808 8.954 8.837 9.590
2.025 2.02 2.005 2.025 2.057 1.993 11.062 11.188 11.372 10.963 12.348 12.444
2.001 2.035 1.974 1.967 1.976 1.942 9.695 9.533 10.030 9.354 9.514 10.299
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1.404 1.344 1.369 1.618 1.657 1.762 0.066 0.093 0.091 0.091 0.09 0.081
1.373 1.558 1.645 1.643 1.716 1.886 0.091 0.093 0.094 0.093 0.094 0.09
1.495 1.517 1.623 1.784 1.766 1.834 0.106 0.114 0.115 0.112 0.119 0.109
1.612 1.556 1.613 1.752 1.67 1.792 0.086 0.084 0.089 0.085 0.084 0.079
1.617 1.506 1.525 1.591 1.739 1.72 0.096 0.094 0.097 0.092 0.096 0.089
1.323 1.412 1.445 1.6 1.676 1.579 0.191 0.169 0.195 0.248 0.276 0.293
1.28 1.384 1.369 1.526 1.542 1.477 0.251 0.224 0.236 0.275 0.29 0.328
0.502 0.601 0.619 0.791 0.793 0.637 0.67 0.682 0.776 0.838 0.845 0.68
1.959 1.983 1.967 1.963 1.932 1.987 0.095 0.09 0.087 0.089 0.085 0.082
1.979 1.942 1.893 1.889 1.883 1.917 0.092 0.089 0.098 0.097 0.097 0.091
1.931 1.893 1.896 1.902 1.864 1.896 0.112 0.125 0.121 0.123 0.129 0.116
1.951 1.919 1.891 1.863 1.863 1.88 0.089 0.087 0.093 0.092 0.089 0.086
1.875 1.881 1.851 1.833 1.848 1.842 0.138 0.128 0.13 0.137 0.134 0.151
1.742 1.711 1.687 1.657 1.652 1.66 0.29 0.272 0.279 0.343 0.387 0.458
1.753 1.733 1.725 1.676 1.686 1.691 0.288 0.26 0.254 0.257 0.299 0.33
0.827 0.912 0.915 0.887 0.927 0.932 0.787 0.742 0.77 0.819 0.779 0.696
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.089 2.129 2.155 2.145 2.086 2.171 8.712 8.549 8.538 7.925 8.437 9.028
2.231 2.145 2.216 2.211 2.145 2.183 8.068 8.671 8.755 7.689 8.858 9.162
2.29 2.262 2.239 2.292 2.219 2.17 9.607 10.787 10.094 10.122 10.816 12.350
2.24 2.149 2.197 2.082 2.211 2.249 13.839 12.192 12.563 12.680 12.302 13.339
2.428 2.304 2.369 2.386 2.392 2.36 28.995 24.826 26.593 27.661 27.090 29.576
2.402 2.27 2.399 2.427 2.276 2.435 30.142 26.256 26.011 27.029 25.747 31.622
2.324 2.28 2.367 2.517 2.405 2.401 28.657 26.140 25.687 29.082 29.854 29.321
2.828 2.688 2.17 2.898 2.68 2.101 76.591 72.545 69.217 75.086 74.104 72.156
1.536 1.53 1.551 1.8 1.837 1.924 8.594 12.157 11.734 10.111 9.799 8.420
1.555 1.744 1.833 1.829 1.904 2.066 11.704 10.665 10.256 10.169 9.874 8.712
1.707 1.745 1.853 2.008 2.004 2.052 12.419 13.066 12.412 11.155 11.876 10.624
1.784 1.724 1.791 1.922 1.838 1.95 9.641 9.745 9.939 8.845 9.140 8.103
1.809 1.694 1.719 1.775 1.931 1.898 10.614 11.098 11.286 10.366 9.943 9.378
1.705 1.75 1.835 2.096 2.228 2.165 22.405 19.314 21.253 23.664 24.776 27.067
1.782 1.832 1.841 2.076 2.122 2.133 28.171 24.454 25.638 26.493 27.333 30.755
1.842 1.965 2.171 2.467 2.483 1.997 72.747 69.415 71.488 67.937 68.063 68.102
2.149 2.163 2.141 2.141 2.102 2.151 8.841 8.322 8.127 8.314 8.088 7.624
2.163 2.12 2.089 2.083 2.077 2.099 8.507 8.396 9.382 9.313 9.340 8.671
2.155 2.143 2.138 2.148 2.122 2.128 10.394 11.666 11.319 11.453 12.158 10.902
2.129 2.093 2.077 2.047 2.041 2.052 8.361 8.313 8.955 8.989 8.721 8.382
2.151 2.137 2.111 2.107 2.116 2.144 12.831 11.979 12.316 13.004 12.665 14.086
2.322 2.255 2.245 2.343 2.426 2.576 24.978 24.124 24.855 29.279 31.904 35.559
2.329 2.253 2.233 2.19 2.284 2.351 24.732 23.080 22.750 23.470 26.182 28.073
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1.975 1.928 1.909 1.866 1.922 1.951 0.093 0.095 0.095 0.098 0.095 0.091
2.002 1.898 1.867 1.846 1.924 1.941 0.098 0.098 0.098 0.094 0.101 0.094
1.985 1.893 1.884 1.804 1.939 1.909 0.114 0.128 0.114 0.121 0.122 0.123
2.008 1.907 1.834 1.805 1.892 1.898 0.094 0.09 0.095 0.092 0.089 0.092
1.941 1.882 1.832 1.835 1.841 1.85 0.1 0.096 0.1 0.097 0.097 0.099
1.854 1.798 1.762 1.733 1.819 1.845 0.17 0.136 0.143 0.162 0.175 0.189
1.943 1.894 1.865 1.85 1.883 1.837 0.109 0.107 0.104 0.104 0.104 0.099
0.691 0.774 0.744 0.72 0.886 0.816 0.982 0.974 0.84 0.883 0.812 0.825
1.939 1.983 2.009 2.022 2.022 1.959 0.1 0.099 0.097 0.099 0.096 0.102
1.996 1.945 1.971 1.983 1.975 1.963 0.099 0.106 0.104 0.101 0.102 0.106
1.978 1.967 1.952 2.009 1.996 1.959 0.117 0.131 0.127 0.141 0.158 0.139
1.994 1.976 1.969 1.982 1.968 1.994 0.093 0.093 0.099 0.119 0.104 0.124
1.979 1.991 1.971 1.959 1.975 1.928 0.099 0.105 0.103 0.102 0.098 0.1
1.947 1.947 1.928 1.947 1.953 1.914 0.104 0.107 0.107 0.111 0.106 0.121
1.93 1.986 1.964 1.958 1.997 1.975 0.099 0.105 0.102 0.099 0.099 0.097
1.061 1.05 1.036 0.987 1.06 0.879 0.583 0.807 0.715 0.728 0.785 0.757
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.357 2.395 2.372 2.353 2.35 2.275 8.061 8.685 8.347 7.905 8.000 7.824
2.421 2.393 2.351 2.406 2.387 2.346 7.931 8.023 8.337 8.229 8.379 8.440
2.404 2.389 2.405 2.391 2.382 2.385 9.068 10.046 10.146 10.038 10.579 10.901
2.349 2.354 2.357 2.345 2.393 2.387 8.174 8.071 9.334 9.296 9.779 10.892
2.458 2.425 2.541 2.555 2.609 2.792 16.355 14.433 19.677 20.587 22.077 27.650
2.395 2.35 2.478 2.449 2.477 2.621 13.946 12.596 17.433 17.068 18.329 25.868
2.373 2.359 2.332 2.318 2.3 2.29 9.440 8.648 8.748 8.887 8.609 8.646
2.69 2.837 3.024 2.808 2.873 2.862 57.546 59.076 59.392 60.684 62.026 64.780
2.161 2.118 2.099 2.062 2.112 2.133 8.607 8.971 9.052 9.505 8.996 8.533
2.198 2.094 2.063 2.034 2.126 2.129 8.917 9.360 9.501 9.243 9.501 8.830
2.213 2.149 2.112 2.046 2.183 2.155 10.303 11.913 10.795 11.828 11.177 11.415
2.196 2.087 2.024 1.989 2.07 2.082 8.561 8.625 9.387 9.251 8.599 8.838
2.141 2.074 2.032 2.029 2.035 2.048 9.341 9.257 9.843 9.561 9.533 9.668
2.194 2.07 2.048 2.057 2.169 2.223 15.497 13.140 13.965 15.751 16.136 17.004
2.161 2.108 2.073 2.058 2.091 2.035 10.088 10.152 10.034 10.107 9.947 9.730
2.655 2.722 2.424 2.486 2.51 2.466 73.974 71.565 69.307 71.038 64.701 66.910
2.139 2.181 2.203 2.22 2.214 2.163 9.350 9.078 8.806 8.919 8.672 9.431
2.194 2.157 2.179 2.185 2.179 2.175 9.025 9.828 9.546 9.245 9.362 9.747
2.212 2.229 2.206 2.291 2.312 2.237 10.579 11.754 11.514 12.309 13.668 12.427
2.18 2.162 2.167 2.22 2.176 2.242 8.532 8.603 9.137 10.721 9.559 11.062
2.177 2.201 2.177 2.163 2.171 2.128 9.095 9.541 9.463 9.431 9.028 9.398
2.155 2.161 2.142 2.169 2.165 2.156 9.652 9.903 9.991 10.235 9.792 11.224
2.128 2.196 2.168 2.156 2.195 2.169 9.305 9.563 9.410 9.184 9.021 8.944
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1.74 1.947 1.951 2.029 2.004 1.983 0.087 0.085 0.09 0.086 0.084 0.089
1.959 1.928 1.974 1.975 1.924 1.891 0.091 0.091 0.096 0.092 0.096 0.1
2.01 1.936 1.913 1.967 1.896 1.806 0.107 0.115 0.113 0.115 0.113 0.114
1.822 1.751 1.891 1.961 1.842 1.853 0.083 0.082 0.087 0.087 0.09 0.091
1.811 1.876 1.861 1.83 1.855 1.822 0.115 0.087 0.09 0.085 0.093 0.091
1.755 1.659 1.697 1.706 1.777 1.781 0.19 0.155 0.16 0.188 0.204 0.186
1.462 1.563 1.622 1.515 1.468 1.434 0.382 0.364 0.395 0.38 0.399 0.445
0.813 0.829 0.855 0.92 0.867 0.739 0.721 0.916 0.794 0.78 0.823 0.831
2.092 2.066 1.979 2.004 2.086 2.076 0.09 0.092 0.089 0.09 0.088 0.087
2.068 2.003 1.975 2.005 2.036 2.022 0.091 0.099 0.097 0.098 0.098 0.098
2.076 1.945 1.959 1.928 2.035 2.009 0.11 0.127 0.118 0.119 0.123 0.123
2.001 1.951 1.915 1.941 1.993 1.985 0.093 0.089 0.093 0.1 0.095 0.088
1.987 1.958 1.947 1.93 1.988 1.967 0.108 0.1 0.098 0.104 0.11 0.101
1.74 1.751 1.655 1.72 1.757 1.725 0.327 0.277 0.332 0.415 0.448 0.482
1.757 1.729 1.693 1.705 1.717 1.705 0.339 0.282 0.35 0.408 0.457 0.512
0.864 1.018 1.043 0.934 1.008 0.828 0.844 0.731 0.738 0.801 0.814 0.788
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.275 2.419 2.355 2.333 2.361 2.325 7.912 7.524 8.238 8.144 7.370 7.312
2.384 2.398 2.37 2.325 2.387 2.368 7.970 7.923 8.270 8.172 8.379 7.939
2.377 2.465 2.42 2.43 2.395 2.388 9.340 10.142 10.165 10.041 10.689 10.637
2.349 2.367 2.327 2.234 2.349 2.346 8.855 7.943 9.024 9.042 9.025 8.781
2.543 2.442 2.47 2.484 2.6 2.691 23.751 17.199 19.595 22.383 25.615 27.573
2.647 2.415 2.465 2.723 2.875 3.024 35.965 28.157 28.722 37.606 40.487 45.833
2.67 2.53 2.428 2.513 2.873 3.045 34.906 29.960 27.924 32.312 39.749 44.138
2.715 3.045 3.052 2.922 3.077 3.001 67.035 71.593 64.155 65.092 65.258 64.445
1.914 2.117 2.131 2.201 2.172 2.161 9.091 8.030 8.447 7.815 7.735 8.237
2.141 2.11 2.166 2.159 2.116 2.091 8.501 8.626 8.864 8.522 9.074 9.565
2.224 2.166 2.139 2.197 2.122 2.034 9.622 10.619 10.566 10.469 10.650 11.209
1.988 1.915 2.065 2.135 2.022 2.035 8.350 8.564 8.426 8.150 8.902 8.943
2.041 2.05 2.041 2 2.041 2.004 11.269 8.488 8.819 8.500 9.113 9.082
2.135 1.969 2.017 2.082 2.185 2.153 17.799 15.744 15.865 18.060 18.673 17.278
2.226 2.291 2.412 2.275 2.266 2.324 34.322 31.777 32.753 33.407 35.216 38.296
2.255 2.661 2.443 2.48 2.513 2.401 63.947 68.846 65.002 62.903 65.499 69.221
2.272 2.25 2.157 2.184 2.262 2.25 7.923 8.178 8.252 8.242 7.781 7.733
2.25 2.201 2.169 2.201 2.232 2.218 8.089 8.996 8.944 8.905 8.781 8.837
2.296 2.199 2.195 2.166 2.281 2.255 9.582 11.551 10.752 10.988 10.785 10.909
2.187 2.129 2.101 2.141 2.183 2.161 8.505 8.361 8.853 9.341 8.704 8.144
2.203 2.158 2.143 2.138 2.208 2.169 9.805 9.268 9.146 9.729 9.964 9.313
2.394 2.305 2.319 2.55 2.653 2.689 27.318 24.035 28.633 32.549 33.773 35.850
2.435 2.293 2.393 2.521 2.631 2.729 27.844 24.597 29.252 32.368 34.740 37.523





































































1 2 3 4 5 6 7 8 9 10 11 12
1.611 1.764 1.799 1.83 1.823 1.793 0.093 0.088 0.086 0.089 0.09 0.085
1.492 1.829 1.824 1.854 1.829 1.842 0.09 0.091 0.09 0.089 0.093 0.086
1.506 1.836 1.831 1.85 1.856 1.853 0.107 0.117 0.113 0.114 0.122 0.114
1.397 1.762 1.769 1.806 1.84 1.807 0.081 0.077 0.083 0.083 0.081 0.08
1.353 1.719 1.696 1.734 1.762 1.721 0.12 0.124 0.133 0.178 0.195 0.2
1.261 1.668 1.712 1.752 1.793 1.657 0.104 0.115 0.112 0.134 0.145 0.152
1.356 1.679 1.774 1.83 1.832 1.833 0.092 0.089 0.088 0.087 0.085 0.083
0.626 0.954 0.921 0.961 1.009 0.943 0.568 0.606 0.682 0.791 0.837 0.778
1.234 1.433 1.505 1.564 1.529 1.499 0.095 0.092 0.088 0.091 0.087 0.085
1.345 1.53 1.578 1.561 1.565 1.527 0.094 0.098 0.093 0.091 0.095 0.089
1.357 1.445 1.566 1.552 1.552 1.501 0.111 0.122 0.119 0.12 0.122 0.116
1.499 1.472 1.546 1.532 1.564 1.533 0.092 0.087 0.09 0.091 0.087 0.087
1.135 1.363 1.461 1.447 1.448 1.433 0.114 0.109 0.135 0.133 0.133 0.138
1.067 1.399 1.447 1.431 1.487 1.393 0.122 0.13 0.15 0.154 0.16 0.17
1.29 1.424 1.534 1.413 1.534 1.529 0.097 0.097 0.101 0.106 0.096 0.093
0.548 0.703 0.669 0.699 0.68 0.635 0.566 0.694 0.659 0.702 0.704 0.643
2.682 2.205 2.143 2.162 2.152 2.11 0.07 0.074 0.07 0.071 0.074 0.075
2.686 2.192 2.132 2.179 2.069 2.034 0.071 0.072 0.078 0.081 0.09 0.088
2.11 2.535 2.152 2.173 2.03 2.022 0.065 0.066 0.065 0.071 0.07 0.075
2.137 2.25 2.157 2.14 2.053 2.077 0.066 0.064 0.068 0.076 0.083 0.077
2.112 2.62 2.152 2.148 2.051 2.047 0.073 0.077 0.079 0.087 0.095 0.099
2.24 2.355 2.226 2.266 2.13 2.186 0.07 0.072 0.075 0.078 0.084 0.088
2.25 2.232 2.152 2.194 2.097 2.045 0.07 0.074 0.077 0.078 0.079 0.091
0.973 1.016 0.894 0.918 0.834 1.043 0.539 0.996 1.171 1.164 1.134 1.249
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.797 1.94 1.971 2.008 2.003 1.963 10.351 9.072 8.727 8.865 8.987 8.660
1.672 2.011 2.004 2.032 2.015 2.014 10.766 9.050 8.982 8.760 9.231 8.540
1.72 2.07 2.057 2.078 2.1 2.081 12.442 11.304 10.987 10.972 11.619 10.956
1.559 1.916 1.935 1.972 2.002 1.967 10.391 8.038 8.579 8.418 8.092 8.134
1.593 1.967 1.962 2.09 2.152 2.121 15.066 12.608 13.558 17.033 18.123 18.859
1.469 1.898 1.936 2.02 2.083 1.961 14.159 12.118 11.570 13.267 13.922 15.502
1.54 1.857 1.95 2.004 2.002 1.999 11.948 9.585 9.026 8.683 8.492 8.304
1.762 2.166 2.285 2.543 2.683 2.499 64.472 55.956 59.694 62.210 62.393 62.265
1.424 1.617 1.681 1.746 1.703 1.669 13.343 11.379 10.470 10.424 10.217 10.186
1.533 1.726 1.764 1.743 1.755 1.705 12.264 11.356 10.544 10.442 10.826 10.440
1.579 1.689 1.804 1.792 1.796 1.733 14.060 14.446 13.193 13.393 13.586 13.387
1.683 1.646 1.726 1.714 1.738 1.707 10.933 10.571 10.429 10.618 10.012 10.193
1.363 1.581 1.731 1.713 1.714 1.709 16.728 13.789 15.598 15.528 15.519 16.150
1.311 1.659 1.747 1.739 1.807 1.733 18.612 15.672 17.172 17.711 17.709 19.619
1.484 1.618 1.736 1.625 1.726 1.715 13.073 11.990 11.636 13.046 11.124 10.845
1.68 2.091 1.987 2.103 2.088 1.921 67.381 66.380 66.331 66.762 67.433 66.944
2.822 2.353 2.283 2.304 2.3 2.26 4.961 6.290 6.132 6.163 6.435 6.637
2.828 2.336 2.288 2.341 2.249 2.21 5.021 6.164 6.818 6.920 8.004 7.964
2.24 2.667 2.282 2.315 2.17 2.172 5.804 4.949 5.697 6.134 6.452 6.906
2.269 2.378 2.293 2.292 2.219 2.231 5.818 5.383 5.931 6.632 7.481 6.903
2.258 2.774 2.31 2.322 2.241 2.245 6.466 5.552 6.840 7.494 8.478 8.820
2.38 2.499 2.376 2.422 2.298 2.362 5.882 5.762 6.313 6.441 7.311 7.451
2.39 2.38 2.306 2.35 2.255 2.227 5.858 6.218 6.678 6.638 7.007 8.172
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Antigen Concentration (ng ml   )
RBL-pEE6 Expressing Dog α Chain Cells Bound With Dog IgE For 16 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Mouse IgE For 16 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Horse IgE 16 hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Horse IgE For 0.5 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Mouse IgE For 0.5 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Horse IgE For 1 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Mouse IgE For 1 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Horse IgE For 3 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Mouse IgE For 3 Hours
-1
 Figure 31: β-hexosaminidase release assays of RBL-2H3.1
  cells expressing canine FcεRIα tested
  with equine IgE      145
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x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.793 1.988 2.019 2.038 2.015 2.06 11.824 10.664 10.104 9.617 9.628 11.165
1.789 1.966 2.011 2.028 2.028 2.09 11.738 9.461 9.448 10.059 10.651 10.622
2.011 2.086 2.111 2.157 2.144 2.19 15.017 13.231 13.169 13.908 14.272 15.708
2.039 2.087 2.224 2.382 2.361 2.331 25.895 17.537 20.863 22.838 24.989 23.681
2.061 2.142 2.445 2.836 2.911 2.754 44.153 33.613 37.301 45.628 46.994 46.841
2.228 2.117 2.511 2.667 2.731 2.74 46.499 39.490 43.090 46.944 51.263 50.073
2.234 2.053 2.2 2.261 2.262 2.388 46.285 39.454 37.182 39.275 39.788 44.137




















































1 2 3 4 5 6 7 8 9 10 11 12
2.565 2.893 2.495 1.992 2.228 1.839 0.068 0.073 0.072 0.073 0.068 0.074
2.471 2.602 2.565 2.068 1.893 1.731 0.115 0.098 0.092 0.094 0.11 0.118
1.726 1.749 1.698 1.67 1.671 1.531 0.395 0.338 0.381 0.464 0.524 0.472
1.881 1.461 1.463 1.399 1.307 1.254 0.587 0.447 0.591 0.771 0.875 0.765
1.502 1.509 1.434 1.35 1.353 1.185 0.693 0.488 0.61 0.822 0.952 0.657
1.484 1.56 1.472 1.428 1.418 1.204 0.623 0.542 0.713 0.791 0.837 0.607
1.982 1.479 1.393 1.369 1.4 1.219 0.642 0.52 0.707 0.786 0.896 0.706
1.312 0.751 0.753 0.781 0.823 0.807 1.024 1.062 0.938 0.986 0.922 0.843
1.632 1.713 1.812 1.764 1.698 1.654 0.096 0.094 0.096 0.105 0.095 0.111
1.684 1.8 1.835 1.756 1.738 1.724 0.102 0.1 0.097 0.103 0.102 0.107
1.661 1.693 1.776 1.776 1.779 1.74 0.179 0.174 0.164 0.17 0.185 0.227
1.272 1.471 1.521 1.538 1.546 1.481 0.319 0.265 0.332 0.439 0.447 0.47
1.271 1.399 1.477 1.451 1.473 1.396 0.368 0.307 0.321 0.465 0.534 0.552
1.183 1.43 1.506 1.444 1.543 1.426 0.32 0.313 0.337 0.344 0.475 0.531
1.132 1.376 1.443 1.42 1.443 1.398 0.352 0.334 0.374 0.365 0.398 0.544
0.548 0.748 0.838 0.78 0.896 0.799 0.651 0.75 0.919 0.875 0.867 0.858
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.701 3.039 2.639 2.138 2.364 1.987 5.035 4.804 5.457 6.829 5.753 7.448
2.701 2.798 2.749 2.256 2.113 1.967 8.515 7.005 6.693 8.333 10.412 11.998
2.516 2.425 2.46 2.598 2 719 2.475 31.399 27.876 30.976 35.720 38.544 38.141
3.055 2.355 2.645 2.941 3.057 2.784 38.429 37.962 44.688 52.431 57.246 54.957
2.888 2.485 2.654 2.994 3.257 2.499 47.992 39.276 45.968 54.910 58.459 52.581
2.73 2.644 2.898 3.01 3.092 2.418 45.641 40.998 49.206 52.558 54.140 50.207
3.266 2.519 2.807 2.941 3 192 2.631 39.314 41.286 50.374 53.451 56.140 53.668
3.36 2.875 2.629 2.753 2.667 2.493 60.952 73.878 71.358 71.631 69.141 67.629
1.824 1.901 2.004 1.974 1.888 1.876 10.526 9.890 9.581 10.638 10.064 11.834
1.888 2 2.029 1.962 1.942 1.938 10.805 10.000 9.561 10.499 10.505 11.042
2. 19 2.041 2.104 2.1 6 2.149 2.194 17.732 17.050 15.589 6.068 17.217 20.693
1.91 2.001 2.185 2.4 6 2.44 2.421 33.403 26.487 30.3 9 36.341 36.639 38.827
2.007 2.013 2.119 2.381 2.541 2.5 36.672 30.502 30.297 39.059 42.031 44.160
1.823 2.056 2.18 2.132 2.493 2.488 35.107 30.447 30.917 32.270 38.107 42.685
1.836 2.044 2.191 2.15 2.239 2.486 38.344 32.681 34.140 33.953 35.552 43.765




































































1 2 3 4 5 6 7 8 9 10 11 12
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1.693 1.807 1.804 1.812 1.809 1.833 0.091 0.091 0.088 0.085 0.087 0.078
1.744 1.779 1.801 1.744 1.772 1.789 0.091 0.096 0.096 0.09 0.091 0.085
1.707 1.793 1.803 1.774 1.793 1.783 0.111 0.124 0.121 0.12 0.123 0.112
1.721 1.719 1.737 1.752 1.796 1.747 0.094 0.086 0.092 0.091 0.087 0.08
1.695 1.762 1.772 1.774 1.796 1.801 0.097 0.095 0.093 0.094 0.092 0.087
1.677 1.636 1.713 1.737 1.695 1.728 0.105 0.105 0.107 0.119 0.116 0.126
1.739 1.746 1.777 1.795 1.756 1.786 0.093 0.091 0.092 0.094 0.091 0.085
0.753 0.826 0.842 0.808 0.814 0.781 0.748 0.774 0.804 0.715 0.603 0.791
1.631 1.553 1.46 1.58 1.674 1.838 0.086 0.094 0.084 0.085 0.084 0.086
1.485 1.651 1.623 1.738 1.74 1.848 0.086 0.089 0.088 0.088 0.089 0.089
1.609 1.57 1.609 1.736 1.772 1.774 0.104 0.118 0.106 0.108 0.113 0.124
1.557 1.654 1.725 1.843 1.727 1.756 0.083 0.081 0.082 0.086 0.086 0.084
1.578 1.673 1.68 1.626 1.645 1.657 0.145 0.137 0.149 0.155 0.172 0.189
1.654 1.595 1.603 1.603 1.625 1.629 0.137 0.129 0.137 0.141 0.152 0.159
1.684 1.696 1.605 1.698 1.716 1.718 0.091 0.093 0.094 0.092 0.092 0.089
0.816 0.707 0.857 0.844 0.748 0.865 0.746 0.639 0.695 0.694 0.733 0.805
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.193 2.256 2.241 2.228 2.238 2.184 8.208 9.043 8.568 8.438 8.490 8.425
2.268 2.28 2.197 2.252 2.232 2.23 7.760 8.246 8.375 8.171 8.333 8.700
2.332 2.295 2.257 2.342 2.29 2.319 11.664 11.678 11.786 12.212 12.751 14.661
2.39 2.314 2.32 2.346 2.326 2.368 17.322 14.088 15.690 18.414 17.713 20.439
2.322 2.229 2.34 2.263 2.322 2.347 17.313 14.177 15.641 16.350 17.916 19.344
2.231 2.22 2.248 2.231 2.176 2.214 11.833 11.081 12.633 12.371 12.868 14.815
2.228 2.222 2.205 2.178 2.188 2.131 8.348 8.281 8.345 8.448 8.501 8.259
2.59 2.732 2.808 2.619 2.713 2.469 67.645 67.204 67.949 67.736 68.264 67.396
1.875 1.989 1.98 1.982 1.983 1.989 9.707 9.150 8.889 8.577 8.775 7.843
1.926 1.971 1.993 1.924 1.954 1.959 9.450 9.741 9.634 9.356 9.314 8.678
1.929 2.041 2.045 2.014 2.039 2.007 11.509 12.151 11.834 11.917 12.065 11.161
1.909 1.891 1.921 1.934 1.97 1.907 9.848 9.096 9.578 9.411 8.832 8.390
1.889 1.952 1.958 1.962 1.98 1.975 10.270 9.734 9.499 9.582 9.293 8.810
1.887 1.846 1.927 1.975 1.927 1.98 11.129 11.376 11.105 12.051 12.039 12.727
1.925 1.928 1.961 1.983 1.938 1.956 9.662 9.440 9.383 9.481 9.391 8.691
2.249 2.374 2.45 2.238 2.02 2.363 66.518 65.206 65.633 63.896 59.703 66.949
1.803 1.741 1.628 1.75 1.842 2.01 9.540 10.798 10.319 9.714 9.121 8.557
1.657 1.829 1.799 1.914 1.918 2.026 10.380 9.732 9.783 9.195 9.281 8.786
1.817 1.806 1.821 1.952 1.998 2.022 11.447 13.068 11.642 11.066 11.311 12.265
1.723 1.816 1.889 2.015 1.899 1.924 9.634 8.921 8.682 8.536 9.057 8.732
1.868 1.947 1.978 1.936 1.989 2.035 15.525 14.073 15.066 16.012 17.295 18.575
1.928 1.853 1.877 1.885 1.929 1.947 14.212 13.923 14.598 14.960 15.759 16.333
1.866 1.882 1.793 1.882 1.9 1.896 9.753 9.883 10.485 9.777 9.684 9.388
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1.679 1.733 1.74 1.805 1.754 1.747 0.096 0.094 0.1 0.094 0.089 0.091
1.746 1.822 1.769 1.833 1.807 1.728 0.091 0.094 0.097 0.093 0.097 0.097
1.681 1.796 1.758 1.728 1.714 1.651 0.106 0.117 0.117 0.115 0.12 0.114
1.621 1.788 1.777 1.724 1.716 1.688 0.096 0.083 0.089 0.09 0.082 0.084
1.706 1.776 1.756 1.739 1.761 1.688 0.095 0.094 0.095 0.099 0.1 0.09
1.605 1.616 1.668 1.687 1.685 1.632 0.166 0.143 0.14 0.16 0.182 0.176
1.645 1.706 1.739 1.726 1.739 1.635 0.164 0.151 0.162 0.16 0.177 0.176
0.697 0.763 0.759 0.83 0.871 0.6 0.784 0.78 0.814 0.886 0.858 0.8
1.843 1.921 1.873 1.932 1.896 1.812 0.084 0.084 0.084 0.082 0.084 0.092
1.834 1.837 1.823 1.823 1.795 1.733 0.09 0.099 0.094 0.087 0.096 0.097
1.831 1.872 1.805 1.825 1.783 1.723 0.107 0.124 0.115 0.109 0.119 0.12
1.797 1.778 1.772 1.796 1.765 1.696 0.087 0.084 0.084 0.083 0.086 0.088
1.77 1.722 1.712 1.697 1.703 1.667 0.141 0.118 0.117 0.116 0.13 0.134
1.683 1.62 1.641 1.649 1.662 1.588 0.199 0.18 0.175 0.172 0.199 0.236
1.773 1.664 1.739 1.694 1.745 1.694 0.173 0.154 0.157 0.149 0.156 0.189
0.792 0.814 0.821 0.762 0.836 0.605 0.801 0.735 0.737 0.668 0.641 0.941
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.091 1.963 1.923 2.02 2.065 2.031 8.800 9.068 9.152 9.010 8.814 8.567
.073 1.969 1.91 2.053 2.058 2.046 8.683 9.243 9.424 9.255 9.038 8.602
2.131 2.008 2.094 2.16 2.21 2.279 10.230 12.251 11.175 11.111 11.131 11.057
2.116 1.998 2.023 2.025 2.154 2.194 12.665 13.113 13.347 12.247 12.535 12.306
2.197 2.198 2.131 2.225 2.355 2.295 19.208 22.020 21.586 22.831 22.166 22.309
2.262 2.266 2.153 2.314 2.39 2.336 21.574 23.124 19.415 20.311 23.264 22.945
2.222 2.208 2.15 2.241 2.162 2.14 18.812 18.569 16.744 17.492 18.316 19.533
2.349 2.317 2.425 2.354 2.372 2.253 70.924 71.644 69.031 66.525 68.212 67.466
1.871 1.921 1.94 1.993 1.932 1.929 10.262 9.787 10.309 9.433 9.213 9.435
1.928 2.01 1.963 2.019 2.001 1.922 9.440 9.353 9.883 9.212 9.695 10.094
1.893 2.03 1.992 1.958 1.954 1.879 11.199 11.527 11.747 11.747 12.282 12.134
1.813 1.954 1.955 1.904 1.88 1.856 10.590 8.495 9.105 9.454 8.723 9.052
1.896 1.964 1.946 1.937 1.961 1.868 10.021 9.572 9.764 10.222 10.199 9.636
1.937 1.902 1.948 2.007 2.049 1.984 17.140 15.037 14.374 15.944 17.765 17.742
1.973 2.008 2.063 2.046 2.093 1.987 16.624 15.040 15.705 15.640 16.914 17.715
2.265 2.323 2.387 2.602 2.587 2.2 69.227 67.155 68.203 68.101 66.332 72.727
2.011 2.089 2.041 2.096 2.064 1.996 8.354 8.042 8.231 7.824 8.140 9.218
2.014 2.035 2.011 1.997 1.987 1.927 8.937 9.730 9.349 8.713 9.663 10.067
2.045 2.12 2.035 2.043 2.021 1.963 10.465 11.698 11.302 10.671 11.776 12.226
1.971 1.946 1.94 1.962 1.937 1.872 8.828 8.633 8.660 8.461 8.880 9.402
2.052 1.958 1.946 1.929 1.963 1.935 13.743 12.053 12.025 12.027 13.245 13.850
2.081 1.98 1.991 1.993 2.06 2.06 19.125 18.182 17.579 17.260 19.320 22.913
2.119 1.972 2.053 1.992 2.057 2.072 16.328 15.619 15.295 14.960 15.168 18.243
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1.712 1.839 1.818 1.868 1.818 1.79 0.097 0.086 0.086 0.086 0.088 0.086
1.959 1.86 1.827 1.883 1.904 1.807 0.091 0.09 0.09 0.087 0.091 0.093
1.932 1.887 1.887 1.863 1.833 1.798 0.107 0.113 0.11 0.107 0.117 0.122
1.816 1.809 1.809 1.832 1.814 1.76 0.089 0.082 0.087 0.089 0.093 0.079
1.666 1.747 1.715 1.738 1.728 1.709 0.173 0.136 0.142 0.164 0.186 0.162
1.662 1.711 1.702 1.783 1.746 1.7 0.164 0.137 0.134 0.141 0.164 0.16
1.703 1.795 1.731 1.79 1.812 1.8 0.099 0.094 0.091 0.095 0.092 0.086
0.807 0.88 0.964 0.933 0.978 0.919 0.718 0.807 0.693 0.775 0.729 0.713
1.793 1.854 1.818 1.781 1.854 1.783 0.093 0.098 0.088 0.096 0.086 0.099
1.839 1.86 1.84 1.821 1.86 1.805 0.089 0.097 0.098 0.091 0.093 0.095
1.771 1.783 1.746 1.842 1.853 1.75 0.109 0.127 0.121 0.116 0.125 0.133
1.874 1.879 1.849 1.865 1.862 1.798 0.085 0.081 0.085 0.085 0.081 0.09
1.881 1.863 1.843 1.81 1.857 1.81 0.096 0.091 0.089 0.089 0.09 0.096
1.801 1.794 1.777 1.803 1.803 1.745 0.112 0.113 0.114 0.111 0.127 0.124
1.807 1.841 1.776 1.783 1.788 1.742 0.097 0.097 0.099 0.092 0.094 0.1
0.743 0.8 0.822 0.824 0.824 0.716 0.846 0.782 0.789 0.673 0.707 0.79
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.136 2.208 2.187 2.225 2.196 2.216 9.551 9.420 9.145 8.899 8.925 8.935
2.272 2.308 2.293 2.265 2.274 2.268 8.627 8.406 8.548 8.124 8.004 7.760
2.298 2.302 2.307 2.32 2.285 2.322 10.531 10.686 10.230 10.345 10.241 11.025
2.289 2.296 2.315 2.362 2.349 2.368 15.378 12.631 13.650 15.411 15.241 17.399
2.377 2.341 2.368 2.373 2.392 2.363 16.912 12.815 14.611 15.929 16.304 17.435
2.225 2.229 2.245 2.199 2.246 2.232 12.135 10.857 10.512 11.824 12.110 13.530
2.186 2.21 2.212 2.179 2.24 2.175 8.783 8.688 8.409 9.913 8.214 8.460
2.813 2.957 3.116 3.09 2.924 2.881 68.539 70.071 69.769 66.731 65.253 70.045
1.906 2.011 1.99 2.04 1.994 1.962 10.178 8.553 8.643 8.431 8.826 8.767
2.141 2.04 2.007 2.057 2.086 1.993 8.501 8.824 8.969 8.459 8.725 9.333
2.146 2.113 2.107 2.077 2.067 2.042 9.972 10.696 10.441 10.303 11.321 11.949
1.994 1.973 1.983 2.01 2 1.918 8.927 8.312 8.775 8.856 9.300 8.238
2.012 2.019 1.999 2.066 2.1 2.033 17.197 13.472 14.207 15.876 17.714 15.937
1.99 1.985 1.97 2.065 2.074 2.02 16.482 13.804 13.604 13.656 15.815 15.842
1.901 1.983 1.913 1.98 1.996 1.972 10.416 9.481 9.514 9.596 9.218 8.722
2.243 2.494 2.35 2.483 2.436 2.345 64.021 64.715 58.979 62.424 59.852 60.810
1.979 2.05 1.994 1.973 2.026 1.981 9.399 9.561 8.826 9.731 8.490 9.995
2.017 2.054 2.036 2.003 2.046 1.995 8.825 9.445 9.627 9.086 9.091 9.524
1.989 2.037 1.988 2.074 2.103 2.016 10.960 12.469 12.173 11.186 11.888 13.194
2.044 2.041 2.019 2.035 2.024 1.978 8.317 7.937 8.420 8.354 8.004 9.100
2.073 2.045 2.021 1.988 2.037 2.002 9.262 8.900 8.808 8.954 8.837 9.590
2.025 2.02 2.005 2.025 2.057 1.993 11.062 11.188 11.372 10.963 12.348 12.444
2.001 2.035 1.974 1.967 1.976 1.942 9.695 9.533 10.030 9.354 9.514 10.299
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1.404 1.344 1.369 1.618 1.657 1.762 0.066 0.093 0.091 0.091 0.09 0.081
1.373 1.558 1.645 1.643 1.716 1.886 0.091 0.093 0.094 0.093 0.094 0.09
1.495 1.517 1.623 1.784 1.766 1.834 0.106 0.114 0.115 0.112 0.119 0.109
1.612 1.556 1.613 1.752 1.67 1.792 0.086 0.084 0.089 0.085 0.084 0.079
1.617 1.506 1.525 1.591 1.739 1.72 0.096 0.094 0.097 0.092 0.096 0.089
1.323 1.412 1.445 1.6 1.676 1.579 0.191 0.169 0.195 0.248 0.276 0.293
1.28 1.384 1.369 1.526 1.542 1.477 0.251 0.224 0.236 0.275 0.29 0.328
0.502 0.601 0.619 0.791 0.793 0.637 0.67 0.682 0.776 0.838 0.845 0.68
1.959 1.983 1.967 1.963 1.932 1.987 0.095 0.09 0.087 0.089 0.085 0.082
1.979 1.942 1.893 1.889 1.883 1.917 0.092 0.089 0.098 0.097 0.097 0.091
1.931 1.893 1.896 1.902 1.864 1.896 0.112 0.125 0.121 0.123 0.129 0.116
1.951 1.919 1.891 1.863 1.863 1.88 0.089 0.087 0.093 0.092 0.089 0.086
1.875 1.881 1.851 1.833 1.848 1.842 0.138 0.128 0.13 0.137 0.134 0.151
1.742 1.711 1.687 1.657 1.652 1.66 0.29 0.272 0.279 0.343 0.387 0.458
1.753 1.733 1.725 1.676 1.686 1.691 0.288 0.26 0.254 0.257 0.299 0.33
0.827 0.912 0.915 0.887 0.927 0.932 0.787 0.742 0.77 0.819 0.779 0.696
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.089 2.129 2.155 2.145 2.086 2.171 8.712 8.549 8.538 7.925 8.437 9.028
2.231 2.145 2.216 2.211 2.145 2.183 8.068 8.671 8.755 7.689 8.858 9.162
2.29 2.262 2.239 2.292 2.219 2.17 9.607 10.787 10.094 10.122 10.816 12.350
2.24 2.149 2.197 2.082 2.211 2.249 13.839 12.192 12.563 12.680 12.302 13.339
2.428 2.304 2.369 2.386 2.392 2.36 28.995 24.826 26.593 27.661 27.090 29.576
2.402 2.27 2.399 2.427 2.276 2.435 30.142 26.256 26.011 27.029 25.747 31.622
2.324 2.28 2.367 2.517 2.405 2.401 28.657 26.140 25.687 29.082 29.854 29.321
2.828 2.688 2.17 2.898 2.68 2.101 76.591 72.545 69.217 75.086 74.104 72.156
1.536 1.53 1.551 1.8 1.837 1.924 8.594 12.157 11.734 10.111 9.799 8.420
1.555 1.744 1.833 1.829 1.904 2.066 11.704 10.665 10.256 10.169 9.874 8.712
1.707 1.745 1.853 2.008 2.004 2.052 12.419 13.066 12.412 11.155 11.876 10.624
1.784 1.724 1.791 1.922 1.838 1.95 9.641 9.745 9.939 8.845 9.140 8.103
1.809 1.694 1.719 1.775 1.931 1.898 10.614 11.098 11.286 10.366 9.943 9.378
1.705 1.75 1.835 2.096 2.228 2.165 22.405 19.314 21.253 23.664 24.776 27.067
1.782 1.832 1.841 2.076 2.122 2.133 28.171 24.454 25.638 26.493 27.333 30.755
1.842 1.965 2.171 2.467 2.483 1.997 72.747 69.415 71.488 67.937 68.063 68.102
2.149 2.163 2.141 2.141 2.102 2.151 8.841 8.322 8.127 8.314 8.088 7.624
2.163 2.12 2.089 2.083 2.077 2.099 8.507 8.396 9.382 9.313 9.340 8.671
2.155 2.143 2.138 2.148 2.122 2.128 10.394 11.666 11.319 11.453 12.158 10.902
2.129 2.093 2.077 2.047 2.041 2.052 8.361 8.313 8.955 8.989 8.721 8.382
2.151 2.137 2.111 2.107 2.116 2.144 12.831 11.979 12.316 13.004 12.665 14.086
2.322 2.255 2.245 2.343 2.426 2.576 24.978 24.124 24.855 29.279 31.904 35.559
2.329 2.253 2.233 2.19 2.284 2.351 24.732 23.080 22.750 23.470 26.182 28.073
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1.975 1.928 1.909 1.866 1.922 1.951 0.093 0.095 0.095 0.098 0.095 0.091
2.002 1.898 1.867 1.846 1.924 1.941 0.098 0.098 0.098 0.094 0.101 0.094
1.985 1.893 1.884 1.804 1.939 1.909 0.114 0.128 0.114 0.121 0.122 0.123
2.008 1.907 1.834 1.805 1.892 1.898 0.094 0.09 0.095 0.092 0.089 0.092
1.941 1.882 1.832 1.835 1.841 1.85 0.1 0.096 0.1 0.097 0.097 0.099
1.854 1.798 1.762 1.733 1.819 1.845 0.17 0.136 0.143 0.162 0.175 0.189
1.943 1.894 1.865 1.85 1.883 1.837 0.109 0.107 0.104 0.104 0.104 0.099
0.691 0.774 0.744 0.72 0.886 0.816 0.982 0.974 0.84 0.883 0.812 0.825
1.939 1.983 2.009 2.022 2.022 1.959 0.1 0.099 0.097 0.099 0.096 0.102
1.996 1.945 1.971 1.983 1.975 1.963 0.099 0.106 0.104 0.101 0.102 0.106
1.978 1.967 1.952 2.009 1.996 1.959 0.117 0.131 0.127 0.141 0.158 0.139
1.994 1.976 1.969 1.982 1.968 1.994 0.093 0.093 0.099 0.119 0.104 0.124
1.979 1.991 1.971 1.959 1.975 1.928 0.099 0.105 0.103 0.102 0.098 0.1
1.947 1.947 1.928 1.947 1.953 1.914 0.104 0.107 0.107 0.111 0.106 0.121
1.93 1.986 1.964 1.958 1.997 1.975 0.099 0.105 0.102 0.099 0.099 0.097
1.061 1.05 1.036 0.987 1.06 0.879 0.583 0.807 0.715 0.728 0.785 0.757
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.357 2.395 2.372 2.353 2.35 2.275 8.061 8.685 8.347 7.905 8.000 7.824
2. 21 2.393 2.351 2.406 2.387 2.346 7.931 8.023 8.337 8.229 8.379 8.440
2.404 2.389 2.405 2.391 2.382 2.385 9.068 10.046 10.146 10.038 10.579 10.901
2.349 2.354 2.357 2.345 2.393 2.387 8.174 8.071 9.334 9.296 9.779 10.892
2.458 2.425 2.541 2.555 2.609 2.792 16.355 14.433 19.677 20.587 22.077 27.650
2.395 2.35 2.478 2.449 2.477 2.621 13.946 12.596 17.433 17.068 18.329 25.868
2.373 2.359 2.332 2.318 2.3 2.29 9.440 8.648 8.748 8.887 8.609 8.646
2.69 2.837 3.024 2.808 2.873 2.862 57.546 59.076 59.392 60.684 62.026 64.780
2.161 2.118 2.099 2.062 2.112 2.133 8.607 8.971 9.052 9.505 8.996 8.533
2.198 2.094 2.063 2.034 2.126 2.129 8.917 9.360 9.501 9.243 9.501 8.830
2.213 2.149 2.112 2.046 2.183 2.155 10.303 11.913 10.795 11.828 11.177 11.415
2.196 2.087 2.024 1.989 2.07 2.082 8.561 8.625 9.387 9.251 8.599 8.838
2.141 2.074 2.032 2.029 2.035 2.048 9.341 9.257 9.843 9.561 9.533 9.668
2.194 2.07 2.048 2.057 2.169 2.223 15.497 13.140 13.965 15.751 16.136 17.004
2.161 2.108 2.073 2.058 2.091 2.035 10.088 10.152 10.034 10.107 9.947 9.730
2.655 2.722 2.424 2.486 2.51 2.466 73.974 71.565 69.307 71.038 64.701 66.910
2.139 2.181 2.203 2.22 2.214 2.163 9.350 9.078 8.806 8.919 8.672 9.431
2.194 2.157 2.179 2.185 2.179 2.175 9.025 9.828 9.546 9.245 9.362 9.747
2.212 2.229 2.206 2.291 2.312 2.237 10.579 11.754 11.514 12.309 13.668 12.427
2.18 2.162 2.167 2.22 2.176 2.242 8.532 8.603 9.137 10.721 9.559 11.062
2.177 2.201 2.177 2.163 2.171 2.128 9.095 9.541 9.463 9.431 9.028 9.398
2.155 2.161 2.142 2.169 2.165 2.156 9.652 9.903 9.991 10.235 9.792 11.224
2.128 2.196 2.168 2.156 2.195 2.169 9.305 9.563 9.410 9.184 9.021 8.944
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1.74 1.947 1.951 2.029 2.004 1.983 0.087 0.085 0.09 0.086 0.084 0.089
1.959 1.928 1.974 1.975 1.924 1.891 0.091 0.091 0.096 0.092 0.096 0.1
2.01 1.936 1.913 1.967 1.896 1.806 0.107 0.115 0.113 0.115 0.113 0.114
1.822 1.751 1.891 1.961 1.842 1.853 0.083 0.082 0.087 0.087 0.09 0.091
1.811 1.876 1.861 1.83 1.855 1.822 0.115 0.087 0.09 0.085 0.093 0.091
1.755 1.659 1.697 1.706 1.777 1.781 0.19 0.155 0.16 0.188 0.204 0.186
1.462 1.563 1.622 1.515 1.468 1.434 0.382 0.364 0.395 0.38 0.399 0.445
0.813 0.829 0.855 0.92 0.867 0.739 0.721 0.916 0.794 0.78 0.823 0.831
2.092 2.066 1.979 2.004 2.086 2.076 0.09 0.092 0.089 0.09 0.088 0.087
2.068 2.003 1.975 2.005 2.036 2.022 0.091 0.099 0.097 0.098 0.098 0.098
2.076 1.945 1.959 1.928 2.035 2.009 0.11 0.127 0.118 0.119 0.123 0.123
2.001 1.951 1.915 1.941 1.993 1.985 0.093 0.089 0.093 0.1 0.095 0.088
1.987 1.958 1.947 1.93 1.988 1.967 0.108 0.1 0.098 0.104 0.11 0.101
1.74 1.751 1.655 1.72 1.757 1.725 0.327 0.277 0.332 0.415 0.448 0.482
1.757 1.729 1.693 1.705 1.717 1.705 0.339 0.282 0.35 0.408 0.457 0.512
0.864 1.018 1.043 0.934 1.008 0.828 0.844 0.731 0.738 0.801 0.814 0.788
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.275 2.419 2.355 2.333 2.361 2.325 7.912 7.524 8.238 8.144 7.370 7.312
2.384 2.398 2.37 2.325 2.387 2.368 7.970 7.923 8.270 8.172 8.379 7.939
2.377 2.465 2.42 2.43 2.395 2.388 9.340 10.142 10.165 10.041 10.689 10.637
2.349 2.367 2.327 2.234 2.349 2.346 8.855 7.943 9.024 9.042 9.025 8.781
2.543 2.442 2.47 2.484 2.6 2.691 23.751 17.199 19.595 22.383 25.615 27.573
2.647 2.415 2.465 2.723 2.875 3.024 35.965 28.157 28.722 37.606 40.487 45.833
2.67 2.53 2.428 2.513 2.873 3.045 34.906 29.960 27.924 32.312 39.749 44.138
2.715 3.045 3.052 2.922 3.077 3.001 67.035 71.593 64.155 65.092 65.258 64.445
1.914 2.117 2.131 2.201 2.172 2.161 9.091 8.030 8.447 7.815 7.735 8.237
2.141 2.11 2.166 2.159 2.116 2.091 8.501 8.626 8.864 8.522 9.074 9.565
2.224 2.166 2.139 2.197 2.122 2.034 9.622 10.619 10.566 10.469 10.650 11.209
1.988 1.915 2.065 2.135 2.022 2.035 8.350 8.564 8.426 8.150 8.902 8.943
2.041 2.05 2.041 2 2.041 2.004 11.269 8.488 8.819 8.500 9.113 9.082
2.135 1.969 2.017 2.082 2.185 2.153 17.799 15.744 15.865 18.060 18.673 17.278
2.226 2.291 2.412 2.275 2.266 2.324 34.322 31.777 32.753 33.407 35.216 38.296
2.255 2.661 2.443 2.48 2.513 2.401 63.947 68.846 65.002 62.903 65.499 69.221
2.272 2.25 2.157 2.184 2.262 2.25 7.923 8.178 8.252 8.242 7.781 7.733
2.25 2.201 2.169 2.201 2.232 2.218 8.089 8.996 8.944 8.905 8.781 8.837
2.296 2.199 2.195 2.166 2.281 2.255 9.582 11.551 10.752 10.988 10.785 10.909
2.187 2.129 2.101 2.141 2.183 2.161 8.505 8.361 8.853 9.341 8.704 8.144
2.203 2.158 2.143 2.138 2.208 2.169 9.805 9.268 9.146 9.729 9.964 9.313
2.394 2.305 2.319 2.55 2.653 2.689 27.318 24.035 28.633 32.549 33.773 35.850
2.435 2.293 2.393 2.521 2.631 2.729 27.844 24.597 29.252 32.368 34.740 37.523





































































1 2 3 4 5 6 7 8 9 10 11 12
1.611 1.764 1.799 1.83 1.823 1.793 0.093 0.088 0.086 0.089 0.09 0.085
1.492 1.829 1.824 1.854 1.829 1.842 0.09 0.091 0.09 0.089 0.093 0.086
1.506 1.836 1.831 1.85 1.856 1.853 0.107 0.117 0.113 0.114 0.122 0.114
1.397 1.762 1.769 1.806 1.84 1.807 0.081 0.077 0.083 0.083 0.081 0.08
1.353 1.719 1.696 1.734 1.762 1.721 0.12 0.124 0.133 0.178 0.195 0.2
1.261 1.668 1.712 1.752 1.793 1.657 0.104 0.115 0.112 0.134 0.145 0.152
1.356 1.679 1.774 1.83 1.832 1.833 0.092 0.089 0.088 0.087 0.085 0.083
0.626 0.954 0.921 0.961 1.009 0.943 0.568 0.606 0.682 0.791 0.837 0.778
1.234 1.433 1.505 1.564 1.529 1.499 0.095 0.092 0.088 0.091 0.087 0.085
1.345 1.53 1.578 1.561 1.565 1.527 0.094 0.098 0.093 0.091 0.095 0.089
1.357 1.445 1.566 1.552 1.552 1.501 0.111 0.122 0.119 0.12 0.122 0.116
1.499 1.472 1.546 1.532 1.564 1.533 0.092 0.087 0.09 0.091 0.087 0.087
1.135 1.363 1.461 1.447 1.448 1.433 0.114 0.109 0.135 0.133 0.133 0.138
1.067 1.399 1.447 1.431 1.487 1.393 0.122 0.13 0.15 0.154 0.16 0.17
1.29 1.424 1.534 1.413 1.534 1.529 0.097 0.097 0.101 0.106 0.096 0.093
0.548 0.703 0.669 0.699 0.68 0.635 0.566 0.694 0.659 0.702 0.704 0.643
2.682 2.205 2.143 2.162 2.152 2.11 0.07 0.074 0.07 0.071 0.074 0.075
2.686 2.192 2.132 2.179 2.069 2.034 0.071 0.072 0.078 0.081 0.09 0.088
2.11 2.535 2.152 2.173 2.03 2.022 0.065 0.066 0.065 0.071 0.07 0.075
2.137 2.25 2.157 2.14 2.053 2.077 0.066 0.064 0.068 0.076 0.083 0.077
2.112 2.62 2.152 2.148 2.051 2.047 0.073 0.077 0.079 0.087 0.095 0.099
2.24 2.355 2.226 2.266 2.13 2.186 0.07 0.072 0.075 0.078 0.084 0.088
2.25 2.232 2.152 2.194 2.097 2.045 0.07 0.074 0.077 0.078 0.079 0.091
0.973 1.016 0.894 0.918 0.834 1.043 0.539 0.996 1.171 1.164 1.134 1.249
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.797 1.94 1.971 2.008 2.003 1.963 10.351 9.072 8.727 8.865 8.987 8.660
1.672 2.011 2.004 2.032 2.015 2.014 10.766 9.050 8.982 8.760 9.231 8.540
1.72 2.07 2.057 2.078 2.1 2.081 12.442 11.304 10.987 10.972 11.619 10.956
1.559 1.916 1.935 1.972 2.002 1.967 10.391 8.038 8.579 8.418 8.092 8.134
1.593 1.967 1.962 2.09 2.152 2.121 15.066 12.608 13.558 17.033 18.123 18.859
1.469 1.898 1.936 2.02 2.083 1.961 14.159 12.118 11.570 13.267 13.922 15.502
1.54 1.857 1.95 2.004 2.002 1.999 11.948 9.585 9.026 8.683 8.492 8.304
1.762 2.166 2.285 2.543 2.683 2.499 64.472 55.956 59.694 62.210 62.393 62.265
1.424 1.617 1.681 1.746 1.703 1.669 13.343 11.379 10.470 10.424 10.217 10.186
1.533 1.726 1.764 1.743 1.755 1.705 12.264 11.356 10.544 10.442 10.826 10.440
1.579 1.689 1.804 1.792 1.796 1.733 14.060 14.446 13.193 13.393 13.586 13.387
1.683 1.646 1.726 1.714 1.738 1.707 10.933 10.571 10.429 10.618 10.012 10.193
1.363 1.581 1.731 1.713 1.714 1.709 16.7 8 3.789 15.598 15.528 15.519 16.150
1.311 1.659 1.747 1.739 1.807 1.733 18.612 15.672 17.172 17.711 17.709 19.619
1.484 1.618 1.736 1.625 1.726 1.715 13.073 11.990 11.636 13.046 11.124 10.845
1.68 2.091 1.987 2.103 2.088 1.921 67.381 66.380 66.331 66.762 67.433 66.944
2.822 2.353 2.283 2.304 2.3 2.26 4.961 6.290 6.132 6.163 6.435 6.637
2.828 2.336 2.288 2.341 2.249 2.21 5.021 6.164 6.818 6.920 8.004 7.964
2.24 2.667 2.282 2.315 2.17 2.172 5.804 4.949 5.697 6.134 6.452 6.906
2.269 2.378 2.293 2.292 2.219 2.231 5.818 5.383 5.931 6.632 7.481 6.903
2.258 2.774 2.31 2.322 2.241 2.245 6.466 5.552 6.840 7.494 8.478 8.820
2.38 2.499 2.376 2.422 2.298 2.362 5.882 5.762 6.313 6.441 7.311 7. 51
2.39 2.38 2.306 2.35 2.255 2.227 5.858 6.218 6.678 6.638 7.007 8.172
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Antigen Concentration (ng ml   )
RBL-pEE6 Expressing Dog α Chain Cells Bound With Dog IgE For 16 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Mouse IgE For 16 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Horse IgE 16 hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Horse IgE For 0.5 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Mouse IgE For 0.5 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Horse IgE For 1 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Mouse IgE For 1 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Horse IgE For 3 Hours
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RBL-pEE6 Expressing Dog α Chain Cells Bound With Dog IgE For 16 Hours
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Comparison of Peak Release Between Different IgE Types 







 Figure : Summary graph of Figure 30’s peak
  release at 100ng ml-1 of antigen    146
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# # # #




                                                                                                     548bp
                                                                                                FcεRIαD1&2
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3000bp
1000bp                                                                                                                                  548bp
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A B  Figure 33: Restriction digestion of sFcεRIαD1&2 and
  the pPIC9k plasmid.      151
A                              B  Figure 34: The structure of the pPIC9k plasmid
  before and after the insertion of the
  sFcεRIαD1&2 gene.      152
 Figure 35: BLAST analysis of the cloned equine
  sFcεRIαD1&2 gene.      152

























51.1 22.55 45.3 0
61.3 23.35 56.9 0
60.85 22.75 61.4 1
54.65 14.65 61.2 1
53.15 11.35 61.5 2
53.15 10.5 60.2 2
63.1 11.85 55.5 3
63.5 12.4 53.8 3
65.35 13.1 53.8 4
68 44.7 52.5 4
69.25 15.5 53.8 5
71.4 18.85 52.5 5
63 6
63.2 6
Standard Deviation 63.8 7
8.20 0.35 63.2 7
0.14 0.07 65.7 8
0.92 0.49 65 8
1.20 0.35 68.5 9
0.92 0.21 67.5 9
0.92 0.14 69.3 10
0.14 0.35 69.2 10
0.42 0.14 71.5 11
0.49 0.00 71.3 11
0.71 0.00 22.3 P0
0.07 1.98 22.8 P0
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Normal Media Overflow Concentrate
Media Concentration Test With Horse IgE
Pure Horse FcεRIαD1&2 5μl At 0.1μg μl-1















0.09 μg μl-1 
Kinetic Dilutions
Horse α Chain μg 
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Total Volume Used 292.26 87.68
 Figure 36: SPR results of the level of sFcεRIαD1&2
 gainst expression time.     154
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 Figure 37: SPR results of the level of sFcεRIαD1&2
  after media harv sting.     155
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 Figure 38: SPR results of the level of








 Figure 39: The SPR viability curve of the






















































































































































































































































































































































































































































































Dilution Curve Bradford Assay























0.480 0.419 0.449 0.572 0 0.480 0.8408 0.4763
0.541 0.516 0.496 0.610 0.1 0.541
0.607 0.550 0.629 0.642 0.2 0.607
0.694 0.681 0.710 0.692 0.3 0.694
0.833 0.836 0.876 0.786 0.4 0.833
1.002 0.895 1.031 1.079 0.5 1.002
0.920 0.943 0.945 0.871 0.6 0.920
1.099 1.118 1.271 0.907 0.7 1.099
1.265 1.082 1.505 1.207 0.8 1.265
1.182 1.131 1.259 1.155 0.9 1.182
1.243 1.248 1.256 1.226 1.0 1.243
1x Dilution 2x Dilution 13.3x Dilution
0.249 0.686 0.403 0.622 0.756 0.802 0.389 0.542
0.430 0.838 0.705 0.602 0.793 0.486 0.425 0.705








0 0.25 0.5 0.75 1
y = 0.8408x + 0.4763












Protein Concentration mg ml-1
HDH Concentration





















0.331 0.321 0.337 0.335 0 0.331 0.7338 0.4217
0.474 0.459 0.483 0.481 0.1 0.474
0.571 0.550 0.596 0.566 0.2 0.571
0.667 0.633 0.675 0.692 0.3 0.667
0.759 0.739 0.774 0.763 0.4 0.759
0.823 0.736 0.854 0.878 0.5 0.823
0.928 0.788 1.056 0.939 0.6 0.928
1.002 0.954 1.035 1.018 0.7 1.002
1.040 0.939 1.076 1.105 0.8 1.040
1.025 0.925 1.046 1.105 0.9 1.025
1.055 0.916 1.098 1.151 1.0 1.055
x By Dilution Factor Final Concentration
100x Dilution 0.402 0.409 0.422 0.411 41.1 55.44
10x Dilution 1.049 0.858 1.108 1.005 12.177 56.01
5x Dilution 1.248 1.099 1.306 1.22 6.088 56.01
5.6  μg μl-1








0 0.25 0.5 0.75 1














 Figure 40: The protein purification graph used to
  calculate the concentration of the purified equine
  sFcεRIαD1&2 protein and later on the HHoH









 Figure 41: The SPR curve of the purified equine
  sFcεRIαD1&2 protein.     159
! 10kDa!         Non-Reduced
! Protein!         Equine








~25  Figure 42: SDS-PAGE of the equine
  sFcεRIαD1&2 protein.     160
Domain 1
Domain 2
















































































































































































100% of ligand bound
to its receptor
Minimum receptor concentration which saturates 
the ligand (binds to all the ligand on the SPR 
chip surface) if injected on to it for a certain 
amount of time
100% receptor
is bound to ligand
ka=
1






 Figure 44: Theoretical binding graph between
  a ligand and its receptor.     164
15





















































 Figure 46: Re-testing the binding between the equine IgE









 Figure 47: Re-testing the binding between the equine IgE











 Figure 48: Testing the binding of rabbit serum raised
  against human IgE Cε3 to equine IgE.   182
Thyroglobulin













































































































 Figure 49: Structure of the 2Fcε2-3 protein, the


































































 Figure 51: HHoH domain construction concept.  197
             1kb DNA




             1kb DNA    pUC18-       pUC18-     pUC18-    pUC18-
























A B  Figure 52: HHoH domain PCR amplifications
  and cloning into pUC18.     197
             1kb DNA   pUC18-      pUC18-    pUC18-
             Ladder      Cε1            Cε1          Cε1
                               Cε2           Cε2          Cε2
                               Cε3           Cε3          Cε3
                               Cε4           Cε4          Cε4 














             1kb DNA pUC18- pUC18-
             Ladder    Cε4      Cε1
                                         Cε2












             1kb DNA             pUC18-             pUC18-
             Ladder                Cε3                   Cε1












             1kb DNA pUC18-  pUC18- pUC18-  pUC18-
             Ladder    Cε1        Cε1       Cε1        Cε1
                            Cε2        Cε2       Cε2        Cε2







B  Figure 53: Constructing the HHoH gene.   198
             1kb DNA    pUC18-  pSV-VNP












    pSV-VNP     pSV-VNP   pSV-VNP  DNA      pSV-VNP  pSV-VNP   pSV-VNP







A B  Figure 54: Transferring the HHoH gene
  from pUC18 plasmid to pSV-VNP plasmid.   199
             1kb DNA    pUC18-           PCR




             1kb DNA     pUC18-      pUC18-   pUC18-    pUC18-    pUC18-     pUC18-













GFPA B  Figure 55: Cloning the GFP gene into pUC18.  200
             1kb DNA      pUC18-      pSV-VNP




             1kb DNA        pSV-VNP       pSV-VNP     pSV-VNP














A B  Figure 56: Cloning the GFP gene into
  the pSV-VNPHHoH plasmid.    200
               1kb DNA  pSV-VNP        pSV-VNP




               1kb DNA      pSV-VNP          pSV-VNP










A B  Figure 57: Confirmation of the presence of























































































































































































































































































































































































































































































Dilution Curve Bradford Assay























0.480 0.419 0.449 0.572 0 0.480 0.8408 0.4763
0.541 0.516 0.496 0.610 0.1 0.541
0.607 0.550 0.629 0.642 0.2 0.607
0.694 0.681 0.710 0.692 0.3 0.694
0.833 0.836 0.876 0.786 0.4 0.833
1.002 0.895 1.031 1.079 0.5 1.002
0.920 0.943 0.945 0.871 0.6 0.920
1.099 1.118 1.271 0.907 0.7 1.099
1.265 1.082 1.505 1.207 0.8 1.265
1.182 1.131 1.259 1.155 0.9 1.182
1.243 1.248 1.256 1.226 1.0 1.243
1x Dilution 2x Dilution 13.3x Dilution
0.249 0.686 0.403 0.622 0.756 0.802 0.389 0.542
0.430 0.838 0.705 0.602 0.793 0.486 0.425 0.705
0.457 0.489 0.682 0.498 0.564 0.470 0.502 0.456
HDH Concentration





















0.331 0.321 0.337 0.335 0 0.331 0.7338 0.4217
0.474 0.459 0.483 0.481 0.1 0.474
0.571 0.550 0.596 0.566 0.2 0.571
0.667 0.633 0.675 0.692 0.3 0.667
0.759 0.739 0.774 0.763 0.4 0.759
0.823 0.736 0.854 0.878 0.5 0.823
0.928 0.788 1.056 0.939 0.6 0.928
1.002 0.954 1.035 1.018 0.7 1.002
1.040 0.939 1.076 1.105 0.8 1.040
1.025 0.925 1.046 1.105 0.9 1.025
1.055 0.916 1.098 1.151 1.0 1.055
x By Dilution Factor Final Concentration
100x Dilution 0.402 0.409 0.422 0.411 41.1 55.44
10x Dilution 1.049 0.858 1.108 1.005 12.177 56.01
5x Dilution 1.248 1.099 1.306 1.22 6.088 56.01
5.6  μg μl-1
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0 0.25 0.5 0.75 1
y = 0.8408x + 0.4763












Protein Concentration mg ml-1
 Figure 58: SPR results of J558L selection for






















































































































































































































































































































































































































































































Dilution Curve Bradford Assay























0.480 0.419 0.449 0.572 0 0.480 0.8408 0.4763
0.541 0.516 0.496 0.610 0.1 0.541
0.607 0.550 0.629 0.642 0.2 0.607
0.694 0.681 0.710 0.692 0.3 0.694
0.833 0.836 0.876 0.786 0.4 0.833
1.002 0.895 1.031 1.079 0.5 1.002
0.920 0.943 0.945 0.871 0.6 0.920
1.099 1.118 1.271 0.907 0.7 1.099
1.265 1.082 1.505 1.207 0.8 1.265
1.182 1.131 1.259 1.155 0.9 1.182
1.243 1.248 1.256 1.226 1.0 1.243
1x Dilution 2x Dilution 13.3x Dilution
0.249 0.686 0.403 0.622 0.756 0.802 0.389 0.542
0.430 0.838 0.705 0.602 0.793 0.486 0.425 0.705
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y = 0.8408x + 0.4763
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0.331 0.321 0.337 0.335 0 0.331 0.7338 0.4217
0.474 0.459 0.483 0.481 0.1 0.474
0.571 0.550 0.596 0.566 0.2 0.571
0.667 0.633 0.675 0.692 0.3 0.667
0.759 0.739 0.774 0.763 0.4 0.759
0.823 0.736 0.854 0.878 0.5 0.823
0.928 0.788 1.056 0.939 0.6 0.928
1.002 0.954 1.035 1.018 0.7 1.002
1.040 0.939 1.076 1.105 0.8 1.040
1.025 0.925 1.046 1.105 0.9 1.025
1.055 0.916 1.098 1.151 1.0 1.055
x By Dilution Factor Final Concentration
100x Dilution 0.4 2 0.409 0.422 0.411 41.1 55.44
10x Dilution 1.049 0.858 1.108 1.005 12.177 56.01
5x Dilution 1.248 1.099 1.306 1.22 6.088 56.01
5.6  μg μl-1
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Protein Concentration  Figure 59: The protein purification graph used
  to calculate the concentration of the purified
  HDH IgE anti NIP-HSA     204
            10kDa      Non-Reduced!                  Reduces
             Protein!       HDH!!                     HDH
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A B  Figure 60: SDS-PAGE of the HHoH


















C  Figure 61: HHoH and HDH IgEs anti
  NIP-HSA viability test.       206-207
DC
BA
 Figure 62: J558L cells cloned with the
  pSV-VNPHHoHGFP plasmid.    209
17
                 1kb DNA     pUC18-                                    HindIII       XhoI        HindIII        XhoI





















































Rat IgE + HRP
Yellow Colour
Native IgE
A                                      B  Figure 64: Bleed test using ELISA assay.   215




1:200 9.999 0.000 0.871 0.030 0.532 0.006 2.915 0.040 0.136 0.016
1:400 9.999 0.000 0.395 0.028 0.239 0.014 1.747 0.005 0.089 0.001
1:800 2.845 0.069 0.185 0.012 0.140 0.004 0.902 0.071 0.070 0.006
1:1,600 1.878 0.178 0.108 0.000 0.091 0.003 0.357 0.003 0.062 0.002
1:3,200 0.877 0.100 0.078 0.002 0.067 0.002 0.163 0.011 0.054 0.002
1:6,400 0.369 0.055 0.067 0.001 0.053 0.001 0.094 0.005 0.052 0.004
1:12,800 0.188 0.016 0.052 0.000 0.052 0.001 0.061 0.002 0.050 0.002
1:25,600 0.079 0.050 0.046 0.000 0.050 0.001 0.054 0.001 0.051 0.003
1:51,200 0.072 0.004 0.048 0.000 0.043 0.000 0.051 0.001
1:102,400 0.059 0.001 0.050 0.003 0.047 0.001 0.053 0.001









9.999 9.999 0.069 0.074 0.052 0.052 0.065 0.068 0.952 0.851 0.125 0.147
9.999 9.999 0.059 0.058 0.046 0.046 0.054 0.052 0.355 0.359 0.089 0.088
2.796 2.893 0.850 0.892 0.048 0.048 0.052 0.051 0.171 0.155 0.066 0.074
1.752 2.004 0.375 0.415 0.052 0.048 0.050 0.049 0.097 0.090 0.060 0.063
0.806 0.947 0.193 0.176 0.536 0.527 0.043 0.043 0.062 0.059 0.052 0.055
0.330 0.408 0.108 0.108 0.229 0.249 0.046 0.047 0.053 0.055 0.049 0.055
0.177 0.199 0.079 0.076 0.137 0.143 2.943 2.886 0.050 0.051 0.048 0.051
0.043 0.114 0.068 0.066 0.089 0.093 1.750 1.743 0.052 0.053 0.049 0.053




1:200 9.999 0.000 2.708 0.000 1.918 0.074 9.999 0.000 0.151 0.011
1:400 9.999 0.000 1.640 0.010 0.955 0.072 6.487 4.967 0.099 0.004
1:800 9.999 0.000 0.677 0.001 0.437 0.022 2.269 0.167 0.080 0.008
1:1,600 9.999 0.000 0.284 0.021 0.209 0.027 0.999 0.096 0.077 0.008
1:3,200 2.211 0.100 0.142 0.001 0.114 0.002 0.464 0.054 0.067 0.014
1:6,400 1.105 0.064 0.096 0.003 0.070 0.006 0.202 0.017 0.060 0.001
1:12,800 0.538 0.030 0.076 0.001 0.066 0.001 0.103 0.005 0.067 0.011
1:25,600 0.284 0.005 0.117 0.078 0.074 0.004 0.085 0.001 0.072 0.007
1:51,200 0.155 0.002 0.060 0.001 0.057 0.006 0.069 0.001
1:102,400 0.101 0.008 0.066 0.006 0.060 0.000 0.072 0.001









9.999 9.999 0.156 0.153 0.075 0.076 0.115 0.112 2.387 2.151 0.143 0.158
9.999 9.999 0.106 0.095 0.172 0.062 0.066 0.074 1.067 0.931 0.096 0.101
9.999 9.999 2.708 2.708 0.059 0.060 0.065 0.067 0.502 0.425 0.074 0.085
9.999 9.999 1.633 1.647 0.062 0.070 0.076 0.071 0.214 0.190 0.071 0.082
2.140 2.281 0.677 0.676 1.865 1.970 0.061 0.053 0.106 0.099 0.057 0.077
1.150 1.060 0.269 0.298 1.006 0.904 0.060 0.060 0.086 0.084 0.059 0.061
0.516 0.559 0.142 0.141 0.421 0.452 9.999 9.999 0.070 0.068 0.059 0.075






1:200 1:400 1:800 1:1,600 1:3,200 1:6,400 1:12,800 1:25,600 1:51,200 1:102,400
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Pre Immunisation Bleed Test 1






1:200 1:400 1:800 1:1,600 1:3,200 1:6,400 1:12,800 1:25,600 1:51,200 1:102,400








1:200 1:400 1:800 1:1,600 1:3,200 1:6,400 1:12,800 1:25,600 1:51,200 1:102,400








1:200 1:400 1:800 1:1,600 1:3,200 1:6,400 1:12,800 1:25,600 1:51,200 1:102,400








1:200 1:400 1:800 1:1,600 1:3,200 1:6,400 1:12,800 1:25,600 1:51,200 1:102,400








1:200 1:400 1:800 1:1,600 1:3,200 1:6,400 1:12,800 1:25,600
Pre Immunisation Bleed
Pre Immunisation Bleed 1
Pre Immunisation Bleed 2
 Figure 65: ELISA test of each rat’s bleed for
  binding to the 2Fcε2-3.        216-217








1:200 0.233 0.008 0.354 0.021 1.986 0.045 2.043 0.009 0.127 0.004 0.941 0.120
1:400 0.132 0.011 0.195 0.001 1.874 0.019 2.081 0.043 0.108 0.002
1:800 0.114 0.006 0.123 0.000 1.737 0.049 1.841 0.159 0.107 0.004
1:1,600 0.104 0.002 0.102 0.003 1.535 0.028 1.714 0.076 0.103 0.003
1:3,200 0.093 0.004 0.094 0.001 1.143 0.019 1.393 0.032 0.096 0.004
1:6,400 0.093 0.004 0.101 0.001 0.756 0.063 1.034 0.043 0.108 0.008
1:12,800 0.097 0.003 0.094 0.001 0.461 0.006 0.670 0.021 0.102 0.013
1:25,600 0.100 0.006 0.092 0.002 0.278 0.004 0.424 0.007
1:51,200 0.092 0.001 0.096 0.002 0.182 0.010 0.271 0.014
1:102,400 0.094 0.000 0.092 0.002 0.147 0.005 0.218 0.001









0.238 0.227 0.091 0.093 0.093 0.095 1.129 1.156 1.728 1.953 0.124 0.130
0.139 0.124 0.094 0.094 0.090 0.093 0.711 0.800 1.768 1.660 0.109 0.106
0.118 0.109 0.339 0.369 0.094 0.097 0.465 0.457 1.370 1.415 0.104 0.109
0.105 0.102 0.194 0.196 0.093 0.090 0.275 0.281 1.003 1.064 0.101 0.105
0.095 0.090 0.123 0.123 1.954 2.017 0.175 0.189 0.655 0.685 0.093 0.098
0.096 0.090 0.100 0.104 1.887 1.860 0.143 0.150 0.419 0.429 0.113 0.102
0.095 0.099 0.094 0.093 1.771 1.702 2.049 2.036 0.261 0.281 0.092 0.111
0.104 0.096 0.101 0.100 1.555 1.515 2.050 2.111 0.218 0.217 0.941 0.120








1:200 1.102 0.009 0.881 0.009 1.907 0.050 2.326 0.030 0.114 0.003 1.276 0.085
1:400 0.622 0.012 0.463 0.027 1.832 0.004 2.243 0.058 0.091 0.007
1:800 0.368 0.013 0.260 0.003 1.721 0.047 1.998 0.109 0.081 0.004
1:1,600 0.232 0.019 0.174 0.001 1.555 0.023 1.704 0.037 0.076 0.004
1:3,200 0.142 0.018 0.128 0.004 1.123 0.011 1.280 0.011 0.066 0.003
1:6,400 0.112 0.016 0.108 0.006 0.694 0.043 0.826 0.000 0.070 0.004
1:12,800 0.093 0.013 0.083 0.003 0.421 0.018 0.469 0.015 0.071 0.002
1:25,600 0.109 0.009 0.070 0.002 0.245 0.008 0.304 0.001
1:51,200 0.075 0.004 0.068 0.001 0.157 0.023 0.195 0.006
1:102,400 0.064 0.001 0.065 0.001 0.114 0.001 0.138 0.007









1.095 1.108 0.077 0.072 0.081 0.085 1.130 1.115 1.921 2.075 0.112 0.116
0.630 0.613 0.063 0.064 0.071 0.068 0.663 0.724 1.678 1.730 0.086 0.096
0.377 0.358 0.874 0.887 0.068 0.067 0.434 0.408 1.272 1.288 0.078 0.084
0.245 0.218 0.482 0.444 0.065 0.064 0.250 0.239 0.826 0.826 0.073 0.079
0.155 0.129 0.258 0.262 1.871 1.942 0.173 0.141 0.479 0.458 0.064 0.068
0.123 0.101 0.173 0.175 1.829 1.834 0.113 0.115 0.304 0.303 0.067 0.072
0.102 0.084 0.125 0.130 1.754 1.687 2.347 2.305 0.190 0.199 0.069 0.072
0.115 0.102 0.112 0.103 1.571 1.539 2.202 2.284 0.143 0.133 1.276 0.085








1:200 1.397 0.112 1.014 0.071 2.288 0.146 2.696 0.076 0.148 0.010 0.560 0.123
1:400 0.810 0.049 0.591 0.037 2.265 0.054 2.716 0.076 0.119 0.001
1:800 0.500 0.008 0.337 0.025 2.170 0.095 2.349 0.198 0.110 0.006
1:1,600 0.293 0.021 0.218 0.006 1.835 0.127 2.094 0.062 0.103 0.000
1:3,200 0.186 0.013 0.154 0.004 1.511 0.000 1.475 0.068 0.095 0.001
1:6,400 0.138 0.010 0.136 0.004 0.854 0.001 0.973 0.013 0.095 0.001
1:12,800 0.121 0.018 0.117 0.005 0.507 0.023 0.533 0.023 0.103 0.002
1:25,600 0.135 0.025 0.099 0.000 0.296 0.003 0.333 0.021
1:51,200 0.105 0.002 0.094 0.001 0.189 0.004 0.212 0.002
1:102,400 0.091 0.002 0.094 0.001 0.142 0.000 0.163 0.011









1.318 1.476 0.106 0.103 0.113 0.120 1.511 1.511 2.209 2.489 0.141 0.155
0.845 0.775 0.089 0.092 0.099 0.099 0.853 0.855 2.050 2.138 0.119 0.118
0.506 0.494 0.964 1.064 0.093 0.094 0.523 0.491 1.427 1.523 0.105 0.114
0.308 0.278 0.565 0.617 0.093 0.094 0.294 0.298 0.964 0.982 0.103 0.103
0.195 0.176 0.319 0.355 2.184 2.391 0.192 0.186 0.516 0.549 0.095 0.094
0.145 0.131 0.214 0.222 2.226 2.303 0.142 0.142 0.318 0.347 0.094 0.096
0.133 0.108 0.151 0.156 2.102 2.237 2.642 2.750 0.210 0.213 0.101 0.104
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1:200 1:400 1:800 1:1,600 1:3,200 1:6,400 1:12,800 1:25,600 1:51,200 1:102,400

















Negative Control  Figure 66: ELISA test of bleed to of all rats














































1.43 1.41 1.32 1.39 1.61 1.29 0.18 0.21 0.19 0.18 0.11 0.12
1.32 1.32 1.32 1.28 1.68 1.37 0.11 0.12 0.11 0.13 0.17 0.17
1.39 1.39 1.42 1.34 1.65 1.41 0.16 0.18 0.17 0.18 0.18 0.18
1.41 1.45 1.48 1.36 1.63 1.41 0.17 0.18 0.19 0.21 0.17 0.19
1.40 1.48 1.41 1.27 1.65 1.43 0.16 0.16 0.17 0.22 0.20 0.21
1.37 1.39 1.31 1.24 1.66 1.36 0.16 0.18 0.23 0.27 0.19 0.20
1.29 1.37 1.26 1.22 1.69 1.35 0.15 0.16 0.23 0.25 0.14 0.14
1.22 1.36 1.23 1.17 1.76 1.39 0.10 0.12 0.17 0.22 0.21 0.22
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% of Total In Cell
x2 because (I used 50 µl instead of the 
100) + Supernatant Value
To Find Original Total In Cell
20.47 22.87 22.63 20.84 12.31 15.58 
 
 	 	 
 
14.73 15.28 14.62 16.99 16.58 19.41      	
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18.60 17.69 19.61 25.64 19.59 23.04 	 
 	 	  

19.22 20.75 25.74 30.26 18.23 22.73 	 	 	 	
  	
18.46 18.93 26.40 29.23 13.95 16.67 
  	 	  
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
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 
   
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    
24.08 25.49 25.20 26.12 24.19 25.48   
   	
23.60 21.08 25.21 24.83 24.16 25.35 	     
25.56 25.55 27.92 32.05 26.30 25.13     	 

23.23 24.58 28.29 33.38 25.64 23.35 	     	
18.41 19.38 27.04 31.67 19.92 18.72      
24.87 26.56 33.17 36.42 21.72 28.66    	 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1.84 1.90 1.81 1.79 1.63 1.80 0.17 0.19 0.21 0.18 0.11 0.09
1.74 1.77 1.60 1.58 1.69 1.66 0.11 0.10 0.17 0.19 0.17 0.16
1.77 1.78 1.44 1.42 1.60 1.70 0.15 0.16 0.36 0.35 0.18 0.15
1.72 1.75 1.24 1.20 1.61 1.78 0.18 0.19 0.50 0.51 0.17 0.18
1.73 1.74 1.08 1.06 1.61 1.25 0.14 0.16 0.54 0.56 0.19 0.44
1.74 1.79 1.05 1.03 1.62 1.14 0.17 0.16 0.59 0.61 0.17 0.53
1.79 1.79 1.04 1.01 1.61 1.24 0.15 0.16 0.62 0.56 0.12 0.41
1.75 1.80 1.08 1.06 1.73 1.20 0.11 0.09 0.55 0.43 0.20 0.54
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% of Total In Cell
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To Find Original Total In Cell
15.83 16.89 18.76 16.90 11.41 9.44     
 
11.04 9.96 17.53 19.06 16.34 15.82  	    	
14.66 14.83 33.46 32.83 18.03 15.25 	     
17.55 17.69 44.49 45.80 17.52 16.59      
14.02 15.37 49.86 51.47 19.10 41.20    
  
16.10 15.33 52.96 54.02 17.18 48.04 	     
14.60 15.09 54.19 52.72 13.16 39.69   	  
 
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 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16.18 16.18 40.04 43.07 19.06 21.22  
  	  
19.15 18.81 47.80 49.71 19.53 30.90      	
17.98 17.77 47.28 51.63 18.78 35.92   
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1.27 1.26 1.28 1.28 1.39 1.11 0.18 0.20 0.19 0.16 0.11 0.11
1.18 1.23 1.19 1.24 1.49 1.16 0.12 0.12 0.13 0.12 0.16 0.15
1.23 1.23 1.22 1.22 1.46 1.18 0.15 0.16 0.18 0.20 0.16 0.17
1.26 1.25 1.19 1.15 1.45 1.20 0.18 0.17 0.22 0.23 0.17 0.16
1.18 1.23 1.13 1.08 1.47 1.19 0.14 0.15 0.21 0.22 0.19 0.20
1.26 1.26 1.13 1.11 1.51 1.17 0.15 0.15 0.20 0.22 0.17 0.19
1.24 1.24 1.14 1.12 1.45 1.16 0.13 0.15 0.21 0.22 0.13 0.15
1.19 1.18 1.09 1.08 1.57 1.24 0.09 0.09 0.15 0.16 0.19 0.21
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1.19 1.19 1.96 2.17 1.71 1.71 0.0898 0.093 0.0937 0.1 0.0928 0.0945
1.23 1.18 1.95 2.12 1.7 1.72 0.148 0.164 0.165 0.17 0.161 0.169
1.23 1.14 1.93 1.94 1.72 1.69 0.164 0.184 0.19 0.2 0.184 0.177
1.16 1.17 1.66 1.71 1.68 1.66 0.16 0.178 0.363 0.36 0.18 0.191
1.08 1.14 1.34 1.4 1.59 1.61 0.236 0.275 0.655 0.72 0.273 0.274
1.14 1.11 1.22 1.19 1.64 1.63 0.205 0.235 0.615 0.65 0.249 0.267
1.18 1.12 1.2 1.26 1.61 1.67 0.131 0.15 0.62 0.52 0.176 0.191
1.24 1.24 1.3 1.44 1.67 1.69 0.178 0.222 0.7 0.69 0.262 0.263
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
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NIP-HSA Antigen Concentration (ng ml   )
RBL-2H3.1 Expressing Human FcεRIα + Human IgE + NIP-HSA
RBL-2H3.1 Expressing Equine FcεRIα + Equine IgE + NIP-HSA
RBL-2H3.1 Expressing Canine FcεRIα + Canine IgE + NIP-HSA
RBL-2H3.1 Expressing Human FcεRIα No IgE + NIP-HSA
RBL-2H3.1 Expressing Human FcεRIα No IgE + NIP-HSA





























1.39 1.42 2.26 2.35 1.62 1.68 0.127 0.118 0.097 0.11 0.107 0.119
1.61 1.45 2.32 2.16 1.65 1.76 0.128 0.125 0.114 0.105 0.101 0.117
1.41 1.43 2.19 2.38 1.7 1.63 0.138 0.129 0.114 0.128 0.105 0.115
1.61 1.44 2.19 2.11 1.6 1.63 0.136 0.14 0.123 0.119 0.115 0.12
1.61 1.4 2.12 2.39 1.58 1.65 0.125 0.123 0.114 0.119 0.124 0.104
1.61 1.4 2.18 2.12 1.61 1.63 0.131 0.151 0.117 0.134 0.12 0.125
1.43 1.37 2.24 2.42 1.63 1.65 0.139 0.136 0.12 0.139 0.118 0.131
1.41 1.34 2.16 2.16 1.65 1.65 0.15 0.147 0.134 0.142 0.139 0.128
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
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B  Figure 7: Release assays of bleed 2












 Figure 68: Concept behind immunization leading to
  massive anaphylactic shock.     223
 Figure 69: Equine and Canine IgE Cε3


























 Figure 70: Locations of potentially immogenic
  sequences to raise non-anaphylactic
  anti self IgE antibodies.     229
 Table 1: Kinetic analysis table.    174
EvilFit Distribution Model    





Horse IgE - Horse FcεRIα 
15122010 1.58x10
-10 6.33x109 2.44x10-5 124.64 0.74 yes
Horse IgE - Human FcεRIα 
25062010 4.66x10
-9 2.15x108 1.20x10-4 7.24 0.61 Broad Distribution
Horse IgE - Dog FcεRIα 
27062010 1.93x10
-8 5.18x107 4.81x10-5 40.67 0.24 yes
Dog IgE - Horse FcεRIα 
16122010 5.43x10
-10 1.84x109 4.75x10-5 161.09 0.63 yes
EvilFit Discrete One Site




Horse IgE - Horse FcεRIα 
15122010 1.09x10
-9 1.51x10-4 166.8 1.66
Horse IgE - Human FcεRIα 
25062010 5.77x10
-9 2.24x10-4 6.4 0.60
Horse IgE - Dog FcεRIα 
27062010 6.89x10
-9 3.50x10-4 14.8 0.64
Dog IgE - Horse FcεRIα 
16122010 1.37x10
-9 1.22x10-4 168.3 0.90
Original Fit Using One Site Model




Horse IgE - Horse FcεRIα 
15122010 1.70x10
-10 3.80x10-4 159 5.11 
Horse IgE - Human FcεRIα 
25062010 5.26x10
-7 1.30x10-5 3 0.75 
Horse IgE - Dog FcεRIα 
27062010 4.03x10
-6 1.60x10-3 999 0.94 
Dog IgE - Horse FcεRIα 
16122010 1.20x10
-10 1.90x10-4 176 1.90 









Horse IgE - Horse FcεRIα 
15122010 0.78 No cc 8.53x10-10 1.20x10-4 1.01x10-7 1.19x10-2 1.86x10-6 0.24
Horse IgE - Human FcεRIα 
25062010 0.59 No cc 4.54x10-9 1.42x10-4 6.11x10-8 6.98x10-3 8.43x10-6 0.16
Horse IgE - Dog FcεRIα 
27062010 0.25 No cc 2.31x10-8 1.74x10-4 1.61x10-7 1.59x10-2 2.94x10-6 0.57
Dog IgE - Horse FcεRIα 
16122010 0.64 No cc 1.26x10-9 1.13x10-4 2.67x10-7 1.59x10-2 1.10x10-7 0.16
 Table 2: EvilFit Distribution Model.   178
Host Antibody Isotype Target Ka (M) Reference
Mouse Antibody IgG3 Human FG loop 1.3x106
Athanassios Vratimos, 
PhD Thesis, University 
of Sheffield, 2003
Mouse Antibody IgG3 Human AB helix 2.4x105
Athanassios Vratimos, 
PhD Thesis, University 
of Sheffield, 2003
Mouse Antibody IgG3 Human Cε2-3 loop 4.7x104
Athanassios Vratimos, 
PhD Thesis, University 
of Sheffield, 2003
Mouse Antibody IgG2A Canine FG loop 9.01x104
Athanassios Vratimos, 
PhD Thesis, University 
of Sheffield, 2003
Mouse Antibody IgG1 Canine Cε2-3 loop 2.88x106
Athanassios Vratimos, 
PhD Thesis, University 
of Sheffield, 2003
Rabbit Antibody Polyclonal Human Cε2-3 loop 7.1x106
Ian Sayers, PhD Thesis, 
University of Sheffield, 
1997  Table 3: Anti IgE antibodies.     187
 Table 4: Sequence of the Cε2-3 linker




Bleed 1 Bleed 2 Bleed 3






Immunised with the 2Fcε2-3 peptide Boosted 1 with the 2Fcε2-3 peptide Boosted 2 with the 2Fcε2-3 peptide
Immunised with the 2Fcε2-3 peptide Boosted 1 with the 2Fcε2-3 peptide Boosted 2 with the 2Fcε2-3 peptide
Immunised with the 2Fcε2-3 peptide Boosted 1 with HDH IgE Boosted 2 with HDH IgE
Immunised with the 2Fcε2-3 peptide Boosted 1 with HDH IgE Boosted 2 with HDH IgE  Table 5: Rat immunization strategy.    214
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Chapter 1 - Introduction:
1.1 - Overview:
Allergy is an inflammatory  disease that  has been observed since ancient times, it 
was first scientifically  tested by Charles Blackley in 1873 when he used aqueous pollen 
extracts on himself (a hayfever allergy sufferer) to prove that pollen is the cause of 
immediate skin inflammation reaction (Chapman, 1998). But the condition and the 
allergy causing agents were first defined by  Clemens Freiherr von Pirquet who 
discovered that  second injections of horse serum or small pox vaccine caused a severe 
reaction in some individuals. He termed this condition allergy from the Greek words 
allos “other” and ergon “works” and thus the allergy causing agent “allergen”(von 
Pirquet, 1906). Robert Cook in 1916 published a paper showing that allergy  has strong 
familial inheritance, and in the 1960s the Ishizakas demonstrated that allergic reactions 
are mediated by a new class of antibodies that they called immunoglobulin E 
(Chapman, 1998; Ishizaka, et al., 1966).
An article dated June 13 2008 in the Healthcare Financial News stated that US$11 
billion are spent on allergy annually in the USA alone, which has doubled since the year 
2000 (Merrill, 2008). 54.6% of Americans suffer from some type of allergic 
manifestation (Cohn, et al., 2006) while in the UK all allergies have been on the 
increase since 1955 (Anderson, et al., 2007), though some data show stability  and a 
slight decrease during the late 1990s and early 2000s (Gupta, et al., 2007), which may 
be due to awareness of the condition and other health factors. This shows that allergy  is 
a serious lifestyle altering disease where many people suffer from, and the health care 
industry spends a lot of money on combating. Though many allergies are associated 
with undesirable and often long-term debilitating side effects, food and insect venom 
allergies can be lethal.
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Allergy is common in males before puberty, but in females after puberty 
(Almqvist, et al., 2008). This phenomenon has been linked to sex hormones where 
asthma has shown to increase with irregular menstruation, intake of contraceptives, post 
menopause, during pregnancy  or undergoing hormone replacement therapy (Jensen-
Jarolim and Untersmayr, 2008). It was discovered that mast and basophil cells express 
estrogen alpha receptor (ER-α), an estrogen receptor (Zhao, et al., 2001), which in the 
presence of estrogen can cause the cells to release mediators (Zaitsu, et al., 2007).
Allergic diseases are not inherited, the tendency  of developing an allergic disease 
is due to deficiencies in the immune system. Atopic patients genetically overproduce 
IgE even in the absence of allergic disease (Ono, 2000). A study has shown that 
monozygotic twins have a 60%-70% higher tendency of developing allergy than 
dizygotic twins, suggesting a strong genetic factor (Duffy, et al., 1990). But identifying 
the genes responsible for the risk of allergy  development proved difficult  due to the 
complex way they function (Ono, 2000). A papery  by (Weidinger, et al., 2008) have 
done a human genome wide scan and identified SNPs and gene sites, such as SNPs 
within the FCER1A gene which codes for the FcεRI receptor. when these genes are 
inherited, they cause humans to develop high IgE serum concentrations, which gives 
them the tendency to develop allergy
There is a hypothesis called the Hygiene Hypothesis and it states that lack of 
exposure to infectious pathogens in early childhood can lead to inadequate immune 
system development which can result in an increase in susceptibility  to develop allergy 
(Strachan, 1989; Strachan, 2000). Further study in the immunology pathway has shed 
light into the viability  of this hypothesis, and some groups are researching an allergy 
cure through it.
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1.2 - The Immune Response and The Allergy Pathway:
The allergy pathway  is the same pathway as the parasitic immunity. The parasitic 
immunity  pathway is very  effective, though it also threatens the host by sensitizing it 
against innocuous substances, if the pathway makes an error, giving it allergy. Some 
mechanisms do exits to protect the host organism from autoimmunity, including allergy, 
which includes compartmentation of B and T cells, within the lymphatic system, so as 
to minimize interactions with self antigens (Gould et al., 2003) as well as producing 
large enough quantities of IgE to saturate mast and basophil cells’ surfaces and thus 










































Figure 1: The allergy pathway:
This is a summary diagram that explains how allergy develops. 
A. the allergen enters the body and penetrates the mucosal tissue 
to the tissue fluid. B. in the tissue fluid, an APC (in this case 
dendritic cells) take up the allergen molecule, breaks it down 
and present its epitopes through the MHC II receptor. The 
activated antigen presenting cells then migrate to the nearest 
lymph node C. where they activate T cells that recognize the 
allergen on the MHC II through their T cell receptor and co-
stimulated by the CD28 and B7 receptors. They  then give the 
decision for the T cell to differentiate to T help  type 2 (Th2) cell. 
D. at  the same time, B cells recognize the allergen through their 
B cell receptor and through the activated Th2 cell E. the B cell 
would be activated through the CD40 and CD40L receptors. F. 
the activated B cell would differentiate into plasma cells that 
actively synthesize antibodies initially IgM. Cytokines secreted 
from the Th2 cell (IL-4) cause the B cell to undergo antibody 
class switching from IgM to IgE. G. the IgE antibody, that now 
recognizes epitopes on the allergen molecule, circulates around 
the body through the lymphatic and cardiovascular systems and 
finally binds to its high-affinity  IgE Fc receptor (FcεRI) on mast 
and basophil cells. H. when the allergen re-enters the body at a 
later time it binds to the IgE’s variable region, which is on the 
cell surface, causing an aggregation of the receptor and thus a 
downstream signal that results in the cell releasing mediators. 
Some of these mediators are histamine, causing inflammation, 
and IL-4, which affects more plasma cells to undergo class 
switching to IgE and thus the cycle continues.
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The pathway starts by the introduction of an allergen to the body (Figure 1 A). 
Allergens are capable of penetrating the mucosal tissue very  effectively  and thus enter 
the tissue fluid. There they are taken up by  antigen presenting cells (APC), usually 
dendritic cells, where they are fragmented by breaking down the protein’s covalent and 
disulphide bridges resulting in smaller peptides (Unanue and Allen, 1987). The 
processed allergen causes the APC (in this case a dendritic cell) to polarize either into a 
DC1 or DC2 polarization depending on the type of antigen being processed, bacterial 
and viral antigens causes DC1 polarization and parasitic extracts causes DC2 
polarization. These polarization states is what induces the Th0 cells to differentiate into 
Th1 or Th2 cells (Gould, et al., 2003; de Jong, et al., 2002). The processed antigen is 
then presented on the cell’s surface using the mega histocompatibility complex II (MHC 
II) receptor (Figure 1 B) exposing its epitopes. The activated APC cell then migrates to 
the nearest lymph node, where it is actively directed towards the subcortical zone and 
interacts with T cells and activates them (Figure 1 C) (Havenith, et al., 1993; Roitt, 
2001; Gould, et al., 2003). Some theories state that the APC polarization decision might 
be coming from the microenvironment (Lambrecht, 2001) and not from the allergen 
itself. Experiments have shown that dendritic cells found in the spleen produce IFN-γ 
which causes T cell there to differentiate to Th1 cells (Iwasaki and Kelsall, 1999), while 
dendritic cells found in aggregated lymphoid nodules (Peyer's patches) tend to causes T 
cell there to differentiate to Th2 cells (Stumbles, et al., 1998). Therefore given a suitable 
cytokine environment, any molecule can be made to induce an IgE response.
T cell differentiation occurs when a naïve T cell (Th0) is activated by recognizing 
an antigen through its T cell receptor when it is presented to it  by an ACP (dendritic 
cell, macrophage or in some occasions B cell) through the MHC II receptor, then co-
stimulated though its CD28 receptor by  B7 protein on the antigen presenting cell’s 
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surface (Roitt, 2001; Linsley, et al., 1990). In Th1 cell development, the antigen 
presenting cell will also release IL-12 which activates STAT-4 (a protein transcription 
factor) which synthesis T-bet (another protein transcription factor) that results in the 
synthesis of IFN-γ. The secretion of IFN-γ by Th1 cells causes B cells to undergo 
antibody class switching to IgG and inhibits the development of Th2 cells (O’Shea and 
Paul, 2002). In the absence of IL-12, the default pathway would be for the Th0 cell to 
differentiates to a Th2 cell when it express GATA-3 (a protein transcription factor) 
which in turn promotes the cell to express and release IL-3, IL-4, IL-5, IL-9, IL-10, 
IL-13 and GM-CSF. The secretion of IL-4 causes B cell to undergo class switching to 
IgE and it also stops Th1 cell differentiation by inhibiting IFN-γ (Nawijn, et al., 2001; 
Gould, et al., 2003; Howard and Paul, 1982).
B cells produce the antibody light chain variable region by random organization 
of the Vκ and Jκ and genes on chromosome 2p11.12, or the Vλ and Jλ genes on 22q11.2 
(Tonegawa, 1983; Paul, 1999). The antibody's heavy chain variable region is assembled 
from V (Variable), D (diversity) and J (joining) genes at chromosome 14q32. Naïve B 
cells have their heavy chain variable region VDJ recombinant genes joined immediately 
to Cµ, therefore they express IgM by default. These cells mature in the bone marrow to 
make sure their new variable region does not recognize self antigens. Once the B cell 
matures it expresses the variable region through the B cell receptor on its surface it 
migrates to germinal centers in lymph nodes. B cell receptors are made up  of IgM 
antibodies bound on to CD79 on the surface of the cell, enabling the cell to detect the 
antigens it  is designed for. The B cell is activated when it  detects its antigen (allergen in 
the case of allergy) (Figure 1 D) and receives a signal from activated T cells by binding 
the T cell’s CD40L receptor into to the B cell’s CD40 (Figure 1 E). Once the B cell is 
activated it differentiates into memory cells and plasma cells. The decision for B cells to 
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differentiate into plasma cells in germinal centers of the lymph nodes occurs in the 
presence of IL-10 from Th2 cells which affects B cells to up regulate CD27 on their 
surface and thus differentiate to plasma cells (Jung, et al., 2000). Activated T cells 
secrete certain cytokines that affect the activated B cell and cause it to undergo class 
switching. In cases of allergy, Th2 cells mainly secrete IL-4 that causes the B cell to 
premaritally  switch from IgM  to IgE antibodies (Figure 1 F) (Roitt, 2001; Manis, et al., 
2002; Li, et al., 2004), this is called antibody class switching. Plasma cells secrete 
~0.1ng of immunoglobulin per day, this is large as antibody synthesis is ~50% of the 
total protein synthesis by these cells (Hibi and Dosch, 1986).
Antibody class switching occurs when cytokines from Th2 cells (IL-4 mainly) 
binds to receptors on the B cell and causes it to remove the Cµ, Cδ, Cγ and Cα genes 
and thus the VDJ genes bind to Cε genes that code for the Cε1-4 domains of the IgE 
antibody heavy chain (Roitt, 2001; Gould, et al., 2003; Manis, et al., 2002; Li, et al., 
2004). In-vitro class switching is a slow process, where switching from the µ chain to 
the ε chain can be achieved by incubating B cells with Th cells and IL-4. The B cells 
would start to secrete IgE after 10 days of incubation (Gauchat, et al., 1990).
The antibody affinity  to the allergen changes over time, usually increasing, this is 
achieved by somatic hypermutation because activated B memory cells undergo high 
rates of mutations in areas of the DNA called hyper variable regions. This results in new 
daughter B cells with slightly different binding affinity to the original antigen. In later 
activations the B cells producing antibody variable regions with the highest binding 
affinity would be activated and differentiate much quicker that the other B cells 
expressing lower binding affinity variable regions. Thus the immune system would 
better target antigens the more frequent it  encounters them (Roitt, 2001; Teng, et al., 
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2007; Rajewsky, et al., 1987). In terms of allergy, the atopic person becomes more 
sensitive to the allergen.
Following the active production of IgE by plasma cells, this antibody would 
circulate the body through the lymph and cardiovascular systems until it finally binds to 
its high-affinity receptor (FcεRI) found on mast and basophil cells (Figure 1 G) or its 
low-affinity receptor (FcεRII) found on B cells, T cells and Langerhans cells. For the 
mast and basophil cell to be maximally  sensitized by IgE to an allergen the antibody 
only needs to bind to 10% of the FcεRI receptors on the cell’s surface (MacGlashan and 
Schroeder, 2000). These cells are the primary mucosal tissue cells that  cause immediate 
hypersensitivity  inflammation (Ehrlich, 1877; Metcalfe, et al., 1997). They have 
granules in their cytoplasm which are vesicles filled with pre-synthesized mediators. 
Upon the cross linking of the FcεRI receptor on the cell surface, when an allergen binds 
to several IgE antibodies, a downstream signal cascade occurs resulting in these vesicles 
migrating and fusing with the plasma membrane, releasing their contents into the 
surrounding tissue fluid (Figure 1 H) (Roitt, 2001; Gould, et al., 2003; Helm, et al., 
1991a). These mediators contribute to the signs and symptoms of immediate-type 
hypersensitivity  (Hypersensitivity Type I). One of these mediators is histamine which 
causes the five symptoms of inflammation: heat, pain, redness, itchiness and swelling 
(Herzenberg, et al., 1996). Some mediators are pre-synthesized such as: histamine, 
proteoglycan, neutral proteases such as β-glucosaminidase, neutrophil chemotactic 
factor, eosinophil chemotactic factor, platelet activating factor, IL-3, IL-4, IL-5, IL-6, 
TNF-α and GM-CSF. Therefore these mediators are released immediately  when a mast 
cell degranulates and they  cause the immediate-type hypersensitivity  symptoms. Later 
on after activation, other mediators are synthesized, through the lipoxygenase and 
cyclooxygenase pathways, and thus their release is delayed. Some of these mediators 
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are: prostaglandins, thrombmoxanes, leukotrienes C4, D4 and B4, and more TNF-α, GM-
CSF, macrophage inflammatory protein-1α, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10 and 
IL-13. These mainly  cause the recruitment of eosinophils (the parasite fighting 
neutralizing cell), but also macrophages, neutrophils and Th2 cells to the site of 
inflammation and this causes the signs and symptoms of delayed-type hypersensitivity 
































































Figure 2: Mast cell effector locations:
Mast and basophil cell mediators affect many other types of 
cells, they cause the epithelial cells to secrete mucous to wash 
away the allergen, they cause the nerve cells to signal pain to 
alarm the host, and cause itchiness to physically  remove the 
allergen from the skin surface, they also cause smooth muscles 
to contract to localize the allergen and prevent it from spreading 
around the body, incase of wound development they cause 
fibroblasts to activate and heal the wound, they also stimulate 
other leukocytes and recruit them to the site of inflammation to 
actively neutralize and remove the penetrated allergen and to 
produce more antibodies (figure inspired from Bischoff, 2007).
Mast and basophil cell mediators affect many  nearby cells, which have the 
receptors for the specific mediators they release. They  affect epithelial cells and 
stimulate them to secrete mucous which washes away  the allergen and expel it from the 
body, for example by coughing. They  stimulate nerve cells and cause them to signal 
pain which alarms the host, and produce the itchiness sensation in the location of the 
inflammation to physically remove the allergen, the nerve cells would also causes 
smooth muscles to contract to localize the allergen and prevent it from spreading around 
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the body. Incase of wound development the mediators would also cause fibroblasts to 
activate and heal the wound. They also stimulate other leukocytes (B cells, eosinophils 
ect.) and recruit them to the site of inflammation to actively neutralize and remove the 
penetrated allergen, and to produce more antibodies (Figure 2) (figure inspired from 
Bischoff, 2007).
Mast and basophil cell mediators are a combination of molecules each having a 
different, but overlapping, biological function and they can be categorized into three 
groups: preformed secretory granule-associated mediators (e.g: histamine, β-
hexosaminidase), lipid-derived mediators, and cytokines.(Metcalfe, et al., 1997). One of 
the cytokines mast cells release is IL-4, which re-stimulates Th2 cells and causes more 
plasma cells to undergo class switching to IgE, this is a positive feedback loop which 
ensures the continual production of IgE (Gould, et al., 2003; Abehsira-Amar, et al., 
1992; Mills, et al., 1992; Bieber, et al., 1989) even in the absence of allergen exposure, 
thus explaining why allergy persist  in patients even after prolonged absence of allergic 
reactions (Smurthwaite, et al., 2001), this can be caused through selective survival of B 
cells if they  undergo many cell divisions (Gould, et al., 2003 and Okudaira, et al., 
1981). Many allergens in fact give rise to IL-4 synthesis and secretion prior to IgE 
synthesis which can contribute to the first stimulus for subsequent development of IgE-
mediated allergies (Machado, et al., 1996). The (Okudaira et al, 1981) paper has found 
that the majority of IgE-secreting plasma cells are resistant to large doses of radiation, 
which makes them resistant to apoptosis. Thus target organs continually  have their mast 
cells sensitized with IgE. The review by  (Gould, et al., 2003) discussed that germinal 
centers appearing in lymph nodes near affected target organs, there plasma cells 
continually synthesis IgE which binds to the mast cells in the nearby tissue even in the 
absence of allergen. Receptor occupancy with IgE even in the absence of allergen leads 
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to an increase in IgE receptor expressing by mast and basophil cells and affects the 
cytokine pattern of these cells (Kinet, 1999), therefore inhibiting IgE synthesis reduces 
the quantity of receptor bound IgE and thus down regulates receptors on the mast and 
basophil cell’s surface, which results in reduction in sensitization to allergens. This 
concept is used later in this project as a basis behind the development of an allergy 
vaccine (Chapter 8).
Allergy commonly develops during early childhood as a result the human 
adaptive immune response being shifted towards the Th2 cell arm when a child is born. 
This is due to placental cells producing IL-4 to inhibit the mother’s cytotoxic leukocytes 
and natural killer cells from attacking the fetus, which is expressing non-maternal 
antigens, this has an effect on the fetus’ T cells and thus the fetus is born with a 
polarized immune response towards the Th2 cell arm. The immune system shifts 
towards the Th1 cell arm by  the introduction of environmental bacterial and viral 
infections later on in life (Roitt, 2001; Prescott, et al., 1998).
1.3 - The Allergen Antigen:
Allergens are one of the essential parts of the allergy  pathway as their structure is 
thought to dictate whether the antigen presenting cell would activate the Th0 cells 
differentiation into Th2 cells. These allergen antigens are one of the most well studied 
proteins in molecular biology due to their significance in medicine (Chapman, 1998). 
They  have a specific nomenclature established by the World Health Organization in 
1994 and its basis are the taxonomic name of the source of the first purified allergen, 
three letters from the genus followed by the first letter of the species followed by an 
arabic numeral in order of purification from the same source. For example the first 
allergen to be purified was from Ragweed Ambrosia artemisiifolia, thus this allergen is 
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called Amb a 1 (Chapman, 1998; Ishizaka, et al., 1966) this was the actual allergen that 
lead to the discovery of IgE.
Allergens have several characteristics that makes them excellent candidates for 
type I hypersensitivity; they all have low molecular weights (5-50 kDa), and they are 
strongly hydrophilic, which makes them readily  penetrate the mucosal tissue. Some 
organic molecule allergens, such as penicillin, need to be conjugated to protein carriers 
(albumin) for them to cross link IgE (Chapman, 1998). The reason allergens are capable 
of cross linking IgE is because they have multiple repeats of epitopes (Beezhold, et al., 
1997; Roitt, 2001) which makes one allergen molecules bind to several IgE antibodies 
and thus, on the surface of mast and basophil cells, this will aggregate the FcεRI 
receptor causing degranulation.
Examples of common allergens: peanuts (Ara h 1) vicilin which is a seed storage 
protein, bee venom (Api m 1) which is phospholipase A2, pollen (Amb a 1) which is 
pectate lyase, house dust  mite (Der p  1) which is a protease, dogs (Can f 1) which is a 
salivary protein (Chapman, 1998; Konieczny, et al., 1997). As seen from this small list, 
most allergens are proteolytic enzymes, and their enzymatic activity  further contributes 
to them readily penetrating mucosal tissues, and causing the immune system to react 
against them using the Th2 immune response arm (Dudler, et al., 1995; Machado, et al., 
1996; Chapman, 1998). But there are also other allergens that are not enzymes such as 
β-lactoglobulin (found in cow milk), still with an un-determined function (Chapman, 
1998).
The allergen enzymatic activity, or lectin type activity, causes dendritic cells to 
release IL-4 that shifts the immune response towards the Th2 arm (Machado, et a.l, 
1996). This has been demonstrated in the paper by  (Dudler et al, 1995) where an 
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enzymatically functional bee venom, phospholipase A2, was introduced into mice in low 
concentration, these mice developed IgE antibodies against the venom. But when the 
same molecule with a non-functional enzymatic activity  was introduced in the same low 
concentration, the mice did not developed IgE antibodies against it. At high enough 
concentration, both the functional and non-functional forms of the venom developed 
immunological responses.
Patients typically  develop asthma if they are exposed to an airborne allergen at 
levels greater than 1 µg year-1, therefore a protocol where infants (0-3 years old) were 
avoided exposure to allergens showed effectiveness in preventing allergies (Simpson, et 
al., 2003)
1.4 - The Immunoglobulin E Antibody:
Binding of several allergens onto many IgE molecules and aggregating them 
initiates allergy symptoms, since the IgE is already bound to its high-affinity  FcεRI 
receptor and acts as sensors on the mast and basophil cells’ surface. IgE is the least 
common antibody in serum and thus it was the last antibody to be discovered by the 
Ishizakas in 1966 (Ishizaka, et al., 1966). Its size is ~192kDa with a half life in serum of 
~3 days, compared with IgG which is ~20 days, the reason for this is that  most of the 
IgE in the body is removed from the serum by binding to basophil and mast cells in 
tissue (Iio, et al., 1978).
There are 5 antibody classes: IgA, IgD, IgE, IgG and IgM (Roitt, 2001). They all 
have a basic structure of two light  (small) chains, two heavy (large) chains, a variable 
region, where the antigen binds, and a constant region made up of several domains with 
internal disulphide bridges (Figure 3). The Fab region contains a variable domain and a 
constant domain in the light chain and a variable domain and the Cε1 domain of the 
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heavy  chain. The light chain and the heavy chain are connected through two disulphide 
bridges, and the two variable domains construct the variable region of the antibody 
where it  binds to its antigen, or the allergen in allergic reactions. The Fc region, made 
up of the two heavy chains connected by two disulphide bridges, is the section of the 
antibody which determines its identity and thus its effector cell type. Contrary to other 
antibodies, IgA, IgD and IgG who have a hinge region, IgE does not have one, it is 
replaced by Cε2, just like IgM (Roitt, 2001). There are two disulphide bridges between 
the Cε2 domains of the two heavy  chains, thus linking the two heavy chains together 
(Helm, et al., 1991b) The nature of the disulphide bridges arrangement is disputed, early 
biochemical evidence (Takatsu, et al., 1975) indicates a parallel arrangement, and so do 
protein chemical studies. There are 5 heavy chain classes: α, δ, ε, γ and µ, but only  2 
types of light chains: κ and λ. IgA and IgG have subclasses due to small sequence 
differences in their heavy chains and their important roles it the wider immune 
response: IgA1, IgA2, IgG1, IgG2, IgG3 and IgG4 (Gould, et al., 2003), this results in 
small adjustments in the binding to different types of target cells during different  types 
of infections. The IgE antibody has three domains in its Fc region, Cε2, Cε3 and Cε4, 
the molecule’s Cε3 domain is the site where the antibody actually binds to the FcεRI 
receptor’s α chain where the strongest binding between the IgE and the FcεRI receptor 
occurs at pH 6.4 and 7.4 (Helm, et al., 1996; Garman, et al., 2000). All heavy chain 




































Figure 3: Structure of immunoglobulin E:
The immunoglobulin E (IgE) antibody is composed of two 
chains, the light (small) chain and the heavy (large) chain. The 
Fab region contains the light chain and part of the heavy chain 
connected through a disulphide bridge, they each are composed 
of two globular domains, and they  both compose the variable 
region where the antibody binds to the antigen it recognizes. The 
Fc region is composed of the other half of the two heavy chains, 
where they  are bound together by a disulphide bridge. The Fc 
region contains Cε2, Cε3 and Cε4 constant  domains. The Cε3 is 
the constant domain and the site where the IgE binds to the 
FcεRI receptor.
Once the IgE binds to its FcεRI receptor, it physically associates and competes 
with the FcγR receptors (which binds IgG) for their common γ chain, the rivalry ends 
with the down regulation of the FcγR receptors in favor of FcεRI receptor (Ra, et al., 
1989; Kurosaki, et al., 1992; Scholl and Geha, 1993; Gould. et al., 2003). IgE can also 
bind to its low-affinity Fc receptor (FcεRII, also known as CD23), though this receptor 
is not classified as an immunoglobulin receptor and more as a lectin receptor (Weis, et 
al., 1998) and its function is to capture serum IgE, that has bound to an allergen, and 
transport the allergen to APCs which activates them and allows for the continual 
maintenance of the Th2 arm immune response. Back to the high-affinity  receptor, once 
IgE binds to the FcεRI receptor it has a half life of ~20 hours (McDonnell, et al., 2001) 
but the restricted diffusion in tissue causes the IgE to rebind to the cell’s surface 
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increasing its half life to ~14 - ~21 days (Ishizaka and Ishizaka, 1971; Geha, et al., 
1984).
IgE is the least abundant antibody in serum, its concentration is ~150ng ml-1 for 
healthy individuals (King, et al., 1991) ~6ng ml-1 of which are allergen specific IgEs 
(Smurthwaite, et at., 2002), compared to 10mg ml-1 for IgG which is the most abundant 
antibody in serum (King, et al., 1991), though sometimes the level of IgE can increase 
to up  to three times the normal level without any signs of inflammation (Patterson, et 
al., 1975). On the other hand, atopic individuals have up to ten times the normal IgE 
level, and if the type of IgE in atopic individuals was analyzed it will show 
approximately one thousand times the normal level of IgEs that are allergen specific 
(Smurthwaite, et at., 2002).
The 11 amino acids found in the Cε3 domain Pro343-Ser353 (PSPFDLFIRKS) also 
called the AB helix (Figure 3), were found to be essential to the binding of the IgE 
molecule to the FcεRI receptor, removal of this sequence results in a complete loss of 
binding of the IgE molecule to the FcεRI receptor. Though this sequence does not 
interact nor bind to the FcεRI receptor, but it does provide structural scaffolding that 
allows the Cε3 domain to be positioned in the right orientation and shape for it  to bind 
to the FcεRI receptor (Helm, et al., 1996). On the other hand this region contain the 
binding site for FcεRII receptor (Sayers, et al., 2004).
The IgE molecule is N-glycosylated at different sites: three in Cε1, one in Cε2 and 
two in Cε3 (Herzenberg, et al., 1996). Oligosaccharides mask epitopes otherwise 
exposed to anti-IgE antibodies, mainly in Cε2 (Björklund, et al., 1999) though the 
absence of Cε3 oligosaccharides does not affect the binding of the IgE to the FcεRI 
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receptor (Wurzburg, et al., 2000; Helm, et al., 1996) as the confirmation of the Cε3 
structure is maintained by the AB helix (Pro343-Ser353).
The binding affinity between the IgE antibody  and its antigen can change through 
Somatic hypermutation, which is point mutations occurring in the variable region after 
the B cell has rearranged its variable region and matured. These point mutation usually 
occur in the sequence RGYW, where R = A or G, Y = C or T, W = A or T (Neuberger, et 
al., 1998). A single point mutation can cause the variable region to lose affinity  to its 
antigen, or become ten times stronger (Berek and Milstein, 1987). Chronic 
inflammation results in the local synthesis of IgE in tissue by the development of local 
germinal centers. As in arthritis (Berek and Kim, 1997) and diabetes (Ludewig, et al., 
1998) large quantities of memory cells allow for the activation of naïve B cells and 
promotes somatic hypermutation (Randen, et al., 1992) which results in the 
accumulation of long lived plasma cells in this micro-environment. This was found to 
be the case in lungs after antigenic challenges (Chvatchko, et al., 1996) which explains 
the reason behind the continues production of IgE even in the absence of antigen 
exposure.
1.5 - The High-Affinity IgE Receptor:
The high-affinity FcεRI receptor is always expressed on the surface of mast and 
basophil cells, but they only have an effect in allergy once the IgE molecule binds onto 
them, this binding is strong and results in cells to be activated against a certain allergen. 
FcεRI receptor is classified as a Multichannel Immune Recognition Receptor (MIRR) 
which makes it similar to the T cell receptor, the B cell receptor and the IgG FcγRIII 
receptor (Keegan and Paul, 1992). The receptor gene is found on the locus 1q23.2 and 
consists of an α chain (50-60 kDa) containing two immunoglobulin like domains (1 and 
2), the site where IgE binds (Garman, et al., 1999), a β chain (32 kDa), which amplifies 
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the downstream signal, and two disulphide linked γ chains (7-9 kDa each), the site 
where the downstream signal initiates, thus is it abbreviated αβγ2 (Figure 4) (Blank, et 
al., 1989; Gould, et al., 2003; Metcalfe, et al., 1997; Donnadieu, et al., 2000). This is 
the tetrameric form of the receptor which is found on mast and basophil cells with a 
concentration of ~2x105 receptor molecules per cell (MacGlashan and Schroeder, 2000). 
The receptor can also be found in a trimeric form with an αγ2 configuration which is 
found on Langerhans cell (Bieber, et al., 1992), monocyte (Maurer, et al., 1994), 
platelet (Joseph, et al., 1997) and eosinophil (Gounni, et al., 1994) membranes, at a 
much lower concentration than mast and basophil cells (Gould, et al., 2003; Garman, et 
al., 2000). This receptor configuration helps these APCs to recognize allergens which 
cause them to increase their uptake leasing to their expression and activation of Th2 
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Figure 4: Structure of the high-affinity IgE Fc receptor 
(FcεRI):
The FcεRI receptor is composed of 3 chains, one α chain with 2 
domains, the second domain is capable of binding to the two IgE 
Cε3 domain heavy  chains. One β chain which amplifies the 
downstream signal, and two γ chains bound together by a 
disulphide bridge, they are the site where the downstream signal 
initiates. Figure adapted from (Blank, et al., 1989).
Since the FcεRI receptor has one α chain capable of binding to the heavy chain of 
the IgE, and the IgE antibody has two heavy chains, the crystal structure of the IgE/
FcεRI complex has shown that the two IgE heavy chains bind at two sites on the FcεRI 
receptor’s α chain thus giving the 1:1 interaction binding ratio (Garman, et al., 2000). 
From this (Figure 5) it can be determined that the two Cε3 domains of the heavy chain 
in the IgE molecule interact mainly with the second domain of the FcεRI receptor 
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(Garman, et al., 2000) thus the first  domain acts as scaffolding to position the second 











Figure 5: Crystal structure of IgE binding to the FcεRI 
receptor:
This crystal structure shows that the Cε4 domains of the IgE and 
the first domain of the FcεRI receptor give structural support to 
assist in the interaction of the two Cε3 domains, from the IgE 
heavy  chain, with the the second domain of the FcεRI α chain 
thus giving a 1:1 interaction binding ratio. Figure was adapted 
from (Garman, et al., 2000).
Human IgE binds to the human FcεRI receptor very strongly with an equilibrium 
dissociation constant of KD = ~10-10 M (i.e: an equilibrium association constant of KA = 
~1010 M-1) (Sayers, et al., 1998; Nissim and Eshhar 1992; Helm, et al., 1996; Schuck 
and Minton 1996; Young, et al., 1995; Hakimi, et al., 1990; Miller, et al., 1989; Gould, 
et al., 2003), compared to IgG1 which is KD = 10-8 M (Ka=108 M-1) to FcγRI (Ravetch 
and Kinet, 1991). The β chain in the FcεRI receptor enhances the strength of signal 
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transduction up to 12-30 times compared to the αγ2 FcεRI receptor with a missing β 
chain (Lin, et al., 1996; Donnadieu, et al., 2000). It also assists in transporting the 
receptor into the plasma membrane (Donnadieu, et al., 2000). There are two variants of 
the β chain in humans, I181L-V183L and E237G, where there are mutations in the β 
chain, though tests have shown that these mutations do not affect the β chain 
amplification function (Donnadieu, et al., 2000) but some other polymorphisms might 
be associated with allergy  (Kinet, 1999). The FcεRI, FcγRI, FcγRII and FcγRIII all 
share the same γ chain (Ra, et al., 1989; Hibbs, et al., 1989; Ernst, et al., 1993; Scholl, 
et al., 1993; Mesuda, et al., 1993; Pfefferkorn, et al., 1994; Saito, et al., 1995; Morton, 
et al., 1995) thus they compete for it, and the cell up-regulates or down-regulates these 
receptors’ expressions depending on the immune response conditions. The binding of 
IgE to the FcεRI receptor on the cell’s surface causes the up-regulation of FcεRI 
receptor expression by ~6 folds (Hsu and MacGlashan, 1996; MacGlashan, et al., 
1999), which agrees with the paper by (Kinet, 1999) which states that FcεRI receptor 
occupancy by IgE increases its expression, or as these papers (Furuichi, et al., 1985; 
Quarto, et al., 1985; Yamaguchi, et al., 1997; Lantz, et al., 1997; MacGlashan, et al., 
1997; MacGlashan, et al., 1998; Saini, et al., 1999; Beck, et al., 2004) argues that IgE 
receptor occupancy  prevent the receptor from being internalized, and thus degraded, 
while maintaing its transcription and transportation to the surface, and thus its 
concentration on the cell surface increases. IgE FcεRII (CD23) receptor occupancy also 
prevents receptor cleavage by ADAM10 (Kisselgof, et al., 1987; Lee, et al., 1987). The 
FcεRIγ is the site of the downstream signal cascade, it also regulates the expression of 
the FcεRIα chain and prevents its degradation in the endoplasmic reticulum (Ernst, et 
al., 1993). It also contributes to the correct folding of the FcεRIα (Suzuki, et al., 1998).
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The equine FcεRIα chain is N-glycosylated 7 times at amino acid numbers 46, 67, 
79, 99, 160, 170, and 195, therefore on domain 1 there are 4 oligosaccharides, domain 2 
has 2 oligosaccharides and one oligosaccharide between domain 2 and the 
transmembrane. These glycosylations are not essential for IgE binding, but they do 
prevent the receptor from binding with adjacent receptors and aggregate on the cell 
surface, this was demonstrated where the de-glycosylated of the FcεRIα chain would 
aggregate in solution (Letourner, et al., 1995; Robertson, et al., 1993; Scarselli, et al., 
1993).
When an allergen binds to the IgE’s variable region, because of the multi epitope 
nature of the allergen, it will bind to several IgE molecules at the same time, since one 
molecule of IgE binds to one molecule of FcεRI receptor, the binding of the allergen 
causes many FcεRI receptors to come close together and aggregate on the cell surface. 
This receptor aggregation causes the downstream signal because Lyn kinase, a protein 
tyrosine kinase, is associated with the β chain. Once the receptor aggregates on the cell 
surface, Lyn is activated and tyrosine phosphorylates a certain sequence on the β and γ 
chains called immunoreceptor tyrosine-based activation motif (ITAM). At this moment 
Syk, also called spleen tyrosine kinase (since it was first discovered in the spleen, but  it 
is an ubiquitous signal transducer), binds to the γ chain where it is phosphorylated by 
Lyn and thus is activated (Cambier, 1995; Jouvin, et al., 1995). From there, the 
activated Syk phosphorylates several other proteins which results in three outcomes: 
stimulation of cytokine synthesis and release, arachidonic acid release and histamine 
release through the influx of Ca2+ ions that promotes vesicles to fuse with the plasma 

































Figure 6: Summary of the IgE/FcεRI mediated downward 
signaling:
This is a simplified diagram that shows the initial downstream 
signal protein cascade. When the receptor aggregates due to 
allergen binding to the IgE antibody on the cell surface, Lyn 
kinase, which is bound on lipid rafts on the cell surface, 
phosphorylates the β and the γ chains. Following that, Fyn and 
Syk kinases are phosphorylated by  the phosphate groups from 
the β and γ chains. The phosphorylation of Syk kinase results in 
the phosphorylation of LAT that  causes the release of preformed 
mediators, and initiates the expression and release of other 
delayed mediators.
Lipid rafts were first identified by their ability to resist non-ionic detergents in cell 
fractions (Simons and Ikonen, 1997). They are thought to be synthesized in the Golgi 
apparatus (Brown and London, 1998) where they are then transported to the plasma 
membrane. Lipid rafts are ridged and thus less fluid than the surrounding phospholipids 
(Brown and London, 1998), and they include a lot of proteins essential for downstream 
signaling (Simons and Toomre, 2000). The IgE/FcεRI signaling initiates from a lipid 
raft (Baird, et al.,1999), and these rafts are essential for the downstream signally 
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because if these rafts were removed by depleting plasma membrane from cholesterol, 
the IgE/FcεRI signaling ceases (Sheets, et al., 1999), therefore these lipid rafts are 
essential for the signaling as they  bring the FcεRI receptors close together that  only a 
small number of receptors needs to be cross linked and thus aggregate for a downstream 
signal to initiate (Simons and Toomre, 2000), they also bring with them Lyn kinase, 
which is associated with lipid rafts, from other reactions close to the aggregated 
receptors so it can phosphorylate their γ chains. 65% of the mast cell surface is made 
from lipid rafts, and they  are assembled once the FcεRI receptor aggregates (Holowka, 
et al., 2005). The main purpose of lipid rafts is to segregate relevant proteins for a 
relevant function, thus the FcεRI receptor, whether bound to IgE or not, freely  moves in 
the plasma membrane, but once it aggregates, due to antigen binding, it gains higher 
affinity to lipids and thus micro lipid rafts accumulate around the aggregated receptors 
bringing with them relevant signaling proteins one of which is Lyn kinase (Holowka, et 
al., 2005).
1.6 - Current Therapeutic Interventions:
Currently allergy has no cure, once allergy develops in an organism it is a life 
long disease, though the severity of symptoms may  change with age. The best and 
oldest way  to prevent allergic reactions was to refrain from contact  with the allergens, 
i.e: not  keep cats or dogs for mite sensitive individuals (Platts-Mills, et al., 2000). 
Although this is effective to some extent, people with air-born allergies i.e: pollen 
sensitive, cannot easily avoid them. Major current allergic treatments aim at alleviating 
allergy symptoms, thus they do not target the fundamental causes of allergy.
1.6.1 - Pharmacotherapy:
This is the use of drugs to interfere with the inflammation pathway  by either 
halting cell degranulation, block mediator receptors or, during delayed-hypersensitivity, 
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halting cell chemotaxis. These drug include histamine antagonists (Antihistamines) 
which are drugs that block the histamine receptors in cells thus rendering them 
unresponsive to histamine, leukotriene inhibitors acts in a similar way where they 
inhibit the inflammatory effects of leukotriene and β2-adrenergic receptor agonists 
which activates the β2-adrenergic receptor and thus causes smooth muscle relaxation in 
bronchioles, these are mainly used against asthma attacks. The most effective current 
treatment for allergies are glucocorticoids, which are a class of corticosteroids. They are 
drugs that up-regulate the expression of anti-inflammatory proteins and down-regulate 
the expression of pro-inflammatory proteins and thus reduce the number of 
inflammatory cells. At high enough doses they  are able to control all types of allergies 
in all patients, but the limiting factor is their side effects (Barnes, 1999).
Other examples are decongestants, anticholinergics, antagonists, beta-
adrenoceptor agonists, theophylline, sodium cromoglycate (Meltzer, 1998). Epinephrine 
(Adrenaline) is a vasoconstrictive drug, thus effective in reducing inflammation 
(Simons, 2004), it is mainly used during emergency anaphylaxis to stop swelling. Mast 
cell stabilizers are drugs that block the Ca2+ channels that are essential for cell 
degranulation (Walsh, et al., 2009).
A new area of research is emerging that  targets the Ca2+ influx. Ca2+ release-
activated Ca2+ (CRAC) are ion channels that transport Ca2+ through the plasma 
membrane into the cytoplasm. They are important in lymphocyte differentiation, and 
essential for mast and basophil cell degranulation. An organic molecule called Synta 66 
discovered by Synta Pharmaceuticals have shown to be an inhibitor of CRAC (Di 




Allergen-specific immunotherapy (SIT) was first used in 1911 (Noon, 1911) to 
desensitizes patents from allergens. It  involves the subcutaneous injection of an allergen 
extract in an effort to desensitize atopic patients to certain allergens. This was proven 
successful to treat certain allergies such as anaphylaxis and allergic rhinitis, but it was 
un-successful in treating asthma (Lewis, 2002). It has remained controversial as it has 
the potential to sensitize patients even more and thus worsening their condition 
(Moverare, et al., 2002). The mechanism behind this is that introducing Th2 cells to 
allergen-derived peptides renders these Th2 cells unresponsive, by increasing the 
intracellular Ca2+ ions, they would also not respond to future co-stimulatory signals 
from antigen presenting cells, this unresponsiveness lasts up to a week in vitro (Jenkins, 
et al., 1987), this treatment is taken subcutaneously and thus called subcutaneous 
immunotherapy (SCIT). Also immediate mast and basophil degranulation would not 
occur due to capping of the FcεRI receptor as a result of a high dose of allergens, this 
was shown by our group as well and discussed in (Chapter 4). Taking this concept to the 
next level developed a novel immunotherapy called sublingual immunotherapy  (SLIT) 
where the allergen extracts are given to patients under their tongue (Gidaro, et al., 2005) 
this have been proven to be a very  safe treatment with rarely  strong reactions. Another 
study showed that epicutaneous immunotherapy (antigen delivery on to the surface of 
intact skin) can have a tolerogenic role, as it was was observed that repeated application 
of ovalbumin (on ovalbumin sensitive mice) on to the surface of their intact skin, down 
regulated T cell responses (Dioszeghy, et al., 2011) this is a potential novel, non-
invasive, therapy.
The use of cytokines to shift the immune system away  from allergy  associated 
inflammation is another immunotherapeutic approach to combatting allergy. IFN-γ is a 
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cytokine that is mainly responsible for the activation of macrophages during an 
immunogenic reaction (Roitt, 2001; Bancroft, et al., 1991). IFN-γ has shown to counter 
the effects of IL-4 on effector Th cells, and thus reduce the synthesis of IgE (Gauchat, et 
al., 1990). Thus the following research paper (Lack, et al., 1994) has shown that the 
introduction of nebulized IFN-γ into the airways of mice that have been previously 
sensitized to ovalbumin, at  closely controlled timing, caused the mice to stop  reacting to 
ovalbumin, this was achieved by  reducing the quantity of ovalbumin specific IgE in 
serum by pushing the immune system towards the Th1 cell response arm, which resulted 
in an increase in IgG production. The removal of serum IgE also contributes by down 
regulating the expression of the FcεRI receptor as discussed earlier by (Kinet, 1999). 
Another two studies have run similar experiments with inhibiting cytokines: Inhibiting 
IL-4 by  introducing a soluble form of its receptor sIL-4R (Renz, et al., 1994; Conrad, et 
al., 2010) and inhibiting IL-5 by introducing anti IL-5 antibodies (Hamelmann, et al., 
1997) all of which have inhibited immediate and delayed hypersensitivity reaction and 
thus restored allergen tolerance. Another proposed therapy is using IL-35 to forcefully 
suppressing Th2 cells in airway inflammation (Huang, et al., 2011).
Secretory leukocyte protease inhibitor (SLPI) is an enzyme protease that is 
secreted by  leukocytes in mucosal tissue, it  has been observed to have anti-
inflammatory effects and is a potential immunotherapeutic molecule that shows good 
promise for asthma treatment (Marino, et al., 2011).
Anti-IgE immunotherapy is a novel immunotherapeutic concept that was first 
pioneered by (Hook, et al., 1981 ) and patented by  an american company called Tanox 
Biosystems Inc. in 1987 (Figure 7). This invention involved the direct neutralization of 
the IgE antibody  and thus its active reduction in serum by developing a monoclonal 
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humanized IgG antibody  anti human’s Cε3 IgE heavy chain domain, and thus disrupt its 
binding to the FcεRI receptor (Davis, et al., 1993). The drug they developed was called 
TNX-901, then the names changed to CGP51-901 when Tanox Biosystems Inc. started 
collaborating on the research with Ciba-Geigy  Ltd. (which later merged with Sandoz to 
form Novartis International AG), finally  the name changed to Talizumab in 1996 when 
Tanox Biosystems Inc., Novartis International AG and Genentech Inc. resolved a legal 
dispute, and all three companies started to research the drug on anti-peanut allergy, 
which showed the successful reduction in patients with severe peanut allergy by the 
introduction of 450mg of Talizumab (TNX-901, CGP51-901) (Leung, et al., 2003).











Figure 7: Representation of the novel anti-IgE 
immunotherapy:
A monoclonal antibody, usually IgG, that binds to the IgE’s Cε3 
heavy  chain domain would prevent it from binding to the FcεRI 
receptor and thus would be actively removed from serum as it 
would be digested by macrophage cells.
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The three companies developed a better molecule named Omalizumab (trade 
name Xolair®), this molecule acts in a very similar way to Talizumab but with a better 
manufacturing process. Omalizumab actively  removes non-bound IgE from serum by 
binding to the HPL loop in the IgE’s Cε3 domain (Zheng, et al., 2008), it therefore also 
contributes to the down regulation of the FcεRI receptor expression on mast and 
basophil cells (Holgate, et al., 2004; Scheinfeld, 2005). It  also reduce the number of 
inflammation cells, eosinophils, T cell and B cell in tissue (Holgate, et al., 2005). It  is 
administered intravenously or subcutaneously  and it  results in 98-99% reduction in non-
bound serum IgE (Scheinfeld, 2005). The Scheinfeld paper reported that Omalizumab’s 
side effects include viral infection, upper respiratory tract infection, sinusitis, headache 
and pharyngitis. It also reports malignancy development, but that was observed in the 
placebo group as well, so it is not yet determined if IgE has a role in cancer 
development or prevention. Due to the high price of Omalizumab it is prescribed only  to 
patients with moderate to very severe atopic conditions, mainly the sever spectrum of 
asthma, and for parties who fail to respond to pharmacotherapy (Holgate, et al., 2005) it 
thus results in a dramatic increase in patients’ quality of life. But since IgE synthesis is 
not inhibited, this treatment has to be repeated every ~3 weeks (Conrad, et al., 2010).
Another drug called mAb12 (Laffer, et al., 2001) used the same concept, but binds 
to a different epitope from that of Omalizumab’s, its added advantage is that it binds 
and removes IgE already bound to the FcεRI receptor, and therefore reduce the 
sensitization by IgE of mast and basophil cells (Laffer, et al., 2008) which means that 
mAb12 has a higher binding affinity to IgE (>KA = 1010M) than IgE has to its FcεRI 
receptor (~KA = 1010M). The down side of these therapeutic strategies is their side 
effect, which includes the development of serum sickness (Dreyfus and Randolph, 
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2006) where the body starts to react, with allergy  like symptoms, to foreign antibody 
proteins.
Lumiliximab is a monoclonal chimeric antibody  made up of human and 
Cynomolgus macaque that is anti-FcεRII. The FcεRII receptor is found on the surface of 
B cells and is involved in the regulation and expression of IgE (Rosenwasser and Meng, 
2005) by transporting allergens to APC, which would then activate Th0 Cells. Thus 
inhibiting this receptor from binding to IgE would result in the down regulation of the 
IgE synthesis by B cell. This was shown in clinical trials to be effective and reduce the 
serum IgE level by  two-thirds, but this is not sufficient enough to stop  the signs and 
symptoms of allergy. On the other hand, the soluble form of FcεRII have also been 
demonstrated to lower IgE synthesis as it binds to free IgE antibody in serum (Conrad, 
et al., 2010).
This concept of synthetic antibodies directed to regulate a biological process in 
vivo branched out and has lead to the development of Trastuzumab by Genentech Inc. 
which targets the HER2/neu receptor to combat breast cancer development.
All these mAbs (humanized mouse antibodies) are an indication of the use of 
these antibodies for passive immunization/immunotherapy, i:e they  do not give 
permanent treatment to autoimmune diseases, rather they reduce their symptoms.
1.7 - Equine Allergy:
Horses (Equus ferus caballus) were found to develop allergy, this impacts the 
economy and some high-end industries as discussed later in Chapter 1.9. Horses have 
also been used as model organisms in physiology, and as a result some advances in 
medicine were achieved, this is due to their close physiology to humans, at one point in 
time their serum was used to treat some human diseases (Eyre and Lewis,1973), this 
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makes horses good model organisms for studying human allergies. In 1887 Stömmer 
was the first person to compare the asthma symptoms between humans and horses 
(Cook and Rossdale, 1963), and since then much more physiological similarities were 
discovered between the two species (Eyre and Lewis,1973). The horse cardiovascular 
response to inflammation due to histamine release is almost identical to that of humans 
and other organisms (Eyre and Lewis,1973). Lung physiological measurements were 
demonstrated to be effective and accurate, which can also be run on conscious horses, 
with no complications due to sedation, giving more accurate drug pharmacokinetic 
measurements, therefore they are a good model organism to study the effect of drugs 
prior to clinical trials (Mirbahar, et al., 1985).
Horses suffer from insect bite hypersensitivity (IBH) (Hellberg, et al., 2006), but 
horse lung inflammation is usually  in the form of recurrent airway obstructions (RAO) 
which is characterized by noticeable wheezing, repeated coughing and labored 
breathing usually to mold spores. High levels of IgE in horse serum has shown to be 
associated with RAO (Künzle, et al., 2007). But RAO is not usually suffered by 
racehorses.
Racehorses usually  suffer from inflammatory airway disease (IAD) which can 
affect horses of any age (Robinson and Hoffman, 2003; Couëtil, et al., 2007). The 
definition of IAD as proposed in 2002 is discussed in details in the paper by (Robinson 
and Hoffman, 2003) but some important points are that horses suffering from IAD do 
not have increased respiration rate at rest, but show poor performance and increased 
airway  mucus after exercise. Also, affected horses do no exhibit signs of illness such as 
depression. Around 80% of young race horses exhibit IAD at their first year of training, 
this is because the gene pool of this population is restricted, which result in some 
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genetic deficiencies such as the tendency of developing allergy, which is a common 
condition that greatly  affects the race horse performance, and thus cause a great deal of 
money  loss to the industry. The IAD illness usually resolves as the horses age, but the 
condition persists in a minority of them. 70% of race horses that  are permanently kept 
indoors would exhibit IAD. That study showed increased bacterial growth and 
minimum viral infection in mucus from affected horses, though it  still did not conclude 
the role of allergy  in IAD, the paper by (Pirie, et al., 2003) showed that allergens such 
as mould spores, 3-β-glucan (Riihimäki, et al., 2008), are a major factor in horse IAD. 
One reason why IAD might have been retained through selective breathing is because it 
is not very apparent when racehorses develop it, it only becomes clear when the horses 
have already grown up and started to show signs of reduced performance.
Racehorse IAD due to allergy greatly  affects their performance, and since there 
are very few studies about the molecular basis of equine allergy, this project should give 
a greater understanding of the allergy kinetics and the condition at the molecular level.
1.8 - Original Antigenic Sin Hypothesis:
This topic is not related to allergy, rather related to vaccine development, which is 
a concept researched later on in this thesis related to the development of an allergy 
vaccine.
Thomas Francis first described the hypothesis while conducting research on 
influenza A virus. There is a schools of thought which stated that  the influenza virus’ 
surface antigens change over time by acquiring new antigens from new sources. He 
noticed, among other researchers, that experimental evidence suggested that all of the 
virus’ antigens are already present, and that different virus variations of the same strain 
express these antigens at different levels on their surface as to have a dominant antigen 
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and several recessive antigens. Thomas Francis discusses in his 1960 paper (Francis, 
1960) the following observed effect: The first antibodies to be developed in childhood 
against influenza is that of the strain A. Of course throughout the life time the person 
would develop antibodies against other influenza strains, but as the population ages, the 
initial antibody that was developed against  influenza A in childhood continues to 
dominate the antibody in serum during an infection by the same strain with different 
dominant antigen configuration. This could be the reason why children as well as the 
elderly are the most susceptible to the influenza virus in a population; children might 
succumb early to the symptoms of the disease, while the elderly are trapped to produce 
ineffective antibodies towards the new configuration of the same virus strain (Lambert, 
et al., 2005). This he called, in 1955, The Doctrine of Original Antigenic Sin (Francis, 
1955). The following is a paragraph from his 1960 paper that summarizes the 
hypothesis: “The effect is attributed not merely to continuation of initial antibody levels 
but to repeated stimulation by persistence of the first dominant antigen as a lesser or 























Figure 8: Representation of The Original Antigenic Sin 
hypothesis:
When the body first encounters an antigen is produces effective 
antibodies against it’s dominant antigens and thus eliminates the 
infection. But when it encounters the same infection with a 
dominant new antigen, with the original antigen now being 
recessive, the immune system will still produce the former 
antibodies against this old antigen and not develop new 
antibodies against the new dominant one, this results in the 
production of ineffective antibodies and thus a weak immunity.
So just to summaries, when the body first  encounters an antigen it produces 
antibodies against it, but when it encounters the same organisms with a new dominant 
antigen but still has some small traces of the old antigen, due to the pathogen’s antigenic 
drift, the body will produce the former antibodies against this old antigen and not 
develop new antibodies against the new dominant antigen. This is an attempted short 
cut where the immune system would react quickly  to infections, but, of course, it also 
works negatively against the immune system where is wastes it energy producing 
ineffective antibodies (Figure 8). This phenomenon is one of the primary reasons why 
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vaccines against organisms with highly antigenic instability, such as an anti HIV 
vaccine and a long term anti influenza vaccine, are not effective using traditional 
methods. Currently one way to by pass this obstacle is through periodic revaccination 
(Lambert, et al., 2005).
1.9 - Aims of This Study:
As discussed earlier in chapter 1.7, horse allergy has an effect on some high-end 
industries. The horse racing industry is worth US$72 billion with a betting turnover of 
US$115 billion annually (Bruggink, 2009). Since race horses are inbred to select for 
desirable characteristics such as speed, durability and straight, and since nearly  all race 
horses are descendants of a few arabian horses (Equus ferus caballus) which were 
collected and selectively bread by Lady Anne Blunt in the Crabbet Arabian Stud in 
Sussex in 1878, they have a great tendency to develop allergy. Therefore this project 
researched the equine allergy and measured the binding between the equine IgE and its 
FcεRI receptor in an attempt to establish a baseline, which can be used for further 
allergy intervention research as a mean of predicting their efficiency in separating the 
two molecules, this should eventually lead to the development of better equine allergy 
interventions. The project also went a bit further, it researched a potential allergy 
vaccine, which involves the host’s development of a polyclonal antibody response 
targeting its own self IgE antibody, the efficiency of the binding between the serum 
antibodies and the host’s self IgE will determine if the binding was greater than the 
measured value of the binding between the IgE and its FcεRI receptor. The development 
of a horse allergy vaccine can also pave the way  from which the human and canine 
models can benefit greatly.
Our group was determining the allergy parameters for different model organisms, 
previous colleagues have established an in vitro model system for the human and the 
55
canine allergies, with the human being the most studied. Therefore this project 
determined the binding kinetics between the equine immunoglobulin E antibody and its 
high-affinity IgE Fc receptor, as a means of broadening the study of allergy to another 
model organism and to attempt to reduce the horse racing industry expenditure on 
expensive treatment for race horses, if a successful treatment was found.
These results were achieved by developing an equine IgE antibody that recognizes 
4-Hydroxy-5-iodo-3-nitrophenylacetis acid conjugated with human serum albumin 
(equine IgE anti NIP-HSA) by synthetically constructing an equine DNA sequenced IgE 
antibody heavy chain, which was cloned downstream of a mouse λ chain variable 
region that recognizes NIP antigen in a plasmid called pSV-VNP (Neuberger, et al., 
1985). This plasmid was transfected into a mouse B cell line (J558L) and was integrated 
into the chromosomes of the cells’ genome, and thus expressed an equine IgE anti NIP-
HSA. Once this was developed, the horse FcεRI receptor’s α chain DNA was 
synthesized and cloned into a plasmid called pEE6 (Stephens and Cockett, 1989) which 
was transfected into a rat basophil leukemia (RBL-2H3.1) cell line, where it was 
integrated into the cells’ genome and expressed the equine FcεRIα chain receptor, this 
receptor was combined with the rat endogenous β and γ2 chains to form a fully 
functional Fc chimeric receptor capable of binding the equine IgE, and causing a 
downstream signal in the cells. Form this, the mediator release was investigated on 
RBL-2H3.1 cells, when they were sensitized with the equine IgE anti NIP-HSA bound 
to its FcεRI receptor and challenged with NIP-HSA.
Since the cell lines were stable, the mediator release on RBL-2H3.1 cell lines 
expressing the human, canine and equine receptors was also investigated and the human 
and canine IgEs were tested on the RBL-2H3.1 cell line expressing the equine receptor, 
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this was to develop a complete picture of how the equine allergy  is related to other 
model organisms. The mouse IgE was used as a mediator release control.
To measure the kinetic binding between the equine IgE and the equine FcεRI 
receptor, a soluble form of the FcεRI α chain protein’s extracellular domains 
(sFcεRIαD1&2) were cloned into a yeast expression vector pPIC9k (Invitrogen) where 
it was cloned into the yeast Pichia pastoris and expressed the soluble form of the 
receptor. The kinetic binding of the two proteins was measured using surface plasmon 
resonance (SPR). Then the human and canine sFcεRIαD1&2 proteins were also tested 
with equine IgE, and equine sFcεRIαD1&2 was tested with human and canine IgEs to 
develop a complete picture of how the allergy is related between model organisms.
Chapter 1.6 mentioned several immunity interventions that target allergy. These 
treatments are all passive immunizations, where the antibodies give temporary 
protection from the allergy autoimmune disease. Our novel approach is the development 
of an active immunization strategy where the patient only needs to take the vaccine 
once, possibly boosted with it several times, to be protected life long from allergy.
In an attempt to develop an equine allergy vaccine a human-horse-human anti 
NIP-HSA (HHoH) IgE antibody chimera was developed where the variable region of 
the antibody was a mouse λ chain that recognizes the NIP antigen, and the heavy chain 
was a human heavy chain except for the Cε3 domain where it was a horse sequence. 
The idea was to use this HHoH chimeric antibody as an immune boost, after 
immunization with a peptide displaying the equine Cε3 domain epitopes, and then test 
their blood for anti equine Cε3 polyclonal antibodies, which the immune system would 
hopefully only target, through the original antigenic sin, and not other parts of the IgE 
chimera. If the affinity  of this antibody is greater than that of the IgE/FcεRI complex, 
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tested earlier in the project, then it can be used as a potential therapeutic treatment 
where horses can be immunized with this chimeric antibody, which will cause them to 
develop IgG antibodies against their own self IgE Cε3 domain, this should not only 
prevents future allergy  symptoms, but also knock out the IgE from its FcεRI receptor, 
which is sensitizing mast and basophil cells, thus permanently treating the organism 
from any future allergies.
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Chapter 2 - Materials and Methods:
2.1 - Materials:
2.1.1 - Equipment:
Equipment Serial Number Company
Centrifuge 86319 Sigma
Centrifuge 89/07/346 MSE
Centrifuge 3k15 Sigma Philip Harris
Magnetic Stirrer B211 Bibby
Balance PJ3000 Mettler
Microwave GSS20 Goodmans
Bottle Shaker Kühner Shaker Kühner Switzerland
Heating Block c123813 Grant
Water Bath 8903/2 Nickel Electric
Vortex WhirliMixer Fisons
Incubator 37 °C Compact Incubator Leec
Incubator 37°C + 5%CO2 
+ 90% Relative Humidity CO2 Incubator Galaxy R
Incubator Room - LTE scientific
Electrophoresis Tank -75.710
Continental Lab Product, 
INC
Class II Laminar Flow 
Hood - BioMAT2
100mm2 Petri Dishes - Sterilin
120mm2 Petri Dishes - Sterilin
24 Well Petri Dishes - Sterilin
69 Well Plate Assay Dish 655 180 Cellstar
10ml Pipettes 4101 Corning Incorporated
Gilson Pipettes Pipetman Gilson
Multi Tip Gilson Pipette - Anachem
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Equipment Serial Number Company
Universal Tubes 50ml - Cellstar
Plate Spectrophotometer Anthos Htll Anthos Labtec HT2
Light Microscope - Fluovert
Haemocytometer - Improved Neubalife
Aspirator - Büchi
QIAprep Spin Mini 
Plasmid Mini Prep Kit 27104 QIAGEN
QIAprep High Speed 
Plasmid Midi Prep Kit 12643 QIAGEN
Wizard® SV Gel And PCR 
Clean-Up System A9281 Promega
30 ml Falcon Tubes Sterile 
With Label 201172 Greiner Bio-One
Nitrile UltraSense Gloves US-INT-M Starlabs
Cryogenic Vile E3100-0011 Starlabs
50 ml Tubes Sterile E1450-0200 Starlabs
1.5 ml Test Tubes Sterile E1415-2231 Starlabs
0.2 ml Test Tubes I1402-4300 Starlabs
10µl Pipette Tips S1111-3700 Starlabs
200µl Pipette Tips S1111-0000 Starlabs
1000 µl Pipette Tips S1112-1720-c Starlabs
Duran Bottles 200ml - Smiax
Flasks - Simax
Parafilm P7793-1EA Sigma
Protection Mask Z300020-1EA Sigma
96 Well Plates CLS3595-50EA Sigma
UV Light Transilluminator - UVP
Freeze and Squeeze DNA 




Equipment Serial Number Company
Gene Pulser® Cuvette 
0.4cm 165-2088 Bio-Rad
Gene Pulser® Cuvette 
0.2cm 165-2082 Bio-Rad
Electric Pulse Machine - Bio-Rad
0.2 µm Sterilisation Filter 16534K Sartorius Stedim
0.45 µm Sterilisation Filter 17829K Sartorius Stedim
Autoclave - -
QickChange II Site 
Directed Mutagenesis Kit 200523 Stratagene
20 ml Syringes SYR213 Medisave
50 ml Syringes SYR566 Medisave
Tissues CMC-717-022U 7308 Fisher Scientific
4°C Fridge - -
-20°C Fridge - -
-80°C Fridge - -
10kDa MW Molecular 
Filters UFC901008 Millipore
3kDa MW Molecular 
Filters UFC900308 Millipore
BiaCore Tubes BR-1002-12 GE Healthcare
BiaCore Tube Caps BR-1002-13 GE Healthcare
Confocal Microscope - -
NanoDrop 2000 - Thermo Scientific
BD FACS Calibur (Flow 
Cytomerty) - BD Biosciences
BD FACS Aria (Cell 
Sorting) - BD Biosciences
Filtered Glass Mesh 
Funnel - Pyrex
3kDa Dialysis Tubings -
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Equipment Serial Number Company
Polypropylene Columns 34964 QIAGEN
SAS-PAGE Mini-protean 
II Electrophoresis System - Bio-Rad
Western Blot Mini Trans-
Blot cell - Bio-Rad
96 Well ELISA Plates 439454 NUNC






Primers - Eurofins -
T4 DNA Ligase M1804 Promega -
EcoRI R6011 Promega -
HindIII R6041 Promega -
BclI R6651 Promega -
SphI R6261 Promega -
XbaI R6181 Promega -
BglII R6081 Promega -
NotI R6431 Promega -
BamHI R6021 Promega -
PstI R6111 Promega -
XhoI R6161 Promega -


























Yeast Extract LP0021 Oxoid -
Mycophenolic 
Acid M3536-250MG Sigma -
HBS-EP Buffer BR-1001-88 GE Healthcare -
NaOH Re-
Generation Buffer BR-1003-58 GE Healthcare -
BiaCore Chips BR-1000-14 GE Healthcare -













Serum 7.01HI Source Bioscience -





Peptone P5905-500G Sigma -
Yeast Nitrogen 













Sulphate 11811-031 Invitrogen -
Sodium Citrate S1804-500G Sigma -



































N9376-250MG Sigma 50mM in DMSO 
25x Stock Solution
High Grade PCR 
Master Mix K0192 Fermentas -
APC LYNX Rapid 
Conjugation Kits® LNK031APC Serotec -
CNBr-activated 
SepharoseTM 4B 17-0430-01 GE Healthcare -
Rats - - -
Tryptone LP0043 Oxoid -








Water - Milli-Q -
Agar (Agarose + 
Agaropectin) LP0011 Oxoid -
Agarose A9539-250G Sigma -
Ethidium Bromide E7637-1G Sigma
10mg ml-1 Stock 
Solution
Sodium Acetate - AnalaR
Ethanol AC39769-0010 Fisher Scientific
Methanol A454-1 Fisher Scientific
Isopropanol A419-1 Fisher Scientific
Acetic Acid SA36-1 Fisher Scientific
Sulfuric Acid SA818-1 Fisher Scientific
Hydrochloric Acid AC12462-0010 Fisher Scientific
EDTA - AnalaR
DNA Loading 6x 
Dye R1151 Fermentas
1kbp DNA Ladder SM1163 Fermentas
10kDa Protein 
Loading Dye SM1811 Fermentas




Citric Acid C2404-500G Sigma
Pipes P1851-100G Sigma









Calcium Chloride - AnalaR
Glucose - AnalaR
Sodium Hydroxide - AnalaR
Hydrochloric Acid - AnalaR
Verkon - Verkon
Liquid Nitrogen - - -
Dimethyl sulfoxide D2650-100ML Sigma
Penicillin/
Streptomycin 100x P4333-100ML Sigma






Hypoxanthine H9636-5G Sigma -





J558L (Mouse B 















































Rabbit IgG Anti 












2.1.3 - In-House Prepared Chemicals:
Solution/Buffer Contents In 1dm3




For plates add 15g agar 
The selective antibiotic ampicillin was 
added to LB to a final concentration of 
50µg ml-1 ampicillin in LB (Sambrook 
and Russell. 2001)
Ampicillin
Stock solution prepared in H2O
50µg ml-1 in LB
DNA Electrophoresis Agarose Gel
1% Agarose (0.5g agarose in 50ml TAE 
buffer)
TAE Buffer (Tris Acitic Acid EDTA 
Buffer) pH 8
4.84g Tris
1.12 ml Acitic acid
0.74g EDTA
70% Ethanol 70ml + 30ml H2O
3M Sodium Acetate pH 5.2 2.4g sodium acetate in 100ml H2O
Sodium Acetate pH 4 for BiaCoreTM 
2000 Ligand Conjugation 10mM sodium acetate pH 4
Tissue Culture Normal Media
Dulbeco’s Modified Eagle’s media 
500ml: 1000mg glucose + 10% FCS + 
50000units of penicillin + 50mg 
streptomycin
Tissue Culture RBL-2H3.1 Cell Selective 
Media
Dulbeco’s Modified Eagle’s media 
500ml: 1000mg glucose + 10% FCS + 
50000units of penicillin + 50mg 
streptomycin + 0.4g geneticin G418 
sulphate
Tissue Culture J558L Cell Selective 
Media
Dulbeco’s Modified Eagle’s media 
500ml: 1000mg glucose + 10% FCS + 
50000units of penicillin + 50mg 
streptomycin + 0.5mg mycophenolic acid 
+ 25mg xanthine + 7.5mg hypoxanthine
1x Trypsin Solution 1x trypsin protease added to PBS
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Solution/Buffer Contents In 1dm3
Phosphate Buffer Saline (PBS)
8g Sodium chloride
0.20g Potassium chloride
1.44g Sodium hydrogen phosphate
0.24g Potassium hydrogen phosphate
pH 7.4
Washing Buffer PBS + 1% FCS






For solid media add 20g Agar
RDB (Regeneration Dextrose Base) 
Yeast Media
186g Sorbitol
For solid media add 20g Agar
Autoclave then add:
20g Glucose
13.4g Yeast nitrogen base
2ml of 0.02% Biotin
10ml of Non-essential Amino Acid 
Solution
BMGY (Buffered Glycerol-complex 




13.4g Yeast nitrogen base
100ml 1M  Potass ium phosphate 
Monobasic solution pH 6
10ml Glycerol





13.4g Yeast nitrogen base
100ml 1M  Potass ium phosphate 
Monobasic solution pH 6
5ml Methanol to give 0.5% final 
concentration
Coupling Buffer








Solution/Buffer Contents In 1dm3
Blocking Buffer
0.1M Acetic acid 













Chromatography column equilibration 
solution
300µl Tween 20 in 50ml H2O (0.6% 
tween 20)
12% Acrylamide Resolving Gel 
4.9 ml H2O







500µl 1M tris pH 6.8







10ml 10% Sodium dodecyl sulfate




Non-reducing Protein Loading Dye
60mM Tris-HCl pH 6.8
20% Glycerol
2% Sodium dodecyl sulfate
0.0025% Bromophenol Blue
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Solution/Buffer Contents In 1dm3
Reducing Protein Loading Dye
60mM Tris-HCl pH 6.8
20% Glycerol











Western Blot Blocking Solution
5g Full Cream Milk
50µl Tween 20
100 1xPSB
Western Blot Washing Solution





















ELISA Wash Buffer 1x PBS + 0.05% Tween 20
ELISA Blocking Buffer
100ml of (1x PBS + 0.05% Tween 20) + 
200mg Gelatin
ELISA Stop Solution 0.2M H2SO4
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2.2 - Molecular Biology Methods:
2.2.1 - Gene Optimization:
Most amino acids have several codons that code for them, and organisms tend to 
favor some codons over others, therefore certain codons for amino acids would have 
higher frequency in some organism’s genomes than others, this is termed Codon Usage 
Bias, and till today has no explanation for it  occurrence. Codon usage bias is used here 
to ensure that the protein of interest is expressed optimally in the host organisms’ cells.
The codon frequency tables for the rat (Rattus norvegicus), the yeast (Pichia 
pastoris) and the mouse (Mus musculus) were obtained from the site: http://
www.kazusa.or.jp/codon (See Appendix). The equine FcεRIα receptor (McAleese, et al., 
2000) and the IgE antibody heavy chain (Hε) (Navarro, et al., 1995) genes were 
optimized using the online program http://genomes.urv.cat/OPTIMIZER/. Then the 
optimized sequences were analyzed in http://gcua.schoedl.de to confirm the correct 
optimization. The equine FcεRIα gene was optimized for both the rat and yeast codons 
as the same gene will be used to express the protein in rat  cells and in yeast cells, while 
the Hε was optimized for mouse only and had half a human intron added to the start. 
The gene sequences were optimized because each organism favors a certain codon for 
its amino acids, and thus this should increase the tendency of taking up gene by  the 
relevant cells and optimize its protein expression.
2.2.2 - Lysogeny Broth (LB) Media:
LB media was prepared using the following formula: 10g tryptone, 10g sodium 
chloride, 5g yeast extract and 15g agar for a 1dm3 solution. The selective antibiotic 
ampicillin was added to the LB media to a final concentration of 50µg ml-1 ampicillin in 
LB (Sambrook and Russell, 2001).
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2.2.3 - Bacterial Inoculation and Growth:
The bacterial strains used for cloning were Escherichia coli XL-1 Blue (for 
general cloning) and JM110 (for cloning DNA that will later be digested using BclI 
restriction enzyme, because normal E.coli bacteria methylates the BclI TGATCA 
sequence using the Dam gene, therefore this strain is deficient in it) and TOP 10 for the 
delivery of synthesized genes from (GenScript). Bacteria were inoculated, using a steel 
metal loop, into 10 ml LB Media + 50µg ml-1 ampicillin and shaken at 37°C for 16 
hours to harvest cells, or spread onto a solid LB Media + 50µg ml-1 ampicillin plate to 
isolate one single bacterial colony (Sambrook and Russell, 2001).
2.2.4 - Vectors:
The first of the three vectors used in this experiment was pEE6 (Stephens and 
Cockett, 1989), this plasmid was sold by CellTech (a defunct UK company since 2004). 
It integrates into a mammalian cell’s chromosome due to sequences from the human 
herpesvirus 5 and therefore is designed for mammalian protein expression. It contains 
the ampicillinase gene and the neo gene that codes for aminoglycoside 3‘-
phosphotransferase which gives resistance to geneticin G418 sulphate (an antibiotic) 
that inhibits polypeptide synthesis by blocking the elongation step, it works in both 
prokaryotic organisms and eukaryotic cells. Using the plasmid in bacteria allows for 
their selection using ampicillin, while using the same plasmid in mammalian cells 
allows for their selection using geneticin G418 sulphate. The plasmid used already had 
an insert in it from a previous colleague therefore it was pEE6+CD23α plasmid and the 
insert was the human low-affinity  α chain gene, this insert was removed and replaced 
with the horse FcεRIα gene. This was helpful as the success of the restriction digest 
could be quickly determined on a gel.
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The second vector used was pSV-VNP plasmid (Neuberger et al, 1985). This 
plasmid is a modified simian immunodeficiency virus (SIV) which infects leukocytes 
and integrates its genome into their chromosomes, therefore this plasmid is useful for 
cloning and expressing proteins in leukocytes. The original plasmid name was pSV2gpt 
because the plasmid contains the ampicillinase gene and the gpt gene that encodes for 
bacterial xanthine guanine phosphoribosyl transferase (XGPRT), therefore gives 
resistance to mycophenolic acid. Mycophenolic acid is an immunosuppressant drug that 
inhibits that de novo synthesis of guanine monophosphate (GMP), a purine nucleotides, 
from xanthosine monophosphate (XMP) by blocking inosine monophosphate 
dehydrogenase from converting inosine monophosphate (IMP) to XMP. Therefore using 
this plasmid can select bacteria using ampicillin and mammalian leukocyte cells using 
mycophenolic acid. The tissue culture selective media should be supplemented with 
xanthine and hypoxanthine as well because XGPRT, from the gpt gene, allows for the 
synthesis of GMP by  converting IMP to XMP, by passing the inhibited inosine 
monophosphate dehydrogenase. Therefore XMP continues to be converted to GMP in 
resistant cells (Figure 9). The hypoxanthine is added to saturate as much of the 
Hypoxanthine-guanine phosphoribosyltransferase as possible to synthesis IMP which 
cannot be used by non-transfected cells, and not convert guanine to GMP which can be 
done by  both transfected and non-transfected cells. This selection is therefore weak, but 
works.
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Figure 9: Mycophenolic acid selection:
IMP is converted to XMP by inosine monophosphate 
dehydrogenase, which in turn is converted to GMP. 
Mycophenolic acid inhibits inosine monophosphate 
dehydrogenase and thus cells cannot synthesis XMP from IMP 
and the GMP in the cell diminishes. The gpt gene codes for 
XGPRT which converts xanthine to XMP and therefore by 
passes the inhibited inosine monophosphate dehydrogenase.
The plasmid also called pSV-VNP because it also contains a mouse λ chain 
variable region that codes for an antibody variable region that binds to the hapten 4-
hydroxy-3-nitrophenylacetic acid (NP). Therefore cloning an antibody heavy  chain 
downstream of this sequence results in an antibody  that is anti NP. 4-hydroxy-5-iodo-3-
nitrophenylacetic acid (NIP) can also be used due to its extreme similarity to NP 




6-(2-Hydroxy-3-nitro-5-iodophenyl)acetamido)hexanoic acid succinimidyl ester















Used complex IgE on the surface of RBL cells to
cause them to release during release assays
NP-OH
4-Hydroxy-3-nitrophenylacetic  acid
Figure 10: Molecule structure of NP and NIP:
The structure of NP and NIP haptens are very similar therefore 
both can bind to the antibodies synthesized using the pSV-VNP 
plasmid. The figure also shows all the NIP structures used in this 
project.
The pSV-VNPHεF424 plasmid already contained a mutated human IgE heavy 
chain, the insert was replaced with the horse IgE heavy chain Hε, as previous, which 
made it easy to determine the efficiency of the restriction enzymes quickly on a gel.
The third vector used was the pPIC9k (Invitrogen). Since this plasmid was 
purchased from a company and not prepared by another research group, a lot was 
known about the plasmid’s characteristics, also it did not contain an insert. This plasmid 
was designed and optimized for Pichia pastoris protein expression. It contained the 
ampicillinase gene to allow for bacterial selection and the neo gene to give resistance to 
geneticin G418 sulphate to allow for yeast selection.
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2.2.5 - Plasmid Mini Prep:
After 16 hours of Escherichia coli bacteria culture incubation at 37°C in 
suspension, the cells were mini prepped to extract their plasmid using the QIAprep Mini 
Plasmid Mini Prep Kit supplied by QIAGEN.
The following is the QIAGEN protocol: 3ml of 16 hours culture incubation at 
37°C was centrifuged at 2000xg for 10 minutes, the supernatant was discarded and the 
pellet re-suspended in 250µl P1 buffer chilled at 4°C. Then 250µl P2 lysis buffer was 
added followed by 350µl N3 precipitation buffer. The sample was then centrifuges at 
10000xg for 10 minuets, the supernatant was transferred to the QIA spin column and 
centrifuged at 10000xg for 1 minute, and the overflow was discarded. 500µl PB binding 
buffer was added to the spin column and centrifuged at 10000xg for 1 minute, and the 
overflow was discarded. 750µl PE wash buffer was added and centrifuged at  10000xg 
for 1 minute, and the overflow was discarded. The column was then centrifuged dry at 
10000xg for 1 minute to remove excess liquid and evaporate the excess ethanol. The 
bottom tube of the spin column was replaced by a 1.5ml Eppendorf tube, 50µl de-
ionized distill water was added directly  to the filter of the spin column and centrifuged 
at 10000xg for 1 minute, the over flow contained the required plasmid at concentration 
of ~200ng ul-1 (QIAgen Mini prep Protocol).
2.2.6 - Polymerase Chain Reaction:
The PCR kit was bought from (Fermentas). 1µl of forward primer and 1µl of 
reverse primer (both at a concentration of ~100ng ul-1) were used along with to 1µl of 
mini prep plasmid DNA, the following was the PCR master mix prepared to a final 
concentration of 50µl:
78
10X High Fidelity PCR buffer with 15 mM MgCl2  5µl
dNTP Mix, 2 mM each      5µl
Forward primer       1µl
Reverse primer       1µl
Mini prep plasmid DNA     1µl
High Fidelity PCR Enzyme Mix    1µl
H2O        36µl
The following program was used:
1 94°C   2:30 minutes  Complete DNA melting
2 94°C   30 seconds   DNA melting
3 44°C   15 seconds   Annealing
4 68°C   30 seconds   Polymerization
Program repeated from step 2-4 for 30 cycles. Then the samples incubated at 4°C 
until removed. The PCR product was purified for cloning purposes using the same 
protocol from the same kit as the gel extraction of DNA band in chapter 2.2.9.
2.2.7 - Restriction Digest and De-Phosphorylation:
The restriction digests used 8µl of plasmid mini prep with 1µl restriction enzymes, 
9µl de-ionized distill water, and 2µl 10x enzyme specific buffer. The samples were 
incubated in a water bath at 37°C for 1 hour. Vectors were de-Phosphorylated by adding 
17µl de-ionized distill water, 1µl alkaline phosphotase enzyme and 2µl alkaline 
phosphotase buffer that was added directly  to the digestion mix and incubated at 37°C 
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for 1 hour. 4µl of loading dye 6x was added to each sample with a volume of 20 µl 
before electrophoresis.
2.2.8 - Electrophoresis:
0.5g agarose was added to 50ml TAE 1x buffer to make a 1% gel with 3.5µl 
ethidium bromide 10mg ml-1 stock solution (Sambrook and Russell, 2001). The DNA 
ladder was prepared as follows: 18µl deionized distill water, 2µl DNA ladder and 4µl 
loading dye 6x to make a 24µl sample, 4µl of loading dye 6x was added to each DNA 
sample with a volume of 20 µl before electrophoresis. All gels were run at 100v 80A for 
1 hour.
2.2.9 - Gel Extraction of DNA Bands:
The required bands were removed from the agarose gel. 1µl of binding solution 
was added to every 1mg of gel, heated at 55°C until all the gel has melted. The sample 
was transferred into the SV Minicolumn and incubated for 1 minute at room 
temperature. The sample was then centrifuged at 10000xg for 1 minute, overflow was 
discarded. Column was washed with 700µl Membrane Wash Solution centrifuged at 
10000xg for 1 minute then washed again with 500µl and centrifuged at 10000xg for 1 
minute, centrifuged dry at 10000xg for 5 minutes. Then samples was transferred to a 
new Eppendorf tube and the DNA was eluted with 50µl de-ionized distill water 
(Promega Wizard® SV Gel and PCR Clean-Up System Protocol).
2.2.10 - Ligation:
3µl of the vector and 12µl of the inserts were ligated together using 1µl T4 DNA 
Ligase enzyme, 11µl de-ionized distill water and 3µl enzyme buffer were all mixed 
together, to a final 30µl sample volume, and incubated at room temperature for 3 hours.
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2.2.11 - Bacterial Transformation:
The ligated samples were transformed into competent Escherichia coli XL-1 Blue 
(or JM110) bacteria using the following protocol: The Escherichia coli XL-1 Blue (or 
JM110) competent bacteria (Stratagen) were thawed on ice for 30 minutes. 50µl of 
competent bacteria were added into each tube along with 10µl of ligated sample. Mixed 
very gently  and incubated in ice for 30 minutes.The bacteria where then heat shocked at 
42°C using a water bath for 45 seconds then placed immediately on ice for 2 minutes. 
1ml liquid LB media with no ampicillin was added to the cells and the samples were 
then placed in a water bath for 45 minutes at 37°C. The samples were then centrifuged 
gently at 180xg for 10 minutes to collect all the bacteria and the pellet  re-suspended in 
200µl of the same media. The concentrated bacteria were then spread on solid LB media 
+ 50µg ml-1 ampicillin and incubated for 16 hours at 37°C.
2.2.12 - Glycerol Stock:
Cryogenically preserved bacteria was prepared with 20% sterile glycerol and 80% 
overnight grown bacteria. Vortexed and quickly frozen in -80°C for long term 
cryopreservation.
2.2.13 - Plasmid Midi Prep:
Using the QIAprep  Mini Plasmid Midi Prep Kit supplied by QIAGEN the 
required colony was inoculated to 50ml of liquid LB media + 50µg ampicillin and 
incubated at 37°C for 16 hours. The 50ml sample was then centrifuged at 2000xg for 15 
min and the supernatant was discarded. The pellet was re-suspended in 6ml chilled P1 
suspension buffer and vortexed. 6ml P2 lysis buffer was added and the sample was 
incubated at room temperature for 5 minutes. 6ml chilled P3 precipitation buffer was 
added mixed gently then immediately added to QIA Filter Cartridge and incubated at 
room temperature for 10 minutes. 4ml QTB buffer was added to the High Speed Midi 
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Tip to equilibrate the filter. After the 10 minute incubation the sample was filtered 
though the QIA Filter Cartridge and into the High Speed Midi Tip. 20ml QC buffer was 
added to wash the DNA in the filter. Then the DNA was eluted by adding 5ml Buffer 
QF into a new tube which was then precipitated by the addition of 3.5ml 100% 
isopropanol and incubated at room temperature for 5 minutes. The sample was added to 
QIA Precipitation Filter using a 20ml syringe. The DNA in the filter was then washed 
with 2ml 70% ethanol, then twice with air. The filter was transferred to a 1.5ml syringe 
where 1ml deionized distill water was added and pushed through the filter to elute the 
DNA into an Eppendorf tube. The eluted DNA was again filtered through the same filter 
to elute more DNA. The final concentration of DNA was ~200µg µl-1 (QIAGEN Midi 
Prep Protocol).
2.2.14 - Quantification of DNA:
DNA was quantified using the NanoDrop 2000 machine where 1µl of DNA 
sample was added to the machine and measure its absorbance at 260nm. The following 
formula was used to measure the concentration of DNA:
Double Stranded DNA: OD260 of 1 = 50 µg ml-1 
Single Stranded DNA: OD260 of 1 = 30 µg ml-1
2.2.15 - Ethanol Precipitation:
This method was used to concentrate DNA. For every 1µl of DNA sample, 2µl 
70% ethanol and 0.1µl 3M  sodium acetate pH 5.2. were added and incubate at room 
temperature for 1 hour. Centrifuged at 10000xg for 20 minutes, washed with 70% 
ethanol and centrifuged again at  10000xg for 5 minutes, this step was repeated twice. 
The pellet was air dried until all ethanol evaporated. The DNA was then re-suspend in 
the desired volume using deionized distill water.
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2.2.16 - DNA Sequencing:
Plasmid DNA was sequenced by diluting the sample down to a final concentration 
of 100ng µl-1 using deionized distill water then sent to Source BioScience Geneservice 
for sequencing using M13 forward and reverse universal primers, after confirming that 
these primer sequences are present in the plasmid between the desired gene:
M13 forward: 5’-TGTAAAACGACGGCCAGT-’3
M13 reverse: 5’- CAGGAAACAGCTATGACC -’3
2.2.17 - Point Nucleotide Mutation Generation:
This protocol was from the QuikChange II Site-Directed Mutagenesis Kit 
(Stratagene): A forward and reverse primer sequence that included the mutated sequence 
was synthesized. A master mix containing:
Mini prep plasmid DNA  2µl
Reaction buffer    5µl
Forward primer    1.25µl
Reverse primer    1.25µl
dNTP mix    1µl
38.5ddH2O    38.5µl
PfuUltra HF DNA polymerase  1µl
This gave a final volume of 50µl. The reaction was then run like a PCR reaction 
with 18 cycles with the following program was:
1 95°C   30 seconds  Complete DNA melting
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2 95°C   30 seconds   DNA melting
3 55°C   60 seconds   Annealing
4 68°C   60 seconds   Polymerization
The final product was an un-methylated plasmid containing the mutated sequence 
and the original methylated plasmid with the un-mutated sequence. Therefore to the 
sample 1µl of Dpn I restriction enzyme was added and incubated at 37°C for 1 hours. 
The sample digested all the original methylated plasmid but no the new un-methylated 
plasmid. Therefore after the digestion the sample was transformed into supercompetent 
cells, using exactly the same protocol as in chapter 2.2.11.
2.3 - Mammalian Cell Tissue Culture Methods:
2.3.1 - Cell Lines:
RBL-2H3.1 (Rat Basophil Leukemia cells) (Bingham, et al., 1994) are cancerous 
basophil cells that are well suited for the study of the FcεRI receptor because basophil 
cell are physiologically very similar to mast cells but are a much more stable cell line in 
tissue culture. This cell line was therefore used to express the equine FcεRIα chain 
where it was expressed onto the cell’s surface and combined with the rat endogenous β 
and two γ chains to form a fully functional chimeric receptor capable of binding the 
equine IgE. An important note to mention is that maintaining this cell line in culture for 
prolonged periods tends to cause the cells to shift to a non-mediator releasing phenotype 
which cannot be reversed, therefore it was advised to keep large stocks of non-
transfected and cloned functional cells. Mycoplasma bacterial infection greatly affects 
the cell release as well, therefore regular Mycoplasma tests were preformed since the 
bacteria colonized the cell surface and could not be visualized through the microscope. 
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Mycoplasma tests were usually preformed through PCR, and removing this bacteria 
from important cell lines were possible but expensive and time consuming.
Since the cells are expressing a protein on their cell surface, isolation of 
expressing cells was done through Fluorescence-Activated Cell Sorting (FACS), see 
chapter 2.3.6 which resulted in colonies rich in expressing cells, and were tested again 
using Flow Cytometry. Inoculating 5x105 cells + 15ml of media in a 100mm2 petri dish 
resulted in plate confluency after ~4 days and must be incubated at 37°C + 5% CO2 + 
90% relative humidity. Healthy RBL-2H3.1 cells have a crescent shape and they  form a 
monolayer, therefore harvesting cells requires trypsin digestion to suspend the cells.
J558L cells (mouse B myeloma cells derived from BALB/c strain isolated by M. 
Bruggeman and M.S. Neuberger) is a stable B cell line used to express antibodies. 
Selection of this cell line is done through mycophenolic acid selection and therefore the 
final cell lines are always a mixture of transfected expressing, transfected non-
expressing and non-transfected cells, and therefore careful selection of high expressing 
colonies is essential. Inoculating 5x105 cells + 15ml of media in a 100mm2 petri dish 
will result in plate confluency after ~4 days and must be incubated at 37°C + 5% CO2 + 
90% relative humidity. Healthy J558L cells have a round spherical shape and they  do 
not form a monolayer, therefore harvesting cells does not requires trypsin digestion to 
suspend the cells, simple pipetting will suspend the cells from the bottom of the dish.
2.3.2 - Cryopreservation of Mammalian Cells:
Cryogenically frozen mammalian cell samples were prepared as follows: A cell 
density  of 5x106 ml-1 suspended in pure fetal calf serum (FCS). To each tube 900µl of 
cell and 100µl dimethyl sulfoxide (DMSO) was added. The tubes were gently  inverted 
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and then quickly placed in liquid nitrogen vapor for 2 hours. The samples were then 
placed in liquid nitrogen for long term cryopreservation.
2.3.3 - Thawing Cryopreserved Mammalian Cells:
Cryopreserved mammalian cells were taken out of the liquid nitrogen and thawed 
by gently adding tissue culture normal media (Dulbeco’s Modified Eagle’s media 
500ml: 1000mg glucose + 10% FCS + 50000units of penicillin + 50mg streptomycin) 
using a pipette and transferring the cells into 20ml of normal media. The cells were then 
centrifuged at 180xg for 3 minutes at  4°C and the media aspirated, this was to remove 
all traces of DMSO (which is toxic to cells when in solution). The cells were then 
resuspended on 15ml of normal media and then plated on a 100mm2 petri dishes and 
incubated at 37°C + 5% CO2 + 90% relative humidity. After 24 hours, it was essential to 
replace the media with fresh media to remove all dead cells (caused by the 
cryopreservation), as dead cell debris cause healthy to undergo apoptosis. Careful 
removal of media was preformed on J558L mouse B cells as they are suspension cells 
and do not stick to the plastic petri dish surface.
2.3.4 - Maintenance of Mammalian Cell Lines:
Non-transfected mammalian cells were grown in normal tissue culture media 
(Dulbeco’s Modified Eagle’s media 500ml: 1000mg glucose + 10% FCS + 50000units 
of penicillin + 50mg streptomycin). Inoculation of 5x105 cells in 15ml of normal media 
in 100mm2 petri dishes was sufficient to give 50%-75% confluency in ~4 days, at which 
point the cell population had to be split in order to maintain the cell growth at the log 
phase, which is when they are most healthy. Chapter 2.3.1 for the description of the two 
cell lines used here.
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In a 75%-90% confluent mammalian cell dish the media was aspirated, the cells 
were washed with 5ml of 1xPBS then 2ml of trypsin solution was added to the cells and 
incubated for 5 minutes at 37°C + 5% CO2 + 90% relative humidity. Cells were then 
added to 20ml media and centrifuge at 180xg for 3 minutes at 4°C. The cells were 
washed with 10 ml 1xPBS and centrifuge at 180xg for 3 minutes at 4°C (since J558L 
cells are suspension cells, no trypsin was needed, simply pipetting the old media several 
times will cause the cells to get  suspended and thus transferred, and therefore no wash 
step was needed simply 15µl of cells were taken to be counted on the haemocytometer). 
The washed cells were resuspended in 10ml of normal media and 15µl of cells were 
taken to be counted on a haemocytometer. Using the calculation at the bottom media 
was added to the cells to reach a final cell density of 5x105ml-1. 1ml (5x105) of cells was 
added 15ml of media and plated into a new petri dish and incubated for another 4 days.
Cell Count 1 + Cell Count 2
2
x10 000 = Cell Density in 10ml(           )
Cell Density in 10ml
5x105
= New Volume
2.3.5 - Transfection of Mammalian Cells:
To a mammalian cell density of 1x107 in 0.8ml-1 0.8ml were placed in an test tube 
and 25µg 50µl-1 of plasmid DNA was added to them and gently mixed. The cells were 
transferred to a 0.4cm electrocuvette (Bio-rad) and incubated on ice for 10 minutes. 
They  were then electric pulsed at 250v 960µF using the electric pulse machine (Bio-
Rad) and quickly  incubated on ice for another 10 minutes. The RBL-2H3.1 cells were 
grown on four 100mm2 petri dishes with normal media for two days followed by 
changing to selective media (Dulbeco’s Modified Eagle’s media 500ml: 1000mg 
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glucose + 10% FCS + 50000units of penicillin + 50mg streptomycin + 0.4g geneticin 
G418 sulphate) and selecting for proximally 1-2 weeks, changing the media every 2 
days, until the cells stopped dying and started to grow, at this point  the cells were 
harvested and sorted using FACS (chapter 2.3.6).
The J558L cells were grown on two 24 well petri dishes with 800µl of normal 
media for the first  two days, then replaced with 800µl selective media (Dulbeco’s 
Modified Eagle’s media 500ml: 1000mg glucose + 10% FCS + 50000units of penicillin 
+ 50mg streptomycin + 0.5mg mycophenolic acid + 25mg xanthine + 7.5mg 
hypoxanthine). The cells where maintained with this selective media, changing it every 
4 days with gentle aspiration as to not remove the suspended cells. The cell population 
decreased very  gently  and the cell morphology will look very  unhealthy (not perfectly 
spherical cells). After 4-6 weeks the wells started to develop small colonies of healthy 
resistant cells, once the wells were confluent, the media of each well (totaling 48 wells) 
was harvested, centrifuged to remove the cells, then tested using SPR for the presence 
and quantity of IgE expressed (chapter 2.3.7), the well with the highest IgE presence 
was isolated, grown and frozen to develop the cell line.
In both mammalian cell lines, a control was setup by adding water without  DNA 
to the 0.4cm electrocuvette and selected as discussed. For RBL-2H3.1 cells the control 
will show no fluorescence during FACS, while J558L cells will show no IgE presence 
in the SPR test. Though both cell lines most likely, but not always, behave like 
transfected cells; i.e: will look healthy and be resistant in selective media.
2.3.6 - Sorting Transfected RBL-2H3.1 Cells (Flow Cytometry and Fluorescence-
Activated Cell Sorting - FACS ):
The RBL-2H3.1 cells were sorted by Fluorescence-Activated Cell Sorting (FACS) 
to separate non-transfected and non-expressive cells from transfected expressive ones. 
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Cells were harvested and re-suspended in 1ml cold 4°C washing buffer (PBS + 1% 
FCS).
1µg of primary  IgE antibody (that binds to the novel expressed FcεRIα chain) was 
added to 1ml of cells and incubated on ice for 30 minutes, then washed twice (by 
centrifuging at 180xg for 3 minutes and re-suspending in 10ml wash buffer). The cells 
were then re-suspended in 1ml wash buffer and 1µg secondary antibody (IgG anti 
primary IgE that was tagged with a florescent dye) was added to the cells and incubated 
for 30 minutes on ice in the dark to minimize dye bleaching, then washed twice. The 
cells were assayed and sorted using a flow cytometry  machine. A FACS control was 
setup by adding water instead of primary antibody, and this control was essential to 
establish the baseline at which the cells were sorted. Another control, where non-
transfected cells were tagged with both primary  and secondary antibodies, was run to 
determine the success of the transfection. Chapter 2.4.2 discusses the concept of FACS.
2.3.7 - Selection of Transfected J558L Cells:
The J558L cells were selected as in chapter 2.3.5 and after ~4 - 6 weeks 
developed healthy cells that dominated the wells. At this point all the cell media in the 
wells (48 wells) were harvested (800µl) into 48 1ml test tubes, taking care not  to 
remove cells as usual. The test tubes were centrifuged gently at 180xg for 4 minutes to 
remove the cells and cell debris form the media. Into 48 BiaCoreTM 2000 test tubes 
180µl HBS-EP buffer (0.01M  HEPES + 0.15M NaCl + 3mM EDTA + 0.005% 
Surfactant P20 (Tween P20) pH 7.4) was added + 20µl of centrifuged cell media, 
vortexted and loaded into the BiaCoreTM 2000 (Surface Plasmon Resonance) SPR 
machine. The SPR results gave a resonance curve, the presence of a curve determined 
the detection of the expressed IgE antibody, the hight of the curve determined strong 
resonance i.e: detection of large quantity  of expressed IgE antibody, the resonance units 
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from the top of the curve is subtracted from the bottom of the curve to give the final 
resonance units for each well sample which was then plotted on a bar graph to give a 
visual representation of IgE contents in all the tested wells. The well with the largest 
resonance unit i,e: greatest quantity  of expressed IgE antibody  was isolated and the cells 
grown and frozen to give the final cell line. Chapter 2.4.1 for the concept of SPR and 
the program used to run BiaCoreTM 2000 tests.
2.4 - Proteomics:
2.4.1 - Surface Plasmon Resonance (BiaCoreTM 2000 System):
Surface Plasmon Resonance (SPR) is an analytical method that uses light to 
analyses the contents of a sample for a desired molecule and the quantity  of this 
molecule. The machine that was used is under the brand name of BiaCoreTM System 
model 2000. Following the is concept of SPR:
When light of a certain wavelength (an electromagnetic wave) strikes the surface 
of a metal (usually silver or gold) it  is reflected back at the angle of reflection. But at a 
certain angle the light will strike the metal surface and its energy is converted into 
energy used to oscillate electrons within the metal atoms (plasmon), this oscillating 
wave (plasmon wave) propagates through the outer surface of the metal, thus the light at 
this angle is absorbed and not reflected (resonance angle). Since the plasmon wave 
propagates the outer surface of the metal, any molecule added or removed will disrupt 
this wave and thus change the resonance angle, therefore the sample angle is measured 
against a reference angle to test the presence of molecules in a sample. The surface of 
the metal in a CM5 chip  supplied by the BiaCoreTM System has dextran (a complex and 
branched glucose polymer) on its outer surface, this molecule is used to bind the amine 



































































Figure 11: SPR metal surface:
This figure shows the configuration of an SPR chip. The metal 
chip  (silver or gold) is prepared with a dextran surface which 
can bind the NH2 end of protein to conjugate them to the metal 
surface. At the bottom a single wavelength laser beam enters a 
prism which results in many light angles striking the metal 
surface, all of them are reflected except for the angle in which 
the metal will absorb and turn its energy into a plasmon wave 
onto its outer surface, at this angle no light is reflected and thus 
appears with very  little intensity on the detector. Since the 
plasmon wave propagates on the outer side of the metal, any 
interaction with the conjugated protein will change the 
resonance angle.
Therefore any binding with this protein will change the resonance angle and 
results in detection of the molecule in question. One chip has 4 channels (usually 2 per 
reaction), these two channels act as two separate metal surfaces, thus give the freedom 
to measure two separate resonance angles simultaneously. Since the resonance angle is 
an absolute value, to measure detection and quantity  of the resonance angle the sample 
channel is referenced against the resonance angle of a reference channel (the control 
channel) with no protein bound on it, thus the sample channel angle will shift when the 
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molecule of question is detected, but the reference channel angle will not shift, therefore 
the difference in angles will give a resonance unit value that is used to measure the 
presence and the quantity of the molecule in question (Figure 12). Therefore in this 
project, on a CM5 chip  the 1st channel is the reference channel with no conjugated 
antigen, but  the second channel has conjugated antigen on it. When a sample containing 
antibody against the conjugated antigen is run on the chip  surface channel’s 2nd 
resonance angle shift while the 1st channel’s angles does not, measuring the difference 
in angle of channel 2 - channel 1 will give a resonance unit that when plotted in a graph 
against time will show an upward curve (if another sample containing the antibody’s 
receptor is run on the same chip, another upward curve is plotted as the antibody 
receptor binds to the antibody). Once the chip is washed the graph curve starts to slope 
downward as some of the antibody dissociated from its antigen, this small downward 
curve therefore indicates strong binding between the antibody and the antigen, while a 
large downward curve indicates weak binding where the bonds between the two 
molecules can be easily  broken when washed with a buffer. The samples in the chip are 
usually  forcefully destroyed by  high or low pH to regenerate the chip so it can be 
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Figure 12: Diagram explaining Surface Plasmon Resonance 
(SPR):
This figure shows the workings of the SPR chip. A. the chip is 
conjugated with an antigen, when a sample runs on the sample 
chip  and the antibody  binds to its antigen, the sample channel 
resonance angle shift, while the reference channel (with no 
antigen conjugated) will not shift. The difference between the 
two angles (channel 2 - channel 1) will give the resonance units 
which when plotted on a graph against time will give an upward 
curve. When the sample is washed out and the antibody starts to 
dissociate from the antigen this effect is reversed and thus gives 
a downward curve. This concept can be used to bind more than 
one protein as in B. when the antibody binds to the antigen 
giving an upward curve, then if another sample containing the 
antibody’s receptor is run on the chip, the antibody receptor 
binds to the antibody giving another upward curve.
The BiaCoreTM 2000 chip used was a CM5 chip and conjugated to channel 2 
(flow cell 2 or Fc2) with human serum albumin conjugated to the antigen, the antigen 
therefore used was (4-hydroxy-5-iodo-3-nitrophenylacetic acid conjugated to human 
serum albumin) NIP-HSA, while the reference channel was (flow cell 1 or Fc1). The 
final resonance units of the chip was measure to be ~2500 RU and was setup by the 
surface preparation wizard. The NIP-HSA was at a stock concentration of 15mg ml-1 
prepared in 1xPBS where 5µl were added to 250µl 10mM  sodium acetate pH 4 solution 
coupling buffer to couple the NIP-HSA to the chip. The concept here is that the human 
serum albumin has an isoelectric point of 4.7 (therefore at pH 4.7 the charge on this 
protein is neutral), when the chip is activated its surface is negatively charged therefore 
to bind the ligand (NIP-HSA antigen) to the surface it should have a positive charge 
which is achieved by lowering the pH, therefore it  is added to the sodium acetate pH 4 
solution. The chip is first activated by  adding 7.5mg of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) + 11.5mg of N-
hydroxysuccinimide (NHS) dissolved in H2O. The ligand (NIP-HSA antigen) is then 
added followed by deactivating the none bound dextran on the chip surface by  with 
100µl 1.0 M ethanolamine-HCl pH 8.5. The machine running buffer used was HBS-EP 
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buffer, and the regeneration buffer used to unsure all ligands are securely bound was 
10mM glycine at pH 1.7.
Once the chip  is made, the setup for the BiaCoreTM 2000 to run normal samples 
was as follows: The machine running buffer used was HBS-EP buffer. The samples 
were prepared in BiaCoreTM test  tubes with 180µl HBS-EP buffer and 20µl of sample 
(1:10 dilution), the tubes were secured with a tube cap  and vortexed to ensure total 
mixing of the sample in it. The samples were loaded into the machine and the 
regeneration buffer used to remove the protein samples form the chip was 50mM 
NaOH. The samples were tested using the Binding Analysis wizard, where each 
samples was tested twice to ensure reproducibility. 
2.4.2 - Flow Cytometry and Fluorescence-Activated Cell Sorting (FACS):
Flow cytometry is a powerful preparatory tool which can allow the identification 
of the size of cells and their identity which can also incorporate fluorescence when the 
cells are tagged with a fluorescent dye inside the cell or on its surface. It is used from 
analyzing the purity of cell lines to biochemical pathways and assays. Flow cytometry 
can have an extra bit of kit added to them to allow the separation of two cell types in a 
mixed population when they  are tagged with different florescent dyes, this process is 
called Fluorescence-Activated Cell Sorting (FACS).
The concept of flow cytometry is simple, a population of cells are 
hydrodynamically-focused to organize random cells from a sample into a fluid stream 
with ordered cells in a straight line, this is done by having a tube (glass or plastic) with 
the inner walls built up of a moving stream of fluid, this is called the sheeth flow. The 
sample of cells is injected into the middle of this sheeth flow where the two liquids will 
not mix as their density/viscosity are different, thus forming a stable two-layer flowing 
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fluid. The tube then narrows into a funnel thus constricting the sheeth fluid along with 
the sample which orders the cells into a single file of cells (Figure 13).
The single file of ordered cells would be passed through a single wavelength laser 
which analyses the sample using two detectors, the light that is scattered through the 
sample and collected forward from the cell (Forward Scatter Channel - FSC) gives 
information on the cells’ size, whether they are healthy big round cells, or small dead 
cell debris. The light that is scattered sideways at  a 90° angle form the laser beam due to 
reflection or fluorescence (Side Scatter Channel - SSC) gives information on the 
fluorescence of a cell or its granularity  (Figure 13) thus enables to identify the type of 
cell. This information is collected and displayed on a SSC by  FSC graph the X-axis 

















































































Figure 13: Diagram explaining Fluorescence-Activated Cell 
Sorting (FACS):
This figure is showing a representation of flow cytometry at the 
top of each diagram, but also shows how additional equipment 
can enable it to be used for FACS. A. the sample containing 
cells is injected in the middle of a fluid sheeth and funneled to 
give an single line of ordered cells. The cells are passed through 
a laser beam that measures the forward scatter (FSC) and side 
scatter (SSC). Usually this flow cytometry result is sufficient for 
analytical methods, but  for a preparatory cell sorting method 
(FACS) the cells passed though a nozzle that vibrates and results 
in cell droplets with approximately one cell per drop, this drop is 
then electrically charged to give a negative charge on it. The 
machine computer calculates (since the distance between the 
laser and the electromagnets is known) when the cell reaches the 
area between the electromagnets, it will switch them on to divert 
the cell path so it lands on the correct vial, and thus accumulate 
the sorted cells. In this case the beam detects no fluorescence 
and therefore sends the droplet of cell into the negative sample 
vial. In B. the laser beam detects the correct fluorescence and 
therefore send the charged cell droplet into the correct positive 
sample vial.
When a sample of cells is injected into the sheeth fluid and funneled to give a 
single line of ordered cells, it  passes through a laser beam where detectors collect the 
FSC and SSC lights to give a description of the sample, this is flow cytometry, and 
sometime it is wrongly termed FACS, because FACS is concerned only  with a specially 
constructed machine that  uses the concept of flow cytometry to sort a mixed cell 
populations. In the case of FACS, the cell fluid is not discarded, instead it passes 
through a vibrating nozzle that is designed to give droplets of fluid with approximately 
one cell per drop. This drop  is then immediately charged to give it  an overall negative 
charge. The information collected from the FSC and SSC detectors will cause the 
machine computer to calculate which droplets to save and which to discard. Since the 
distance between the laster beam and the electromagnets in the machine is knows, when 
the droplet  with the positive cells reaches the electromagnets, the computer switch them 
and deviate the droplet’s path to land into the positive sample vial, if the droplet 
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contains cell that are of no interest, the computer will switch the electromagnets on to 
deviate the droplet’s path so it  lands into the waste vial. This results into collecting and 
sorting the cells of interest so they can grow and form a pure cell line (Figure 13).
2.4.3 - Protein Expression And Quantification in Mammalian Cells:
The J558L cell line was the sole mammalian cell line that was producing a protein 
(equine IgE antibody) requiring purification. It was realized that an initial cell density of 
5x105 cells in 20ml of J558L selective media was the optimal cell density  for 
expression. The cells were incubated in 37°C + 5% CO2 + 90% relative humidity for 5 
days which was found to be the ideal length of time where the expressed protein would 
accumulate enough in the media, but not left long enough for it to start degrading. 
Therefore after 5 days of expression, the media was harvested by  collecting all the cells 
and media and centrifuged at 180xg for 3 min, which sediments the cells and therefore 
the media was gently  transferred and filter sterilized using a 0.45µm filter to remove all 
cells from the media. This was essential as mammalian cells, because when they die, or 
when a bacterial or fungal infection develops in the harvested media, proteases would 
be released that will degrade the expressed protein. The sterile harvested media was 
stored at -20°C until the equipment for affinity purification was ready see chapter 2.4.5. 
The media was concentrated at some points by  a 3kDa molecular filter to concentrate 
the expressed protein and reduce the liquid volume to allow for ease of handling, but it 
was clear that this will give a low purification yield and results sometimes in albumin 
impurities, therefore it is recommended not to concentrate the media and use it as it is to 
purify the expressed protein.
2.4.4 - Protein Expression And Quantification in Yeast Cells:
The protein of interest here was the soluble equine FcεRI α chain’s domain 1 and 
2 (sFcεRIαD1&2), this gene was cloned into the pPIC9k plasmid. This plasmid was 
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chosen as the sFcεRIαD1&2 was required to be secreted out of the cell and purified 
from the media.
The Pichia pastoris yeast protocol was taken from Invitrogen’s Pichia Multi-Copy 
pichia Expression Kit  Version F, pichia Fermentation Process Guidelines and pichia 
EasyCompTM Kit. The yeast cells were first streaked on a solid YPD (10g yeast extract 
+ 20g peptone, autoclave then added: 20g dextrose [glucose] + for solid media added 
20g agar) media and incubated at 30°C for 2 days until colonies appeared, a single 
colony  was picked and inoculated a10ml liquid YPD media in 250ml braided flasks, to 
allow for adequate aeration, and incubated at 30°C for ~16 hours until an OD600 = 0.1 - 
0.2. The cells were pelleted by centrifuging at 500xg for 5 minutes and resuspended in 
10ml Solution I. The cells were then centrifuged and resuspended in 1ml Solution I 
again. At this point the cells were competent and they  were aliquoted at 50µl aliquots 
and stored at -80°C, even though repeated freezing and thawing did not affect cell 
competency.
3µg of the final plasmid pPIC9K-sFcεRIαD1&2 was linearized by digesting the 
DNA with SacI restriction enzyme, therefore when transformed the resultant yeast cell 
phenotype was His+Mut+ which was determined to be the best cell phenotype to express 
this specific protein. The 3µg of linearized DNA was added to 50µl of competent yeast 
cells then 1ml of Solution II was added to the cells and incubated at 30°C for 1 hour, 
vortexing every 15 minutes to ensure highest cell transfection. The cells were then heat 
shocked at 42°C for 10 minutes and the cells pelleted by centrifuging at 3000xg for 5 
minutes and re-suspending at 1ml solution III. The cells were then re-pelleted and re-
suspended in 150µl of Solution III. All the cells were plated on a solid RDB (186g 
sorbitol + for solid media add 20g agar, autoclave then add: 20g glucose + 13.4g yeast 
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nitrogen base + 2ml of 0.02% biotin + 10ml of non-essential amino acid solution) plate 
which after ~5 days at 30°C revealed ~50 colonies.
The design of the plasmid is such that it allows it to be inserted multiple of times 
in the yeast genome. The higher copy number of the insert present, the higher the 
protein expression of that strain, therefore to select the colony with the highest gene 
copy number 50 transfected colonies from the solid RDB plate were picked and added 
to 1ml of liquid YPD media and vortexed. A geneticin G418 sulphate solid YPD plates 
were prepared with the following final concentrations: 0mg ml-1, 0.25mg ml-1, 0.50mg 
ml-1, 0.75mg ml-1, 1mg ml-1, 1.25mg ml-1, 1.50mg ml-1, 1.75mg ml-1, 2mg ml-1, 3mg 
ml-1, 4mg ml-1. From the mixture of the cell colonies 10µl were spread on each plate, 
and the plates incubated at 30°C for ~ 7 days until colonies appear. Colonies will appear 
in the 0mg ml-1 control within 2 days, while colonies in higher geneticin G418 sulphate 
concentrations will take longer to grow. Once the colonies were large enough to pick, 
the colony form the highest geneticin G418 sulphate concentration plate was picked 
(relatively the colony with the highest gene copy number) and protein expression was 
commenced immediately. It was observed that these colonies would rapidly lose their 
protein expression if they were frozen for stock. Therefore the colonies were kept in the 
plates at 4°C if repeated protein expression was required, otherwise the whole protocol 
needed to be repeated.
The picked yeast colony  was added to 25ml BMGY (10g yeast extract + 20g 
peptone, autoclave then add: 13.4g yeast nitrogen base + 100ml 1M potassium 
phosphate Monobasic solution pH 6 + 10ml glycerol) media and grown for two days. 
The cells were harvested by centrifuging at 1500xg for 5 minutes. The cells were then 
resuspended in BMMY (10g yeast extract + 20g peptone, autoclave then add: 13.4g 
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yeast nitrogen base + 100ml 1M potassium phosphate Monobasic solution pH 6 + 5ml 
methanol) media to a final OD600= 1, which will require ~1200ml BMMY media, where 
400ml of media was added to 1000ml braided flask to allow for adequate aeration, then 
all the flasks were incubated at 30°C for 6 days. Every 24 hours the 0.5% methanol in 
the media would be exhausted as the cells would use it for the expression of the protein 
in question, therefore it needs to be replenished, therefore every 24 hours 2ml of 
methanol was added to 400ml of media to result in 0.5% methanol. Noting that adding 
too much methanol is toxic to the cells.
On the 6th day, the media was harvested by centrifuging at 1500xg for 15 minutes 
pelleting and discarding the cells. The media was further sterilized by filtering through a 
0.45µm filter to removed all traces of the yeast cells, then protease inhibitors (P8215 
From Sigma) were added to slowdown the breakdown of the expressed protein, and 
sodium azide was added to a final concentration of 0.5mg ml-1 to inhibit any  further 
microbial growth that might compromise the expressed protein. The media was then 
concentrated using a 3kDa molecular filter from 1200ml down to 50ml to allow easy  of 
handling during protein purification, chapter 2.4.5.
2.4.5 - Affinity Purification of Proteins:
To purify expressed proteins a chromatography column was setup using CNBr-
activated SepharoseTM as the gel medium which the ligand molecule was immobilized 
in. To prepare the SepharoseTM gel the following protocol was used from GE Healthcare 
CNBr-activated SepharoseTM 4B manual:
A filtered glass mesh funnel was washed several times with concentrated sulfuric 
acid to remove all contamination and microorganisms that can affect  the quality  of the 
final chromatography  gel. Care was taken as to not allow the acid to over heat, which 
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might lead to an EXPLOSION. 2g of CNBr-activated SepharoseTM was added to 50ml 
of 1mM  HCl and incubated while rotating at room temperature for 60 minutes at which 
point the powder swelled up. The gel was filtered through the funnel using a vacuum 
and then washed with further 200ml of mM HCl. This activated the gel at  which point it 
was collected and re-suspended in 50ml of coupling buffer (0.1M sodium hydrogen 
carbonate + 0.5M sodium chloride pH 8.3). 35mg of the ligand NIP-CAP-OSu 
(dissolved in dimethylformamide) was added to the gel. The mixture was incubated at 
room temperature for 2 hours with gentle shaking, at that point the gel colour turned 
from white to yellow, indicated the coupling of the NIP-CAP to the SepharoseTM beads. 
The OSu section of the NIP-CAP-OSu molecule was cleaved and the NIP-CAP was 
then covalently bonded to the SepharoseTM beads to give NIP-CAP-SepharoseTM. The 
gel was then washed in the funnel with 600ml of coupling buffer to remove all the 
unbound NIP-CAP-OSu. The gel was then collected and re-suspended in 50 ml 
denaturing buffer (0.1M tris-HCl pH 8) to de-activate all the non-bound sites in the 
SepharoseTM, to prevent binding of unwanted molecules, and incubated at room 
temperature for 2 hour without shaking. To further block any active groups in the gel it 
was washed three times with alternating pH starting with 50ml blocking buffer (0.1M 
acetic acid + 0.1M sodium acetate + 0.5M sodium chloride pH 4) then with 50 ml 
denaturing buffer. The gel was filtered and washed with 500ml 1xPBS, then collected 
and stored in 1xPBS + 50mg ml-1 sodium azide at 4°C for later use. It is advised to use 
the gel as soon as possible as the longer it is stored in the fridge the more NIP-CAP 
dissociates from the SepharoseTM beads giving low purified protein yield. This column 
was used to purify IgE anti NIP-HSA antibody, but the same protocol was used to 
couple IgE into the SepharoseTM beads to purify sFcεRIαD1&2 protein, using 10mg of 
IgE.
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To load the gel and make a chromatography column (QIAgen kit Polypropylene 
Columns) the filers were first equilibrated by chromatography column equilibration 
solution (0.6% Tween 20 in water) by  rotating for 1 hour at room temperature, washed 
with water and incubate while rotating for 15 minutes at room temperature, this step 
was repeated twice. When the filters were equilibrated, the bottom filter was placed in 
the plastic column and added the prepare SepharoseTM gel until it  forms, after it settled, 
a 2cm high gel bed (capable of binding ~6mg of protein). Using too little gel will not 
result in insufficient quantity of protein, using too much gel will results in very slow 
fluid migration through the gel resulting is the retainment of other proteins, mainly 
albumin, which will result in very low protein yield with poor protein purity. When the 
gel bed settled, the top filter was added leaving ~1mm distance between the gel and the 
filter to prevent compacting the gel. At this point the gel was washed with 100 ml of 
1xPBS to remove all the dissociated NIP-CAP (or IgE antibody) molecules and sodium 
azide. To re-use the column it  was washed with regeneration buffer (0.1M  tris + 0.5M 
sodium chloride pH 8) to remove all bound specific and non-specific proteins.
The media containing the expressed protein was passed through the column three 
times to ensure saturation of the protein in the column. The column was then washed 
with 300ml 1xPBS to ensure all non-bound proteins were washed out.
Eluting the IgE antibody: 12ml of 1.5mM NIP-CAP-OH was added to the column 
to elute the IgE, the eluting liquid was passed only once through the column and 
collected, and the remaining eluting liquid in the column was pushed by passing 1xPBS 
until all the eluting liquid has passed. The eluting liquid was then dialyzed using a 3kDa 
dialysis tubing in 1xPBS for 5 days until all the NIP-CAP-OH (yellow in colour) has 
been removed and the liquid became clear. The antibody was then concentrated using a 
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3kDa molecular filter down to 200µl and this resulted in the IgE antibody being 
dissolved in 1xPBS.
Eluting the sFcεRIαD1&2 protein: three fractions, each of 3ml of elution buffer 
(0.2M glycine pH 2.8) was added to the column and dropped on to 3ml of neutralizing 
buffer (1M tris-HCl pH 8). The low pH of the elution buffer dissociated the 
sFcεRIαD1&2 from the IgE, but when it landed on to the high pH neutralizing buffer 
the pH equilibrates into ~pH 7 which is ideal for the protein to prevent it from 
denaturing. The three fractions were then pooled together and washed with 1xPBS by 
concentrating them through a 3kDa molecular filter, and finally  concentrated down to 
200µl. This resulted in sFcεRIαD1&2 being dissolved in 1xPBS.
2.4.6 - Quantification of Purified Proteins:
The bradford assay was used: a concentration curve was setup using bovine serum 
albumin (BSA) as the control protein: 0mg ml-1, 0.1mg ml-1, 0.2mg ml-1, 0.3mg ml-1, 
0.4mg ml-1, 0.5mg ml-1, 0.6mg ml-1, 0.7mg ml-1, 0.8mg ml-1, 0.9mg ml-1, 1.0mg ml-1. 
Using more then 1mg ml-1 concentration did not give accurate results, and therefore if 
the protein of interest  was suspected to be more than 1mg ml-1, it was diluted down to a 
level that was between 0.1 - 1mg ml-1. The concentration curve was setup in 1xPBS, 
because all protein resulting from the affinity  purification in chapter 2.4.5 were 
dissolved in 1xPBS. Once the concentration curve was setup and the sample diluted 
down to the proper level, the protein assay buffer (Bio-Rad) was diluted to 1x. in a 96 
well plate, 10µl of each of the BSA concentration curve was added to wells, along with 
the protein of interest, in triplicates. 200µl of 1x protein assay buffer was added to each 
of the wells with protein and incubated at room temperature for 10 minutes. The 
intensity of the blue colour that results was read on a plate reader at 620nm. The 
absorptions of the concentration curve was plotted on a graph of absorbance (optical 
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density  - OD) against the actual concentration. From that a line of best fit  was plotted 
and its equation determined, from this equation the concentration of the protein sample 
was found using its absorbance. This method was proven to be very accurate if done 
carefully.
2.4.7 - Protein Separation (SDS-PAGE):
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was the 
method used to separate proteins for analysis. This method preceded the protein 
identification (western blot). The protocol was taken from (Sambrook and Russell, 
2001) and it was run on the Mini-protean II Electrophoresis System (Bio-Rad):
The resolving gel used was 12% acrylamide (4.9 ml H2O + 3.8ml [1.5M tris pH 
8.8 + 0.4% Sodium dodecyl sulfate] + 6ml 30% acrylamide + 150µl ammonium 
persulfate + 6µl TEMED) with the ammonium persulfate being freshly  prepared. The 
5% stacking gel used was (2.7 ml H2O + 500µl 1M tris pH 6.8 + 40µl 10% Sodium 
dodecyl sulfate + 670µl 30% acrylamide + 40µl ammonium persulfate + 4µl TEMED), 
these gels were loaded onto the Mini-protean II Electrophoresis System.
The protein sample was added to a protein loading dye at a 1:1 quantitative ratio 
and then boiled at 100°C using a water bath for 5 minutes. The non-reducing protein 
loading dye (60mM  tris-HCl pH 6.8 + 20% glycerol + 2% sodium dodecyl sulfate + 
0.0025% bromophenol Blue) was used to denature and separate whole proteins, while 
the reducing protein loading dye (60mM tris-HCl pH 6.8 + 20% glycerol + 2% sodium 
dodecyl sulfate + 0.0025% bromophenol Blue + 5% β-mercaptoethanol) was used to 
break disulphide bridges and thus separate different domains of a protein molecule. A 
10kDa protein ladder was used as a molecular weight standard. The gel was placed in 
an electrophoresis running buffer (14.4g glycine + 3.07g tris + 10ml 10% sodium 
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dodecyl sulfate) and separation carried out at  50v until the protein has passed the 
stacking gel and entered the resolving gel, at which point the voltage was increased to 
120v which took ~2 hours for the protein to run through the entire gel. The gel was 
stained using coomassie stain (2g coomassie blue + 250ml acetic acid + 1000ml H2O + 
1000ml methanol) for 20 minutes at which point the proteins and gel took up the stain, 
then the gel was de-stained by  washing in coomassie de-stain (10% acetic acid + 30% 
Methanol) for 16 hours at which point the gel lost almost all the blue colour, while the 
protein maintained it allowing the protein bands to be visualized.
2.4.8 - Protein Identification (Western Blotting):
Protein identity  was essential to prove that the purified protein is the protein of 
interest and not mistakingly another protein of a similar size, this test is very  accurate as 
it incorporates the binding of antibodies to restricted epitopes within the protein of 
interest, even though there are no results in this project from western blots, due to the 
commercial scarcity of the required antibodies, non the less this protocol was used in 
this project.
The proteins were separated using SDS-PAGE as in chapter 2.4.7 but  the gel was 
not coomassie stained, as that would have interfered with the antibody binding to the 
protein. The clear gel was placed in the Mini Trans-Blot cell cassette (Bio-Rad) with the 
following configuration: the gel was placed on a (Polyvinylidene fluoride) PVDF 
membrane (Amersham Hybond-LFP Western Blotting Membrane) and the two were 
placed between two pieces of filter paper on each side followed by  one sponge on each 
side. This ‘sandwich’ was placed in the Mini Trans-Blot cell cassette with the negative 
end facing the PVDF membrane and run in western blot  running buffer (14.4g glycine + 
3.07g tis + 200ml methanol) for two hours at 4°C with 60v. The membrane was then 
removed and checked for the complete transfer of the protein ladder, the protein of 
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interest is not visible and therefore to check its presence it was incubated for 5 minute in 
Ponceau S stain, the stain was washed under distilled water where the protein bands 
would appear before the stain got completely washed away.
Since the membrane is capable of binding all proteins, it had to be blocked before 
antibody priming, therefore to allow the protein antibodies to bind only to the protein 
epitopes and not to the active membrane. The membrane was therefore placed in 
blocking solution (5g full cream milk + 50µl tween 20 + 100 1xPSB) and shaken for 2 
hours at room temperature. To the blocking solution 1µg of primary antibody, that binds 
to the protein, was added and the membrane was incubated while shaking for 1 hour at 
room temperature. The membrane was then washed with 200ml of wash solution (50µl 
tween 20 + 100 1xPSB) to remove all the blocking solution and the primary antibody. 
1µg of secondary  antibody, that binds to the primary antibody and has a horseradish 
peroxidase enzyme tagged to it, was added to the membrane in wash solution and 
incubated while shaking for 1 hour at room temperature. The membrane was washed 
with 200ml wash solution.
The protein on the membrane was detected according to the (Amersham ECL™ 
Western Blotting Detection Reagents) protocol which resulted in chemiluminescence 
from the secondary antibody and thus was photographed on light sensitive photographic 
paper (Kodak), which was then developed according to the protocol from Kodak. The 
success of the western blot resulted in a single band in the photographic paper.
2.4.9 - RBL-2H3.1 β-hexosaminidase Release Assay:
This assay was preformed on RBL-2H3.1 cells to determine the percentage of 
inflammatory mediators released by these cells when their FcεRI receptors binds to IgE.
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The RBL-2H3.1 cells were harvested from a 75% confluent petri dish as in 
chapter 2.3.4. The cell were diluted to a density  of 5x105 cell ml-1 and 1µg of IgE 
antibody was added to every  1ml of cells to reach a final IgE concentration of 1ng ml-1, 
the cells were then gently shaken. To a 96 well plate 100µl of cells + IgE was added to 
columns 1-6 of the plate. The plate was incubated at 37°C + 5% CO2 + 90% relative 
humidity for 16 hours. This reaction allowed the interaction of the IgE with the FcεRI 
receptor for 16 hours, some experiments were done where the IgE was only allowed to 
interact with the FcεRI receptor for 0.5, 1 and 3 hours. At these experiment the cells 
were incubated for 16 hours without any  IgE, this was to allow the cells to adhere to the 
plate surface, then the media was discarded and a new warm (37°C) media containing 
IgE was added to them and incubated for the required amount of time (usually  16 hours 
for normal, no kinetic studies, release assays).
The plate was flicked up-side-down to discard the media, and all the wells were 
washed twice with worm (37°C) release buffer (25mM  pipes + 120mM sodium chloride 
+ 5mM potassium chloride + 0.04mM magnesium chloride + 1mM  calcium chloride). 
A serial dilution of the antigen (NIP-HSA or DNP-HSA) of 0 ng ml-1, 0.1 ng ml-1, 1 ng 
ml-1, 10 ng ml-1, 100 ng ml-1, 1000 ng ml-1, 10 000 ng ml-1 was prepared in release 
buffer. 100µl of this serial dilution was added to the washed cell wells form rows A-G 
with raw H having 100µl of triton-X buffer (5% Triton-X 100) to lyse the cells, this was 
done for columns 1-6, thus repeating the experiment six times. The plate was incubated 
at 37°C + 5% CO2 + 90% for 20 minutes, this was the point where the mediators were 
released.
After the incubation, 50µl of the liquid above the cells form each well was 
transferred to the corresponding well on the other half of the plate, i.e: columns 7-12. 
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The remaining 50µl of liquid above the cells was discarded, and replaced with 50µl of 
triton-X buffer. This setup allowed for each well to measure the amount of released 
mediators (columns 7-12) as a mean of percentage of the total mediators inside the cell 
(column 1-6). Raw H was therefore not needed to be used in the calculations, but rather 
useful to test the workings of the experiment.
One of the mediators released was β-hexosaminidase, and therefore to all the 
wells 50µl of the β-hexosaminidase substrate (50mM 4-nitrophenyl N-acetyl-β-D-
glucosaminide prepared in DMSO diluted down to 2mM  by adding it to citrate buffer 
[0.2M citric acid + 0.2M sodium acetate pH 4.5]) was added. The plates were incubated 





This reaction was stopped by adding 150µl of tris buffer (1M tris-HCl pH9) 
which, with its high pH, caused 4-nitrophenyl to turn yellow. This allowed its 
absorbance to be measured at 405nm in a plate reader, and thus the percentage of β-
hexosaminidase was calculated using the following formula:
A7x100
(A7x2)+A1
x2(       )
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A1 and A7 represent  the location of the wells in the 96 well pate. This formula 
was applied to each well, then an average was taken for each row, with the standard 
deviation calculate as well, then plotted on a graph of percentage of β-hexosaminidase 
release against antigen concentration.
2.4.10 - Kinetic Analysis Using Surface Plasmon Resonance:
The SPR BiaCoreTM System was the machine of choice to measure the kinetic 
binding between the sFcεRIαD1&2 and the IgE. This was because the SPR uses only 
micrograms of the required proteins. Another method considered was Isothermal 
Titration Calorimetry (ITC), but it requires milligrams of the proteins, and the 
expression levels of the systems used in this project would have been very expensive to 
reach milligram concentrations, therefore SPR was chosen. Since the CM5 chip used 
was immobilized with NIP-HSA, IgE anti NIP-HSA was used and added as the 
capturing molecule until it reached a resonance unit  of ~2500 which correspond to ~2µg 
ml-1 of IgE. Then the binding of sFcεRIαD1&2 to the IgE was tested by adding the 
following concentration to the sFcεRIαD1&2: 0µg ml-1, 1µg ml-1, 2.5µg ml-1, 5µg ml-1, 
7.5µg ml-1, 10µg ml-1, (0µM, 0.02µM, 0.05µM, 0.10µM, 0.15µM and 2µM  respectively 
assuming the molecular weight is 51000g mol-1), only  300µl of each sample was 
required, and the kinetic analysis was preformed at 25°C. All tests were repeated twice 
and the regeneration buffer used was 10mM  glycine pH 1.7. The BiaCoreTM software 
had an application wizard that automatically configured the machine to allow for kinetic 
binding measurements. The kinetic values were calculated and generated automatically 
by the BiaCoreTM software with the molecular weight of the sFcεRIαD1&2 taken to be 
50kDa.
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2.5 - Mammalian Immunization:
2.5.1 - Immunization Schedules:
Rats (species: Rattus norvegicus also known as Hannovers rats, only males were 
used) at age ~ 10 weeks old were used for the immunization protocol. Each rat was 
initially injected subcutaneously, using a 25 gage glass needle, with 100µl of 1mg ml-1 
of vaccine that was mixed with an equal volume of complete Freund's adjuvant 
(Mycobacterium tuberculosis + mineral oil), which is an immunopotentiator that directs 
the immune system to attack the vaccine instead of just  dissolving it  away. Before 
injection the mixture was votrexted to insure emulsification of the final mixture. 14 
days later, and all subsequent injections, another injection was preformed by  mixing the 
vaccine with incomplete Freund's adjuvant (just mineral oil), this was to insure the 
immune system keeps attacking the vaccine instead of the Mycobacterium tuberculosis. 
10 days after the injection ~ 200 µl of blood was taken from their tails or leg veins. This 
was followed by  ~20 days recovery before the rats were re-injected again to give an 
immune boost, then 10 days later another bleed was taken:
1. Pre-immunization bleed (used as a negative control).
2. Rats were immunized with the vaccine (2Fcε2-3 peptide + complete Freund's 
adjuvant).
3. 14 days later, the rats were again immunized with the vaccine (2Fcε2-3 peptide + 
incomplete Freund's adjuvant).
4. 10 days later the first bleed was taken to analyze the immune response.
5. ~14 days later the rats were boosted, boost 1, by  a re-injection of (2Fcε2-3 peptide 
or the HDH IgE anti NIP-HSA antibody chimera + incomplete Freund's adjuvant).
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6. 10 days later the second bleed was taken to analyze the immune response.
7. Steps 5 - 6 were repeated for boosts 2 and 3.
Each bleed taken was prepared for analysis by incubating at room temperature for 
~1 hour for the red and white blood cells to settle. This was followed by incubating at 
4°C for ~24 hours for the blood to clot. The bleed was then centrifuged at high speed 
(10000xg) to remove all blood clots and reveal the bleed serum in the supernatant ~50% 
of the original bleed volume. The serum was used to test the rat immune response.
Ideally, at the end of the experiment, the rats get  bleed out, ~10ml of blood, and 
treated in the same manner to harvest the serum. And this serum would contain the 
polyclonal IgG antibodies against what ever antigen used. But this was not used here as 
our objective was to analyze the state of the immune response.
2.5.2 - Bleed Assay Protocol (ELISA):
The rat bleeds were analyzed using the enzyme-linked immunosorbent assay 
(ELISA). the ligand (2Fcε2-3 or NIP-HSA) was prepared to a final concentration of 
1µg ml-1 in ELISA immobilization buffer (15mM  Na2CO3 + 35mM NaHCO3 pH 9.6). 
To an ELISA flat bottom 96 well plate 100µl of prepared ligand was added and 
incubated at 4°C for 16 hours. The plate in all incubations was covered with plastic film 
to prevent evaporation. After the immobilization step, the plate was washed vigorously 
using a squeeze bottle with ELISA washing buffer (1x PBS + 0.05% Tween 20) 3 times 
and completely dried. 150µl of blocking buffer (100ml of [1x PBS + 0.05% Tween 20] 
+ 200mg Gelatin) was added to each well and incubated at 37°C for 2 hours and then 
washed as before. If NIP-HSA was immobilized, 50µl of 1µg ml-1 native IgE was added 
to bind the antigen and incubated at 37°C for 2 hours. Following that prepared rat serum 
was serially diluted ten steps (from 1:200 - 1:102400) in blocking buffer and 50µl were 
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added to each well, a control of pre-immunization serum was used with the same 
dilution strategy. The wells were incubated at  37°C for 1.5 hour and then washed as 
before. 50µl of the secondary antibody used was rabbit IgG anti rat IgE conjugated with 
horseradish peroxidase enzyme (Sigma) at 1:1000 dilution factor and incubated at 37°C 
for 1 hour. The plate was washed for a final time as before followed by  an extra 2 
washes with distilled water to remove all traces of un-bound secondary  antibody. 50µl 
of TMB substrate (3,3’,5,5’-tetramethylbenzine) was added to the plate and incubated 
for ~ 3 minutes at room temperature, depending on the amount of blue colour generated. 
The reaction was stopped by  adding 50µl ELISA stop solution (0.2M H2SO4) where the 
blue colour changed to yellow due to the low pH. The plate was read on a plate reader at 
450nm.
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Chapter 3 - Generation of Equine IgE:
3.1 - Introduction:
Since this project  is concerned with the study of the interaction between the 
equine FcεRI receptor and the equine IgE, and since this IgE is not available 
commercially, this required the synthesis of this antibody in-house. The concept of the 
synthesis was based on the published sequence of the equine IgE heavy chain wild type 
gene sequence (Navarro, et al., 1995) from the GenBank sequence database (part of the 
United States’ National Center for Biotechnology Information, NCBI), which then had 
its DNA codons optimized (changed) for mouse codons (Mus musculus) to increase the 
efficiency of protein expression in mouse cells. The optimized gene was constructed 
digitally and sent to the company (GenScript) which synthesized the gene (Appendix). 
The equine IgE heavy  chain gene was then cloned into a plasmid downstream of a gene 
sequence that codes for a mouse antibody variable region that recognizes and binds to 
the antigen 4-hydroxy-5-iodo-3-nitrophenylacetic acid (NIP). Therefore, when 
expressed, the protein would be a full equine IgE antibody with a mouse variable region 
that binds to NIP (equine IgE anti NIP). The final plasmid was transfected into mouse B 
cells, and after antibiotic selection of the cloned cells, a mouse B cell line that expressed 
equine IgE was developed.
The expressed equine IgE was secreted outside of the cells into the cell media, 
and therefore harvesting of the media, and running it through an affinity  column, 
resulted in pure equine IgE anti NIP. Just to be clear, the produced antibody binds to the 
NIP molecule, but since it was an organic molecule, for it to be used in the SPR 
machine it  has to be conjugated to human serum albumin (HSA) therefore the actual 




3.2.1 - Optimizing The Equine IgE Heavy Chain Gene:
The equine IgE heavy  chain (Hε) was searched and found in a paper by (Navarro, 
et al., 1995), the protein sequence is included in the Appendix. This protein sequence 
was used to construct a gene optimized for the mouse (Mus musculus) as in chapter 
2.2.1. The final optimized DNA sequence used had a TAA ending sequence added, two 
BamHI restriction sites at each end of the sequence to allow for cloning and half a 
human intron at the start that completed the endogenous intron in the plasmid, this 
allowed for the cloning of the gene into the pSV-VNP plasmid. The intron with the first 
restriction was spliced out and the gene of the variable region and the heavy chain were 
fused to form one single gene, in frame, that was expressed into one single IgE protein. 
A BglII restriction site was placed right  at the end of the gene after the TAA ending 
sequence but behind the BamHI site to check for the orientation of the gene after its 
ligation, this was because both ends of the gene were digested with the same restriction 
enzyme, which allowed for the ligation of the gene in either direction.
3.2.2 - Cloning The Equine IgE Heavy Chain Gene Into Plasmid:
As discussed in chapter 2.2.4 the vector used in this experiment was pSV-VNP 
plasmid where the equine heavy chain gene (Hε) was cloned downstream of a mouse λ 
chain variable region that binds to NIP-HSA. As outlined in chapter 3.2.1 the 
synthesized Hε gene was delivered in the plasmid pUC57 (which had characteristics 
similar to that  of pUC19) and was transformed into E.coli TOP 10 bacteria. The bacteria 
were cultured as described in chapter 2.2.3 and the cells harvested, followed by 
purifying the pUC57-Hε plasmid as outlined in chapter 2.2.5.
The pUC57-Hε plasmid was digested with BamHI to remove the Hε gene, the 
plasmid pSV-VNPF424 plasmid was also digested with BamHI to remove the F424 gene 
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and thus allowed the Hε gene to replace it. The restriction digestion was carried out as 
shown in chapter 2.2.7 followed by de-phosphorylation of the pSV-VNP plasmid to 
prevent it from self ligating since both ends of the plasmid had the same restriction 
sites. Figure 14A shows the restriction digestion results.
The DNA bands of interest were analyzed by agarose gel electrophoresis. see 
chapter 2.2.8 and then isolated, see chapter 2.2.9 and ligated as shown in chapter 2.2.10. 
The resulting ligation mixture was transformed into bacterial cells XL-1 Blue as in 
chapter 2.2.11 and the cells were spread on a plate as in chapter 2.2.3 using the media 
described in chapter 2.2.2. The colonies that grew after the 16 hour incubation were the 
transformed colonies with the pSV-VNPHε plasmid. Six colonies were isolated, grown, 
harvested and the pSV-VNPHε plasmids purified to check for the successful insertion of 
the gene, and since the same restriction enzyme on both end of the gene was used to 
insert it, the plasmids was also analyzed for the correct orientation of the gene by 
digesting them with BglII restriction enzyme. Figure 14B shows the gene insertion and 
the orientation tests, and Figure 15 shows the structure of the pSV-VNP plasmid before 
and after the Hε insert. The gene and plasmid sizes was calculated to check for the 
presence of the gene and its orientation, were the pSV-VNP plasmid on its owen had a 
size of ~7000bp, the F424 gene had a size of 3000bp, the pUC57 plasmid had a size of 
2710bp and the Hε had a size of 1302bp. The plasmid with the correct  orientation had 
two bands at 2000bp and 7000bp, while the plasmid with the wrong orientation had two 
bands at 3000bp and 6000bp.
117
                  1kb DNA           pUC57-            pSV-VNP
                   Ladder                Hε"                HεF424
" " "                                                   7000bp pSV-VNP
6000bp
3000bp "" "                                                   3000bp HεF424
                                                 2710bp pUC57
                                                                                        1302bp Hε
1000bp "" "                                
A
                              pSV-VNP                                                       pSV-VNP
              1kb DNA  CD23 α                                         1kb DNA CD23 α
                 Ladder  Control  1        2      3       4        5   Ladder  Control   1  2       3       4        5       6 
   pSV-VNP        
       6000bp " " " " " "                                                                        Right
" " " " " " "                                                                        Orientation
       3000bp
          
          Hε" " " " " " "             " " " " " "             
       1000bp
B
Figure 14: Restriction digestion of pUC57-Hε and pSV-
VNPF424:
A. the plasmids were digested with BamHI followed by  de-
phosphorylation. This was done in preparation to clone the Hε 
gene into the pSV-VNP plasmid. B. the left side of the figure 
shows the successful insertion of the Hε gene into all of the 
isolated pSV-VNPHε plasmids where they were digested with 
BamHI. The right side of the figure shows the gene orientation 
test, where the plasmids were digested with BglII, with all the 
colonies being in the correct orientation, but the gene isolated 
from the 3rd colony being in the wrong orientation.
BamHI
A                      B
Figure 15: The structure of the pSV-VNP plasmid before and 
after the insertion of the Hε gene:
A. shows the structure of the pSV-VNP plasmid (without the 
F424 gene) while B. shows the final structure of the pSV-VNPHε 
plasmid.
Once the bacterial colony with the pSV-VNPHε containing the correct Hε gene 
orientation was identified and a backup bacterial culture was frozen as in chapter 2.2.12, 
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it was grown and the pSV-VNPHε plasmid DNA harvested in a larger concentration as in 
chapter 2.2.13 followed by concentrating the plasmid DNA as in chapter 2.2.15 and the 
DNA quantified as in chapter 2.2.14 which enabled the required concentration adjusted 
for mammalian cell transfection.
3.2.3 - Transfecting J558L Cells With Equine IgE Heavy Chain Gene:
The pSV-VNPHε plasmid was transfected into J558L mouse B cells as outlined in 
chapter 2.3.5. The cells were then plated onto two 24 well plates, thus dividing them 
into 48 wells. A control was setup by  replacing the plasmid DNA with water and 
running the experiment normally, this control was plated on to a separate plate.
The first 48 hours after transfection the cells were grown on normal media to 
allow the transfected cells to express the relevant selected genes. The media was then 
replaced with selective media and the cells selected as in chapter 2.3.7.
3.2.4 - Selecting Equine IgE Anti NIP-HSA Expressing J558L Cells:
The cells went through a population decline as the majority of the non-transfected 
cells died. Then after ~5-6 weeks healthy  cell colonies, around three to four cells, 
started to appear, which rapidly  grew in number and at  ~6 weeks after transfection the 
well were full of healthy cells, Figure 16 shows what the wells looked like at different 
selection stages.
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G
Figure 16: J558L cell morphology during selection:
This figure shows the cell morphology and the general look of 
the wells at different stages on cell selection. In A. the cells were 
just transfected but not yet selected, therefore their morphology 
shows very  healthy spherical cells that fills the well. In B. a 
week after the introduction of selective media, at this point 
nearly all the cells in the well look very unhealthy as in C. as the 
healthy cells cannot be distinguished at this stage, wells look 
like this for the majority of the selection process. In D. as the 
selection progresses, dead cells are removed and the healthy 
ones remain behind and they  start to appear. E. The healthy  cells 
then have the freedom to grow and develop very small colonies, 
which grow quickly as in F. until they fill the wells as in G.
The media from all 48 wells was harvested and centrifuged at 180xg for 3 minutes 
to remove all the cells and the supernatant was analyzed by SPR for the presence and 
quantity of equine IgE as in chapter 2.4.3. Figure 17 shows the SPR results from all 48 
wells. The cells in the well with the highest quantity of expressed IgE (in this case well 
BB3) were collected and grown to develop a J558L cell line that expressed equine IgE 
anti NIP-HSA. The values for Figure 17 came from the average of the difference 
between the bottom point and the top point for two SRP well curves, Figure 18 shows 
120
the top actual SPR curve of the BB3 well with the bottom curve being the control media 
from non-transfected cells and some other selected cells that are not expressing the 
antibody.
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Figure 17: SPR results of J558L selection of equine IgE anti 
NIP-HSA expression:
This is the SPR result of the transfected and selected J558L cell 
media from each well. Each bar represents the quantity of 
equine IgE anti NIP-HSA, therefore well BB3 ,marked with the 
red arrows, was selected as the well expressing the most IgE, 
therefore the cells of this well were collected and grown 
separately  where the J558L cell line expressing equine IgE anti 







Figure 18: BB3 well SPR curve:
This figure shows the top  actual SRP curve of the highest well 
expressing equine IgE anti NIP-HSA (well BB3 from Figure 
17). The bottom curve is the control media from non-transfected 
cells and some other selected cells that are not expressing the 
antibody. The values for Figure 14 came from the average of the 
difference between the bottom point and the top  point for the 
two SRP well curves.
3.2.5 - Collecting And Purifying The Equine IgE Anti NIP-HSA:
A density  of 5x105 cells ml-1 of the J558L cells expressing equine IgE anti NIP-
HSA was plated on a 100mm2 petri dish with 20ml of selective media, then incubated 
for 5 days at 37°C + 5% CO2 + 90% relative humidity as in chapter 2.4.3. This was 
found to be the optimal cell density and length of time for expression, where the 
expressed protein accumulated in the media, but not left long enough for it to start 
degrading. Figure 19 shows that level of IgE relative to incubation time.
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Figure 19: SPR results of the level  of IgE against expression 
time:
This figure is shows the increase in the level of IgE in the cell 
media against the incubation time. 5 days of expression (marked 
by the red arrows) was found to be the ideal expression time for 
this cell line where the level of IgE was at its highest before it 
started to degrade. Therefore the cell supernatant media was 
harvested after 5 days of expression.
IgE was expressed in 200ml of media was expressed and collected by centrifuging 
at 180xg for 3 minutes to remove the cells, then the media was filter sterilized through a 
0.45µm filter to remove all cells and debris to prevent dead cell proteases from 
degrading the IgE. Due to the large volume of the media, it was concentrated using a 
3kDa molecular filter to reduce the volume. Figure 20 shows the results of the level of 
IgE after media concentration, which corresponds to ~3600 resonance units. Values for 
this graph are in the Appendix. The concentrated media was purified through a 
chromatography column as in chapter 2.4.5.
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Figure 20: SPR results of the level of IgE after media 
concentration:
This is the SRP result of the level of the IgE after the media was 
concentrated through a 3kDa molecular filter. Values for this 
graph are in the Appendix.
3.2.6 - Checking Equine IgE Anti NIP-HSA Viability And Purity:
The purified equine IgE anti NIP-HSA was concentrated down to ~200µl, using a 
3kDa molecular filter, and its concentration was found by using a NanoDrop (Thermo 
Scientific) spectrophotometer, where the OD280 of a 1µl of the protein was measured 
and the weight extension coefficient of IgE (1.62) used to find the final concentration of 
the protein, in this case it was 3.64 mg ml-1. The following equation was used to 
measure the concentration:
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(           )OD280Weight Extension Coefficient x Dilution Factor = Concentration mg ml-1
The equine IgE anti NIP-HSA was then tested in an SDS-PAGE for its purity 
(Figure 21). The SDS-PAGE result showed that the non-reduced IgE had a single strong 
back band above the level of the ladder as the IgE size was ~192kDa, it also showed 
very little IgE degradation by the very faint lines under the IgE band, and almost no 
albumin impurity, which would have shown a band at 65kDa. The equine IgE was also 
reduced, using β-mercaptoethanol, to break the disulphide bridges between the two 
heavy  chains and between the heavy  chain and the light chain, and this resulted in two 
bands at ~70kDa for the heavy chain, and ~25kDa for the light chain as predicted.
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Figure 21: SDS-PAGE of the equine IgE anti NIP-HSA:
SDS-PAGE analysis of the equine IgE anti NIP-HSA, on the left 
is the non-reduced IgE showing a single strong band above the 
ladder as the IgE size is ~192kDa, the result also show very little 
IgE degradation by  the very faint lines under the IgE band, it 
also show almost  no albumin impurity, which would show a 
band at 65kDa. On the right is the reduced equine IgE anti NIP-
HSA, by β-mercaptoethanol, therefore the disulphide bridges 
between the two heavy chains and between the heavy chain and 
the light chain are broken, therefore the top band shows the 
heavy  chain as predicted at ~70kDa, and the bottom line very 
faintly showing the light chain at ~25kDa as predicted.
The antibody was then tested for viability using SPR, Figure 22 shows the result 
of the test with a large curve confirming that the antibody recognizes NIP-HSA. It also 







Figure 22: Equine IgE anti NIP-HSA viability test:
This figure is showing the curve of the purified equine IgE anti 
NIP-HSA. The bottom curve is the overflow from the 
concentrated purified IgE, the middle curve is the non-
concentrated IgE and the top curve is the concentrated IgE. This 
figure showed no protein loss during the concentration process, 
it also confirmed that the antibody recognizes its cognate 
antigen NIP-HSA.
3.3 - Discussion:
This experiment was successful in producing a cell line that expressed equine IgE 
anti NIP-HSA, purification of the antibody and confirmed its viability in preparation for 
the next set of experiments. This experiment was necessary as equine IgE anti NIP-
HSA was not available commercially. Some shortcuts and efficiencies were also 
realized while running this experiment.
First of all it was realized that not concentrating the expressed cell media down to 
a small volume yielded more IgE from the chromatography column, this was because 
concentrating the media concentrated nearly  all the other serum proteins, therefore the 
washing process did not effectively remove all protein impurities, this should be noted 
in future antibody purifications by this or similar protocols. The column used was 2cm 
long, exactly as the protocol stated, this resulted is a large quantity  of IgE to be 
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collected, this is an important note, as in chapter 5 and 7 a larger 12cm column was used 
and proved to be very inefficient, as the flow rate through it  was very slow that it did 
not remove enough of the protein impurities, and did not elute enough of the protein of 
interest. It was also realized that using the NanoDrop spectrophotometer did not result 
in an accurate measurement of proteins, it was better suited for DNA quantification. 
Therefore the protocol from chapter 2.4.6 was used in later protein quantifications.
Ideally a western blot would have been used to confirm that the antibody was 
indeed equine IgE, but this was not possible as commercial anti-equine IgE antibodies 
were not found. An indirect way could have been used where anti mouse λ chain 
antibodies would bind to the antibody’s variable region, but since all the antibodies 
synthesized in the lab had this chain, this would not have proved anything. A mouse 
anti-cat IgE antibody was purchased from (Serotec) where the manufacturer stated it 
might cross react with equine IgE, but when tested by SPR this was shown to be not 
true and there was no cross reaction, therefore mouse anti-cat IgE antibody would not 
have been successful in preforming a western blot. The only way  the equine IgE anti 
NIP-HSA identity was confirmed was later on in the project when the kinetic bindings 
were run and the equine sFcεRIαD1&2 receptor bound to the equine IgE with the 
highest binding affinity (see Chapter 6).
During the molecular biology, where the plasmids were developed, it was realized 
that ligating DNA failed when the digested genes were ethanol precipitated after being 
extracted from agarose gels. This was because the salts from the TAE buffer also 
precipitated which to a high concentration. Therefore when the final DNA bands were 
added to the ligation master mix, the T4 DNA ligase enzyme got denatured, and thus the 
DNA did not ligate, resulting in the cloning process failing. This happened to all the 
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DNA cloning steps in the following chapters. The problem was overcame by purchasing 
the Wizard® SV Gel And PCR Clean-Up System (Promega), which purified small DNA 
strands by binding affinity, ensuring all eluted DNA is in pure de-ionized distilled water. 
Furthermore,  the ethanol precipitation protocol was used later on just to concentrate 
DNA from samples that had DNA in pure de-ionized distilled water.
A problem was faced when the 1/2 human intron was inserted. Introns have a start 
sequence of GT and an end sequence of AG, and since the first half of the intron, which 
is included in the plasmid, was not sequenced, the second half of the intron had to be 
guessed. Therefore a normal 1/2 human intron was inserted with only the ending 
sequence of AG.
It was later realized that in humans the G of the AG ending sequence was the first 
nucleotide of the codon of the amino acid. Thus when the intron was removed, it 
removed the G from the next condon, but it was replaced by  the G behind the starting 
intron code, therefore in the human wild type IgE gene, the introns are removed 
normally with no problems. This was not realized, and therefore when the 1/2 human 
intron was inserted, the ending sequence was AG, i,e: there was an extra G between the 
intron ending sequence and the first nucleotide of the next codon. This caused a frame 
shift in the final mRNA sequence and thus did not code for a full equine IgE anti NIP-
HSA. This problem was fixed by removing the extra G my point mutation as in chapter 




TGT GCA GTACGTTCCCACCTGCTCTAGAAGATGAGGGCCAAGGCACGCCCTCATGCAGCCTCTCACTCGAGCACACTGCAG GAG AGC
 C   A                                    Intron                                     E   S
TGT GCA GAG AGC
 C   A   E   S
GTACGTTCCCACCTGCTCTAGAAGATGAGGGCCAAGGCACGCCCTCATGCAGCCTCTCACTCGAGCACACTGCAG
TGT GCA GGTACGTTCCCACCTGCTCTAGAAGATGAGGGCCAAGGCACGCCCTCATGCAGCCTCTCACTCGAGCACACTGCAG GAG AGC
 C   A                                    Intron                                      E   S
TGT GCA GGA GAG C
 C   A   G   E  .... Early Stop Codon
GTACGTTCCCACCTGCTCTAGAAGATGAGGGCCAAGGCACGCCCTCATGCAGCCTCTCACTCGAGCACACTGCAG
TGT GCA GGTACGTTCCCACCTGCTCTAGAAGATGAGGGCCAAGGCACGCCCTCATGCAGCCTCTCACTCGAGCACACTGCA GAG AGC
 C   A                                    Intron                                     E   S
TGT GCA GAG AGC







Fixed Normal Intron 
According To The Wild Type 
Human IgE Gene
Figure 23: Intron problem and how it was solved:
This figure shows the configuration of a normal human intron, 
and the human intron found in the wild type IgE gene. This 
caused a problem when the gene was constructed as an extra G 
was replaced, since the first half of the human intron was in the 
plasmid and not sequenced. This was solved by deleting the 
extra G.
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Chapter 4 - Generation of an RBL-2H3.1 
Cell Line Expressing Equine FcεRIα:
4.1 - Introduction:
A cell based assay called the β-hexosaminidase release assay (very similar to 
ELISA) tested the effect of IgE on cell degranulation when it bound to its FcεRI 
receptor and subsequently challenged with a cognate antigen (allergen). The assay was 
preformed on rat basophilic leukemia (RBL-2H3.1) cells, this represented and accepted 
a model system to study IgE mediated degranulation of cellular mediators, which occurs 
in both mast cells (in the tissue) and basophil cells (in the blood). RBL-2H3.1 cells 
responses to IgE and antigen provide a key assay representative of the cell biology of 
allergy in the blood and tissue. As described in chapter 2.4.9 β-hexosaminidase is an 
enzyme that is released with the mediators, along with histamine and IL-4, during IgE 
assisted cell degranulation. This works in our favor as the enzyme catalyses a reaction 
leading to a yellow product that can be measured by a spectrophotometer and the 
quantity of mediators released can be determined.
For this assay to be used in this project, RBL-2H3.1 cells were transfected with 
the gene encoding the equine FcεRI receptor’s α chain, this chain was translocated into 
the cell membrane, where it was coupled with the endogenous rat β and two γ chains to 
make a fully functional FcεRI chimeric receptor capable of binding equine IgE 
mediated transmembrane signaling via the transfected ligand binding domain. This 
enabled the investigation of cell degranulation by equine IgE in RBL-2H3.1, and 
therefore the behavior of IgE and the FcεRI receptor in the equine model was 
determined.
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The equine FcεRI receptor’s α chain protein sequence was determined from 
(McAleese, et al., 2000) using the GenBank sequence database (part of the United 
States’ National Center for Biotechnology Information, NCBI), which then had its 
DNA codons optimized (changed) for rat codons (Rattus norvegicus) and yeast  (Pichia 
pastoris) to increase the efficiency of protein expression in rat cells, and also yeast cells 
for the experiment in chapter 5. The optimized gene was constructed digitally  and sent 
to the company (GenScript) which synthesized the gene (Appendix). The equine FcεRIα 
gene was then cloned into a plasmid and transfected into RBL-2H3.1 cells which 
expressed the receptor on its surface.
4.2 - Results:
4.2.1 - Optimizing The Equine FcεRIα Gene:
The equine FcεRI receptor’s α chain had been previously published (McAleese, et 
al., 2000), and the protein sequence is included in the Appendix. This protein sequence 
was used to construct a gene optimized for the rat (Rattus norvegicus) and and the yeast 
(Pichia pastoris) as outlined in chapter 2.2.1. The final optimized DNA sequence used 
had a TAA ending sequence added along with two restriction sites, HindII at the start 
and EcoRI at the end, which allowed for cloning into the pEE6 plasmid.
4.2.2 - Cloning The Equine FcεRIα Gene Into Plasmid:
As discussed in chapter 2.2.4 the vector used for this experiment was pEE6 
plasmid (sequence in Appendix). Form chapter 3.2.1 the synthesized FcεRIα gene was 
delivered in the plasmid pUC57 (which had characteristics similar to that of pUC19) 
and was transformed into E.coli TOP 10 bacteria. Therefore the bacteria were grown as 
in chapter 2.2.3 and the cells harvested, followed by purifying the pUC57-FcεRIα 
plasmid as in chapter 2.2.5.
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The pUC57-FcεRIα plasmid was digested with HindIII and EcoRI to remove the 
FcεRIα gene, the plasmid pEE6-CD23α plasmid was also digested with HindIII and 
EcoRI to remove the CD23α gene and thus allowed the FcεRIα gene to replace it. The 
restriction digestion was done as in chapter 2.2.7 followed by de-phosphorylation of the 
pEE6 plasmid to prevent it from self ligating, but this was not really  necessary as both 
ends of the plasmid did not have the same restriction sites. Figure 24A shows the 
restriction digestion results.
The DNA bands of interest were analyzed on an electrophoresis gel as in chapter 
2.2.8 and then isolated as in chapter 2.2.9 and ligated together as in chapter 2.2.10. The 
resulting ligation mixture was transformed into bacterial cells XL-1 Blue as in chapter 
2.2.11 and the cells were spread on a plate as in chapter 2.2.3 using the media from 
chapter 2.2.2. The colonies that grew after the 16 hour incubation were the transformed 
colonies with the pEE6-FcεRIα plasmid. Therefore six colonies were isolated, grown, 
harvested and the pEE6-FcεRIα plasmids purified to check for the successful insertion 
of the gene. Figure 24B shows the gene insertion, and Figure 25 shows the structure of 
the pEE6 plasmid before and after the FcεRIα insert. The gene and plasmid sizes was 
calculated to check for the presence of the gene, were the pEE6 plasmid on its own had 
a size of 6583bp, the CD23α gene had a size of 1200bp, the pUC57 plasmid had a size 
of 2710bp and the FcεRIα had a size of 780bp.
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A B
Figure 24: Restriction digestion of pUC57-FcεRIα snd 
pEE6-CD23α:
A. the plasmids were digested with HindIII and EcoRI followed 
by de-phosphorylation. This was done in preparation to clone 
the FcεRIα gene into the pEE6 plasmid. The pEE6 plasmid had 
a size of 6583bp and the FcεRIα gene had a size of 780bp B. 
shows the successful insertion of the FcεRIα gene into all of the 
isolated pEE6 plasmids where they were digested with HindIII 
and EcoRI.
A                     B
Figure 25: The structure of the pEE6 plasmid before and 
after the insertion of the FcεRIα gene:
A. shows the structure of the pEE6 plasmid (without the CD23α 
gene) while B. shows the final structure of the pEE6-FcεRIα 
plasmid.
Once the bacterial colony with the pEE6-FcεRIα was identified and a backup 
culture was frozen as in chapter 2.2.12, it was grown and the pEE6-FcεRIα plasmid 
harvested in a larger concentration as in chapter 2.2.13 followed by concentrating the 
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plasmid DNA as in chapter 2.2.15 and the DNA quantified as in chapter 2.2.14 which 
enabled the required concentration adjusted for mammalian cell transfection.
4.2.3 - Transfecting RBL-2H3.1 Cells With Equine FcεRIα Gene:
The pEE6-FcεRIα plasmid was transfected into RBL-2H3.1 cells as in chapter 
2.3.5. The cells were then plated onto two 100mm2 dishes. A control was setup  by 
replacing the plasmid DNA with water and running the experiment normally, this was 
plated out on to a separate dish.
The first 48 hours after transfection the cells were grown on normal media to 
allow the transfected cells to express the relevant genes. The media was then replaced 
with selective media and the cells selected as in chapter 2.3.5.
4.2.4 - Selecting And Sorting Equine FcεRIα Expressing RBL-2H3.1 Cells:
The transfected RBL-2H3.1 cells were selected as in chapter 2.3.5 using selective 
media (Dulbeco’s Modified Eagle’s media 500ml: 1000mg glucose + 10% FCS + 5000 
units of penicillin + 50mg streptomycin + 0.4g geneticin G418 sulphate) and selecting 
for proximally 1-2 weeks, changing the media every 2 days where the cell population 
declined as the non-transfected cells died, then the population started to increase, but the 
cells were harvested early  before the dish became confluent, because since the 
RBL-2H3.1 cells are a monolayer cell line, they can only form a certain colony  size 
before the cells in the middle of the colony  starts to die. Therefore the cells were 
harvested as in chapter 2.3.4 and sorter as in chapter 2.3.6. Figure 25 shows the FACS 
results, noting that the cells were sorted using canine IgE as the equine IgE was not 
synthesized at that time. The results show (Figure 26A) very few cells in the negative 
control (0.3% of the population) that are fluorescent (false auto florescence) these cells 
were not tagged with any antibody. The cells that were tagged with human IgE (Figure 
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26B) also showed to be negative as the florescent cells were only 0.7% of the 
population, therefore it was labeled as negative, these cells were tagged with human IgE 
- mouse IgG anti human IgE - anti mouse IgG antibody tagged with phycoerythrin. The 
cells that  were tagged with canine IgE showed 1.3% of the population to be florescent 
positive cells, the rest of the population was transfected cells but not expressing the 
equine FcεRIα receptor. This percentage was high enough for it to be taken as the 
positive sample and thus the cells were sorted from it (Figure 26C), these cells were 
tagged with canine IgE - mouse IgG anti canine IgE - anti mouse IgG antibody tagged 
with phycoerythrin. It was later realized that the human IgE does not bind to the equine 
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Figure 26: FACS results of RBL-2H3.1 cells transfected with 
pEE6-FcεRIα:
A. shows the FACS results of the negative control (not tagged 
with any IgE) showing 0.3% of the population with false auto 
florescence. The graph on the left is the side scatter against 
forward scatter graph with the tested population within the 
circle, and the graph on the right is the side scatter against 
florescence graph showing the selected population’s florescence 
with the positive florescence within the selected box area. 
Therefore the 0.3% is the percentage of cells within box in the 
right graph compared to total number of cells within the total 
population selected form the left graph. B. Shows the FACS 
results of the cells tagged with human IgE, only 0.7% of the 
population was positive, therefore it was too little and was 
considered to be negative. C. shows the FACS results of the 
cells tagged with canine IgE, 1.3% of the population was 
positive, therefore the positive cells from this sample were 
sorted and collected, and when grown resulted in an RBL-2H3.1 
cell line that expressed equine FcεRIα receptor on its surface.
The sorted cells gave ~10,000 cells back, which were grown up to develop an 
RBL-2H3.1 cell line that expressed the equine FcεRIα chain. This cell line was tested 
before the release assays to ensure that the entire population was expressing the receptor 
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instead of the cells being resistant but not expressing the receptor, which is tends to 
happen in RBL-2H3.1 cells if they  are left in culture for a prolonged period. Figure 27 
shows the test results, here the cells were tested with equine IgE tagged with 
allophycocyanin (APC), and the test showed that almost the entire cell population 
expressed the equine FcεRIα receptor as there was a complete shift in cell population 
during the tested between the control and the florescent test.
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Figure 27: Flow cytometry test of RBL-2H3.1 cells 
expressing equine FcεRIα:
The top graph shows the side scatter against forward scatter of 
the cells that represent the cell size and granularity, the circled 
population of cells are the healthy cells that which the 
florescence was tested. The middle graph (cell count against 
florescence) shows the non-florescence of the circled 
population. The bottom graph (cell count against  florescence) 
shows the florescence of the same circled population. As can be 
seen almost the entire population shifts from non-florescence to 
florescence, indicating that almost the entire cell population is 
expressing the equine FcεRIα receptor subunit. The cell 
population not circled in the top  graph are dead cells due to the 
preparation process.
To confirm this further, the cells were visualized under a confocal microscope, 
Figure 28 shows the result of the difference between the control (Figure 28A and B) and 




Figure 28: Confocal image of RBL-2H3.1 cells expressing 
equine FcεRIα:
A. is the figure of the control sample of cells that were not 
tagged with florescent equine IgE under white light. B. is the 
same cell under 650 nm showing no florescence. C. is the 
positive sample cells tagged with florescent equine IgE under 
white light. D. is the same cell under 650 nm showing 
florescence.
4.2.5 - β-hexosaminidase Release Assays:
The cells were assayed as in chapter 2.4.9. Figure 29 shows the main β-
hexosaminidase release assay data where the RBL-2H3.1 cells expressing equine 
FcεRIα were tested, using non-transfected RBL-2H3.1 cells as a control, the data for 
this graph is found in the Appendix, and Figure 30 shows the relative maximum release 
(at 100ng ml-1 of antigen) between the different tests. These cells were tested with 
mouse, equine, human and canine IgEs to compare equine IgE mediated cell 
degranulation to them, and also to test how related and similar this is to human and 
canine IgE mediated release. All positive releases showed the expected sigmoid curve 
where cells challenged with little antigen concentration would release little mediators, 
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as there is only  little receptor aggregation on the cell surface, but on the other end of the 
graph, when cells are challenged with a higher antigens concentration, the cells would 
release little mediators, due to the fact the the receptors would aggregate so much 
forming a cap on the cell surface, forming a polarized cell, which is not efficient in 
causing a downward signal cascade. Therefore the maximum release by the cells is in 
the middle of the graph around 100ng ml-1 of antigen, this concentration allows for a 
uniform distribution of receptor aggregation on the cell surface causing the most 
efficient downward signal cascade and therefore resulting in the highest mediator 
release.
The results showed that non-transfected (RBL-parental) cells when tested with 
mouse IgE anti DNP-HSA showed a maximum release of 51.55% at 100ng ml-1 of 
antigen. This was the control experiment. Transfected cells (RBL-pEE6) tested with 
mouse IgE anti DNP-HSA showed a similar maximum release of 45.99% at 100ng ml-1 
of antigen, thus confirming that the cells positively released as the mouse IgE bound to 
the endogenous rat receptor on the cell surface. When the non-transfected cells were 
tested with equine IgE anti NIP-HSA a maximum release of only  11.81% at 100ng ml-1 
of antigen, this was the negative control, as equine IgE was thought not to bind to the rat 
receptor, and thus showed so due to the very low release.
On the other hand, transfected cells expressing the equine FcεRIα showed a 
maximum release of 36.68% at 100ng ml-1 of antigen when tested with equine IgE anti-
NIP-HSA, and therefore showed the successful expression of the receptor and its viable 
function in causing cells to degranulate. It also showed that the IgE binding to its 
receptor causes high release, as it was close to the positive control maximum release, 
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but smaller than the controls as the receptor is competing with the endogenous receptor 
on the cell receptor and thus its number is small.
The cells were then tested for similarity with human IgE-mediated release, and 
therefore non-transfected cells were tested with human IgE anti NIP-HSA which 
showed a flat line with only 7.97% release at 100ng ml-1 of antigen, and thus this was 
the negative control. Transfected cells expressing the equine FcεRIα also showed 8.88% 
release at 100ng ml-1 of antigen. This concluded that the human IgE does not bind to the 
equine FcεRIα, and thus the human and equine protein sequences are different enough 
as not  to interact with each other. This point is discussed further in the discussion since 
it was not expected.
The cells were then tested for similarity with canine allergy, and therefore non-
transfected cells were tested with canine IgE anti NIP-HSA which showed only 11.50% 
release at 100ng ml-1 of antigen and thus this was the negative control. But transfected 
cells expressing equine FcεRIα showed 32% release at 100ng ml-1 of antigen when 
sensitized with canine IgE. This concludes that the canine IgE binds to the equine 
FcεRIα strong enough to cause release, which is almost the same as the equine IgE 
when bound to the FcεRIα.
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1 2 3 4 5 6 7 8 9 10 11 12
1.633 1.749 1.787 1.773 1.830 1.858 0.074 0.078 0.088 0.124 0.100 0.102
1.709 1.896 1.909 1.887 1.920 1.868 0.070 0.072 0.069 0.101 0.091 0.084
1.737 1.865 1.891 1.904 1.989 1.966 0.076 0.077 0.072 0.073 0.076 0.080
1.809 1.897 1.927 1.993 1.984 1.963 0.065 0.064 0.066 0.070 0.079 0.073
1.793 2.020 2.023 2.005 1.953 2.107 0.085 0.086 0.083 0.088 0.086 0.086
1.719 1.910 1.967 2.028 1.952 2.010 0.089 0.080 0.085 0.081 0.080 0.086
1.736 1.854 1.963 1.994 1.994 1.970 0.088 0.096 0.092 0.091 0.098 0.096
0.542 0.688 0.642 0.723 0.742 0.907 0.941 1.220 0.747 1.247 1.207 0.819
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.781 1.905 1.963 2.021 2.03 2.062 8.310 8.189 8.966 12.271 9.852 9.893
1.849 2.04 2.047 2.089 2.102 2.036 7.572 7.059 6.742 9.670 8.658 8.251
1.889 2.019 2.035 2.05 2.141 2.126 8.047 7.628 7.076 7.122 7.099 7.526
1.939 2.025 2.059 2.133 2.142 2.109 6.704 6.321 6.411 6.564 7.376 6.923
1.963 2.192 2.189 2.181 2.125 2.279 8.660 7.847 7.583 8.070 8.094 7.547
1.897 2.07 2.137 2.19 2.112 2.182 9.383 7.729 7.955 7.397 7.576 7.883
1.912 2.046 2.147 2.176 2.19 2.162 9.205 9.384 8.570 8.364 8.950 8.881




































1 2 3 4 5 6 7 8 9 10 11 12
1.558 1.607 1.635 1.633 1.530 1.566 0.081 0.089 0.093 0.088 0.085 0.089
1.538 1.668 1.661 1.829 1.563 1.637 0.068 0.067 0.067 0.070 0.068 0.070
1.549 1.720 1.748 1.749 1.629 0.992 0.073 0.072 0.075 0.071 0.070 0.078
1.741 1.656 1.748 1.843 1.824 1.869 0.066 0.064 0.066 0.065 0.071 0.065
1.742 1.798 1.776 1.870 1.754 1.760 0.087 0.086 0.087 0.086 0.086 0.089
1.766 1.832 1.762 1.758 1.766 1.796 0.083 0.078 0.087 0.079 0.080 0.077
1.722 1.780 1.711 1.794 1.738 1.799 0.100 0.084 0.090 0.091 0.093 0.090
0.391 0.365 0.290 0.656 0.436 0.615 1.072 0.812 1.109 0.881 0.996 0.623
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.72 1.785 1.821 1.809 1.7 1.744 9.419 9.972 10.214 9.729 10.000 10.206
1.674 1.802 1.795 1.969 1.699 1.777 8.124 7.436 7.465 7.110 8.005 7.878
1.695 1.864 1.898 1.891 1.769 1.148 8.614 7.725 7.903 7.509 7.914 13.589
1.873 1.784 1.88 1.973 1.966 1.999 7.048 7.175 7.021 6.589 7.223 6.503
1.916 1.97 1.95 2.042 1.926 1.938 9.081 8.731 8.923 8.423 8.930 9.185
1.932 1.988 1.936 1.916 1.926 1.95 8.592 7.847 8.988 8.246 8.307 7.897
1.922 1.948 1.891 1.976 1.924 1.979 10.406 8.624 9.519 9.211 9.667 9.096




















































































1 2 3 4 5 6 7 8 9 10 11 12
1.803 1.779 1.797 1.959 1.730 1.239 0.036 0.064 0.044 0.048 0.054 0.018
1.910 1.851 1.874 1.936 1.804 1.682 0.032 0.041 0.036 0.043 0.038 0.019
1.641 1.733 1.789 1.842 1.744 1.555 0.131 0.157 0.178 0.160 0.185 0.124
1.275 1.361 1.350 1.367 1.307 1.175 0.314 0.428 0.554 0.551 0.609 0.510
1.349 1.236 1.166 1.080 1.025 0.936 0.433 0.537 0.726 0.704 0.707 0.517
1.173 1.236 1.192 1.156 1.081 1.374 0.385 0.669 0.695 0.716 0.584 0.517
1.284 1.189 1.277 1.492 1.113 1.177 0.414 0.652 0.472 0.574 0.323 0.324
1.094 0.964 0.888 0.969 1.037 0.933 0.351 0.413 0.463 0.517 0.494 0.410
2.165 2.283 2.206 2.189 2.244 2.257 0.039 0.037 0.050 0.036 0.036 0.028
2.215 2.233 2.221 2.218 2.169 2.265 0.053 0.048 0.051 0.045 0.054 0.033
2.133 2.170 2.114 2.049 1.909 1.983 0.168 0.166 0.142 0.161 0.148 0.153
1.651 1.693 1.743 1.722 1.747 1.713 0.680 0.586 0.469 0.514 0.435 0.513
1.296 1.260 1.356 1.303 1.301 1.283 0.906 0.689 0.699 0.710 0.767 0.774
1.288 1.306 1.285 1.334 1.248 1.285 0.779 0.553 0.672 0.992 0.718 0.545
1.336 1.296 1.459 1.332 1.392 1.416 0.842 0.433 0.641 0.727 0.552 0.697
0.636 0.653 0.603 0.668 0.658 0.422 1.060 0.713 0.966 0.858 0.680 0.397
2.730 2.660 2.686 2.649 2.646 2.674 0.036 0.052 0.044 0.038 0.037 0.038
2.790 2.668 2.708 2.829 2.667 2.623 0.074 0.063 0.066 0.060 0.056 0.064
2.696 2.719 2.698 2.565 2.611 2.540 0.175 0.165 0.168 0.167 0.123 0.162
2.339 2.392 2.264 2.295 2.247 2.281 0.653 0.596 0.598 0.585 0.542 0.530
1.902 1.917 1.858 1.890 1.824 1.883 0.947 0.849 0.888 0.874 0.870 0.823
2.099 2.062 1.920 1.938 1.911 1.881 0.902 0.879 0.916 0.821 0.793 0.804
2.052 2.091 1.934 2.049 1.856 1.958 0.830 0.777 0.894 0.849 0.784 0.806
0.356 0.141 0.182 0.173 0.207 0.158 1.940 1.679 1.847 1.482 1.300 1.689
2.458 2.438 2.560 2.387 2.265 2.278 0.062 0.045 0.046 0.032 0.047 0.033
2.584 2.681 2.702 2.686 2.249 2.587 0.076 0.058 0.071 0.043 0.065 0.051
2.591 2.600 2.544 2.543 2.434 2.263 0.255 0.212 0.287 0.257 0.208 0.214
2.187 2.159 2.254 2.154 1.940 1.915 0.737 0.747 0.713 0.613 0.582 0.529
1.875 1.704 1.772 1.839 1.519 1.505 1.024 1.195 1.154 0.745 0.906 0.791
1.929 1.686 1.742 1.720 1.590 1.804 1.001 1.019 1.152 0.791 0.835 0.714
1.936 1.795 1.756 1.768 1.411 1.713 1.036 1.045 1.096 0.871 0.884 0.710
1.170 0.300 0.250 0.247 0.237 0.198 0.981 1.384 1.601 1.321 1.385 1.538
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.875 1.907 1.885 2.055 1.838 1.275 3.840 6.712 4.668 4.672 5.876 2.824
1.974 1.933 1.946 2.022 1.88 1.72 3.242 4.242 3.700 4.253 4.043 2.209
1.903 2.047 2.145 2.162 2.114 1.803 13.768 15.340 16.597 14.801 17.502 13.755
1.903 2.217 2.458 2.469 2.525 2.195 33.001 38.611 45.077 44.633 48.238 46.469
2.215 2.31 2.618 2.488 2.439 1.97 39.097 46.494 55.462 56.592 57.975 52.487
1.943 2.574 2.582 2.588 2.249 2.408 39.629 51.981 53.834 55.332 51.934 42.940
2.112 2.493 2.221 2.64 1.759 1.825 39.205 52.306 42.503 43.485 36.725 35.507
1.796 1.79 1.814 2.003 2.025 1.753 39.087 46.145 51.047 51.623 48.790 46.777
2.243 2.357 2.306 2.261 2.316 2.313 3.477 3.140 4.337 3.184 3.109 2.421
2.321 2.329 2.323 2.308 2.277 2.331 4.567 4.122 4.391 3.899 4.743 2.831
2.469 2.502 2.398 2.371 2.205 2.289 13.609 13.269 11.843 13.581 13.424 13.368
3.011 2.865 2.681 2.75 2.617 2.739 45.168 40.908 34.987 37.382 33.244 37.459
3.108 2.638 2.754 2.723 2.835 2.831 58.301 52.237 50.763 52.148 54.109 54.680
2.846 2.412 2.629 3.318 2.684 2.375 54.743 45.854 51.122 59.795 53.502 45.895
3.02 2.162 2.741 2.786 2.496 2.81 55.762 40.056 46.771 52.190 44.231 49.609
2.756 2.079 2.535 2.384 2.018 1.216 76.923 68.591 76.213 71.980 67.393 65.296
2.802 2.764 2.774 2.725 2.72 2.75 2.570 3.763 3.172 2.789 2.721 2.764
2.938 2.794 2.84 2.949 2.779 2.751 5.037 4.510 4.648 4.069 4.030 4.653
3.046 3.049 3.034 2.899 2.857 2.864 11.490 10.823 11.074 11.521 8.610 11.313
3.645 3.584 3.46 3.465 3.331 3.341 35.830 33.259 34.566 33.766 32.543 31.727
3.796 3.615 3.634 3.638 3.564 3.529 49.895 46.971 48.872 48.048 48.822 46.642
3.903 3.82 3.752 3.58 3.497 3.489 46.221 46.021 48.827 45.866 45.353 46.088
3.712 3.645 3.722 3.747 3.424 3.57 44.720 42.634 48.039 45.316 45.794 45.154
4.236 3.499 3.876 3.137 2.807 3.536 91.596 95.970 95.304 94.485 92.626 95.532
2.582 2.528 2.652 2.451 2.359 2.344 4.802 3.560 3.469 2.611 3.985 2.816
2.736 2.797 2.844 2.772 2.379 2.689 5.556 4.147 4.993 3.102 5.464 3.793
3.101 3.024 3.118 3.057 2.85 2.691 16.446 14.021 18.409 16.814 14.596 15.905
3.661 3.653 3.68 3.38 3.104 2.973 40.262 40.898 38.750 36.272 37.500 35.587
3.923 4.094 4.08 3.329 3.331 3.087 52.205 58.378 56.569 44.758 54.398 51.247
3.931 3.724 4.046 3.302 3.26 3.232 50.929 54.726 56.945 47.910 51.227 44.183
4.008 3.885 3.948 3.51 3.179 3.133 51.697 53.797 55.522 49.630 55.615 45.324




































































1 2 3 4 5 6 7 8 9 10 11 12
2.143 2.239 2.136 2.131 2.056 2.069 0.015 0.016 0.011 0.015 0.015 0.009
2.124 2.222 2.143 2.179 2.147 2.093 0.029 0.021 0.028 0.022 0.019 0.027
2.119 2.219 2.166 2.208 2.168 2.095 0.096 0.058 0.077 0.061 0.091 0.088
1.730 1.943 1.821 1.913 1.869 1.777 0.453 0.260 0.362 0.228 0.394 0.383
1.368 1.518 1.508 1.538 1.492 1.417 0.730 0.510 0.692 0.488 0.765 0.778
1.514 1.680 1.551 1.682 1.552 1.519 0.697 0.504 0.635 0.362 0.661 0.396
1.515 1.597 1.566 1.357 1.583 1.564 0.575 0.475 0.577 0.485 0.647 0.609
0.075 0.278 0.216 0.259 0.255 0.244 1.323 1.628 1.392 1.108 1.451 1.686
2.050 2.132 2.115 2.131 2.145 2.138 0.021 0.023 0.011 0.008 0.010 0.036
2.052 2.201 2.241 2.245 2.201 2.123 0.028 0.038 0.041 0.023 0.003 0.030
1.967 2.173 2.201 2.252 2.177 2.091 0.121 0.093 0.106 0.114 0.156 0.175
1.592 1.898 1.873 1.856 1.896 1.716 0.398 0.268 0.314 0.469 0.435 0.547
1.387 1.525 1.521 1.498 1.508 1.399 0.605 0.374 0.487 0.743 0.765 0.799
1.479 1.606 1.594 1.583 1.629 1.543 0.572 0.303 0.354 0.619 0.435 0.679
1.467 1.622 1.591 1.570 1.638 1.539 0.507 0.283 0.360 0.485 0.462 0.582
0.455 0.336 0.445 0.430 0.350 0.225 1.443 0.925 0.711 1.188 0.787 0.930
2.032 2.082 2.010 2.123 2.078 2.081 0.016 0.020 0.014 0.025 0.022 0.013
2.048 2.152 2.124 2.210 2.116 2.058 0.038 0.037 0.029 0.032 0.022 0.037
2.010 2.180 2.194 2.158 2.175 2.079 0.094 0.052 0.061 0.056 0.062 0.083
1.807 1.919 1.947 2.008 2.021 1.893 0.310 0.228 0.306 0.259 0.261 0.293
1.301 1.454 1.438 1.427 1.413 1.433 0.629 0.454 0.654 0.592 0.593 0.664
1.361 1.469 1.455 1.454 1.525 1.487 0.598 0.475 0.593 0.600 0.570 0.538
1.429 1.520 1.529 1.510 1.582 1.531 0.496 0.371 0.618 0.481 0.397 0.538
0.080 0.940 0.116 0.096 0.185 0.186 1.419 1.351 1.714 1.532 0.905 0.806
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.173 2.271 2.158 2.161 2.086 2.087 1.381 1.409 1.019 1.388 1.438 0.862
2.182 2.264 2.199 2.223 2.185 2.147 2.658 1.855 2.547 1.979 1.739 2.515
2.311 2.335 2.32 2.33 2.35 2.271 8.308 4.968 6.638 5.236 7.745 7.750
2.636 2.463 2.545 2.369 2.657 2.543 34.370 21.112 28.448 19.249 29.658 30.122
2.828 2.538 2.892 2.514 3.022 2.973 51.627 40.189 47.856 38.823 50.629 52.338
2.908 2.688 2.821 2.406 2.874 2.311 47.937 37.500 45.019 30.091 45.999 34.271
2.665 2.547 2.72 2.327 2.877 2.782 43.152 37.299 42.426 41.685 44.977 43.781
2.721 3.534 3 2.475 3.157 3.616 97.244 92.134 92.800 89.535 91.923 93.252
2.092 2.178 2.137 2.147 2.165 2.21 2.008 2.112 1.029 0.745 0.924 3.258
2.108 2.277 2.323 2.291 2.207 2.183 2.657 3.338 3.530 2.008 0.272 2.749
2.209 2.359 2.413 2.48 2.489 2.441 10.955 7.885 8.786 9.194 12.535 14.338
2.388 2.434 2.501 2.794 2.766 2.81 33.333 22.021 25.110 33.572 31.453 38.932
2.597 2.273 2.495 2.984 3.038 2.997 46.592 32.908 39.038 49.799 50.362 53.320
2.623 2.212 2.302 2.821 2.499 2.901 43.614 27.396 30.756 43.885 34.814 46.811
2.481 2.188 2.311 2.54 2.562 2.703 40.871 25.868 31.155 38.189 36.066 43.063
3.341 2.186 1.867 2.806 1.924 2.085 86.381 84.629 76.165 84.676 81.809 89.209
2.064 2.122 2.038 2.173 2.122 2.107 1.550 1.885 1.374 2.301 2.074 1.234
2.124 2.226 2.182 2.274 2.16 2.132 3.578 3.324 2.658 2.814 2.037 3.471
2.198 2.284 2.316 2.27 2.299 2.245 8.553 4.553 5.268 4.934 5.394 7.394
2.427 2.375 2.559 2.526 2.543 2.479 25.546 19.200 23.916 20.507 20.527 23.639
2.559 2.362 2.746 2.611 2.599 2.761 49.160 38.442 47.633 45.347 45.633 48.099
2.557 2.419 2.641 2.654 2.665 2.563 46.774 39.272 44.907 45.215 42.777 41.982
2.421 2.262 2.765 2.472 2.376 2.607 40.975 32.803 44.702 38.916 33.418 41.273




































































1 2 3 4 5 6 7 8 9 10 11 12
2.022 2.211 2.063 2.021 2.043 2.018 0.012 0.015 0.015 0.012 0.017 0.017
2.064 2.197 2.147 2.055 2.002 1.951 0.040 0.021 0.040 0.022 0.033 0.048
1.978 2.176 2.055 2.092 2.129 2.058 0.110 0.075 0.082 0.059 0.094 0.096
1.697 1.839 1.832 1.799 1.846 1.678 0.382 0.145 0.369 0.248 0.268 0.377
1.581 1.811 1.661 1.749 1.711 1.699 0.382 0.229 0.316 0.268 0.391 0.409
1.659 1.876 1.738 1.733 1.776 1.733 0.259 0.148 0.364 0.245 0.332 0.416
1.624 1.761 1.693 1.675 1.802 1.614 0.244 0.123 0.305 0.244 0.424 0.391
0.680 0.560 0.709 0.674 0.657 0.639 1.130 0.500 0.806 0.628 0.907 0.828
1.903 1.950 0.194 1.925 2.039 1.963 0.012 0.013 0.011 0.013 0.010 0.013
1.889 1.930 1.948 1.890 1.875 1.921 0.034 0.035 0.042 0.032 0.038 0.033
1.739 1.828 1.876 1.879 1.902 1.920 0.159 0.126 0.129 0.159 0.159 0.157
1.464 1.548 1.583 1.640 1.650 1.639 0.422 0.406 0.376 0.404 0.363 0.320
1.412 1.461 1.502 1.421 1.527 1.482 0.355 0.267 0.283 0.443 0.507 0.461
1.472 1.493 1.673 1.469 1.553 1.491 0.344 0.260 0.352 0.421 0.457 0.447
1.432 1.409 1.470 1.406 1.505 1.448 0.327 0.325 0.340 0.334 0.442 0.474
0.347 0.315 0.375 0.324 0.279 0.365 1.208 1.045 1.180 1.106 1.023 1.028
1.987 2.134 2.167 2.127 2.052 2.016 0.022 0.020 0.019 0.023 0.022 0.017
2.073 2.170 2.175 2.192 2.114 2.058 0.043 0.028 0.033 0.032 0.021 0.047
2.066 2.142 2.147 2.190 2.180 2.147 0.110 0.085 0.081 0.082 0.086 0.105
1.632 1.753 1.746 1.779 1.784 1.700 0.431 0.310 0.426 0.506 0.488 0.447
1.660 1.639 1.651 1.637 1.688 1.528 0.422 0.317 0.351 0.455 0.542 0.464
1.524 1.638 1.664 1.676 1.750 1.577 0.431 0.357 0.289 0.504 0.510 0.505
1.529 1.620 1.649 1.606 1.674 1.454 0.445 0.350 0.403 0.373 0.467 0.465
0.383 0.701 0.507 0.469 0.530 0.507 1.269 1.391 1.412 1.061 1.253 1.180
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.046 2.241 2.093 2.045 2.077 2.052 1.173 1.339 1.433 1.174 1.637 1.657
2.144 2.239 2.227 2.099 2.068 2.047 3.731 1.876 3.592 2.096 3.191 4.690
2.198 2.326 2.219 2.21 2.317 2.25 10.009 6.449 7.391 5.339 8.114 8.533
2.461 2.129 2.57 2.295 2.382 2.432 31.044 13.621 28.716 21.612 22.502 31.003
2.345 2.269 2.293 2.285 2.493 2.517 32.580 20.185 27.562 23.457 31.368 32.499
2.177 2.172 2.466 2.223 2.44 2.565 23.794 13.628 29.521 22.042 27.213 32.437
2.112 2.007 2.303 2.163 2.65 2.396 23.106 12.257 26.487 22.561 32.000 32.638
2.94 1.56 2.321 1.93 2.471 2.295 76.871 64.103 69.453 65.078 73.412 72.157
1.927 1.976 0.216 1.951 2.059 1.989 1.245 1.316 10.185 1.333 0.971 1.307
1.957 2 2.032 1.954 1.951 1.987 3.475 3.500 4.134 3.275 3.895 3.322
2.057 2.08 2.134 2.197 2.22 2.234 15.459 12.115 12.090 14.474 14.324 14.056
2.308 2.36 2.335 2.448 2.376 2.279 36.568 34.407 32.206 33.007 30.556 28.082
2.122 1.995 2.068 2.307 2.541 2.404 33.459 26.767 27.369 38.405 39.906 38.353
2.16 2.013 2.377 2.311 2.467 2.385 31.852 25.832 29.617 36.434 37.049 37.484
2.086 2.059 2.15 2.074 2.389 2.396 31.352 31.569 31.628 32.208 37.003 39.566
2.763 2.405 2.735 2.536 2.325 2.421 87.441 86.902 86.289 87.224 88.000 84.924
2.031 2.174 2.205 2.173 2.096 2.05 2.166 1.840 1.723 2.117 2.099 1.659
2.159 2.226 2.241 2.256 2.156 2.152 3.983 2.516 2.945 2.837 1.948 4.368
2.286 2.312 2.309 2.354 2.352 2.357 9.624 7.353 7.016 6.967 7.313 8.910
2.494 2.373 2.598 2.791 2.76 2.594 34.563 26.127 32.794 36.259 35.362 34.464
2.504 2.273 2.353 2.547 2.772 2.456 33.706 27.893 29.834 35.728 39.105 37.785
2.386 2.352 2.242 2.684 2.77 2.587 36.127 30.357 25.781 37.556 36.823 39.041
2.419 2.32 2.455 2.352 2.608 2.384 36.792 30.172 32.831 31.718 35.813 39.010


































1 2 3 4 5 6 7 8 9 10 11 12
1.165 1.115 1.113 1.14 1.132 1.153 0.079 0.074 0.082 0.073 0.073 0.072
1.149 1.106 1.16 1.149 1.177 1.12 0.073 0.082 0.07 0.078 0.083 0.09
1.178 1.178 1.196 1.176 1.176 1.257 0.07 0.069 0.065 0.069 0.07 0.068
1.191 1.154 1.201 1.199 1.19 1.188 0.066 0.063 0.06 0.066 0.067 0.069
1.167 1.16 1.203 1.239 1.169 1.16 0.076 0.074 0.073 0.08 0.077 0.081
1.177 1.203 1.242 1.236 1.245 1.167 0.077 0.073 0.077 0.081 0.077 0.08
1.171 1.142 1.205 1.189 1.162 1.094 0.078 0.079 0.069 0.081 0.079 0.089
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.323 1.263 1.277 1.286 1.278 1.297 11.943 11.718 12.843 11.353 11.424 11.103
1.295 1.27 1.3 1.305 1.343 1.3 11.274 12.913 10.769 11.954 12.360 13.846
1.318 1.316 1.326 1.314 1.316 1.393 10.622 10.486 9.804 10.502 10.638 9.763
1.323 1.28 1.321 1.331 1.324 1.326 9.977 9.844 9.084 9.917 10.121 10.407
1.319 1.308 1.349 1.399 1.323 1.322 11.524 11.315 10.823 11.437 11.640 12.254
1.331 1.349 1.396 1.398 1.399 1.327 11.570 10.823 11.032 11.588 11.008 12.057




































1 2 3 4 5 6 7 8 9 10 11 12
1.229 1.183 1.196 1.178 1.143 1.103 0.088 0.074 0.076 0.076 0.069 0.084
1.206 1.207 1.209 1.189 1.173 1.12 0.083 0.082 0.079 0.08 0.073 0.08
1.234 1.232 1.248 1.228 1.201 1.151 0.068 0.068 0.069 0.071 0.068 0.07
1.228 1.252 1.242 1.171 1.218 1.141 0.065 0.071 0.068 0.074 0.067 0.069
1.24 1.252 1.274 1.155 1.248 1.19 0.076 0.078 0.083 0.09 0.08 0.085
1.153 1.329 1.278 1.254 1.3 1.191 0.075 0.076 0.075 0.082 0.077 0.074
1.245 1.273 1.252 1.211 1.237 1.236 0.073 0.079 0.079 0.088 0.078 0.075
0.215 0.204 0.233 0.233 0.284 0.222 0.473 0.74 0.693 0.689 0.535 0.474
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.405 1.331 1.348 1.33 1.281 1.271 12.527 11.119 11.276 11.429 10.773 13.218
1.372 1.371 1.367 1.349 1.319 1.28 12.099 11.962 11.558 11.861 11.069 12.500
1.37 1.368 1.386 1.37 1.337 1.291 9.927 9.942 9.957 10.365 10.172 10.844
1.358 1.394 1.378 1.319 1.352 1.279 9.573 10.187 9.869 11.221 9.911 10.790
1.392 1.408 1.44 1.335 1.408 1.36 10.920 11.080 11.528 13.483 11.364 12.500
1.303 1.481 1.428 1.418 1.454 1.339 11.512 10.263 10.504 11.566 10.591 11.053
1.391 1.431 1.41 1.387 1.393 1.386 10.496 11.041 11.206 12.689 11.199 10.823




















































































1 2 3 4 5 6 7 8 9 10 11 12
1.734 1.65 1.614 1.587 1.616 1.564 0.068 0.077 0.051 0.068 0.063 0.067
1.767 1.739 1.695 1.632 1.663 1.556 0.066 0.065 0.07 0.069 0.069 0.074
1.733 1.713 1.697 1.617 1.663 1.523 0.088 0.087 0.086 0.087 0.089 0.106
1.441 1.441 1.429 1.401 1.411 1.272 0.245 0.292 0.305 0.35 0.401 0.404
1.438 1.426 1.392 1.364 1.364 1.304 0.26 0.337 0.376 0.434 0.405 0.488
1.433 1.457 1.43 1.393 1.379 1.302 0.256 0.346 0.401 0.413 0.454 0.466
1.442 1.411 1.389 1.34 1.35 1.237 0.293 0.346 0.393 0.399 0.452 0.428
0.696 0.675 0.666 0.6 0.687 0.594 0.761 0.763 0.886 0.738 0.769 0.776
1.747 1.781 1.722 1.662 1.632 1.484 0.07 0.069 0.071 0.073 0.076 0.073
1.69 1.763 1.746 1.66 1.543 1.599 0.072 0.082 0.069 0.07 0.083 0.082
1.693 1.72 1.694 1.7 1.641 1.613 0.101 0.097 0.096 0.095 0.097 0.107
1.477 1.454 1.471 1.425 1.401 1.295 0.355 0.327 0.407 0.386 0.415 0.447
1.391 1.374 1.357 1.357 1.326 1.266 0.367 0.45 0.486 0.462 0.534 0.548
1.408 1.396 1.374 1.302 1.335 1.325 0.381 0.402 0.475 0.416 0.5 0.502
1.413 1.357 1.371 1.335 1.375 1.311 0.416 0.421 0.465 0.432 0.541 0.578
0.672 0.627 0.601 0.63 0.55 0.57 0.877 0.763 0.79 0.504 0.652 0.752
1.682 1.719 1.653 1.674 1.684 1.915 0.063 0.062 0.063 0.063 0.061 0.064
1.725 1.737 1.701 1.658 1.696 1.577 0.061 0.061 0.059 0.057 0.058 0.059
1.712 1.704 1.695 1.679 1.707 1.597 0.075 0.079 0.079 0.069 0.066 0.088
1.369 1.371 1.455 1.377 1.392 1.357 0.215 0.231 0.338 0.271 0.268 0.335
1.349 1.36 1.364 1.317 1.317 1.382 0.32 0.34 0.418 0.319 0.377 0.478
1.321 1.345 1.365 1.334 1.277 1.214 0.303 0.334 0.458 0.334 0.369 0.458
1.316 1.288 1.333 1.218 1.206 1.161 0.353 0.304 0.351 0.303 0.332 0.475
0.596 0.695 0.607 0.628 0.563 0.651 0.611 0.391 0.675 0.329 0.489 0.542
1.696 1.696 1.688 1.69 1.662 1.622 0.063 0.067 0.067 0.067 0.066 0.064
1.659 1.665 1.643 1.618 1.662 1.585 0.063 0.063 0.061 0.069 0.066 0.068
1.675 1.695 1.657 1.614 1.654 1.57 0.075 0.073 0.071 0.079 0.084 0.08
1.402 1.465 1.409 1.354 1.567 1.301 0.295 0.287 0.296 0.308 0.361 0.327
1.351 1.379 1.369 1.349 1.39 1.269 0.309 0.321 0.296 0.401 0.442 0.377
1.4 1.401 1.419 1.362 1.418 1.463 0.261 0.308 0.305 0.373 0.436 0.394
1.355 1.362 1.349 1.319 1.357 1.223 0.291 0.364 0.336 0.421 0.45 0.443
0.589 0.639 0.568 0.582 0.665 0.577 0.607 0.672 0.708 0.795 0.71 0.787
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.87 1.804 1.716 1.723 1.742 1.698 7.273 8.537 5.944 7.893 7.233 7.892
1.899 1.869 1.835 1.77 1.801 1.704 6.951 6.956 7.629 7.797 7.662 8.685
1.909 1.887 1.869 1.791 1.841 1.735 9.219 9.221 9.203 9.715 9.669 12.219
1.931 2.025 2.039 2.101 2.213 2.08 25.375 28.840 29.917 33.317 36.240 38.846
1.958 2.1 2.144 2.232 2.174 2.28 26.558 32.095 35.075 38.889 37.259 42.807
1.945 2.149 2.232 2.219 2.287 2.234 26.324 32.201 35.932 37.224 39.703 41.719
2.028 2.103 2.175 2.138 2.254 2.093 28.895 32.905 36.138 37.325 40.106 40.898
2.218 2.201 2.438 2.076 2.225 2.146 68.620 69.332 72.683 71.098 69.124 72.321
1.887 1.919 1.864 1.808 1.784 1.63 7.419 7.191 7.618 8.075 8.520 8.957
1.834 1.927 1.884 1.8 1.709 1.763 7.852 8.511 7.325 7.778 9.713 9.302
1.895 1.914 1.886 1.89 1.835 1.827 10.660 10.136 10.180 10.053 10.572 11.713
2.187 2.108 2.285 2.197 2.231 2.189 32.465 31.025 35.624 35.139 37.203 40.841
2.125 2.274 2.329 2.281 2.394 2.362 34.541 39.578 41.735 40.509 44.612 46.401
2.17 2.2 2.324 2.134 2.335 2.329 35.115 36.545 40.878 38.988 42.827 43.109
2.245 2.199 2.301 2.199 2.457 2.467 37.060 38.290 40.417 39.291 44.037 46.859
2.426 2.153 2.181 1.638 1.854 2.074 72.300 70.878 72.444 61.538 70.334 72.517
1.808 1.843 1.779 1.8 1.806 2.043 6.969 6.728 7.083 7.000 6.755 6.265
1.847 1.859 1.819 1.772 1.812 1.695 6.605 6.563 6.487 6.433 6.402 6.962
1.862 1.862 1.853 1.817 1.839 1.773 8.056 8.485 8.527 7.595 7.178 9.927
1.799 1.833 2.131 1.919 1.928 2.027 23.902 25.205 31.722 28.244 27.801 33.054
1.989 2.04 2.2 1.955 2.071 2.338 32.177 33.333 38.000 32.634 36.408 40.890
1.927 2.013 2.281 2.002 2.015 2.13 31.448 33.184 40.158 33.367 36.625 43.005
2.022 1.896 2.035 1.824 1.87 2.111 34.916 32.068 34.496 33.224 35.508 45.002
1.818 1.477 1.957 1.286 1.541 1.735 67.217 52.945 68.983 51.166 63.465 62.478
1.822 1.83 1.822 1.824 1.794 1.75 6.915 7.322 7.355 7.346 7.358 7.314
1.785 1.791 1.765 1.756 1.794 1.721 7.059 7.035 6.912 7.859 7.358 7.902
1.825 1.841 1.799 1.772 1.822 1.73 8.219 7.930 7.893 8.916 9.221 9.249
1.992 2.039 2.001 1.97 2.289 1.955 29.618 28.151 29.585 31.269 31.542 33.453
1.969 2.021 1.961 2.151 2.274 2.023 31.386 31.766 30.189 37.285 38.874 37.271
1.922 2.017 2.029 2.108 2.29 2.251 27.159 30.540 30.064 35.389 38.079 35.007
1.937 2.09 2.021 2.161 2.257 2.109 30.046 34.833 33.251 38.963 39.876 42.010
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FceRIa Identity:
Horse / Horse! ! 100%
Horse / Human! ! 63%!! Human/Dog! 53%
Horse / Mouse! ! 45%
Horse / Rat! ! 43%
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Figure 29: β-hexosaminidase release assays of RBL-2H3.1 
cells expressing equine FcεRIα:
This figure shows the release assays of the RBL-2H3.1 cells 
expressing equine FcεRIα and non-transfected cells (as a 
control) when tested with mouse,equine, human and canine 
IgEs. When both cell lines were tested with mouse IgE the cells 
responded by releasing mediators: maximum 51.55% for non-
transfected and 45.99% for transfected cells at 100ng ml-1 of 
antigen, this was the positive control as the mouse IgE binds to 
the endogenous rat receptor. When tested with equine IgE the 
non-transfected cells had a maximum release of only 11.81% at 
100ng ml-1 of antigen, while transfected cells expressing the 
equine FcεRIα had a maximum release of 36.68% at 100ng ml-1 
of antigen. When the cells were tested with human IgE both cell 
lines had very  low release, maximum release at 100ng ml-1 of 
antigen of 7.97% for non-transfected cells and 8.88% for 
transfected cells expressing the equine FcεRIα. When the cells 
were tested with canine IgE non-transfected cells had a 
maximum release of 11.50% at 100ng ml-1 of antigen, while the 
transfected cells had a maximum release of 32.00% at 100ng 
ml-1 of antigen. Values for this graph are in the Appendix.
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1 2 3 4 5 6 7 8 9 10 11 12
1.633 1.749 1.787 1.773 1.830 1.858 0.074 0.078 0.088 0.124 0.100 0.102
1.709 1.896 1.909 1.887 1.920 1.868 0.070 0.072 0.069 0.101 0.091 0.084
1.737 1.865 1.891 1.904 1.989 1.966 0.076 0.077 0.072 0.073 0.076 0.080
1.809 1.897 1.927 1.993 1.984 1.963 0.065 0.064 0.066 0.070 0.079 0.073
1.793 2.020 2.023 2.005 1.953 2.107 0.085 0.086 0.083 0.088 0.086 0.086
1.719 1.910 1.967 2.028 1.952 2.010 0.089 0.080 0.085 0.081 0.080 0.086
1.736 1.854 1.963 1.994 1.994 1.970 0.088 0.096 0.092 0.091 0.098 0.096
0.542 0.688 0.642 0.723 0.742 0.907 0.941 1.220 0.747 1.247 1.207 0.819
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.781 1.905 1.963 2.021 2.03 2.062 8.310 8.189 8.966 12.271 9.852 9.893
1.849 2.04 2.047 2.089 2.102 2.036 7.572 7.059 6.742 9.670 8.658 8.251
1.889 2.019 2.035 2.05 2.141 2.126 8.047 7.628 7.076 7.122 7.099 7.526
1.939 2.025 2.059 2.133 2.142 2.109 6.704 6.321 6.411 6.564 7.376 6.923
1.963 2.192 2.189 2.181 2.125 2.279 8.660 7.847 7.583 8.070 8.094 7.547
1.897 2.07 2.137 2.19 2.112 2.182 9.383 7.729 7.955 7.397 7.576 7.883
1.912 2.046 2.147 2.176 2.19 2.162 9.205 9.384 8.570 8.364 8.950 8.881




































1 2 3 4 5 6 7 8 9 10 11 12
1.558 1.607 1.635 1.633 1.530 1.566 0.081 0.089 0.093 0.088 0.085 0.089
1.538 1.668 1.661 1.829 1.563 1.637 0.068 0.067 0.067 0.070 0.068 0.070
1.549 1.720 1.748 1.749 1.629 0.992 0.073 0.072 0.075 0.071 0.070 0.078
1.741 1.656 1.748 1.843 1.824 1.869 0.066 0.064 0.066 0.065 0.071 0.065
1.742 1.798 1.776 1.870 1.754 1.760 0.087 0.086 0.087 0.086 0.086 0.089
1.766 1.832 1.762 1.758 1.766 1.796 0.083 0.078 0.087 0.079 0.080 0.077
1.722 1.780 1.711 1.794 1.738 1.799 0.100 0.084 0.090 0.091 0.093 0.090
0.391 0.365 0.290 0.656 0.436 0.615 1.072 0.812 1.109 0.881 0.996 0.623
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.72 1.785 1.821 1.809 1.7 1.744 9.419 9.972 10.214 9.729 10.000 10.206
1.674 1.802 1.795 1.969 1.699 1.777 8.124 7.436 7.465 7.110 8.005 7.878
1.695 1.864 1.898 1.891 1.769 1.148 8.614 7.725 7.903 7.509 7.914 13.589
1.873 1.784 1.88 1.973 1.966 1.999 7.048 7.175 7.021 6.589 7.223 6.503
1.916 1.97 1.95 2.042 1.926 1.938 9.081 8.731 8.923 8.423 8.930 9.185
1.932 1.988 1.936 1.916 1.926 1.95 8.592 7.847 8.988 8.246 8.307 7.897
1.922 1.948 1.891 1.976 1.924 1.979 10.406 8.624 9.519 9.211 9.667 9.096




















































































1 2 3 4 5 6 7 8 9 10 11 12
1.803 1.779 1.797 1.959 1.730 1.239 0.036 0.064 0.044 0.048 0.054 0.018
1.910 1.851 1.874 1.936 1.804 1.682 0.032 0.041 0.036 0.043 0.038 0.019
1.641 1.733 1.789 1.842 1.744 1.555 0.131 0.157 0.178 0.160 0.185 0.124
1.275 1.361 1.350 1.367 1.307 1.175 0.314 0.428 0.554 0.551 0.609 0.510
1.349 1.236 1.166 1.080 1.025 0.936 0.433 0.537 0.726 0.704 0.707 0.517
1.173 1.236 1.192 1.156 1.081 1.374 0.385 0.669 0.695 0.716 0.584 0.517
1.284 1.189 1.277 1.492 1.113 1.177 0.414 0.652 0.472 0.574 0.323 0.324
1.094 0.964 0.888 0.969 1.037 0.933 0.351 0.413 0.463 0.517 0.494 0.410
2.165 2.283 2.206 2.189 2.244 2.257 0.039 0.037 0.050 0.036 0.036 0.028
2.215 2.233 2.221 2.218 2.169 2.265 0.053 0.048 0.051 0.045 0.054 0.033
2.133 2.170 2.114 2.049 1.909 1.983 0.168 0.166 0.142 0.161 0.148 0.153
1.651 1.693 1.743 1.722 1.747 1.713 0.680 0.586 0.469 0.514 0.435 0.513
1.296 1.260 1.356 1.303 1.301 1.283 0.906 0.689 0.699 0.710 0.767 0.774
1.288 1.306 1.285 1.334 1.248 1.285 0.779 0.553 0.672 0.992 0.718 0.545
1.336 1.296 1.459 1.332 1.392 1.416 0.842 0.433 0.641 0.727 0.552 0.697
0.636 0.653 0.603 0.668 0.658 0.422 1.060 0.713 0.966 0.858 0.680 0.397
2.730 2.660 2.686 2.649 2.646 2.674 0.036 0.052 0.044 0.038 0.037 0.038
2.790 2.668 2.708 2.829 2.667 2.623 0.074 0.063 0.066 0.060 0.056 0.064
2.696 2.719 2.698 2.565 2.611 2.540 0.175 0.165 0.168 0.167 0.123 0.162
2.339 2.392 2.264 2.295 2.247 2.281 0.653 0.596 0.598 0.585 0.542 0.530
1.902 1.917 1.858 1.890 1.824 1.883 0.947 0.849 0.888 0.874 0.870 0.823
2.099 2.062 1.920 1.938 1.911 1.881 0.902 0.879 0.916 0.821 0.793 0.804
2.052 2.091 1.934 2.049 1.856 1.958 0.830 0.777 0.894 0.849 0.784 0.806
0.356 0.141 0.182 0.173 0.207 0.158 1.940 1.679 1.847 1.482 1.300 1.689
2.458 2.438 2.560 2.387 2.265 2.278 0.062 0.045 0.046 0.032 0.047 0.033
2.584 2.681 2.702 2.686 2.249 2.587 0.076 0.058 0.071 0.043 0.065 0.051
2.591 2.600 2.544 2.543 2.434 2.263 0.255 0.212 0.287 0.257 0.208 0.214
2.187 2.159 2.254 2.154 1.940 1.915 0.737 0.747 0.713 0.613 0.582 0.529
1.875 1.704 1.772 1.839 1.519 1.505 1.024 1.195 1.154 0.745 0.906 0.791
1.929 1.686 1.742 1.720 1.590 1.804 1.001 1.019 1.152 0.791 0.835 0.714
1.936 1.795 1.756 1.768 1.411 1.713 1.036 1.045 1.096 0.871 0.884 0.710
1.170 0.300 0.250 0.247 0.237 0.198 0.981 1.384 1.601 1.321 1.385 1.538
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.875 1.907 1.885 2.055 1.838 1.275 3.840 6.712 4.668 4.672 5.876 2.824
1.974 1.933 1.946 2.022 1.88 1.72 3.242 4.242 3.700 4.253 4.043 2.209
1.903 2.047 2.145 2.162 2.114 1.803 13.768 15.340 16.597 14.801 17.502 13.755
1.903 2.217 2.458 2.469 2.525 2.195 33.001 38.611 45.077 44.633 48.238 46.469
2.215 2.31 2.618 2.488 2.439 1.97 39.097 46.494 55.462 56.592 57.975 52.487
1.943 2.574 2.582 2.588 2.249 2.408 39.629 51.981 53.834 55.332 51.934 42.940
2.112 2.493 2.221 2.64 1.759 1.825 39.205 52.306 42.503 43.485 36.725 35.507
1.796 1.79 1.814 2.003 2.025 1.753 39.087 46.145 51.047 51.623 48.790 46.777
2.243 2.357 2.306 2.261 2.316 2.313 3.477 3.140 4.337 3.184 3.109 2.421
2.321 2.329 2.323 2.308 2.277 2.331 4.567 4.122 4.391 3.899 4.743 2.831
2.469 2.502 2.398 2.371 2.205 2.289 13.609 13.269 11.843 13.581 13.424 13.368
3.011 2.865 2.681 2.75 2.617 2.739 45.168 40.908 34.987 37.382 33.244 37.459
3.108 2.638 2.754 2.723 2.835 2.831 58.301 52.237 50.763 52.148 54.109 54.680
2.846 2.412 2.629 3.318 2.684 2.375 54.743 45.854 51.122 59.795 53.502 45.895
3.02 2.162 2.741 2.786 2.496 2.81 55.762 40.056 46.771 52.190 44.231 49.609
2.756 2.079 2.535 2.384 2.018 1.216 76.923 68.591 76.213 71.980 67.393 65.296
2.802 2.764 2.774 2.725 2.72 2.75 2.570 3.763 3.172 2.789 2.721 2.764
2.938 2.794 2.84 2.949 2.779 2.751 5.037 4.510 4.648 4.069 4.030 4.653
3.046 3.049 3.034 2.899 2.857 2.864 11.490 10.823 11.074 11.521 8.610 11.313
3.645 3.584 3.46 3.465 3.331 3.341 35.830 33.259 34.566 33.766 32.543 31.727
3.796 3.615 3.634 3.638 3.564 3.529 49.895 46.971 48.872 48.048 48.822 46.642
3.903 3.82 3.752 3.58 3.497 3.489 46.221 46.021 48.827 45.866 45.353 46.088
3.712 3.645 3.722 3.747 3.424 3.57 44.720 42.634 48.039 45.316 45.794 45.154
4.236 3.499 3.876 3.137 2.807 3.536 91.596 95.970 95.304 94.485 92.626 95.532
2.582 2.528 2.652 2.451 2.359 2.344 4.802 3.560 3.469 2.611 3.985 2.816
2.736 2.797 2.844 2.772 2.379 2.689 5.556 4.147 4.993 3.102 5.464 3.793
3.101 3.024 3.118 3.057 2.85 2.691 16.446 14.021 18.409 16.814 14.596 15.905
3.661 3.653 3.68 3.38 3.104 2.973 40.262 40.898 38.750 36.272 37.500 35.587
3.923 4.094 4.08 3.329 3.331 3.087 52.205 58.378 56.569 44.758 54.398 51.247
3.931 3.724 4.046 3.302 3.26 3.232 50.929 54.726 56.945 47.910 51.227 44.183
4.008 3.885 3.948 3.51 3.179 3.133 51.697 53.797 55.522 49.630 55.615 45.324




































































1 2 3 4 5 6 7 8 9 10 11 12
2.143 2.239 2.136 2.131 2.056 2.069 0.015 0.016 0.011 0.015 0.015 0.009
2.124 2.222 2.143 2.179 2.147 2.093 0.029 0.021 0.028 0.022 0.019 0.027
2.119 2.219 2.166 2.208 2.168 2.095 0.096 0.058 0.077 0.061 0.091 0.088
1.730 1.943 1.821 1.913 1.869 1.777 0.453 0.260 0.362 0.228 0.394 0.383
1.368 1.518 1.508 1.538 1.492 1.417 0.730 0.510 0.692 0.488 0.765 0.778
1.514 1.680 1.551 1.682 1.552 1.519 0.697 0.504 0.635 0.362 0.661 0.396
1.515 1.597 1.566 1.357 1.583 1.564 0.575 0.475 0.577 0.485 0.647 0.609
0.075 0.278 0.216 0.259 0.255 0.244 1.323 1.628 1.392 1.108 1.451 1.686
2.050 2.132 2.115 2.131 2.145 2.138 0.021 0.023 0.011 0.008 0.010 0.036
2.052 2.201 2.241 2.245 2.201 2.123 0.028 0.038 0.041 0.023 0.003 0.030
1.967 2.173 2.201 2.252 2.177 2.091 0.121 0.093 0.106 0.114 0.156 0.175
1.592 1.898 1.873 1.856 1.896 1.716 0.398 0.268 0.314 0.469 0.435 0.547
1.387 1.525 1.521 1.498 1.508 1.399 0.605 0.374 0.487 0.743 0.765 0.799
1.479 1.606 1.594 1.583 1.629 1.543 0.572 0.303 0.354 0.619 0.435 0.679
1.467 1.622 1.591 1.570 1.638 1.539 0.507 0.283 0.360 0.485 0.462 0.582
0.455 0.336 0.445 0.430 0.350 0.225 1.443 0.925 0.711 1.188 0.787 0.930
2.032 2.082 2.010 2.123 2.078 2.081 0.016 0.020 0.014 0.025 0.022 0.013
2.048 2.152 2.124 2.210 2.116 2.058 0.038 0.037 0.029 0.032 0.022 0.037
2.010 2.180 2.194 2.158 2.175 2.079 0.094 0.052 0.061 0.056 0.062 0.083
1.807 1.919 1.947 2.008 2.021 1.893 0.310 0.228 0.306 0.259 0.261 0.293
1.301 1.454 1.438 1.427 1.413 1.433 0.629 0.454 0.654 0.592 0.593 0.664
1.361 1.469 1.455 1.454 1.525 1.487 0.598 0.475 0.593 0.600 0.570 0.538
1.429 1.520 1.529 1.510 1.582 1.531 0.496 0.371 0.618 0.481 0.397 0.538
0.080 0.940 0.116 0.096 0.185 0.186 1.419 1.351 1.714 1.532 0.905 0.806
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.173 2.271 2.158 2.161 2.086 2.087 1.381 1.409 1.019 1.388 1.438 0.862
2.182 2.264 2.199 2.223 2.185 2.147 2.658 1.855 2.547 1.979 1.739 2.515
2.311 2.335 2.32 2.33 2.35 2.271 8.308 4.968 6.638 5.236 7.745 7.750
2.636 2.463 2.545 2.369 2.657 2.543 34.370 21.112 28.448 19.249 29.658 30.122
2.828 2.538 2.892 2.514 3.022 2.973 51.627 40.189 47.856 38.823 50.629 52.338
2.908 2.688 2.821 2.406 2.874 2.311 47.937 37.500 45.019 30.091 45.999 34.271
2.665 2.547 2.72 2.327 2.877 2.782 43.152 37.299 42.426 41.685 44.977 43.781
2.721 3.534 3 2.475 3.157 3.616 97.244 92.134 92.800 89.535 91.923 93.252
2.092 2.178 2.137 2.147 2.165 2.21 2.008 2.112 1.029 0.745 0.924 3.258
2.108 2.277 2.323 2.291 2.207 2.183 2.657 3.338 3.530 2.008 0.272 2.749
2.209 2.359 2.413 2.48 2.489 2.441 10.955 7.885 8.786 9.194 12.535 14.338
2.388 2.434 2.501 2.794 2.766 2.81 33.333 22.021 25.110 33.572 31.453 38.932
2.597 2.273 2.495 2.984 3.038 2.997 46.592 32.908 39.038 49.799 50.362 53.320
2.623 2.212 2.302 2.821 2.499 2.901 43.614 27.396 30.756 43.885 34.814 46.811
2.481 2.188 2.311 2.54 2.562 2.703 40.871 25.868 31.155 38.189 36.066 43.063
3.341 2.186 1.867 2.806 1.924 2.085 86.381 84.629 76.165 84.676 81.809 89.209
2.064 2.122 2.038 2.173 2.122 2.107 1.550 1.885 1.374 2.301 2.074 1.234
2.124 2.226 2.182 2.274 2.16 2.132 3.578 3.324 2.658 2.814 2.037 3.471
2.198 2.284 2.316 2.27 2.299 2.245 8.553 4.553 5.268 4.934 5.394 7.394
2.427 2.375 2.559 2.526 2.543 2.479 25.546 19.200 23.916 20.507 20.527 23.639
2.559 2.362 2.746 2.611 2.599 2.761 49.160 38.442 47.633 45.347 45.633 48.099
2.557 2.419 2.641 2.654 2.665 2.563 46.774 39.272 44.907 45.215 42.777 41.982
2.421 2.262 2.765 2.472 2.376 2.607 40.975 32.803 44.702 38.916 33.418 41.273




































































1 2 3 4 5 6 7 8 9 10 11 12
2.022 2.211 2.063 2.021 2.043 2.018 0.012 0.015 0.015 0.012 0.017 0.017
2.064 2.197 2.147 2.055 2.002 1.951 0.040 0.021 0.040 0.022 0.033 0.048
1.978 2.176 2.055 2.092 2.129 2.058 0.110 0.075 0.082 0.059 0.094 0.096
1.697 1.839 1.832 1.799 1.846 1.678 0.382 0.145 0.369 0.248 0.268 0.377
1.581 1.811 1.661 1.749 1.711 1.699 0.382 0.229 0.316 0.268 0.391 0.409
1.659 1.876 1.738 1.733 1.776 1.733 0.259 0.148 0.364 0.245 0.332 0.416
1.624 1.761 1.693 1.675 1.802 1.614 0.244 0.123 0.305 0.244 0.424 0.391
0.680 0.560 0.709 0.674 0.657 0.639 1.130 0.500 0.806 0.628 0.907 0.828
1.903 1.950 0.194 1.925 2.039 1.963 0.012 0.013 0.011 0.013 0.010 0.013
1.889 1.930 1.948 1.890 1.875 1.921 0.034 0.035 0.042 0.032 0.038 0.033
1.739 1.828 1.876 1.879 1.902 1.920 0.159 0.126 0.129 0.159 0.159 0.157
1.464 1.548 1.583 1.640 1.650 1.639 0.422 0.406 0.376 0.404 0.363 0.320
1.412 1.461 1.502 1.421 1.527 1.482 0.355 0.267 0.283 0.443 0.507 0.461
1.472 1.493 1.673 1.469 1.553 1.491 0.344 0.260 0.352 0.421 0.457 0.447
1.432 1.409 1.470 1.406 1.505 1.448 0.327 0.325 0.340 0.334 0.442 0.474
0.347 0.315 0.375 0.324 0.279 0.365 1.208 1.045 1.180 1.106 1.023 1.028
1.987 2.134 2.167 2.127 2.052 2.016 0.022 0.020 0.019 0.023 0.022 0.017
2.073 2.170 2.175 2.192 2.114 2.058 0.043 0.028 0.033 0.032 0.021 0.047
2.066 2.142 2.147 2.190 2.180 2.147 0.110 0.085 0.081 0.082 0.086 0.105
1.632 1.753 1.746 1.779 1.784 1.700 0.431 0.310 0.426 0.506 0.488 0.447
1.660 1.639 1.651 1.637 1.688 1.528 0.422 0.317 0.351 0.455 0.542 0.464
1.524 1.638 1.664 1.676 1.750 1.577 0.431 0.357 0.289 0.504 0.510 0.505
1.529 1.620 1.649 1.606 1.674 1.454 0.445 0.350 0.403 0.373 0.467 0.465
0.383 0.701 0.507 0.469 0.530 0.507 1.269 1.391 1.412 1.061 1.253 1.180
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.046 2.241 2.093 2.045 2.077 2.052 1.173 1.339 1.433 1.174 1.637 1.657
2.144 2.239 2.227 2.099 2.068 2.047 3.731 1.876 3.592 2.096 3.191 4.690
2.198 2.326 2.219 2.21 2.317 2.25 10.009 6.449 7.391 5.339 8.114 8.533
2.461 2.129 2.57 2.295 2.382 2.432 31.044 13.621 28.716 21.612 22.502 31.003
2.345 2.269 2.293 2.285 2.493 2.517 32.580 20.185 27.562 23.457 31.368 32.499
2.177 2.172 2.466 2.223 2.44 2.565 23.794 13.628 29.521 22.042 27.213 32.437
2.112 2.007 2.303 2.163 2.65 2.396 23.106 12.257 26.487 22.561 32.000 32.638
2.94 1.56 2.321 1.93 2.471 2.295 76.871 64.103 69.453 65.078 73.412 72.157
1.927 1.976 0.216 1.951 2.059 1.989 1.245 1.316 10.185 1.333 0.971 1.307
1.957 2 2.032 1.954 1.951 1.987 3.475 3.500 4.134 3.275 3.895 3.322
2.057 2.08 2.134 2.197 2.22 2.234 15.459 12.115 12.090 14.474 14.324 14.056
2.308 2.36 2.335 2.448 2.376 2.279 36.568 34.407 32.206 33.007 30.556 28.082
2.122 1.995 2.068 2.307 2.541 2.404 33.459 26.767 27.369 38.405 39.906 38.353
2.16 2.013 2.377 2.311 2.467 2.385 31.852 25.832 29.617 36.434 37.049 37.484
2.086 2.059 2.15 2.074 2.389 2.396 31.352 31.569 31.628 32.208 37.003 39.566
2.763 2.405 2.735 2.536 2.325 2.421 87.441 86.902 86.289 87.224 88.000 84.924
2.031 2.174 2.205 2.173 2.096 2.05 2.166 1.840 1.723 2.117 2.099 1.659
2.159 2.226 2.241 2.256 2.156 2.152 3.983 2.516 2.945 2.837 1.948 4.368
2.286 2.312 2.309 2.354 2.352 2.357 9.624 7.353 7.016 6.967 7.313 8.910
2.494 2.373 2.598 2.791 2.76 2.594 34.563 26.127 32.794 36.259 35.362 34.464
2.504 2.273 2.353 2.547 2.772 2.456 33.706 27.893 29.834 35.728 39.105 37.785
2.386 2.352 2.242 2.684 2.77 2.587 36.127 30.357 25.781 37.556 36.823 39.041
2.419 2.32 2.455 2.352 2.608 2.384 36.792 30.172 32.831 31.718 35.813 39.010


































1 2 3 4 5 6 7 8 9 10 11 12
1.165 1.115 1.113 1.14 1.132 1.153 0.079 0.074 0.082 0.073 0.073 0.072
1.149 1.106 1.16 1.149 1.177 1.12 0.073 0.082 0.07 0.078 0.083 0.09
1.178 1.178 1.196 1.176 1.176 1.257 0.07 0.069 0.065 0.069 0.07 0.068
1.191 1.154 1.201 1.199 1.19 1.188 0.066 0.063 0.06 0.066 0.067 0.069
1.167 1.16 1.203 1.239 1.169 1.16 0.076 0.074 0.073 0.08 0.077 0.081
1.177 1.203 1.242 1.236 1.245 1.167 0.077 0.073 0.077 0.081 0.077 0.08
1.171 1.142 1.205 1.189 1.162 1.094 0.078 0.079 0.069 0.081 0.079 0.089
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.323 1.263 1.277 1.286 1.278 1.297 11.943 11.718 12.843 11.353 11.424 11.103
1.295 1.27 1.3 1.305 1.343 1.3 11.274 12.913 10.769 11.954 12.360 13.846
1.318 1.316 1.326 1.314 1.316 1.393 10.622 10.486 9.804 10.502 10.638 9.763
1.323 1.28 1.321 1.331 1.324 1.326 9.977 9.844 9.084 9.917 10.121 10.407
1.319 1.308 1.349 1.399 1.323 1.322 11.524 11.315 10.823 11.437 11.640 12.254
1.331 1.349 1.396 1.398 1.399 1.327 11.570 10.823 11.032 11.588 11.008 12.057




































1 2 3 4 5 6 7 8 9 10 11 12
1.229 1.183 1.196 1.178 1.143 1.103 0.088 0.074 0.076 0.076 0.069 0.084
1.206 1.207 1.209 1.189 1.173 1.12 0.083 0.082 0.079 0.08 0.073 0.08
1.234 1.232 1.248 1.228 1.201 1.151 0.068 0.068 0.069 0.071 0.068 0.07
1.228 1.252 1.242 1.171 1.218 1.141 0.065 0.071 0.068 0.074 0.067 0.069
1.24 1.252 1.274 1.155 1.248 1.19 0.076 0.078 0.083 0.09 0.08 0.085
1.153 1.329 1.278 1.254 1.3 1.191 0.075 0.076 0.075 0.082 0.077 0.074
1.245 1.273 1.252 1.211 1.237 1.236 0.073 0.079 0.079 0.088 0.078 0.075
0.215 0.204 0.233 0.233 0.284 0.222 0.473 0.74 0.693 0.689 0.535 0.474
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.405 1.331 1.348 1.33 1.281 1.271 12.527 11.119 11.276 11.429 10.773 13.218
1.372 1.371 1.367 1.349 1.319 1.28 12.099 11.962 11.558 11.861 11.069 12.500
1.37 1.368 1.386 1.37 1.337 1.291 9.927 9.942 9.957 10.365 10.172 10.844
1.358 1.394 1.378 1.319 1.352 1.279 9.573 10.187 9.869 11.221 9.911 10.790
1.392 1.408 1.44 1.335 1.408 1.36 10.920 11.080 11.528 13.483 11.364 12.500
1.303 1.481 1.428 1.418 1.454 1.339 11.512 10.263 10.504 11.566 10.591 11.053
1.391 1.431 1.41 1.387 1.393 1.386 10.496 11.041 11.206 12.689 11.199 10.823




















































































1 2 3 4 5 6 7 8 9 10 11 12
1.734 1.65 1.614 1.587 1.616 1.564 0.068 0.077 0.051 0.068 0.063 0.067
1.767 1.739 1.695 1.632 1.663 1.556 0.066 0.065 0.07 0.069 0.069 0.074
1.733 1.713 1.697 1.617 1.663 1.523 0.088 0.087 0.086 0.087 0.089 0.106
1.441 1.441 1.429 1.401 1.411 1.272 0.245 0.292 0.305 0.35 0.401 0.404
1.438 1.426 1.392 1.364 1.364 1.304 0.26 0.337 0.376 0.434 0.405 0.488
1.433 1.457 1.43 1.393 1.379 1.302 0.256 0.346 0.401 0.413 0.454 0.466
1.442 1.411 1.389 1.34 1.35 1.237 0.293 0.346 0.393 0.399 0.452 0.428
0.696 0.675 0.666 0.6 0.687 0.594 0.761 0.763 0.886 0.738 0.769 0.776
1.747 1.781 1.722 1.662 1.632 1.484 0.07 0.069 0.071 0.073 0.076 0.073
1.69 1.763 1.746 1.66 1.543 1.599 0.072 0.082 0.069 0.07 0.083 0.082
1.693 1.72 1.694 1.7 1.641 1.613 0.101 0.097 0.096 0.095 0.097 0.107
1.477 1.454 1.471 1.425 1.401 1.295 0.355 0.327 0.407 0.386 0.415 0.447
1.391 1.374 1.357 1.357 1.326 1.266 0.367 0.45 0.486 0.462 0.534 0.548
1.408 1.396 1.374 1.302 1.335 1.325 0.381 0.402 0.475 0.416 0.5 0.502
1.413 1.357 1.371 1.335 1.375 1.311 0.416 0.421 0.465 0.432 0.541 0.578
0.672 0.627 0.601 0.63 0.55 0.57 0.877 0.763 0.79 0.504 0.652 0.752
1.682 1.719 1.653 1.674 1.684 1.915 0.063 0.062 0.063 0.063 0.061 0.064
1.725 1.737 1.701 1.658 1.696 1.577 0.061 0.061 0.059 0.057 0.058 0.059
1.712 1.704 1.695 1.679 1.707 1.597 0.075 0.079 0.079 0.069 0.066 0.088
1.369 1.371 1.455 1.377 1.392 1.357 0.215 0.231 0.338 0.271 0.268 0.335
1.349 1.36 1.364 1.317 1.317 1.382 0.32 0.34 0.418 0.319 0.377 0.478
1.321 1.345 1.365 1.334 1.277 1.214 0.303 0.334 0.458 0.334 0.369 0.458
1.316 1.288 1.333 1.218 1.206 1.161 0.353 0.304 0.351 0.303 0.332 0.475
0.596 0.695 0.607 0.628 0.563 0.651 0.611 0.391 0.675 0.329 0.489 0.542
1.696 1.696 1.688 1.69 1.662 1.622 0.063 0.067 0.067 0.067 0.066 0.064
1.659 1.665 1.643 1.618 1.662 1.585 0.063 0.063 0.061 0.069 0.066 0.068
1.675 1.695 1.657 1.614 1.654 1.57 0.075 0.073 0.071 0.079 0.084 0.08
1.402 1.465 1.409 1.354 1.567 1.301 0.295 0.287 0.296 0.308 0.361 0.327
1.351 1.379 1.369 1.349 1.39 1.269 0.309 0.321 0.296 0.401 0.442 0.377
1.4 1.401 1.419 1.362 1.418 1.463 0.261 0.308 0.305 0.373 0.436 0.394
1.355 1.362 1.349 1.319 1.357 1.223 0.291 0.364 0.336 0.421 0.45 0.443
0.589 0.639 0.568 0.582 0.665 0.577 0.607 0.672 0.708 0.795 0.71 0.787
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.87 1.804 1.716 1.723 1.742 1.698 7.273 8.537 5.944 7.893 7.233 7.892
1.899 1.869 1.835 1.77 1.801 1.704 6.951 6.956 7.629 7.797 7.662 8.685
1.909 1.887 1.869 1.791 1.841 1.735 9.219 9.221 9.203 9.715 9.669 12.219
1.931 2.025 2.039 2.101 2.213 2.08 25.375 28.840 29.917 33.317 36.240 38.846
1.958 2.1 2.144 2.232 2.174 2.28 26.558 32.095 35.075 38.889 37.259 42.807
1.945 2.149 2.232 2.219 2.287 2.234 26.324 32.201 35.932 37.224 39.703 41.719
2.028 2.103 2.175 2.138 2.254 2.093 28.895 32.905 36.138 37.325 40.106 40.898
2.218 2.201 2.438 2.076 2.225 2.146 68.620 69.332 72.683 71.098 69.124 72.321
1.887 1.919 1.864 1.808 1.784 1.63 7.419 7.191 7.618 8.075 8.520 8.957
1.834 1.927 1.884 1.8 1.709 1.763 7.852 8.511 7.325 7.778 9.713 9.302
1.895 1.914 1.886 1.89 1.835 1.827 10.660 10.136 10.180 10.053 10.572 11.713
2.187 2.108 2.285 2.197 2.231 2.189 32.465 31.025 35.624 35.139 37.203 40.841
2.125 2.274 2.329 2.281 2.394 2.362 34.541 39.578 41.735 40.509 44.612 46.401
2.17 2.2 2.324 2.134 2.335 2.329 35.115 36.545 40.878 38.988 42.827 43.109
2.245 2.199 2.301 2.199 2.457 2.467 37.060 38.290 40.417 39.291 44.037 46.859
2.426 2.153 2.181 1.638 1.854 2.074 72.300 70.878 72.444 61.538 70.334 72.517
1.808 1.843 1.779 1.8 1.806 2.043 6.969 6.728 7.083 7.000 6.755 6.265
1.847 1.859 1.819 1.772 1.812 1.695 6.605 6.563 6.487 6.433 6.402 6.962
1.862 1.862 1.853 1.817 1.839 1.773 8.056 8.485 8.527 7.595 7.178 9.927
1.799 1.833 2.131 1.919 1.928 2.027 23.902 25.205 31.722 28.244 27.801 33.054
1.989 2.04 2.2 1.955 2.071 2.338 32.177 33.333 38.000 32.634 36.408 40.890
1.927 2.013 2.281 2.002 2.015 2.13 31.448 33.184 40.158 33.367 36.625 43.005
2.022 1.896 2.035 1.824 1.87 2.111 34.916 32.068 34.496 33.224 35.508 45.002
1.818 1.477 1.957 1.286 1.541 1.735 67.217 52.945 68.983 51.166 63.465 62.478
1.822 1.83 1.822 1.824 1.794 1.75 6.915 7.322 7.355 7.346 7.358 7.314
1.785 1.791 1.765 1.756 1.794 1.721 7.059 7.035 6.912 7.859 7.358 7.902
1.825 1.841 1.799 1.772 1.822 1.73 8.219 7.930 7.893 8.916 9.221 9.249
1.992 2.039 2.001 1.97 2.289 1.955 29.618 28.151 29.585 31.269 31.542 33.453
1.969 2.021 1.961 2.151 2.274 2.023 31.386 31.766 30.189 37.285 38.874 37.271
1.922 2.017 2.029 2.108 2.29 2.251 27.159 30.540 30.064 35.389 38.079 35.007
1.937 2.09 2.021 2.161 2.257 2.109 30.046 34.833 33.251 38.963 39.876 42.010
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Figure 30: Summary graph of Figure 29’s peak release at 
100ng ml-1 of antigen:
This figure shows only  the peak releases at 100ng ml-1 of 
antigen of the cells from figure 29.
Since the canine IgE was found to bind to the equine FcεRIα, the opposite was 
tested; if the equine IgE binds to the canine FcεRIα  When cells were sensitized with 
IgE for 16 hours the cells showed no release, while the positive control showed normal 
release, therefore the cells were tested for 0.5, 1 and 3 hour IgE sensitization times 
(Figure 31, with the Summary of the peak releases at 100ng ml-1 of antigen in Figure 
32) and the following was observed:
The equine IgE interacts with the canine FcεRIα but very weakly, as increasing 
interaction time (0.5, 1 and 3 hours) resulted in no significant  higher releases than the 
negative control (no NIP-HSA antigen added), even when incubated for the full 16 hour. 
Therefore this result suggests that the equine IgE doe not interacts with the canine 
FcεRIα. When compared to the mouse IgE control, the increasing interaction time (0.5, 
1 and 3 hours) resulted similar non-significant releases, but when incubated for the full 
144
16 hours, the maximum release was 42.42% i.e: very high. The cells were also tested 
with canine IgE at  16 hours (43.49% maximum release) as a control, since these cells 
were tested in a similar manner by (Hongtu Ye, PhD Thesis, The University of 
Sheffield, 2010).
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x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.793 1.988 2.019 2.038 2.015 2.06 11.824 10.664 10.104 9.617 9.628 11.165
1.789 1.966 2.011 2.028 2.028 2.09 11.738 9.461 9.448 10.059 10.651 10.622
2.011 2.086 2.111 2.157 2.144 2.19 15.017 13.231 13.169 13.908 14.272 15.708
2.039 2.087 2.224 2.382 2.361 2.331 25.895 17.537 20.863 22.838 24.989 23.681
2.061 2.142 2.445 2.836 2.911 2.754 44.153 33.613 37.301 45.628 46.994 46.841
2.228 2.117 2.511 2.667 2.731 2.74 46.499 39.490 43.090 46.944 51.263 50.073
2.234 2.053 2.2 2.261 2.262 2.388 46.285 39.454 37.182 39.275 39.788 44.137




















































1 2 3 4 5 6 7 8 9 10 11 12
2.565 2.893 2.495 1.992 2.228 1.839 0.068 0.073 0.072 0.073 0.068 0.074
2.471 2.602 2.565 2.068 1.893 1.731 0.115 0.098 0.092 0.094 0.11 0.118
1.726 1.749 1.698 1.67 1.671 1.531 0.395 0.338 0.381 0.464 0.524 0.472
1.881 1.461 1.463 1.399 1.307 1.254 0.587 0.447 0.591 0.771 0.875 0.765
1.502 1.509 1.434 1.35 1.353 1.185 0.693 0.488 0.61 0.822 0.952 0.657
1.484 1.56 1.472 1.428 1.418 1.204 0.623 0.542 0.713 0.791 0.837 0.607
1.982 1.479 1.393 1.369 1.4 1.219 0.642 0.52 0.707 0.786 0.896 0.706
1.312 0.751 0.753 0.781 0.823 0.807 1.024 1.062 0.938 0.986 0.922 0.843
1.632 1.713 1.812 1.764 1.698 1.654 0.096 0.094 0.096 0.105 0.095 0.111
1.684 1.8 1.835 1.756 1.738 1.724 0.102 0.1 0.097 0.103 0.102 0.107
1.661 1.693 1.776 1.776 1.779 1.74 0.179 0.174 0.164 0.17 0.185 0.227
1.272 1.471 1.521 1.538 1.546 1.481 0.319 0.265 0.332 0.439 0.447 0.47
1.271 1.399 1.477 1.451 1.473 1.396 0.368 0.307 0.321 0.465 0.534 0.552
1.183 1.43 1.506 1.444 1.543 1.426 0.32 0.313 0.337 0.344 0.475 0.531
1.132 1.376 1.443 1.42 1.443 1.398 0.352 0.334 0.374 0.365 0.398 0.544
0.548 0.748 0.838 0.78 0.896 0.799 0.651 0.75 0.919 0.875 0.867 0.858
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.701 3.039 2.639 2.138 2.364 1.987 5.035 4.804 5.457 6.829 5.753 7.448
2.701 2.798 2.749 2.256 2.113 1.967 8.515 7.005 6.693 8.333 10.412 11.998
2.516 2.425 2.46 2.598 2.719 2.475 31.399 27.876 30.976 35.720 38.544 38.141
3.055 2.355 2.645 2.941 3.057 2.784 38.429 37.962 44.688 52.431 57.246 54.957
2.888 2.485 2.654 2.994 3.257 2.499 47.992 39.276 45.968 54.910 58.459 52.581
2.73 2.644 2.898 3.01 3.092 2.418 45.641 40.998 49.206 52.558 54.140 50.207
3.266 2.519 2.807 2.941 3.192 2.631 39.314 41.286 50.374 53.451 56.140 53.668
3.36 2.875 2.629 2.753 2.667 2.493 60.952 73.878 71.358 71.631 69.141 67.629
1.824 1.901 2.004 1.974 1.888 1.876 10.526 9.890 9.581 10.638 10.064 11.834
1.888 2 2.029 1.962 1.942 1.938 10.805 10.000 9.561 10.499 10.505 11.042
2.019 2.041 2.104 2.116 2.149 2.194 17.732 17.050 15.589 16.068 17.217 20.693
1.91 2.001 2.185 2.416 2.44 2.421 33.403 26.487 30.389 36.341 36.639 38.827
2.007 2.013 2.119 2.381 2.541 2.5 36.672 30.502 30.297 39.059 42.031 44.160
1.823 2.056 2.18 2.132 2.493 2.488 35.107 30.447 30.917 32.270 38.107 42.685
1.836 2.044 2.191 2.15 2.239 2.486 38.344 32.681 34.140 33.953 35.552 43.765
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1.693 1.807 1.804 1.812 1.809 1.833 0.091 0.091 0.088 0.085 0.087 0.078
1.744 1.779 1.801 1.744 1.772 1.789 0.091 0.096 0.096 0.09 0.091 0.085
1.707 1.793 1.803 1.774 1.793 1.783 0.111 0.124 0.121 0.12 0.123 0.112
1.721 1.719 1.737 1.752 1.796 1.747 0.094 0.086 0.092 0.091 0.087 0.08
1.695 1.762 1.772 1.774 1.796 1.801 0.097 0.095 0.093 0.094 0.092 0.087
1.677 1.636 1.713 1.737 1.695 1.728 0.105 0.105 0.107 0.119 0.116 0.126
1.739 1.746 1.777 1.795 1.756 1.786 0.093 0.091 0.092 0.094 0.091 0.085
0.753 0.826 0.842 0.808 0.814 0.781 0.748 0.774 0.804 0.715 0.603 0.791
1.631 1.553 1.46 1.58 1.674 1.838 0.086 0.094 0.084 0.085 0.084 0.086
1.485 1.651 1.623 1.738 1.74 1.848 0.086 0.089 0.088 0.088 0.089 0.089
1.609 1.57 1.609 1.736 1.772 1.774 0.104 0.118 0.106 0.108 0.113 0.124
1.557 1.654 1.725 1.843 1.727 1.756 0.083 0.081 0.082 0.086 0.086 0.084
1.578 1.673 1.68 1.626 1.645 1.657 0.145 0.137 0.149 0.155 0.172 0.189
1.654 1.595 1.603 1.603 1.625 1.629 0.137 0.129 0.137 0.141 0.152 0.159
1.684 1.696 1.605 1.698 1.716 1.718 0.091 0.093 0.094 0.092 0.092 0.089
0.816 0.707 0.857 0.844 0.748 0.865 0.746 0.639 0.695 0.694 0.733 0.805
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.193 2.256 2.241 2.228 2.238 2.184 8.208 9.043 8.568 8.438 8.490 8.425
2.268 2.28 2.197 2.252 2.232 2.23 7.760 8.246 8.375 8.171 8.333 8.700
2.332 2.295 2.257 2.342 2.29 2.319 11.664 11.678 11.786 12.212 12.751 14.661
2.39 2.314 2.32 2.346 2.326 2.368 17.322 14.088 15.690 18.414 17.713 20.439
2.322 2.229 2.34 2.263 2.322 2.347 17.313 14.177 15.641 16.350 17.916 19.344
2.231 2.22 2.248 2.231 2.176 2.214 11.833 11.081 12.633 12.371 12.868 14.815
2.228 2.222 2.205 2.178 2.188 2.131 8.348 8.281 8.345 8.448 8.501 8.259
2.59 2.732 2.808 2.619 2.713 2.469 67.645 67.204 67.949 67.736 68.264 67.396
1.875 1.989 1.98 1.982 1.983 1.989 9.707 9.150 8.889 8.577 8.775 7.843
1.926 1.971 1.993 1.924 1.954 1.959 9.450 9.741 9.634 9.356 9.314 8.678
1.929 2.041 2.045 2.014 2.039 2.007 11.509 12.151 11.834 11.917 12.065 11.161
1.909 1.891 1.921 1.934 1.97 1.907 9.848 9.096 9.578 9.411 8.832 8.390
1.889 1.952 1.958 1.962 1.98 1.975 10.270 9.734 9.499 9.582 9.293 8.810
1.887 1.846 1.927 1.975 1.927 1.98 11.129 11.376 11.105 12.051 12.039 12.727
1.925 1.928 1.961 1.983 1.938 1.956 9.662 9.440 9.383 9.481 9.391 8.691
2.249 2.374 2.45 2.238 2.02 2.363 66.518 65.206 65.633 63.896 59.703 66.949
1.803 1.741 1.628 1.75 1.842 2.01 9.540 10.798 10.319 9.714 9.121 8.557
1.657 1.829 1.799 1.914 1.918 2.026 10.380 9.732 9.783 9.195 9.281 8.786
1.817 1.806 1.821 1.952 1.998 2.022 11.447 13.068 11.642 11.066 11.311 12.265
1.723 1.816 1.889 2.015 1.899 1.924 9.634 8.921 8.682 8.536 9.057 8.732
1.868 1.947 1.978 1.936 1.989 2.035 15.525 14.073 15.066 16.012 17.295 18.575
1.928 1.853 1.877 1.885 1.929 1.947 14.212 13.923 14.598 14.960 15.759 16.333
1.866 1.882 1.793 1.882 1.9 1.896 9.753 9.883 10.485 9.777 9.684 9.388
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1.679 1.733 1.74 1.805 1.754 1.747 0.096 0.094 0.1 0.094 0.089 0.091
1.746 1.822 1.769 1.833 1.807 1.728 0.091 0.094 0.097 0.093 0.097 0.097
1.681 1.796 1.758 1.728 1.714 1.651 0.106 0.117 0.117 0.115 0.12 0.114
1.621 1.788 1.777 1.724 1.716 1.688 0.096 0.083 0.089 0.09 0.082 0.084
1.706 1.776 1.756 1.739 1.761 1.688 0.095 0.094 0.095 0.099 0.1 0.09
1.605 1.616 1.668 1.687 1.685 1.632 0.166 0.143 0.14 0.16 0.182 0.176
1.645 1.706 1.739 1.726 1.739 1.635 0.164 0.151 0.162 0.16 0.177 0.176
0.697 0.763 0.759 0.83 0.871 0.6 0.784 0.78 0.814 0.886 0.858 0.8
1.843 1.921 1.873 1.932 1.896 1.812 0.084 0.084 0.084 0.082 0.084 0.092
1.834 1.837 1.823 1.823 1.795 1.733 0.09 0.099 0.094 0.087 0.096 0.097
1.831 1.872 1.805 1.825 1.783 1.723 0.107 0.124 0.115 0.109 0.119 0.12
1.797 1.778 1.772 1.796 1.765 1.696 0.087 0.084 0.084 0.083 0.086 0.088
1.77 1.722 1.712 1.697 1.703 1.667 0.141 0.118 0.117 0.116 0.13 0.134
1.683 1.62 1.641 1.649 1.662 1.588 0.199 0.18 0.175 0.172 0.199 0.236
1.773 1.664 1.739 1.694 1.745 1.694 0.173 0.154 0.157 0.149 0.156 0.189
0.792 0.814 0.821 0.762 0.836 0.605 0.801 0.735 0.737 0.668 0.641 0.941
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.091 1.963 1.923 2.02 2.065 2.031 8.800 9.068 9.152 9.010 8.814 8.567
2.073 1.969 1.91 2.053 2.058 2.046 8.683 9.243 9.424 9.255 9.038 8.602
2.131 2.008 2.094 2.16 2.21 2.279 10.230 12.251 11.175 11.111 11.131 11.057
2.116 1.998 2.023 2.025 2.154 2.194 12.665 13.113 13.347 12.247 12.535 12.306
2.197 2.198 2.131 2.225 2.355 2.295 19.208 22.020 21.586 22.831 22.166 22.309
2.262 2.266 2.153 2.314 2.39 2.336 21.574 23.124 19.415 20.311 23.264 22.945
2.222 2.208 2.15 2.241 2.162 2.14 18.812 18.569 16.744 17.492 18.316 19.533
2.349 2.317 2.425 2.354 2.372 2.253 70.924 71.644 69.031 66.525 68.212 67.466
1.871 1.921 1.94 1.993 1.932 1.929 10.262 9.787 10.309 9.433 9.213 9.435
1.928 2.01 1.963 2.019 2.001 1.922 9.440 9.353 9.883 9.212 9.695 10.094
1.893 2.03 1.992 1.958 1.954 1.879 11.199 11.527 11.747 11.747 12.282 12.134
1.813 1.954 1.955 1.904 1.88 1.856 10.590 8.495 9.105 9.454 8.723 9.052
1.896 1.964 1.946 1.937 1.961 1.868 10.021 9.572 9.764 10.222 10.199 9.636
1.937 1.902 1.948 2.007 2.049 1.984 17.140 15.037 14.374 15.944 17.765 17.742
1.973 2.008 2.063 2.046 2.093 1.987 16.624 15.040 15.705 15.640 16.914 17.715
2.265 2.323 2.387 2.602 2.587 2.2 69.227 67.155 68.203 68.101 66.332 72.727
2.011 2.089 2.041 2.096 2.064 1.996 8.354 8.042 8.231 7.824 8.140 9.218
2.014 2.035 2.011 1.997 1.987 1.927 8.937 9.730 9.349 8.713 9.663 10.067
2.045 2.12 2.035 2.043 2.021 1.963 10.465 11.698 11.302 10.671 11.776 12.226
1.971 1.946 1.94 1.962 1.937 1.872 8.828 8.633 8.660 8.461 8.880 9.402
2.052 1.958 1.946 1.929 1.963 1.935 13.743 12.053 12.025 12.027 13.245 13.850
2.081 1.98 1.991 1.993 2.06 2.06 19.125 18.182 17.579 17.260 19.320 22.913
2.119 1.972 2.053 1.992 2.057 2.072 16.328 15.619 15.295 14.960 15.168 18.243
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1.712 1.839 1.818 1.868 1.818 1.79 0.097 0.086 0.086 0.086 0.088 0.086
1.959 1.86 1.827 1.883 1.904 1.807 0.091 0.09 0.09 0.087 0.091 0.093
1.932 1.887 1.887 1.863 1.833 1.798 0.107 0.113 0.11 0.107 0.117 0.122
1.816 1.809 1.809 1.832 1.814 1.76 0.089 0.082 0.087 0.089 0.093 0.079
1.666 1.747 1.715 1.738 1.728 1.709 0.173 0.136 0.142 0.164 0.186 0.162
1.662 1.711 1.702 1.783 1.746 1.7 0.164 0.137 0.134 0.141 0.164 0.16
1.703 1.795 1.731 1.79 1.812 1.8 0.099 0.094 0.091 0.095 0.092 0.086
0.807 0.88 0.964 0.933 0.978 0.919 0.718 0.807 0.693 0.775 0.729 0.713
1.793 1.854 1.818 1.781 1.854 1.783 0.093 0.098 0.088 0.096 0.086 0.099
1.839 1.86 1.84 1.821 1.86 1.805 0.089 0.097 0.098 0.091 0.093 0.095
1.771 1.783 1.746 1.842 1.853 1.75 0.109 0.127 0.121 0.116 0.125 0.133
1.874 1.879 1.849 1.865 1.862 1.798 0.085 0.081 0.085 0.085 0.081 0.09
1.881 1.863 1.843 1.81 1.857 1.81 0.096 0.091 0.089 0.089 0.09 0.096
1.801 1.794 1.777 1.803 1.803 1.745 0.112 0.113 0.114 0.111 0.127 0.124
1.807 1.841 1.776 1.783 1.788 1.742 0.097 0.097 0.099 0.092 0.094 0.1
0.743 0.8 0.822 0.824 0.824 0.716 0.846 0.782 0.789 0.673 0.707 0.79
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.136 2.208 2.187 2.225 2.196 2.216 9.551 9.420 9.145 8.899 8.925 8.935
2.272 2.308 2.293 2.265 2.274 2.268 8.627 8.406 8.548 8.124 8.004 7.760
2.298 2.302 2.307 2.32 2.285 2.322 10.531 10.686 10.230 10.345 10.241 11.025
2.289 2.296 2.315 2.362 2.349 2.368 15.378 12.631 13.650 15.411 15.241 17.399
2.377 2.341 2.368 2.373 2.392 2.363 16.912 12.815 14.611 15.929 16.304 17.435
2.225 2.229 2.245 2.199 2.246 2.232 12.135 10.857 10.512 11.824 12.110 13.530
2.186 2.21 2.212 2.179 2.24 2.175 8.783 8.688 8.409 9.913 8.214 8.460
2.813 2.957 3.116 3.09 2.924 2.881 68.539 70.071 69.769 66.731 65.253 70.045
1.906 2.011 1.99 2.04 1.994 1.962 10.178 8.553 8.643 8.431 8.826 8.767
2.141 2.04 2.007 2.057 2.086 1.993 8.501 8.824 8.969 8.459 8.725 9.333
2.146 2.113 2.107 2.077 2.067 2.042 9.972 10.696 10.441 10.303 11.321 11.949
1.994 1.973 1.983 2.01 2 1.918 8.927 8.312 8.775 8.856 9.300 8.238
2.012 2.019 1.999 2.066 2.1 2.033 17.197 13.472 14.207 15.876 17.714 15.937
1.99 1.985 1.97 2.065 2.074 2.02 16.482 13.804 13.604 13.656 15.815 15.842
1.901 1.983 1.913 1.98 1.996 1.972 10.416 9.481 9.514 9.596 9.218 8.722
2.243 2.494 2.35 2.483 2.436 2.345 64.021 64.715 58.979 62.424 59.852 60.810
1.979 2.05 1.994 1.973 2.026 1.981 9.399 9.561 8.826 9.731 8.490 9.995
2.017 2.054 2.036 2.003 2.046 1.995 8.825 9.445 9.627 9.086 9.091 9.524
1.989 2.037 1.988 2.074 2.103 2.016 10.960 12.469 12.173 11.186 11.888 13.194
2.044 2.041 2.019 2.035 2.024 1.978 8.317 7.937 8.420 8.354 8.004 9.100
2.073 2.045 2.021 1.988 2.037 2.002 9.262 8.900 8.808 8.954 8.837 9.590
2.025 2.02 2.005 2.025 2.057 1.993 11.062 11.188 11.372 10.963 12.348 12.444
2.001 2.035 1.974 1.967 1.976 1.942 9.695 9.533 10.030 9.354 9.514 10.299
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1.404 1.344 1.369 1.618 1.657 1.762 0.066 0.093 0.091 0.091 0.09 0.081
1.373 1.558 1.645 1.643 1.716 1.886 0.091 0.093 0.094 0.093 0.094 0.09
1.495 1.517 1.623 1.784 1.766 1.834 0.106 0.114 0.115 0.112 0.119 0.109
1.612 1.556 1.613 1.752 1.67 1.792 0.086 0.084 0.089 0.085 0.084 0.079
1.617 1.506 1.525 1.591 1.739 1.72 0.096 0.094 0.097 0.092 0.096 0.089
1.323 1.412 1.445 1.6 1.676 1.579 0.191 0.169 0.195 0.248 0.276 0.293
1.28 1.384 1.369 1.526 1.542 1.477 0.251 0.224 0.236 0.275 0.29 0.328
0.502 0.601 0.619 0.791 0.793 0.637 0.67 0.682 0.776 0.838 0.845 0.68
1.959 1.983 1.967 1.963 1.932 1.987 0.095 0.09 0.087 0.089 0.085 0.082
1.979 1.942 1.893 1.889 1.883 1.917 0.092 0.089 0.098 0.097 0.097 0.091
1.931 1.893 1.896 1.902 1.864 1.896 0.112 0.125 0.121 0.123 0.129 0.116
1.951 1.919 1.891 1.863 1.863 1.88 0.089 0.087 0.093 0.092 0.089 0.086
1.875 1.881 1.851 1.833 1.848 1.842 0.138 0.128 0.13 0.137 0.134 0.151
1.742 1.711 1.687 1.657 1.652 1.66 0.29 0.272 0.279 0.343 0.387 0.458
1.753 1.733 1.725 1.676 1.686 1.691 0.288 0.26 0.254 0.257 0.299 0.33
0.827 0.912 0.915 0.887 0.927 0.932 0.787 0.742 0.77 0.819 0.779 0.696
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.089 2.129 2.155 2.145 2.086 2.171 8.712 8.549 8.538 7.925 8.437 9.028
2.231 2.145 2.216 2.211 2.145 2.183 8.068 8.671 8.755 7.689 8.858 9.162
2.29 2.262 2.239 2.292 2.219 2.17 9.607 10.787 10.094 10.122 10.816 12.350
2.24 2.149 2.197 2.082 2.211 2.249 13.839 12.192 12.563 12.680 12.302 13.339
2.428 2.304 2.369 2.386 2.392 2.36 28.995 24.826 26.593 27.661 27.090 29.576
2.402 2.27 2.399 2.427 2.276 2.435 30.142 26.256 26.011 27.029 25.747 31.622
2.324 2.28 2.367 2.517 2.405 2.401 28.657 26.140 25.687 29.082 29.854 29.321
2.828 2.688 2.17 2.898 2.68 2.101 76.591 72.545 69.217 75.086 74.104 72.156
1.536 1.53 1.551 1.8 1.837 1.924 8.594 12.157 11.734 10.111 9.799 8.420
1.555 1.744 1.833 1.829 1.904 2.066 11.704 10.665 10.256 10.169 9.874 8.712
1.707 1.745 1.853 2.008 2.004 2.052 12.419 13.066 12.412 11.155 11.876 10.624
1.784 1.724 1.791 1.922 1.838 1.95 9.641 9.745 9.939 8.845 9.140 8.103
1.809 1.694 1.719 1.775 1.931 1.898 10.614 11.098 11.286 10.366 9.943 9.378
1.705 1.75 1.835 2.096 2.228 2.165 22.405 19.314 21.253 23.664 24.776 27.067
1.782 1.832 1.841 2.076 2.122 2.133 28.171 24.454 25.638 26.493 27.333 30.755
1.842 1.965 2.171 2.467 2.483 1.997 72.747 69.415 71.488 67.937 68.063 68.102
2.149 2.163 2.141 2.141 2.102 2.151 8.841 8.322 8.127 8.314 8.088 7.624
2.163 2.12 2.089 2.083 2.077 2.099 8.507 8.396 9.382 9.313 9.340 8.671
2.155 2.143 2.138 2.148 2.122 2.128 10.394 11.666 11.319 11.453 12.158 10.902
2.129 2.093 2.077 2.047 2.041 2.052 8.361 8.313 8.955 8.989 8.721 8.382
2.151 2.137 2.111 2.107 2.116 2.144 12.831 11.979 12.316 13.004 12.665 14.086
2.322 2.255 2.245 2.343 2.426 2.576 24.978 24.124 24.855 29.279 31.904 35.559
2.329 2.253 2.233 2.19 2.284 2.351 24.732 23.080 22.750 23.470 26.182 28.073
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1.975 1.928 1.909 1.866 1.922 1.951 0.093 0.095 0.095 0.098 0.095 0.091
2.002 1.898 1.867 1.846 1.924 1.941 0.098 0.098 0.098 0.094 0.101 0.094
1.985 1.893 1.884 1.804 1.939 1.909 0.114 0.128 0.114 0.121 0.122 0.123
2.008 1.907 1.834 1.805 1.892 1.898 0.094 0.09 0.095 0.092 0.089 0.092
1.941 1.882 1.832 1.835 1.841 1.85 0.1 0.096 0.1 0.097 0.097 0.099
1.854 1.798 1.762 1.733 1.819 1.845 0.17 0.136 0.143 0.162 0.175 0.189
1.943 1.894 1.865 1.85 1.883 1.837 0.109 0.107 0.104 0.104 0.104 0.099
0.691 0.774 0.744 0.72 0.886 0.816 0.982 0.974 0.84 0.883 0.812 0.825
1.939 1.983 2.009 2.022 2.022 1.959 0.1 0.099 0.097 0.099 0.096 0.102
1.996 1.945 1.971 1.983 1.975 1.963 0.099 0.106 0.104 0.101 0.102 0.106
1.978 1.967 1.952 2.009 1.996 1.959 0.117 0.131 0.127 0.141 0.158 0.139
1.994 1.976 1.969 1.982 1.968 1.994 0.093 0.093 0.099 0.119 0.104 0.124
1.979 1.991 1.971 1.959 1.975 1.928 0.099 0.105 0.103 0.102 0.098 0.1
1.947 1.947 1.928 1.947 1.953 1.914 0.104 0.107 0.107 0.111 0.106 0.121
1.93 1.986 1.964 1.958 1.997 1.975 0.099 0.105 0.102 0.099 0.099 0.097
1.061 1.05 1.036 0.987 1.06 0.879 0.583 0.807 0.715 0.728 0.785 0.757
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.357 2.395 2.372 2.353 2.35 2.275 8.061 8.685 8.347 7.905 8.000 7.824
2.421 2.393 2.351 2.406 2.387 2.346 7.931 8.023 8.337 8.229 8.379 8.440
2.404 2.389 2.405 2.391 2.382 2.385 9.068 10.046 10.146 10.038 10.579 10.901
2.349 2.354 2.357 2.345 2.393 2.387 8.174 8.071 9.334 9.296 9.779 10.892
2.458 2.425 2.541 2.555 2.609 2.792 16.355 14.433 19.677 20.587 22.077 27.650
2.395 2.35 2.478 2.449 2.477 2.621 13.946 12.596 17.433 17.068 18.329 25.868
2.373 2.359 2.332 2.318 2.3 2.29 9.440 8.648 8.748 8.887 8.609 8.646
2.69 2.837 3.024 2.808 2.873 2.862 57.546 59.076 59.392 60.684 62.026 64.780
2.161 2.118 2.099 2.062 2.112 2.133 8.607 8.971 9.052 9.505 8.996 8.533
2.198 2.094 2.063 2.034 2.126 2.129 8.917 9.360 9.501 9.243 9.501 8.830
2.213 2.149 2.112 2.046 2.183 2.155 10.303 11.913 10.795 11.828 11.177 11.415
2.196 2.087 2.024 1.989 2.07 2.082 8.561 8.625 9.387 9.251 8.599 8.838
2.141 2.074 2.032 2.029 2.035 2.048 9.341 9.257 9.843 9.561 9.533 9.668
2.194 2.07 2.048 2.057 2.169 2.223 15.497 13.140 13.965 15.751 16.136 17.004
2.161 2.108 2.073 2.058 2.091 2.035 10.088 10.152 10.034 10.107 9.947 9.730
2.655 2.722 2.424 2.486 2.51 2.466 73.974 71.565 69.307 71.038 64.701 66.910
2.139 2.181 2.203 2.22 2.214 2.163 9.350 9.078 8.806 8.919 8.672 9.431
2.194 2.157 2.179 2.185 2.179 2.175 9.025 9.828 9.546 9.245 9.362 9.747
2.212 2.229 2.206 2.291 2.312 2.237 10.579 11.754 11.514 12.309 13.668 12.427
2.18 2.162 2.167 2.22 2.176 2.242 8.532 8.603 9.137 10.721 9.559 11.062
2.177 2.201 2.177 2.163 2.171 2.128 9.095 9.541 9.463 9.431 9.028 9.398
2.155 2.161 2.142 2.169 2.165 2.156 9.652 9.903 9.991 10.235 9.792 11.224
2.128 2.196 2.168 2.156 2.195 2.169 9.305 9.563 9.410 9.184 9.021 8.944
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1.74 1.947 1.951 2.029 2.004 1.983 0.087 0.085 0.09 0.086 0.084 0.089
1.959 1.928 1.974 1.975 1.924 1.891 0.091 0.091 0.096 0.092 0.096 0.1
2.01 1.936 1.913 1.967 1.896 1.806 0.107 0.115 0.113 0.115 0.113 0.114
1.822 1.751 1.891 1.961 1.842 1.853 0.083 0.082 0.087 0.087 0.09 0.091
1.811 1.876 1.861 1.83 1.855 1.822 0.115 0.087 0.09 0.085 0.093 0.091
1.755 1.659 1.697 1.706 1.777 1.781 0.19 0.155 0.16 0.188 0.204 0.186
1.462 1.563 1.622 1.515 1.468 1.434 0.382 0.364 0.395 0.38 0.399 0.445
0.813 0.829 0.855 0.92 0.867 0.739 0.721 0.916 0.794 0.78 0.823 0.831
2.092 2.066 1.979 2.004 2.086 2.076 0.09 0.092 0.089 0.09 0.088 0.087
2.068 2.003 1.975 2.005 2.036 2.022 0.091 0.099 0.097 0.098 0.098 0.098
2.076 1.945 1.959 1.928 2.035 2.009 0.11 0.127 0.118 0.119 0.123 0.123
2.001 1.951 1.915 1.941 1.993 1.985 0.093 0.089 0.093 0.1 0.095 0.088
1.987 1.958 1.947 1.93 1.988 1.967 0.108 0.1 0.098 0.104 0.11 0.101
1.74 1.751 1.655 1.72 1.757 1.725 0.327 0.277 0.332 0.415 0.448 0.482
1.757 1.729 1.693 1.705 1.717 1.705 0.339 0.282 0.35 0.408 0.457 0.512
0.864 1.018 1.043 0.934 1.008 0.828 0.844 0.731 0.738 0.801 0.814 0.788
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.275 2.419 2.355 2.333 2.361 2.325 7.912 7.524 8.238 8.144 7.370 7.312
2.384 2.398 2.37 2.325 2.387 2.368 7.970 7.923 8.270 8.172 8.379 7.939
2.377 2.465 2.42 2.43 2.395 2.388 9.340 10.142 10.165 10.041 10.689 10.637
2.349 2.367 2.327 2.234 2.349 2.346 8.855 7.943 9.024 9.042 9.025 8.781
2.543 2.442 2.47 2.484 2.6 2.691 23.751 17.199 19.595 22.383 25.615 27.573
2.647 2.415 2.465 2.723 2.875 3.024 35.965 28.157 28.722 37.606 40.487 45.833
2.67 2.53 2.428 2.513 2.873 3.045 34.906 29.960 27.924 32.312 39.749 44.138
2.715 3.045 3.052 2.922 3.077 3.001 67.035 71.593 64.155 65.092 65.258 64.445
1.914 2.117 2.131 2.201 2.172 2.161 9.091 8.030 8.447 7.815 7.735 8.237
2.141 2.11 2.166 2.159 2.116 2.091 8.501 8.626 8.864 8.522 9.074 9.565
2.224 2.166 2.139 2.197 2.122 2.034 9.622 10.619 10.566 10.469 10.650 11.209
1.988 1.915 2.065 2.135 2.022 2.035 8.350 8.564 8.426 8.150 8.902 8.943
2.041 2.05 2.041 2 2.041 2.004 11.269 8.488 8.819 8.500 9.113 9.082
2.135 1.969 2.017 2.082 2.185 2.153 17.799 15.744 15.865 18.060 18.673 17.278
2.226 2.291 2.412 2.275 2.266 2.324 34.322 31.777 32.753 33.407 35.216 38.296
2.255 2.661 2.443 2.48 2.513 2.401 63.947 68.846 65.002 62.903 65.499 69.221
2.272 2.25 2.157 2.184 2.262 2.25 7.923 8.178 8.252 8.242 7.781 7.733
2.25 2.201 2.169 2.201 2.232 2.218 8.089 8.996 8.944 8.905 8.781 8.837
2.296 2.199 2.195 2.166 2.281 2.255 9.582 11.551 10.752 10.988 10.785 10.909
2.187 2.129 2.101 2.141 2.183 2.161 8.505 8.361 8.853 9.341 8.704 8.144
2.203 2.158 2.143 2.138 2.208 2.169 9.805 9.268 9.146 9.729 9.964 9.313
2.394 2.305 2.319 2.55 2.653 2.689 27.318 24.035 28.633 32.549 33.773 35.850
2.435 2.293 2.393 2.521 2.631 2.729 27.844 24.597 29.252 32.368 34.740 37.523





































































1 2 3 4 5 6 7 8 9 10 11 12
1.611 1.764 1.799 1.83 1.823 1.793 0.093 0.088 0.086 0.089 0.09 0.085
1.492 1.829 1.824 1.854 1.829 1.842 0.09 0.091 0.09 0.089 0.093 0.086
1.506 1.836 1.831 1.85 1.856 1.853 0.107 0.117 0.113 0.114 0.122 0.114
1.397 1.762 1.769 1.806 1.84 1.807 0.081 0.077 0.083 0.083 0.081 0.08
1.353 1.719 1.696 1.734 1.762 1.721 0.12 0.124 0.133 0.178 0.195 0.2
1.261 1.668 1.712 1.752 1.793 1.657 0.104 0.115 0.112 0.134 0.145 0.152
1.356 1.679 1.774 1.83 1.832 1.833 0.092 0.089 0.088 0.087 0.085 0.083
0.626 0.954 0.921 0.961 1.009 0.943 0.568 0.606 0.682 0.791 0.837 0.778
1.234 1.433 1.505 1.564 1.529 1.499 0.095 0.092 0.088 0.091 0.087 0.085
1.345 1.53 1.578 1.561 1.565 1.527 0.094 0.098 0.093 0.091 0.095 0.089
1.357 1.445 1.566 1.552 1.552 1.501 0.111 0.122 0.119 0.12 0.122 0.116
1.499 1.472 1.546 1.532 1.564 1.533 0.092 0.087 0.09 0.091 0.087 0.087
1.135 1.363 1.461 1.447 1.448 1.433 0.114 0.109 0.135 0.133 0.133 0.138
1.067 1.399 1.447 1.431 1.487 1.393 0.122 0.13 0.15 0.154 0.16 0.17
1.29 1.424 1.534 1.413 1.534 1.529 0.097 0.097 0.101 0.106 0.096 0.093
0.548 0.703 0.669 0.699 0.68 0.635 0.566 0.694 0.659 0.702 0.704 0.643
2.682 2.205 2.143 2.162 2.152 2.11 0.07 0.074 0.07 0.071 0.074 0.075
2.686 2.192 2.132 2.179 2.069 2.034 0.071 0.072 0.078 0.081 0.09 0.088
2.11 2.535 2.152 2.173 2.03 2.022 0.065 0.066 0.065 0.071 0.07 0.075
2.137 2.25 2.157 2.14 2.053 2.077 0.066 0.064 0.068 0.076 0.083 0.077
2.112 2.62 2.152 2.148 2.051 2.047 0.073 0.077 0.079 0.087 0.095 0.099
2.24 2.355 2.226 2.266 2.13 2.186 0.07 0.072 0.075 0.078 0.084 0.088
2.25 2.232 2.152 2.194 2.097 2.045 0.07 0.074 0.077 0.078 0.079 0.091
0.973 1.016 0.894 0.918 0.834 1.043 0.539 0.996 1.171 1.164 1.134 1.249
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.797 1.94 1.971 2.008 2.003 1.963 10.351 9.072 8.727 8.865 8.987 8.660
1.672 2.011 2.004 2.032 2.015 2.014 10.766 9.050 8.982 8.760 9.231 8.540
1.72 2.07 2.057 2.078 2.1 2.081 12.442 11.304 10.987 10.972 11.619 10.956
1.559 1.916 1.935 1.972 2.002 1.967 10.391 8.038 8.579 8.418 8.092 8.134
1.593 1.967 1.962 2.09 2.152 2.121 15.066 12.608 13.558 17.033 18.123 18.859
1.469 1.898 1.936 2.02 2.083 1.961 14.159 12.118 11.570 13.267 13.922 15.502
1.54 1.857 1.95 2.004 2.002 1.999 11.948 9.585 9.026 8.683 8.492 8.304
1.762 2.166 2.285 2.543 2.683 2.499 64.472 55.956 59.694 62.210 62.393 62.265
1.424 1.617 1.681 1.746 1.703 1.669 13.343 11.379 10.470 10.424 10.217 10.186
1.533 1.726 1.764 1.743 1.755 1.705 12.264 11.356 10.544 10.442 10.826 10.440
1.579 1.689 1.804 1.792 1.796 1.733 14.060 14.446 13.193 13.393 13.586 13.387
1.683 1.646 1.726 1.714 1.738 1.707 10.933 10.571 10.429 10.618 10.012 10.193
1.363 1.581 1.731 1.713 1.714 1.709 16.728 13.789 15.598 15.528 15.519 16.150
1.311 1.659 1.747 1.739 1.807 1.733 18.612 15.672 17.172 17.711 17.709 19.619
1.484 1.618 1.736 1.625 1.726 1.715 13.073 11.990 11.636 13.046 11.124 10.845
1.68 2.091 1.987 2.103 2.088 1.921 67.381 66.380 66.331 66.762 67.433 66.944
2.822 2.353 2.283 2.304 2.3 2.26 4.961 6.290 6.132 6.163 6.435 6.637
2.828 2.336 2.288 2.341 2.249 2.21 5.021 6.164 6.818 6.920 8.004 7.964
2.24 2.667 2.282 2.315 2.17 2.172 5.804 4.949 5.697 6.134 6.452 6.906
2.269 2.378 2.293 2.292 2.219 2.231 5.818 5.383 5.931 6.632 7.481 6.903
2.258 2.774 2.31 2.322 2.241 2.245 6.466 5.552 6.840 7.494 8.478 8.820
2.38 2.499 2.376 2.422 2.298 2.362 5.882 5.762 6.313 6.441 7.311 7.451
2.39 2.38 2.306 2.35 2.255 2.227 5.858 6.218 6.678 6.638 7.007 8.172
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Antigen Concentration (ng ml   )
RBL-pEE6 Expressing Dog α Chain Cells Bound With Dog IgE For 16 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Mouse IgE For 16 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Horse IgE 16 hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Horse IgE For 0.5 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Mouse IgE For 0.5 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Horse IgE For 1 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Mouse IgE For 1 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Horse IgE For 3 Hours
RBL-pEE6 Expressing Dog α Chain Cells Bound With Mouse IgE For 3 Hours
-1
Figure 31: β-hexosaminidase release assays of RBL-2H3.1 
cells expressing canine FcεRIα tested with equine IgE:
This figure shows the release assays run on RBL-2H3.1 cells 
expressing canine FcεRIα sensitized with equine IgE, using 
mouse and canine IgEs as the control. From this graph it can be 
seen that the equine IgE does not interacts with the canine 
FcεRIα, as increasing interaction time (0.5, 1 and 3 hours) 
resulted in no significant releases, even when incubated for full 
time (16 hours), compared to the negative control. When these 
results were c mpar d to the mouse and canine IgE controls, the 
increasing interaction time (0.5, 1 and 3 hours) resulted in 
similar non-significant releases, but when incubated for the full 
16 hours, the maximum release was very high (42. 2% when 
tested with mouse IgE and 43.49% when tested with canine 
IgE). Values for this graph are in the Appendix.
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x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.793 1.988 2.019 2.038 2.015 2.06 11.824 10.664 10.104 9.617 9.628 11.165
1.789 1.966 2.011 2.028 2.028 2.09 11.738 9.461 9.448 10.059 10.651 10.622
2.011 2.086 2.111 2.157 2.144 2.19 15.017 13.231 13.169 13.908 14.272 15.708
2.039 2.087 2.224 2.382 2.361 2.331 25.895 17.537 20.863 22.838 24.989 23.681
2.061 2.142 2.445 2.836 2.911 2.754 44.153 33.613 37.301 45.628 46.994 46.841
2.228 2.117 2.511 2.667 2.731 2.74 46.499 39.490 43.090 46.944 51.263 50.073
2.234 2.053 2.2 2.261 2.262 2.388 46.285 39.454 37.182 39.275 39.788 44.137




















































1 2 3 4 5 6 7 8 9 10 11 12
2.565 2.893 2.495 1.992 2.228 1.839 0.068 0.073 0.072 0.073 0.068 0.074
2.471 2.602 2.565 2.068 1.893 1.731 0.115 0.098 0.092 0.094 0.11 0.118
1.726 1.749 1.698 1.67 1.671 1.531 0.395 0.338 0.381 0.464 0.524 0.472
1.881 1.461 1.463 1.399 1.307 1.254 0.587 0.447 0.591 0.771 0.875 0.765
1.502 1.509 1.434 1.35 1.353 1.185 0.693 0.488 0.61 0.822 0.952 0.657
1.484 1.56 1.472 1.428 1.418 1.204 0.623 0.542 0.713 0.791 0.837 0.607
1.982 1.479 1.393 1.369 1.4 1.219 0.642 0.52 0.707 0.786 0.896 0.706
1.312 0.751 0.753 0.781 0.823 0.807 1.024 1.062 0.938 0.986 0.922 0.843
1.632 1.713 1.812 1.764 1.698 1.654 0.096 0.094 0.096 0.105 0.095 0.111
1.684 1.8 1.835 1.756 1.738 1.724 0.102 0.1 0.097 0.103 0.102 0.107
1.661 1.693 1.776 1.776 1.779 1.74 0.179 0.174 0.164 0.17 0.185 0.227
1.272 1.471 1.521 1.538 1.546 1.481 0.319 0.265 0.332 0.439 0.447 0.47
1.271 1.399 1.477 1.451 1.473 1.396 0.368 0.307 0.321 0.465 0.534 0.552
1.183 1.43 1.506 1.444 1.543 1.426 0.32 0.313 0.337 0.344 0.475 0.531
1.132 1.376 1.443 1.42 1.443 1.398 0.352 0.334 0.374 0.365 0.398 0.544
0.548 0.748 0.838 0.78 0.896 0.799 0.651 0.75 0.919 0.875 0.867 0.858
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.701 3.039 2.639 2.138 2.364 1.987 5.035 4.804 5.457 6.829 5.753 7.448
2.701 2.798 2.749 2.256 2.113 1.967 8.515 7.005 6.693 8.333 10.412 11.998
2.516 2.425 2.46 2.598 2.719 2.475 31.399 27.876 30.976 35.720 38.544 38.141
3.055 2.355 2.645 2.941 3.057 2.784 38.429 37.962 44.688 52.431 57.246 54.957
2.888 2.485 2.654 2.994 3.257 2.499 47.992 39.276 45.968 54.910 58.459 52.581
2.73 2.644 2.898 3.01 3.092 2.418 45.641 40.998 49.206 52.558 54.140 50.207
3.266 2.519 2.807 2.941 3.192 2.631 39.314 41.286 50.374 53.451 56.140 53.668
3.36 2.875 2.629 2.753 2.667 2.493 60.952 73.878 71.358 71.631 69.141 67.629
1.824 1.901 2.004 1.974 1.888 1.876 10.526 9.890 9.581 10.638 10.064 11.834
1.888 2 2.029 1.962 1.942 1.938 10.805 10.000 9.561 10.499 10.505 11.042
2.019 2.041 2.104 2.116 2.149 2.194 17.732 17.050 15.589 16.068 17.217 20.693
1.91 2.001 2.185 2.416 2.44 2.421 33.403 26.487 30.389 36.341 36.639 38.827
2.007 2.013 2.119 2.381 2.541 2.5 36.672 30.502 30.297 39.059 42.031 44.160
1.823 2.056 2.18 2.132 2.493 2.488 35.107 30.447 30.917 32.270 38.107 42.685
1.836 2.044 2.191 2.15 2.239 2.486 38.344 32.681 34.140 33.953 35.552 43.765




































































1 2 3 4 5 6 7 8 9 10 11 12
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1.693 1.807 1.804 1.812 1.809 1.833 0.091 0.091 0.088 0.085 0.087 0.078
1.744 1.779 1.801 1.744 1.772 1.789 0.091 0.096 0.096 0.09 0.091 0.085
1.707 1.793 1.803 1.774 1.793 1.783 0.111 0.124 0.121 0.12 0.123 0.112
1.721 1.719 1.737 1.752 1.796 1.747 0.094 0.086 0.092 0.091 0.087 0.08
1.695 1.762 1.772 1.774 1.796 1.801 0.097 0.095 0.093 0.094 0.092 0.087
1.677 1.636 1.713 1.737 1.695 1.728 0.105 0.105 0.107 0.119 0.116 0.126
1.739 1.746 1.777 1.795 1.756 1.786 0.093 0.091 0.092 0.094 0.091 0.085
0.753 0.826 0.842 0.808 0.814 0.781 0.748 0.774 0.804 0.715 0.603 0.791
1.631 1.553 1.46 1.58 1.674 1.838 0.086 0.094 0.084 0.085 0.084 0.086
1.485 1.651 1.623 1.738 1.74 1.848 0.086 0.089 0.088 0.088 0.089 0.089
1.609 1.57 1.609 1.736 1.772 1.774 0.104 0.118 0.106 0.108 0.113 0.124
1.557 1.654 1.725 1.843 1.727 1.756 0.083 0.081 0.082 0.086 0.086 0.084
1.578 1.673 1.68 1.626 1.645 1.657 0.145 0.137 0.149 0.155 0.172 0.189
1.654 1.595 1.603 1.603 1.625 1.629 0.137 0.129 0.137 0.141 0.152 0.159
1.684 1.696 1.605 1.698 1.716 1.718 0.091 0.093 0.094 0.092 0.092 0.089
0.816 0.707 0.857 0.844 0.748 0.865 0.746 0.639 0.695 0.694 0.733 0.805
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.193 2.256 2.241 2.228 2.238 2.184 8.208 9.043 8.568 8.438 8.490 8.425
2.268 2.28 2.197 2.252 2.232 2.23 7.760 8.246 8.375 8.171 8.333 8.700
2.332 2.295 2.257 2.342 2.29 2.319 11.664 11.678 11.786 12.212 12.751 14.661
2.39 2.314 2.32 2.346 2.326 2.368 17.322 14.088 15.690 18.414 17.713 20.439
2.322 2.229 2.34 2.263 2.322 2.347 17.313 14.177 15.641 16.350 17.916 19.344
2.231 2.22 2.248 2.231 2.176 2.214 11.833 11.081 12.633 12.371 12.868 14.815
2.228 2.222 2.205 2.178 2.188 2.131 8.348 8.281 8.345 8.448 8.501 8.259
2.59 2.732 2.808 2.619 2.713 2.469 67.645 67.204 67.949 67.736 68.264 67.396
1.875 1.989 1.98 1.982 1.983 1.989 9.707 9.150 8.889 8.577 8.775 7.843
1.926 1.971 1.993 1.924 1.954 1.959 9.450 9.741 9.634 9.356 9.314 8.678
1.929 2.041 2.045 2.014 2.039 2.007 11.509 12.151 11.834 11.917 12.065 11.161
1.909 1.891 1.921 1.934 1.97 1.907 9.848 9.096 9.578 9.411 8.832 8.390
1.889 1.952 1.958 1.962 1.98 1.975 10.270 9.734 9.499 9.582 9.293 8.810
1.887 1.846 1.927 1.975 1.927 1.98 11.129 11.376 11.105 12.051 12.039 12.727
1.925 1.928 1.961 1.983 1.938 1.956 9.662 9.440 9.383 9.481 9.391 8.691
2.249 2.374 2.45 2.238 2.02 2.363 66.518 65.206 65.633 63.896 59.703 66.949
1.803 1.741 1.628 1.75 1.842 2.01 9.540 10.798 10.319 9.714 9.121 8.557
1.657 1.829 1.799 1.914 1.918 2.026 10.380 9.732 9.783 9.195 9.281 8.786
1.817 1.806 1.821 1.952 1.998 2.022 11.447 13.068 11.642 11.066 11.311 12.265
1.723 1.816 1.889 2.015 1.899 1.924 9.634 8.921 8.682 8.536 9.057 8.732
1.868 1.947 1.978 1.936 1.989 2.035 15.525 14.073 15.066 16.012 17.295 18.575
1.928 1.853 1.877 1.885 1.929 1.947 14.212 13.923 14.598 14.960 15.759 16.333
1.866 1.882 1.793 1.882 1.9 1.896 9.753 9.883 10.485 9.777 9.684 9.388
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1.679 1.733 1.74 1.805 1.754 1.747 0.096 0.094 0.1 0.094 0.089 0.091
1.746 1.822 1.769 1.833 1.807 1.728 0.091 0.094 0.097 0.093 0.097 0.097
1.681 1.796 1.758 1.728 1.714 1.651 0.106 0.117 0.117 0.115 0.12 0.114
1.621 1.788 1.777 1.724 1.716 1.688 0.096 0.083 0.089 0.09 0.082 0.084
1.706 1.776 1.756 1.739 1.761 1.688 0.095 0.094 0.095 0.099 0.1 0.09
1.605 1.616 1.668 1.687 1.685 1.632 0.166 0.143 0.14 0.16 0.182 0.176
1.645 1.706 1.739 1.726 1.739 1.635 0.164 0.151 0.162 0.16 0.177 0.176
0.697 0.763 0.759 0.83 0.871 0.6 0.784 0.78 0.814 0.886 0.858 0.8
1.843 1.921 1.873 1.932 1.896 1.812 0.084 0.084 0.084 0.082 0.084 0.092
1.834 1.837 1.823 1.823 1.795 1.733 0.09 0.099 0.094 0.087 0.096 0.097
1.831 1.872 1.805 1.825 1.783 1.723 0.107 0.124 0.115 0.109 0.119 0.12
1.797 1.778 1.772 1.796 1.765 1.696 0.087 0.084 0.084 0.083 0.086 0.088
1.77 1.722 1.712 1.697 1.703 1.667 0.141 0.118 0.117 0.116 0.13 0.134
1.683 1.62 1.641 1.649 1.662 1.588 0.199 0.18 0.175 0.172 0.199 0.236
1.773 1.664 1.739 1.694 1.745 1.694 0.173 0.154 0.157 0.149 0.156 0.189
0.792 0.814 0.821 0.762 0.836 0.605 0.801 0.735 0.737 0.668 0.641 0.941
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.091 1.963 1.923 2.02 2.065 2.031 8.800 9.068 9.152 9.010 8.814 8.567
2.073 1.969 1.91 2.053 2.058 2.046 8.683 9.243 9.424 9.255 9.038 8.602
2.131 2.008 2.094 2.16 2.21 2.279 10.230 12.251 11.175 11.111 11.131 11.057
2.116 1.998 2.023 2.025 2.154 2.194 12.665 13.113 13.347 12.247 12.535 12.306
2.197 2.198 2.131 2.225 2.355 2.295 19.208 22.020 21.586 22.831 22.166 22.309
2.262 2.266 2.153 2.314 2.39 2.336 21.574 23.124 19.415 20.311 23.264 22.945
2.222 2.208 2.15 2.241 2.162 2.14 18.812 18.569 16.744 17.492 18.316 19.533
2.349 2.317 2.425 2.354 2.372 2.253 70.924 71.644 69.031 66.525 68.212 67.466
1.871 1.921 1.94 1.993 1.932 1.929 10.262 9.787 10.309 9.433 9.213 9.435
1.928 2.01 1.963 2.019 2.001 1.922 9.440 9.353 9.883 9.212 9.695 10.094
1.893 2.03 1.992 1.958 1.954 1.879 11.199 11.527 11.747 11.747 12.282 12.134
1.813 1.954 1.955 1.904 1.88 1.856 10.590 8.495 9.105 9.454 8.723 9.052
1.896 1.964 1.946 1.937 1.961 1.868 10.021 9.572 9.764 10.222 10.199 9.636
1.937 1.902 1.948 2.007 2.049 1.984 17.140 15.037 14.374 15.944 17.765 17.742
1.973 2.008 2.063 2.046 2.093 1.987 16.624 15.040 15.705 15.640 16.914 17.715
2.265 2.323 2.387 2.602 2.587 2.2 69.227 67.155 68.203 68.101 66.332 72.727
2.011 2.089 2.041 2.096 2.064 1.996 8.354 8.042 8.231 7.824 8.140 9.218
2.014 2.035 2.011 1.997 1.987 1.927 8.937 9.730 9.349 8.713 9.663 10.067
2.045 2.12 2.035 2.043 2.021 1.963 10.465 11.698 11.302 10.671 11.776 12.226
1.971 1.946 1.94 1.962 1.937 1.872 8.828 8.633 8.660 8.461 8.880 9.402
2.052 1.958 1.946 1.929 1.963 1.935 13.743 12.053 12.025 12.027 13.245 13.850
2.081 1.98 1.991 1.993 2.06 2.06 19.125 18.182 17.579 17.260 19.320 22.913
2.119 1.972 2.053 1.992 2.057 2.072 16.328 15.619 15.295 14.960 15.168 18.243
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1.712 1.839 1.818 1.868 1.818 1.79 0.097 0.086 0.086 0.086 0.088 0.086
1.959 1.86 1.827 1.883 1.904 1.807 0.091 0.09 0.09 0.087 0.091 0.093
1.932 1.887 1.887 1.863 1.833 1.798 0.107 0.113 0.11 0.107 0.117 0.122
1.816 1.809 1.809 1.832 1.814 1.76 0.089 0.082 0.087 0.089 0.093 0.079
1.666 1.747 1.715 1.738 1.728 1.709 0.173 0.136 0.142 0.164 0.186 0.162
1.662 1.711 1.702 1.783 1.746 1.7 0.164 0.137 0.134 0.141 0.164 0.16
1.703 1.795 1.731 1.79 1.812 1.8 0.099 0.094 0.091 0.095 0.092 0.086
0.807 0.88 0.964 0.933 0.978 0.919 0.718 0.807 0.693 0.775 0.729 0.713
1.793 1.854 1.818 1.781 1.854 1.783 0.093 0.098 0.088 0.096 0.086 0.099
1.839 1.86 1.84 1.821 1.86 1.805 0.089 0.097 0.098 0.091 0.093 0.095
1.771 1.783 1.746 1.842 1.853 1.75 0.109 0.127 0.121 0.116 0.125 0.133
1.874 1.879 1.849 1.865 1.862 1.798 0.085 0.081 0.085 0.085 0.081 0.09
1.881 1.863 1.843 1.81 1.857 1.81 0.096 0.091 0.089 0.089 0.09 0.096
1.801 1.794 1.777 1.803 1.803 1.745 0.112 0.113 0.114 0.111 0.127 0.124
1.807 1.841 1.776 1.783 1.788 1.742 0.097 0.097 0.099 0.092 0.094 0.1
0.743 0.8 0.822 0.824 0.824 0.716 0.846 0.782 0.789 0.673 0.707 0.79
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.136 2.208 2.187 2.225 2.196 2.216 9.551 9.420 9.145 8.899 8.925 8.935
2.272 2.308 2.293 2.265 2.274 2.268 8.627 8.406 8.548 8.124 8.004 7.760
2.298 2.302 2.307 2.32 2.285 2.322 10.531 10.686 10.230 10.345 10.241 11.025
2.289 2.296 2.315 2.362 2.349 2.368 15.378 12.631 13.650 15.411 15.241 17.399
2.377 2.341 2.368 2.373 2.392 2.363 16.912 12.815 14.611 15.929 16.304 17.435
2.225 2.229 2.245 2.199 2.246 2.232 12.135 10.857 10.512 11.824 12.110 13.530
2.186 2.21 2.212 2.179 2.24 2.175 8.783 8.688 8.409 9.913 8.214 8.460
2.813 2.957 3.116 3.09 2.924 2.881 68.539 70.071 69.769 66.731 65.253 70.045
1.906 2.011 1.99 2.04 1.994 1.962 10.178 8.553 8.643 8.431 8.826 8.767
2.141 2.04 2.007 2.057 2.086 1.993 8.501 8.824 8.969 8.459 8.725 9.333
2.146 2.113 2.107 2.077 2.067 2.042 9.972 10.696 10.441 10.303 11.321 11.949
1.994 1.973 1.983 2.01 2 1.918 8.927 8.312 8.775 8.856 9.300 8.238
2.012 2.019 1.999 2.066 2.1 2.033 17.197 13.472 14.207 15.876 17.714 15.937
1.99 1.985 1.97 2.065 2.074 2.02 16.482 13.804 13.604 13.656 15.815 15.842
1.901 1.983 1.913 1.98 1.996 1.972 10.416 9.481 9.514 9.596 9.218 8.722
2.243 2.494 2.35 2.483 2.436 2.345 64.021 64.715 58.979 62.424 59.852 60.810
1.979 2.05 1.994 1.973 2.026 1.981 9.399 9.561 8.826 9.731 8.490 9.995
2.017 2.054 2.036 2.003 2.046 1.995 8.825 9.445 9.627 9.086 9.091 9.524
1.989 2.037 1.988 2.074 2.103 2.016 10.960 12.469 12.173 11.186 11.888 13.194
2.044 2.041 2.019 2.035 2.024 1.978 8.317 7.937 8.420 8.354 8.004 9.100
2.073 2.045 2.021 1.988 2.037 2.002 9.262 8.900 8.808 8.954 8.837 9.590
2.025 2.02 2.005 2.025 2.057 1.993 11.062 11.188 11.372 10.963 12.348 12.444
2.001 2.035 1.974 1.967 1.976 1.942 9.695 9.533 10.030 9.354 9.514 10.299
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1.404 1.344 1.369 1.618 1.657 1.762 0.066 0.093 0.091 0.091 0.09 0.081
1.373 1.558 1.645 1.643 1.716 1.886 0.091 0.093 0.094 0.093 0.094 0.09
1.495 1.517 1.623 1.784 1.766 1.834 0.106 0.114 0.115 0.112 0.119 0.109
1.612 1.556 1.613 1.752 1.67 1.792 0.086 0.084 0.089 0.085 0.084 0.079
1.617 1.506 1.525 1.591 1.739 1.72 0.096 0.094 0.097 0.092 0.096 0.089
1.323 1.412 1.445 1.6 1.676 1.579 0.191 0.169 0.195 0.248 0.276 0.293
1.28 1.384 1.369 1.526 1.542 1.477 0.251 0.224 0.236 0.275 0.29 0.328
0.502 0.601 0.619 0.791 0.793 0.637 0.67 0.682 0.776 0.838 0.845 0.68
1.959 1.983 1.967 1.963 1.932 1.987 0.095 0.09 0.087 0.089 0.085 0.082
1.979 1.942 1.893 1.889 1.883 1.917 0.092 0.089 0.098 0.097 0.097 0.091
1.931 1.893 1.896 1.902 1.864 1.896 0.112 0.125 0.121 0.123 0.129 0.116
1.951 1.919 1.891 1.863 1.863 1.88 0.089 0.087 0.093 0.092 0.089 0.086
1.875 1.881 1.851 1.833 1.848 1.842 0.138 0.128 0.13 0.137 0.134 0.151
1.742 1.711 1.687 1.657 1.652 1.66 0.29 0.272 0.279 0.343 0.387 0.458
1.753 1.733 1.725 1.676 1.686 1.691 0.288 0.26 0.254 0.257 0.299 0.33
0.827 0.912 0.915 0.887 0.927 0.932 0.787 0.742 0.77 0.819 0.779 0.696
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.089 2.129 2.155 2.145 2.086 2.171 8.712 8.549 8.538 7.925 8.437 9.028
2.231 2.145 2.216 2.211 2.145 2.183 8.068 8.671 8.755 7.689 8.858 9.162
2.29 2.262 2.239 2.292 2.219 2.17 9.607 10.787 10.094 10.122 10.816 12.350
2.24 2.149 2.197 2.082 2.211 2.249 13.839 12.192 12.563 12.680 12.302 13.339
2.428 2.304 2.369 2.386 2.392 2.36 28.995 24.826 26.593 27.661 27.090 29.576
2.402 2.27 2.399 2.427 2.276 2.435 30.142 26.256 26.011 27.029 25.747 31.622
2.324 2.28 2.367 2.517 2.405 2.401 28.657 26.140 25.687 29.082 29.854 29.321
2.828 2.688 2.17 2.898 2.68 2.101 76.591 72.545 69.217 75.086 74.104 72.156
1.536 1.53 1.551 1.8 1.837 1.924 8.594 12.157 11.734 10.111 9.799 8.420
1.555 1.744 1.833 1.829 1.904 2.066 11.704 10.665 10.256 10.169 9.874 8.712
1.707 1.745 1.853 2.008 2.004 2.052 12.419 13.066 12.412 11.155 11.876 10.624
1.784 1.724 1.791 1.922 1.838 1.95 9.641 9.745 9.939 8.845 9.140 8.103
1.809 1.694 1.719 1.775 1.931 1.898 10.614 11.098 11.286 10.366 9.943 9.378
1.705 1.75 1.835 2.096 2.228 2.165 22.405 19.314 21.253 23.664 24.776 27.067
1.782 1.832 1.841 2.076 2.122 2.133 28.171 24.454 25.638 26.493 27.333 30.755
1.842 1.965 2.171 2.467 2.483 1.997 72.747 69.415 71.488 67.937 68.063 68.102
2.149 2.163 2.141 2.141 2.102 2.151 8.841 8.322 8.127 8.314 8.088 7.624
2.163 2.12 2.089 2.083 2.077 2.099 8.507 8.396 9.382 9.313 9.340 8.671
2.155 2.143 2.138 2.148 2.122 2.128 10.394 11.666 11.319 11.453 12.158 10.902
2.129 2.093 2.077 2.047 2.041 2.052 8.361 8.313 8.955 8.989 8.721 8.382
2.151 2.137 2.111 2.107 2.116 2.144 12.831 11.979 12.316 13.004 12.665 14.086
2.322 2.255 2.245 2.343 2.426 2.576 24.978 24.124 24.855 29.279 31.904 35.559
2.329 2.253 2.233 2.19 2.284 2.351 24.732 23.080 22.750 23.470 26.182 28.073
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1.975 1.928 1.909 1.866 1.922 1.951 0.093 0.095 0.095 0.098 0.095 0.091
2.002 1.898 1.867 1.846 1.924 1.941 0.098 0.098 0.098 0.094 0.101 0.094
1.985 1.893 1.884 1.804 1.939 1.909 0.114 0.128 0.114 0.121 0.122 0.123
2.008 1.907 1.834 1.805 1.892 1.898 0.094 0.09 0.095 0.092 0.089 0.092
1.941 1.882 1.832 1.835 1.841 1.85 0.1 0.096 0.1 0.097 0.097 0.099
1.854 1.798 1.762 1.733 1.819 1.845 0.17 0.136 0.143 0.162 0.175 0.189
1.943 1.894 1.865 1.85 1.883 1.837 0.109 0.107 0.104 0.104 0.104 0.099
0.691 0.774 0.744 0.72 0.886 0.816 0.982 0.974 0.84 0.883 0.812 0.825
1.939 1.983 2.009 2.022 2.022 1.959 0.1 0.099 0.097 0.099 0.096 0.102
1.996 1.945 1.971 1.983 1.975 1.963 0.099 0.106 0.104 0.101 0.102 0.106
1.978 1.967 1.952 2.009 1.996 1.959 0.117 0.131 0.127 0.141 0.158 0.139
1.994 1.976 1.969 1.982 1.968 1.994 0.093 0.093 0.099 0.119 0.104 0.124
1.979 1.991 1.971 1.959 1.975 1.928 0.099 0.105 0.103 0.102 0.098 0.1
1.947 1.947 1.928 1.947 1.953 1.914 0.104 0.107 0.107 0.111 0.106 0.121
1.93 1.986 1.964 1.958 1.997 1.975 0.099 0.105 0.102 0.099 0.099 0.097
1.061 1.05 1.036 0.987 1.06 0.879 0.583 0.807 0.715 0.728 0.785 0.757
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.357 2.395 2.372 2.353 2.35 2.275 8.061 8.685 8.347 7.905 8.000 7.824
2.421 2.393 2.351 2.406 2.387 2.346 7.931 8.023 8.337 8.229 8.379 8.440
2.404 2.389 2.405 2.391 2.382 2.385 9.068 10.046 10.146 10.038 10.579 10.901
2.349 2.354 2.357 2.345 2.393 2.387 8.174 8.071 9.334 9.296 9.779 10.892
2.458 2.425 2.541 2.555 2.609 2.792 16.355 14.433 19.677 20.587 22.077 27.650
2.395 2.35 2.478 2.449 2.477 2.621 13.946 12.596 17.433 17.068 18.329 25.868
2.373 2.359 2.332 2.318 2.3 2.29 9.440 8.648 8.748 8.887 8.609 8.646
2.69 2.837 3.024 2.808 2.873 2.862 57.546 59.076 59.392 60.684 62.026 64.780
2.161 2.118 2.099 2.062 2.112 2.133 8.607 8.971 9.052 9.505 8.996 8.533
2.198 2.094 2.063 2.034 2.126 2.129 8.917 9.360 9.501 9.243 9.501 8.830
2.213 2.149 2.112 2.046 2.183 2.155 10.303 11.913 10.795 11.828 11.177 11.415
2.196 2.087 2.024 1.989 2.07 2.082 8.561 8.625 9.387 9.251 8.599 8.838
2.141 2.074 2.032 2.029 2.035 2.048 9.341 9.257 9.843 9.561 9.533 9.668
2.194 2.07 2.048 2.057 2.169 2.223 15.497 13.140 13.965 15.751 16.136 17.004
2.161 2.108 2.073 2.058 2.091 2.035 10.088 10.152 10.034 10.107 9.947 9.730
2.655 2.722 2.424 2.486 2.51 2.466 73.974 71.565 69.307 71.038 64.701 66.910
2.139 2.181 2.203 2.22 2.214 2.163 9.350 9.078 8.806 8.919 8.672 9.431
2.194 2.157 2.179 2.185 2.179 2.175 9.025 9.828 9.546 9.245 9.362 9.747
2.212 2.229 2.206 2.291 2.312 2.237 10.579 11.754 11.514 12.309 13.668 12.427
2.18 2.162 2.167 2.22 2.176 2.242 8.532 8.603 9.137 10.721 9.559 11.062
2.177 2.201 2.177 2.163 2.171 2.128 9.095 9.541 9.463 9.431 9.028 9.398
2.155 2.161 2.142 2.169 2.165 2.156 9.652 9.903 9.991 10.235 9.792 11.224
2.128 2.196 2.168 2.156 2.195 2.169 9.305 9.563 9.410 9.184 9.021 8.944
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1.74 1.947 1.951 2.029 2.004 1.983 0.087 0.085 0.09 0.086 0.084 0.089
1.959 1.928 1.974 1.975 1.924 1.891 0.091 0.091 0.096 0.092 0.096 0.1
2.01 1.936 1.913 1.967 1.896 1.806 0.107 0.115 0.113 0.115 0.113 0.114
1.822 1.751 1.891 1.961 1.842 1.853 0.083 0.082 0.087 0.087 0.09 0.091
1.811 1.876 1.861 1.83 1.855 1.822 0.115 0.087 0.09 0.085 0.093 0.091
1.755 1.659 1.697 1.706 1.777 1.781 0.19 0.155 0.16 0.188 0.204 0.186
1.462 1.563 1.622 1.515 1.468 1.434 0.382 0.364 0.395 0.38 0.399 0.445
0.813 0.829 0.855 0.92 0.867 0.739 0.721 0.916 0.794 0.78 0.823 0.831
2.092 2.066 1.979 2.004 2.086 2.076 0.09 0.092 0.089 0.09 0.088 0.087
2.068 2.003 1.975 2.005 2.036 2.022 0.091 0.099 0.097 0.098 0.098 0.098
2.076 1.945 1.959 1.928 2.035 2.009 0.11 0.127 0.118 0.119 0.123 0.123
2.001 1.951 1.915 1.941 1.993 1.985 0.093 0.089 0.093 0.1 0.095 0.088
1.987 1.958 1.947 1.93 1.988 1.967 0.108 0.1 0.098 0.104 0.11 0.101
1.74 1.751 1.655 1.72 1.757 1.725 0.327 0.277 0.332 0.415 0.448 0.482
1.757 1.729 1.693 1.705 1.717 1.705 0.339 0.282 0.35 0.408 0.457 0.512
0.864 1.018 1.043 0.934 1.008 0.828 0.844 0.731 0.738 0.801 0.814 0.788
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
2.275 2.419 2.355 2.333 2.361 2.325 7.912 7.524 8.238 8.144 7.370 7.312
2.384 2.398 2.37 2.325 2.387 2.368 7.970 7.923 8.270 8.172 8.379 7.939
2.377 2.465 2.42 2.43 2.395 2.388 9.340 10.142 10.165 10.041 10.689 10.637
2.349 2.367 2.327 2.234 2.349 2.346 8.855 7.943 9.024 9.042 9.025 8.781
2.543 2.442 2.47 2.484 2.6 2.691 23.751 17.199 19.595 22.383 25.615 27.573
2.647 2.415 2.465 2.723 2.875 3.024 35.965 28.157 28.722 37.606 40.487 45.833
2.67 2.53 2.428 2.513 2.873 3.045 34.906 29.960 27.924 32.312 39.749 44.138
2.715 3.045 3.052 2.922 3.077 3.001 67.035 71.593 64.155 65.092 65.258 64.445
1.914 2.117 2.131 2.201 2.172 2.161 9.091 8.030 8.447 7.815 7.735 8.237
2.141 2.11 2.166 2.159 2.116 2.091 8.501 8.626 8.864 8.522 9.074 9.565
2.224 2.166 2.139 2.197 2.122 2.034 9.622 10.619 10.566 10.469 10.650 11.209
1.988 1.915 2.065 2.135 2.022 2.035 8.350 8.564 8.426 8.150 8.902 8.943
2.041 2.05 2.041 2 2.041 2.004 11.269 8.488 8.819 8.500 9.113 9.082
2.135 1.969 2.017 2.082 2.185 2.153 17.799 15.744 15.865 18.060 18.673 17.278
2.226 2.291 2.412 2.275 2.266 2.324 34.322 31.777 32.753 33.407 35.216 38.296
2.255 2.661 2.443 2.48 2.513 2.401 63.947 68.846 65.002 62.903 65.499 69.221
2.272 2.25 2.157 2.184 2.262 2.25 7.923 8.178 8.252 8.242 7.781 7.733
2.25 2.201 2.169 2.201 2.232 2.218 8.089 8.996 8.944 8.905 8.781 8.837
2.296 2.199 2.195 2.166 2.281 2.255 9.582 11.551 10.752 10.988 10.785 10.909
2.187 2.129 2.101 2.141 2.183 2.161 8.505 8.361 8.853 9.341 8.704 8.144
2.203 2.158 2.143 2.138 2.208 2.169 9.805 9.268 9.146 9.729 9.964 9.313
2.394 2.305 2.319 2.55 2.653 2.689 27.318 24.035 28.633 32.549 33.773 35.850
2.435 2.293 2.393 2.521 2.631 2.729 27.844 24.597 29.252 32.368 34.740 37.523





































































1 2 3 4 5 6 7 8 9 10 11 12
1.611 1.764 1.799 1.83 1.823 1.793 0.093 0.088 0.086 0.089 0.09 0.085
1.492 1.829 1.824 1.854 1.829 1.842 0.09 0.091 0.09 0.089 0.093 0.086
1.506 1.836 1.831 1.85 1.856 1.853 0.107 0.117 0.113 0.114 0.122 0.114
1.397 1.762 1.769 1.806 1.84 1.807 0.081 0.077 0.083 0.083 0.081 0.08
1.353 1.719 1.696 1.734 1.762 1.721 0.12 0.124 0.133 0.178 0.195 0.2
1.261 1.668 1.712 1.752 1.793 1.657 0.104 0.115 0.112 0.134 0.145 0.152
1.356 1.679 1.774 1.83 1.832 1.833 0.092 0.089 0.088 0.087 0.085 0.083
0.626 0.954 0.921 0.961 1.009 0.943 0.568 0.606 0.682 0.791 0.837 0.778
1.234 1.433 1.505 1.564 1.529 1.499 0.095 0.092 0.088 0.091 0.087 0.085
1.345 1.53 1.578 1.561 1.565 1.527 0.094 0.098 0.093 0.091 0.095 0.089
1.357 1.445 1.566 1.552 1.552 1.501 0.111 0.122 0.119 0.12 0.122 0.116
1.499 1.472 1.546 1.532 1.564 1.533 0.092 0.087 0.09 0.091 0.087 0.087
1.135 1.363 1.461 1.447 1.448 1.433 0.114 0.109 0.135 0.133 0.133 0.138
1.067 1.399 1.447 1.431 1.487 1.393 0.122 0.13 0.15 0.154 0.16 0.17
1.29 1.424 1.534 1.413 1.534 1.529 0.097 0.097 0.101 0.106 0.096 0.093
0.548 0.703 0.669 0.699 0.68 0.635 0.566 0.694 0.659 0.702 0.704 0.643
2.682 2.205 2.143 2.162 2.152 2.11 0.07 0.074 0.07 0.071 0.074 0.075
2.686 2.192 2.132 2.179 2.069 2.034 0.071 0.072 0.078 0.081 0.09 0.088
2.11 2.535 2.152 2.173 2.03 2.022 0.065 0.066 0.065 0.071 0.07 0.075
2.137 2.25 2.157 2.14 2.053 2.077 0.066 0.064 0.068 0.076 0.083 0.077
2.112 2.62 2.152 2.148 2.051 2.047 0.073 0.077 0.079 0.087 0.095 0.099
2.24 2.355 2.226 2.266 2.13 2.186 0.07 0.072 0.075 0.078 0.084 0.088
2.25 2.232 2.152 2.194 2.097 2.045 0.07 0.074 0.077 0.078 0.079 0.091
0.973 1.016 0.894 0.918 0.834 1.043 0.539 0.996 1.171 1.164 1.134 1.249
x2 because (I used 50 µl instead of the 100) + Supernatant Value % of Total In CellTo Find Original Total In Cell
1.797 1.94 1.971 2.008 2.003 1.963 10.351 9.072 8.727 8.865 8.987 8.660
1.672 2.011 2.004 2.032 2.015 2.014 10.766 9.050 8.982 8.760 9.231 8.540
1.72 2.07 2.057 2.078 2.1 2.081 12.442 11.304 10.987 10.972 11.619 10.956
1.559 1.916 1.935 1.972 2.002 1.967 10.391 8.038 8.579 8.418 8.092 8.134
1.593 1.967 1.962 2.09 2.152 2.121 15.066 12.608 13.558 17.033 18.123 18.859
1.469 1.898 1.936 2.02 2.083 1.961 14.159 12.118 11.570 13.267 13.922 15.502
1.54 1.857 1.95 2.004 2.002 1.999 11.948 9.585 9.026 8.683 8.492 8.304
1.762 2.166 2.285 2.543 2.683 2.499 64.472 55.956 59.694 62.210 62.393 62.265
1.424 1.617 1.681 1.746 1.703 1.669 13.343 11.379 10.470 10.424 10.217 10.186
1.533 1.726 1.764 1.743 1.755 1.705 12.264 11.356 10.544 10.442 10.826 10.440
1.579 1.689 1.804 1.792 1.796 1.733 14.060 14.446 13.193 13.393 13.586 13.387
1.683 1.646 1.726 1.714 1.738 1.707 10.933 10.571 10.429 10.618 10.012 10.193
1.363 1.581 1.731 1.713 1.714 1.709 16.728 13.789 15.598 15.528 15.519 16.150
1.311 1.659 1.747 1.739 1.807 1.733 18.612 15.672 17.172 17.711 17.709 19.619
1.484 1.618 1.736 1.625 1.726 1.715 13.073 11.990 11.636 13.046 11.124 10.845
1.68 2.091 1.987 2.103 2.088 1.921 67.381 66.380 66.331 66.762 67.433 66.944
2.822 2.353 2.283 2.304 2.3 2.26 4.961 6.290 6.132 6.163 6.435 6.637
2.828 2.336 2.288 2.341 2.249 2.21 5.021 6.164 6.818 6.920 8.004 7.964
2.24 2.667 2.282 2.315 2.17 2.172 5.804 4.949 5.697 6.134 6.452 6.906
2.269 2.378 2.293 2.292 2.219 2.231 5.818 5.383 5.931 6.632 7.481 6.903
2.258 2.774 2.31 2.322 2.241 2.245 6.466 5.552 6.840 7.494 8.478 8.820
2.38 2.499 2.376 2.422 2.298 2.362 5.882 5.762 6.313 6.441 7.311 7.451
2.39 2.38 2.306 2.35 2.255 2.227 5.858 6.218 6.678 6.638 7.007 8.172
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Figure 32: Summary graph of Figure 30’s peak release at 
100ng ml-1 of antigen:
This figure shows only  the peak releases at 100ng ml-1 of 
antigen of the cells from figure 31.
4.3 - Discussion:
In conclusion, the cell cloning and cell line development was successful. One 
point to note is that RBL-2H3.1 cells tend to shift to a non-releasing phenotype if they 
were maintained in culture for a long time (3-4 months). Therefore a large stock of non-
transfected cells that  were tested for excellent release, and were free from Mycoplasma 
bacterial infection (which disrupts cell metabolism and release) was frozen and stored. 
Then from this stock a sample was taken, thawed and quickly transfected with the 
plasmid. Once the cells were selected, sorted and grown to develop a new cell line, this 
cell line was again tested for adequate release and infections then a large stock of it  was 
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frozen, in case the cells in culture shift to the non-releasing phenotype, there was plenty 
of cell stock to complete the experiments.
The release assays tested the mediator release from cells expressing equine 
FcεRIα when sensitized with equine IgE and challenged with an antigen. The peak 
release at 100ng ml-1 of antigen was 36.68% compared to the control of 45.99% (using 
mouse IgE on the same cell line) and the negative control was 11.81% (using non-
transfected cell with equine IgE). This was within the normal peak release of mediators 
of these cells under these conditions, and this proved that the equine allergy behaves, in-
vitro, in a similar manner to that of human and canine IgE-mediated cell degranulation, 
where they have a peak release at 100ng ml-1 of antigen at ~40% (Jonathan E. M. 
Housden, PhD Thesis, The University  of Sheffield, 2007) and ~36% (Athanassios P. 
Vratimos, PhD Thesis, The University of Sheffield, 2003) respectively.
The RBL-2H3.1 cells are very  sensitive to the environment, therefore they tend to 
release some mediators when they are stressed, such as exposed to a cold environment 
or the liquid on top  of them was pipetted a bit strong. This explains the reason behind 
the high negative control values, here they are around 10% while they ideally should be 
around 5%. Nonetheless, the difference between the phenomena tested here is 
significant enough that this error did not interfere with it.
From the FACS results it can be seen that the human IgE does not bind to the 
equine FcεRI receptor while the canine IgE does, therefore these IgEs were tested on 
the RBL-2H3.1 expressing equine FcεRIα cell line. The results showed that is human 
IgE does not cause any release on the cells, which confirmed that the human IgE does 
not bind to the equine FcεRI receptor. On the other hand, the canine IgE caused release 
in the cells with a peak release at 100ng ml-1 of antigen at  32.00%, therefore the canine 
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IgE does bind to the equine FcεRI receptor and causes cells to release mediators. This 
came as a surprise, and later experiments (Chapter 8) showed indications that the human 
IgE might be defective, since anti IgE antibodies cause the cells to release mediators, 
while the human IgE did not. Therefore this result is open to question.
Since the canine IgE binds to the equine FcεRI receptor, the opposite was tested, 
i,e: if the equine IgE binds to the canine FcεRI receptor. The results showed that no it 
does not, when tested for a shorter incubation time (0.5, 1 and 3 hours) the released 
mediator percentage of the peak release at 100ng ml-1 of antigen kept steady around 
10%, which is the same level as the negative control, and finally when tested for the full 
16 hours, there was no significant change in the level of released mediators. Therefore it 
was determined that the equine IgE does not bind to the canine FcεRI receptor. The 
positive controls for this experiment were around 40% (mouse and canine IgE).
One explanation of why only the cells would be sensitized enough and thus give 
off a full release after 16 hours, is because the binding of the IgE to the receptor 
enhances receptor synthesis which would bind more IgE and this would accumulate 
after 16 hours which would result in adequate mediator release
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Chapter 5 - Generation of Soluble 
Equine FcεRIα:
5.1 - Introduction:
In preparation for next  chapter’s kinetic analysis between the equine IgE and the 
equine FcεRIα, the receptor had to be in solution to be analyzed by SPR, therefore the 
approach to this was to express only the extracellular domains of the receptor, without 
the transmembrane region, which would aggregate in aqueous solution. That is why the 
original equine FcεRIα sequence was codon optimized for both rat and yeast cells. 
The equine FcεRI receptor’s α chain protein sequence was determined from 
(McAleese. et al,, 2000) using the GenBank sequence database (part of the United 
States’ National Center for Biotechnology Information, NCBI), which then had its 
DNA codons optimized (changed) for rat codon (Rattus norvegicus) and yeast (Pichia 
pastoris) to increase the efficiency of protein expression in rat  cells and yeast  cells. The 
optimized gene was constructed digitally  and sent to the company (GenScript) which 
synthesized the gene (Appendix). The equine FcεRIα’s extra cellular domains 1 and 2 
(Figure 4) were then amplified by PCR and cloned into the pPIC9k plasmid 
(Invitrogen). The plasmid was then transfected into Pichia pastoris yeast cells which 
expressed the sFcεRIαD1&2 protein extracellularly and in to the media.
5.2 - Results:
5.2.1 - Optimizing The Equine FcεRIα Gene:
The equine FcεRI receptor’s α chain was searched and found to be published in a 
paper by (McAleese, et al., 2000), the protein sequence is included in the Appendix. 
This protein sequence was used to construct a gene optimized for the rat (Rattus 
norvegicus) and and the yeast (Pichia pastoris) as in chapter 2.1.1.
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5.2.2 - Amplifying And Cloning The FcεRIα’s Domain 1 And 2 Sequence Into Plasmid:
The FcεRIα gene from chapter 4 had its extracellular domains amplified by PCR 
as in chapter 2.2.6. There was not much freedom in designing the primers as they had to 
amplify a certain region of the gene, what was added to them was a six base overhang 
(Red), to allow for the restriction enzymes to bind, followed by a restriction site 
(Purple), the forward primer had EcoRI and the reverse had NotI, this was to allow for 
cloning of the PCR product into the pPIC9k plasmid. The reverse primer also had the 
ending sequence TGA (Black) added to terminate the gene. The resulting PCR product 
coded for a protein sequence found in the Appendix.
Forward: 5'-CCGCACGAATTCATGGTCCCAGCTGCTATTAGAAAGTC-3'
Reverse: 5'-GATCTTGCGGCCGCTCACAGGTAATCAGAAGTGTATC-3'
The pUC57-FcεRIα was amplified to give a PCR product of sFcεRIαD1&2 as in 
chapter 2.2.6, the PCR sample was then purified as in chapter 2.2.9 to give a pure 
sFcεRIαD1&2 PCR product. The sFcεRIαD1&2 was then digested with EcoRI and NotI 
along with the pPIC9k plasmid as in chapter 2.2.7. The DNA bands of interest were run 
on an electrophoresis gel as in chapter2.2.8 and then isolated as in chapter 2.2.9. The 
sFcεRIαD1&2 PCR product and the pPIC9k plasmid were ligated together as in chapter 
2.2.10 and the ligation product was transformed into XL-1 Blue bacteria as in chapter 
2.2.11 and the cells were spread on a plate as in chapter 2.2.3 using the media from 
chapter 2.2.2.. The colonies that resulted contained the pPIC9k-sFcεRIαD1&2 plasmid, 
therefore they were grown and the plasmid purified as in chapter 2.2.5 and digested 
again with EcoRI and NotI enzymes to check for the successful insertion of the 
sFcεRIαD1&2 gene. Figure 33A shows the restriction digest results with the pPIC9k 
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plasmid had a size of 9276bp and the sFcεRIαD1&2 PCR product had a size of 548bp, 
Figure 33B shows the successful insertion of the sFcεRIαD1&2 gene in to the pPIC9k 
plasmid and Figure 34 shows that pPIC9k plasmid before and after the insertion of the 
sFcεRIαD1&2 gene. The colony that  contained the sFcεRIαD1&2 gene insert was sent 
for sequencing, as in chapter 2.2.16, to determine if any  mutations occurred during the 
amplification process, Figure 35 showing the result of the sequence of the chosen 
colony, with not a single point mutation.
               1kb DNA  PCR             PCR
                 Ladder   FcεR1α        FcεR1α        pPIC9k 
" " " "




                                                                                                     548bp
                                                                                                sFcεRIαD1&2
"                      PCR
               1kb DNA     FcεR1α
                   Ladder    Control       1             2            3             4           
                                                                                                                                              9276bp
6000bp "" " " "                                                                              pPIC9k
3000bp
1000bp                                                                                                                                  548bp
" " " " "                                                                             sFcεRIαD1&2
A B
Figure 33: Restriction digestion of sFcεRIαD1&2 and the 
pPIC9k plasmid:
A. shows PCR product sFcεRIαD1&2 and the pPIC9k plasmid 
were digested with EcoRI and NotI restriction enzymes, this was 
done in preparation to clone the sFcεRIαD1&2 gene into the 
pPIC9k plasmid, the pPIC9k plasmid had a size of 9276bp  and 
the sFcεRIαD1&2 PCR product had a size of 548bp B. shows 
the successful insertion of the sFcεRIαD1&2 gene into one of 
the isolated pPIC9k plasmids where they were digested with 
EcoRI and NotI.
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A                      B
s
Figure 34: The structure of the pPIC9k plasmid before and 
after the insertion of the sFcεRIαD1&2 gene:
A. shows the structure of the pPIC9k plasmid (without the 
sFcεRIαD1&2 gene) while B. shows the final structure of the 
pPIC9k-sFcεRIαD1&2 plasmid.
Figure 35: BLAST analysis of the cloned equine 
sFcεRIαD1&2 gene:
This figure shows the BLAST result of the cloned equine 
sFcεRIαD1&2 gene (bottom) compared to the original 
synthesized equine sFcεRIαD1&2 gene (top). The result  showed 
not a single pint mutation in the gene (100% identical is circled 
in blue).
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Once a bacterial colony with the pPIC9k-sFcεRIαD1&2, containing no mutations, 
was identified and a backup culture was frozen as in chapter 2.2.12, it was grown and 
the pPIC9k-sFcεRIαD1&2 plasmid harvested in a larger concentration as in chapter 
2.2.13 followed by concentrating the plasmid DNA as in chapter 2.2.15 and the DNA 
quantified as in chapter 2.2.14 which enabled the required concentration adjusted for 
yeast cell transfection.
5.2.3 - Transfecting And Selecting Pichia pastoris Yeast Cells With The sFcεRIαD1&2 
Gene:
The protocol for this experiment is found in chapter 2.4.4. The Piachia pastoris 
yeast cells were streaked on a YPD plate and a single colony was extracted and grown. 
The cells were harvested and made competent, then a stock of them was frozen. From 
this stock the competent  cells were transformed with the pPIC9k-sFcεRIαD1&2 
plasmid and grown in RDB plates. The colonies that grew on the plate had the 
sFcεRIαD1&2 gene integrated into their genome at various repeats. To select  for the 
colony  with the highest sFcεRIαD1&2 repeat 50 colonies were isolated, pooled together 
and then colony mix was them spread on plates with increasing geneticin G418 
sulphate. The colony that grew in the highest geneticin G418 sulphate concentration had 
the highest number of the sFcεRIαD1&2 gene repeats, therefore it was isolated and used 
to express the sFcεRIαD1&2 protein.
5.2.4 - Expressing And Purifying the sFcεRIαD1&2 Protein:
The protocol is found in chapter 2.4.4. The isolated colony with the highest 
sFcεRIαD1&2 gene repeat was added to 25ml of BMGY media. The grown cells were 
harvested and added to 1200ml BMMY expressing media to a concentration of 
OD600=1. The cells were incubated in this media and expressed the protein for 6 days, at 
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which point the media was harvested, filter sterilized and protease inhibitors were 
added.
The media was tested by SPR by adding equine IgE anti NIP-HSA to a chip 
immobilized with NIP-HSA, therefore the equine IgE bound and gave a resonance 
curve. This was followed by the addition of the yeast media. Since the media contained 
the equine sFcεRIαD1&2 protein, it bound to the equine IgE and thus gave a second 
resonance curve. The optimal time for expression was 6 days as shown in Figure 36, 
where the expressed protein accumulated enough in the media, but not left long enough 
for it to start degrading. After the media was harvested it was tested again to insure the 
protein did not degrade, Figure 37. 
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Figure 36: SPR results of the level  of sFcεRIαD1&2 against 
expression time:
This figure shows the level of sFcεRIαD1&2 in the cell media 
against the incubation time. 6 days of expression (marked by the 
red arrow) was found to be the ideal expression time for the 
yeast. Therefore the cell media was harvested after 6 days of 
expression. Values for this graph are in the Appendix.
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Figure 37: SPR results of the level  of sFcεRIαD1&2 after 
media harvesting:
The figure shows the media right after harvesting still expresses 
enough of the protein, and that it did not degrade due to the 
harvesting process. Values for this graph are in the Appendix.
Since the media still contained the equine sFcεRIαD1&2 protein, and it did not 
degrade due to the presence of proteases, the media was concentrated using a 3kDa 
molecular filter from 1200ml down to ~50ml to allow for ease of handling during the 
purification process. After concentration, the media was tested to show the successful 
concentration of the equine sFcεRIαD1&2 protein and the amount of leakage of the 
protein in the overflow, Figure 38 shows the level of sFcεRIαD1&2 after media 
concentration and Figure 39 shows the SPR curve of the concentrated media, indicating 
that the protein was still viable at that point.
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Figure 38: SPR results of the level  of sFcεRIαD1&2 after 
media concentration:
This figure shows the SRP result of the level of the equine 
sFcεRIαD1&2 protein after the media was concentrated through 










Figure 39: The SPR viability curve of the concentrated 
media prior to purification:
This figure shows the SPR curve of the concentrated media prior 
to purification. The curve indicates large quantity of the 
correctly folded equine sFcεRIαD1&2 protein. The first 
resonance curve if the equine IgE anti NIP-HSA binding to the 
NIP-HSA in the chip, the second curve is the equine 
sFcεRIαD1&2 protein binding to the equine IgE
The media was run through an affinity  column, three times, to purify  the equine 
sFcεRIαD1&2 protein as in chapter 2.4.5. The ligand used to purify the equine 
sFcεRIαD1&2 was canine IgE, that was because the canine IgE was proven to bind to 
the equine sFcεRIαD1&2 (chapter 4) strong enough to purify  the protein, but weak to 
allow for efficient elution. The equine sFcεRIαD1&2 protein was eluted by passing low 
pH buffer through the column, and it dropped into a high pH column which neutralized 
the final buffer mixture. The protein elution was washed in 1xPBS buffer by 
concentration and dilution twice using a 3kDa molecular filter. The final concentrated 
purified equine sFcεRIαD1&2 protein was ~200µl and its concentration was determined 
as in chapter 2.4.6 (Figure 40), in this case the protein concentration was 0.25 mg ml-1 
because its OD625 = 0.686. The protein was also tested by SPR again for viability, 























































































































































































































































































































































































































































































Dilution Curve Bradford Assay























0.480 0.419 0.449 0.572 0 0.480 0.8408 0.4763
0.541 0.516 0.496 0.610 0.1 0.541
0.607 0.550 0.629 0.642 0.2 0.607
0.694 0.681 0.710 0.692 0.3 0.694
0.833 0.836 0.876 0.786 0.4 0.833
1.002 0.895 1.031 1.079 0.5 1.002
0.920 0.943 0.945 0.871 0.6 0.920
1.099 1.118 1.271 0.907 0.7 1.099
1.265 1.082 1.505 1.207 0.8 1.265
1.182 1.131 1.259 1.155 0.9 1.182
1.243 1.248 1.256 1.226 1.0 1.243
1x Dilution 2x Dilution 13.3x Dilution
0.249 0.686 0.403 0.622 0.756 0.802 0.389 0.542
0.430 0.838 0.705 0.602 0.793 0.486 0.425 0.705








0 0.25 0.5 0.75 1
y = 0.8408x + 0.4763












Protein Concentration mg ml-1
HDH Concentration





















0.331 0.321 0.337 0.335 0 0.331 0.7338 0.4217
0.474 0.459 0.483 0.481 0.1 0.474
0.571 0.550 0.596 0.566 0.2 0.571
0.667 0.633 0.675 0.692 0.3 0.667
0.759 0.739 0.774 0.763 0.4 0.759
0.823 0.736 0.854 0.878 0.5 0.823
0.928 0.788 1.056 0.939 0.6 0.928
1.002 0.954 1.035 1.018 0.7 1.002
1.040 0.939 1.076 1.105 0.8 1.040
1.025 0.925 1.046 1.105 0.9 1.025
1.055 0.916 1.098 1.151 1.0 1.055
x By Dilution Factor Final Concentration
100x Dilution 0.402 0.409 0.422 0.411 41.1 55.44
10x Dilution 1.049 0.858 1.108 1.005 12.177 56.01
5x Dilution 1.248 1.099 1.306 1.22 6.088 56.01
5.6  μg μl-1
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Figure 40: The protein purification graph used to calculate 
the concentration of the purified equine sFcεRIαD1&2 
protein and later on the HHoH IgE anti NIP-HSA:
This figure shows the concentration curve of bovine albumin 
solutions. At the bottom right of the graph is the equation for the 
line of best fit, from this equation the concentration of the 
equine sFcεRIαD1&2 protein was determined. Values for this 










Figure 41: The SPR curve of the purified equine 
sFcεRIαD1&2 protein:
This figure shows the positive SPR curve of the purified equine 
sFcεRIαD1&2 protein, the first resonance curve if the equine 
IgE anti NIP-HSA binding to the NIP-HSA in the chip, the 
second curve is the equine sFcεRIαD1&2 protein binding to the 
equine IgE.
The equine sFcεRIαD1&2 protein was then run in an SDS-PAGE to test  its purity 
as in chapter 2.4.7, Figure 42 shows the final gel result with several protein bands, 
because the equine sFcεRIαD1&2 protein is glycosylated which results in the protein 
sequence having several different masses. If the protein was de-glycosylated and run on 
the gel it would have shown a single band at ~22.19kDa. Ideally a western blot would 
have also been run to confirm the identity  of the protein, but no anti equine FcεRIα 
protein were found commercially, and therefore the western blot was not run. Canine 
IgE was a good candidate to test for the equine sFcεRIαD1&2 protein in a western blot 
as it does bind to the protein, and there are commercial anti canine IgE antibodies, but 
since the laboratory also synthesized canine sFcεRIαD1&2 protein, cross contamination 
could not have been tested. The only way the identity of the protein was confirmed is 
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when it showed strong binding kinetics with the equine IgE anti NIP-HSA in Chapter 6 
as predicted.
" 10kDa"         Non-Reduced
" Protein"         Equine









Figure 42: SDS-PAGE of the equine sFcεRIαD1&2 protein:
This Figure shows the SDS-PAGE. There are several bands in 
the gel as the equine sFcεRIαD1&2 protein is glycosylated 
which results in the protein sequence having several different 
masses. If the protein was de-glycosylated and run on the gel it 
would have shown a single band at ~22.19kDa.
5.3 - Discussion:
The sFcεRIαD1&2 protein (Figure 43) was expressed and purified in the end. 
This experiment protocol appears to be easy, though it was difficult to setup the controls 
to test its efficiency. Some difficulty was faced during filter sterilizing the media, since 
it contained many agents that were heat sensitive. Many  obstacles were faced but were 
solved. First of all, after yeast  cells were transfected and selected for colonies with the 
highest equine sFcεRIαD1&2 gene copy number, they  were frozen to be kept as a 
backup  as in chapter 2.2.12. This proved fatal as the cells would quickly stop  expressing 
the protein once they  were thawed, this problem was solved by not freezing a backup of 
cells, instead immediately  using the isolated colony  for expression. This meant that 
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when more of the protein (Figure 43) was needed, the whole protocol had to be 
repeated. Therefore in conclusion, even though the protocol seemed easy, its cost was 
still high, with small protein yield, especially as the selection process required large 
quantities of geneticin G418 sulphate, which was expensive. For future notice, a paper 
by (Garman, et al., 1999) showed that the sFcεRIαD1&2 protein can be expressed in 
large enough quantity  for crystallization using the baculovirus expression system. 
Furthermore, using the FreeStyle™ CHO-S Cells (Invitrogen) kit can yield large 
quantities of the protein in mammalian (Chinese Hamster Ovary) cells. All these cell 





Figure 43: Structure of the sFcεRIαD1&2:
This figure shows the structure of the human sFcεRIαD1&2, the 
equine sFcεRIαD1&2 would look almost the same as it has the 
exact same function, but with a different amino acid sequence. 
This figure was taken from (Garman, et al., 1998).
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Second of all, initially when the expressed media was tested for the presence of 
the equine sFcεRIαD1&2 protein, canine IgE anti NIP-HSA was used, as the equine IgE 
anti NIP-HSA was not yet synthesized. This did not detect the equine s sFcεRIαD1&2 
protein as the canine IgE used was in low concentration. This was solved by using 
equine IgE anti NIP-HSA, once it was synthesized, or canine IgE in large enough 
concentration to detect the equine sFcεRIαD1&2 protein.
Finally, low levels of the equine sFcεRIαD1&2 protein were collected after the 
purification, first because the column was prepared using non-purified media containing 
canine IgE, therefore much of the column had other proteins (such as albumin) bound to 
it, which reduced the exposure of the canine antibody to the equine sFcεRIαD1&2 
protein, thus bound little of it. Also a large column was used to purify the media, ideally 
only a 2cm long column is sufficient to purify enough of the protein for many 
experiments, therefore when a long column (12cm) was used it reduced the fluid flow 
rate through it. This was not ideal to remove enough of the protein impurities, though 
the yeast media had little protein impurities, which still resulted in a pure sample. It also 
was not good to elute enough of the protein. Therefore for future work, only a 2cm long 
column would be used, and prepared using purified canine IgE.
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Chapter 6 - Kinetic Analysis of Equine 
IgE/FcεRIα Binding:
6.1 - Introduction:
In the present chapter the studies of kinetic bindings between the equine IgE and 
its sFcεRIαD1&2 receptor was preformed. In previous chapters the synthesis of the 
equine IgE and the equine sFcεRIαD1&2 were successful, therefore they were run on an 
SPR machine to measure their kinetic binding as in chapter 2.4.10.
The following is an explanation of the different kinetic constants, note that the 
explanation will be in such a way where the ligand is bound to an SPR chip surface, 
while the receptor is injected onto it: in Figure 44 there is a theoretical binding graph 
between a ligand and its receptor. The association rate constant (ka) is the time at which 
half of the total number of receptors in a sample, of a certain concentration, binds to 
their ligand. Therefore it is the inverse of the time at which half of a receptors bind to 
their ligand (τa) multiplied by the sample’s concentration. The dissociation rate constant 
(kd) is simply the inverse of the time it takes all the bound receptors to dissociating from 

















































































































































































100% of ligand bound
to its receptor
Minimum receptor concentration which saturates 
the ligand (binds to all the ligand on the SPR 
chip surface) if injected on to it for a certain 
amount of time
100% receptor
is bound to ligand
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Figure 44: Theoretical binding graph between a ligand and 
its receptor:
A. this figure shows a mock binding graph between a ligand and 
its receptor, from a graph like this the ka and kd rate constants 
can be calculated. B. shows an alternative way the KD 
equilibrium dissociation constant can be calculated from testing 
different receptor concentrations and injecting them on the a 
surface conjugated with a ligand for a certain amount of time.
KD is the equilibrium dissociation constant, it is the equilibrium constant which 
measures the tendency of two bound molecules to separate, the smaller the KD value, 
the least  likely the two molecules will separate. It can also be calculated by dividing the 
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dissociation rate constant (kd) by  the association rate constant (ka). The equilibrium 
association binding (KA), also known as the affinity constant, is simply  the reciprocal of 
the equilibrium dissociation constant KD value (1/KD), therefore the higher the KA value 








The KD unit indicate the receptor concentration at which half of the ligand 
molecules in the SPR chip surface were bound after the receptor solution was injected 
on to it and allowed to reach equilibrium. Therefore (Figure 45B) shows an alternative 
way KD can be calculated.
If the receptor concentration is less than the KD value then most of the receptors in 
solution will not bind to the ligand. But if the receptor concentration is greater than the 
KD value then most of the receptors in solution will bind to the ligand.
This form of measurements were made through pseudo-first-order reaction. It is 
difficult to measure binding analysis by monitoring both the concentration of the ligand 
and the sample (second-order reaction) or by following one reactant's concentration and 
deducing the other reactant's concentration by their difference is not very accurate. 
Therefore to solve this problem an approximation called pseudo-first-order is used, 
where the concentration of a ligand is maintained constant (bound to a surface or 
presented in a very large concentration), this allows knowledge of one of the reactant's 
concentration (the ligand) at all time while measuring the other (the sample) accurately: 
r = ka[A][B] ∴ ka[B] where r (previously labeled as τa) is the reaction rate, ka is the 
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association rate constant, [A] is the concentration of the ligand and [B] is the 
concentration of the sample.
6.2 - Results:
The BiaCoreTM 2000 System SPR machine had the function of automatically 
calculating the kinetic binding parameters using the serial concentrations of the one 
protein as it binds to another. In this case the the equine IgE was tested with the equine, 
human and canine sFcεRIαD1&2. Also the canine IgE was tested with the equine 
sFcεRIαD1&2 protein. The graph results are on Figure 44, where on the left of the 
figure is the binding between the IgE (first curve from the left) and the highest 
sFcεRIαD1&2 concentration of 10µg ml-1 (second curve from the left). And right of the 
figure there can be seen a complex graph where the red lines indicate the actual results 
of the experiment (showing only the sFcεRIαD1&2 binding portion of the curve), and 
the blue lines indicate the predicted binding at 1:1 Langmuir binding model (which 
relates the adsorption of molecules onto a solid surface). It  can be seen that once the 
sFcεRIαD1&2 is added to the IgE it binds (association) until it the chip is saturated (all 
the IgEs mobilized on the chip have sFcεRIαD1&2 bound to them), then HBS-EP buffer 
is run through the chip  where the curve start  to go down slightly  (dissociation) as some 
of the weakly  bound sFcεRIαD1&2 would break off the IgE. Figure 45 A shows the 
kinetic analysis between equine IgE and equine sFcεRIαD1&2, and the binding shows 
to be as predicted for a 1:1 binding ratio, since 1 molecule of IgE binds to 1 molecule to 
sFcεRIαD1&2. Figure 45 B shows the binding analysis between the equine IgE and the 
human sFcεRIαD1&2, they show no binding between the two protein, as the 
sFcεRIαD1&2 curve is extremely  small for the highest concentration of 10µg ml-1, and 
the blue lines in the graph show that the binding does not  fit the 1:1 Langmuir binding 
model. Figure 45 C shows the binding between the equine IgE and the canine 
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sFcεRIαD1&2, the graphs show a successful binding in the 1:1 Langmuir binding 
model, but the association curve us followed immediately  by strong dissociation, 
therefore it can be determined that the equine IgE binds weakly  to the canine 
sFcεRIαD1&2, and from chapter 4 it was determined that this binding is so weak that it 
does not cause any released in RBL-2H3.1 cells. Because of the weak binding between 
the equine IgE and the canine sFcεRIαD1&2, the opposite was tested, just as in chapter 
4‘s release assays; Figure 45 D shows the binding between the canine IgE and the 
equine sFcεRIαD1&2 to be even very stable in the 1:1 Langmuir binding model, and 
this, of course, completes the picture of the observed effects on cell release in Chapter 
4. The numerical results of Figure 45 were automatically calculated by the BiaCoreTM 
2000 System SPR machine software, and they are displayed on Table 1.
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Figure 45: Kinetic analysis graphs:
A. shows the binding between the equine IgE and the equine 
sFcεRIαD1&2 protein with the left  graph showing the entire 
test, the middle graph only shows the sFcεRIαD1&2 binding 
and the right graph shows the kinetic analysis graph with the red 
lines being the actual measurements and the blue lines are the 
results fitted to the 1:1 Langmuir binding model. The results 
show a strong binding association between the equine IgE and 
the equine sFcεRIαD1&2 protein followed by weak dissociation 
indication their binding stability. B. shows the binding between 
the equine IgE and the human sFcεRIαD1&2 protein with the 
left graph showing the entire test. The middle graph only shows 
the sFcεRIαD1&2 binding, with the bottom having the actual 
axis for comparison, and the top having its axis modified to 
show the actual curves. The right graph shows the kinetic 
analysis graph with the red lines being the actual measurements 
and the blue lines are the results fitted to the 1:1 Langmuir 
binding model. The results show very week binding association 
between the equine IgE and the human sFcεRIαD1&2 protein 
followed by rapid dissociation indication their binding 
instability. C. shows the binding between the equine IgE and the 
canine sFcεRIαD1&2 protein with the left graph showing the 
entire test. The middle graph only  shows the sFcεRIαD1&2 
binding, with the bottom having the actual axis for comparison, 
and the top  having its axis modified to show the actual curves. 
The right graph shows the kinetic analysis graph with the red 
lines being the actual measurements and the blue lines are the 
results fitted to the 1:1 Langmuir binding model. The results 
show strong binding association between the equine IgE and the 
canine sFcεRIαD1&2 protein followed by  rapid dissociation 
indication their binding instability. D. shows the binding 
between the canine IgE and the equine sFcεRIαD1&2 protein 
with the left graph showing the entire test, the middle graph only 
shows the sFcεRIαD1&2 binding and the right graph shows the 
kinetic analysis graph with the red lines being the actual 
measurements and the blue lines are the results fitted to the 1:1 
Langmuir binding model. The results show a strong binding 
association between the canine IgE and the equine 
sFcεRIαD1&2 protein followed by weak dissociation indication 
their binding stability.
The research group  lead by  Dr. Gould (Henry, et al., 1997) discuss a biphasic 
interaction model between the IgE and its FcεRI receptor to form a successful strong 
bond; they came to the conclusion that the IgE binds to its FcεRI receptor through low-
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affinity first followed by binding through high-affinity, to give the final binding 
between the two proteins KA = ~1010M.
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Table 1: Kinetic analysis table:
This table shows the kinetic analysis of equine IgE binding to 
the FcεRI receptor of different species, and that of canine IgE 
binding to the equine FcεRI receptor. Noting that the original 
results of Equine IgE - Equine sFcεRIαD1&2 and the Canine 
IgE - Equine sFcεRIαD1&2 had their concentrations 
accidentally wrongly inputed into the SPR machine as µM 
instead of µg ml-1. Also the Equine IgE - Human sFcεRIαD1&2 
and the Equine IgE - Canine sFcεRIαD1&2 had their molecular 
weights for the sFcεRIαD1&2 accidentally wrongly  inputed into 
the SPR machine as 36kDa instead of 50kDa. Therefore these 
results are raw data without them being re-calculated and fixed.
Equine IgE - 
Equine 
sFcεRIαD1&2
Equine IgE - 
Human 
sFcεRIαD1&2
Equine IgE - 
Canine 
sFcεRIαD1&2
Canine IgE - 
Equine 
sFcεRIαD1&2
ka (M-1s-1) 2.3x106 1.8x101 2.8x102 1.5x106
KA (M-1) 5.9x109 1.4x106 1.8x105 8.0x109
kd (s-1) 3.8x10-4 1.3x10-5 1.6x10-3 1.9x10-4
KD (M) 1.7x10-10 7.3x10-7 5.6x10-6 1.2x10-10
RUMax (RU) 159 3.00 999 176
It is important to note that these results of Equine IgE - Equine sFcεRIαD1&2 and 
the Canine IgE - Equine sFcεRIαD1&2 had their concentrations accidentally  wrongly 
inputed into the SPR machine as µM instead of µg ml-1. Also the Equine IgE - Human 
sFcεRIαD1&2 and the Equine IgE - Canine FcεRIα had their molecular weights for the 
FcεRIα accidentally  wrongly inputed into the SPR machine as 36kDa instead of 50kDa. 
Therefore the results in figure 45 and their values in table 1 are raw data without them 
being re-calculated and fixed. These results were sent to Dr. Peter Schuck and Dr. 
Huaying Zhao where they  re-calculated the results and applied them to three kinetic 
models.
6.3 - Discussion:
6.3.1 - Explanation of The Three Macromolecular Binding Process Models:
The following is the explanation of the three macromolecular binding process 
models for SPR biosensing according to the research by (Schuck and Zhao, 2010). 
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When using SPR for measuring rate and affinity constants using the pseudo-first-order 
reactions, two very common sources of deviation occur, they are the heterogeneity  of 
the surface sites and mass transport limitations. The heterogeneity of the surface sites 
discusses the concept that, since ligands need to be immobilized onto a surface for a 
sample to bind to, and measurements can be commenced, the idea of immobilizing a 
ligand onto a surface raises questions as to the nature of the final bound ligand and the 
best strategy to go about  this immobilization; does the ligand denature and results in a 
mixture of high-affinity  and low-affinity  binding epitopes to the sample, which adds 
errors to the final kinetic constant measurement values? Other questions such as; does 
the ligand get partially de-natured, and thus its biochemistry changes? Does the sample 
interact with the actual surface as well as the ligand? The other source of deviation is 
the concept of mass transport  limitations, which explains the actual transfer of sample 
onto the surface with immobilized ligand; when the sample binds to the ligand on a 
surface. On the macroscopic scale, does the sample concentration near the surface 
defers from the actual bulk concentration, resulting in either a local depletion zone? Or 
incase of washing, a retention zone? On the microscopic scale, does the sample 
concentration differs through the thickness of the immobilizing matrix (the sensing 
volume itself.), which is around 100 - 400nm thick. All these result in sample 
concentration gradients. Therefore to correct for these errors mathematical model were 
developed that accounts for these phenomenons and thus gives more precise values for 
kinetic constants measured using SPR.
Discrete One Site Model: This is a model that explains the results in terms of 
having uniform binding epitopes of the immobilized ligand; i.e: no differences in 
binding affinity  nor configuration (no heterogeneity  of the surface sites). This model 
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usually  does not describe SPR bindings because there usually is heterogeneity  in the 
ligand epitope binding sites due to the strategy of binding the ligand to a surface.
Conformational Change Model: This is a model that  explains the results in terms 
of not having all the binding epitopes of the immobilized ligand to be the same; i.e: 
there are multiples of different confirmations of the same sample binding site on the 
ligand where the sample can bind at different high and low affinities (having 
heterogeneity of the surface sites). This model usually describes the majority  of protein-
protein SPR bindings because of the heterogeneity in the ligand epitope binding sites 
due to the strategy of binding the ligand to a surface.
Distribution Model: This is a model that explains the results in terms of having a 
range of binding affinities between the immobilized ligand and the sample due to the 
fact that the immobilized ligand has different confirmations of its binding site caused by 
the immobilization process (having heterogeneity of the surface sites), and at  the same 
time the sample interacts at different concentrations with the immobilized ligand due to 
the effect of mass transport limitations on the interacting surface. This model takes into 
account both sources of errors found in SPR biosensing and thus gives the most 
accurate values for the measured kinetic constants.
6.3.2 - Re-Calculated Kinetic Binding Values For Different Macromolecular Binding 
Process Models:
The results were re-calculated for the correct concentrations of the sFcεRIαD1&2 
in µg ml-1 and for the molecular weight of 50kDa. They then applied the new re-
calculated data to the three macromolecular binding process models described above; 
the Discrete One Site Model, the Conformational Change Model and the Distribution 
Model. The software used to apply these models was EVILFIT software. A note, the kd 
constant is sometimes referred to as koff and the KD constant is sometimes referred to as 
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Kd in the following figures. Of all the three models, the Distribution Model was the one 
that best  fitted and described the data as it had the lowest Root Mean Square Deviation 
and resulted in two peeks in the log10 kd against log10 KD distribution (plots are in the 
Appendix).
According to Dr. Peter Schuck’s and Dr. Huaying Zhao’s calculations, the 
Discrete One Site Model usually did not give reliable results, and so it was not a 
surprise that  this model did not fit the data (Appendix) in the log10 kd against log10 KD 
distribution plot. The Conformational Change Model resulted in a very slow 
conformational rate constants (kcc = ~10-6), this meant that during the binding there is 
no structural conformational change.
The Distribution Model was the one that best fitted and described the data (Table 
2). The equine IgE binding to the equine sFcεRIαD1&2, equine IgE binding to the 
canine sFcεRIαD1&2 and canine IgE binding to the equine sFcεRIαD1&2 showed two 
peaks in the log10 kd against log10 KD distribution (plots are in the Appendix), only the 
equine IgE binding to the human sFcεRIαD1&2 resulted in a single peak. The equine 
IgE binding to the equine sFcεRIαD1&2 had the value of the 7µg ml-1 concentration 
deviate greatly from the model, it resulted in the model to give an final Root Mean 
Square Deviation = 2.52. Therefore removing this value resulted in a better fit to this 
model and a final Root Mean Square Deviation = 0.74.
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Table 2: EvilFit Distribution Model:
This table shows the Distribution Model values calculated in the 
EVIFIT software, note the small Root Mean Square Deviation 
(compared to the other tables’ values) indicating that the results 
indeed do fit this model.
EvilFit Distribution Model    














-5 124.64 0.74 yes


















-5 40.67 0.24 yes







-5 161.09 0.63 yes
From the Distribution Model results table (Table 2) it  can be seen that the equine 
IgE binding to the equine sFcεRIαD1&2 has the lowest (weakest) equilibrium 
dissociation constant KD = 1.58x10-10 M  (KA = 6.33x109 M-1) this indicates that the two 
proteins have high affinity to each other, are very stable and unlikely to dissociate once 
bound. Second comes the canine IgE binding to the equine sFcεRIαD1&2 having a 
similar equilibrium dissociation constant KD = 5.43x10-10 M  (KA = 1.84x109 M-1) this 
indicates that the two proteins also have high affinity  to each other, are very stable and 
unlikely to dissociate once bound, their KD is 3.4 times higher (KA 3.4 times lower) than 
the equine IgE-equine sFcεRIαD1&2 complex, this is expected since the two molecules 
come from two different species, this is again expected since the IgE protein sequences 
between the equine and canine IgEs are 80% similar.
The equine IgE binding to the human sFcεRIαD1&2 and the equine IgE binding 
to the canine sFcεRIαD1&2 showed to have several magnitudes higher equilibrium 
dissociation constants KD = 4.66x10-9 M  (lower KA = 2.15x108 M-1) and KD = 1.93x10-8 
M (lower KA = 5.18x107 M-1) respectively than the previous complexes. This was 
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supported previously by results shown in chapter 4 for flow cytometry and cell mediator 
release assays, where the equine IgE failed to bind to the canine sFcεRIαD1&2 and the 
human IgE failed to bind to the equine sFcεRIαD1&2. Even though these predictions 
can be confirmed by biological studies on living cells, these values should be 
considered with caution because they  way the kinetic measurements were preformed 
was less than optimal. As can be seen from Figure 45 B and C, the IgE was not bound to 
the chip  in high enough quantity to allow for the gathering for information about the 
weak binding of the sFcεRIαD1&2 onto it. Ideally ~2500 resonance units needs to be 
achieved by the IgE when bound to the SPR chip in order to give a complete picture of 
the sFcεRIαD1&2 binding onto it, this was achieved in the equine IgE binding to the 
equine sFcεRIαD1&2 and canine IgE binding to the equine sFcεRIαD1&2, but in the 
equine IgE binding to the human sFcεRIαD1&2 and the equine IgE binding to the 
canine sFcεRIαD1&2 only ~ 250 resonance units was achieved by  the IgE, and this was 
not adequate. These two kinetic analyses should be repeated with binding more IgE in 
order to collect more information about the binding kinetics, even though the biological 
studies indicate low affinity. This was tested as can be seen in Figures 46 and 47, where 
more equine IgE was added, even though it did not reach ~2500 RU, it was enough to 
see that the canine and human sFcεRIαD1&2 protein better bind. From these graphs it 
can be seen, especially with the canine sFcεRIαD1&2 protein, that they will still have a 
high enough KD (low KA) that agrees with the biological results in chapter 4 (and the 
fact that the IgE protein sequences between the equine and human are only 68% 
similar.), which showed the equine IgE causes not  mediator release on RBL-2H3.1 cells 
expressing canine FcεRIα or human FcεRI receptors, especially that in this case 20µg 
ml-1 of each sFcεRIαD1&2 protein was added, twice as much as the highest 
concentration used in the kinetic analysis, and it  still gave a slightly smaller curve than 
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expected. But nonetheless the calculated KD would be more precise for further research 










Figure 46: Re-testing the binding between the equine IgE 
and the human sFcεRIαD1&2:
This figure shows the re-test of the binding between the equine 
IgE and the human sFcεRIαD1&2 protein. The addition of more 
equine IgE, even though it did not reach ~2500 RU, was 
adequate to show clear binding between the equine IgE and the 
human sFcεRIαD1&2. Though the concentration of the human 
sFcεRIαD1&2 protein here was (20µg ml-1) twice as much as 
the highest concentration used in the kinetic analysis, the curve 
is slightly  smaller than expected, this supports the biological 
results described in Chapter 4 that showed the equine IgE 











Figure 47: Re-testing the binding between the equine IgE 
and the canine sFcεRIαD1&2:
This figure shows the re-test of the binding between the equine 
IgE and the canine sFcεRIαD1&2 protein. The addition of more 
equine IgE, even though it did not reach ~2500 RU, was still 
enough to show clear binding between the equine IgE and the 
canine sFcεRIαD1&2. Though the concentration of the canine 
sFcεRIαD1&2 protein here was (20µg ml-1) twice as much as 
the highest concentration used in the kinetic analysis, the curve 
is slightly  smaller than expected, this fits with the biological 
results obtained in Chapter 4 that showed the equine IgE causes 
no release in RBL-2H3.1 cell expressing the canine FcεRI 
receptor.
A rabbit IgG antibody  was raised against the human IgE AB helix in order to map 
the binding site of the low-affinity FcεRII receptor by  (Ian Sayers, PhD Thesis, The 
University  of Sheffield, 1997) and the helix’s effect on the FcεRI receptor, the detailed 
concept and protocol can be found in chapter 7 of Ian Sayers’ thesis, which showed that 
immunization with a cyclized peptide is more successful than a linearized peptide. From 
that study it was discovered that this rabbit IgG anti human IgE AB helix bound to the 
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IgE antibody and prevented its binding to the FcεRI receptor. When the human and 
equine IgE sequences were analyzed by  BLAST, it was confirmed that the two IgEs are 
only 68% similar. But  when the AB helixes of the two IgEs (equine = PSPLDLYVSKS 
and human = PSPFDLFIRKS) were analyzed by BLAST, it showed that they are up to 
82% similar. Therefore the binding between the rabbit IgG anti human IgE AB helix 











Figure 48: Testing the binding of rabbit serum raised against 
human IgE AB helix to equine IgE:
This figure shows the successful binding of rabbit serum raised 
against human IgE AB helix to equine IgE.
This result  concludes that antibodies raised against conserved sections of the 
human IgE can bind to equine IgE, and thus prevent the equine IgE from binding to its 
FcεRI receptor. This means that the equine organism can be used as a model for 
developing and studying potential allergy vaccines for humans. Furthermore, it 
indicates that it might be possible to develop an IgE-derived immunogen that will be 
relevant to more than one species, e.g: human, horse and dog, where the same 
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immunogen can be tested in the animal species before clinical trial in human are 
embarked on.
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Chapter 7 - Generation of A Human-
Horse-Human IgE Chimera:
7.1 - Introduction:
Since the binding between the equine IgE and the FcεRI receptor was measured in 
the last chapter to be KD = 1.7x10-10 M, and the crystal structure of human IgE binding 
to its FcεRI receptor was determined by (Garman, et al., 2000), this chapter will 
investigate a concept of molecule design, in which an antibody response raised against 
epitopes in IgE that are involved in receptor binding, and thus prevent receptor binding, 
provided this antibody could bind to the equine IgE at a stronger affinity than the equine 
FcεRI receptor, in hopes that this molecule can be used as a cure for allergy. Antibodies 
can bind very strongly  to their antigens, and antibodies can be designed to bind to 
virtually  any type of molecule, therefore the aim here is to develop an IgG antibody anti 
equine IgE, precisely  binding to the Cε2-Cε3 linker region of the IgE, which if it binds 
strongly enough could separate the IgE from its FcεRI receptor, and prevent  it from re-
binding, and thus stop  the initial step of the IgE mediated cell degranulation that leads 
to allergy.
In a paper by  (Hook, et al., 1981) the research group developed a monoclonal 
antibody that can bind to human serum IgE, but it did not recognize receptor bound IgE. 
This concept has been pioneered by other research groups, and a drug called 
(Omalizumab) was developed by  Genentech and Novartis (Chapter 1.6.2) where mice 
were injected with adjuvants that developed monoclonal IgGs against epitopes within 
the IgE antibody  that are involved in its binding to the FcεRI receptor. Omalizumab 
targets an epitope called HPL (amino acids 424-426) within the Cε3 domain (Zheng, et 
al., 2008), and thus binds to free floating human serum IgE and thus causes reduction in 
its quantity. Another drug called mAb12 (Laffer, et al., 2001) uses the same concept, but 
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binds to a different epitope from that recognized by Omalizumab. Its added advantage is 
that it  binds and removes IgE already bound to its FcεRI receptor, and therefore reduces 
the sensitization by  IgE of mast and basophil cells (Laffer, et al., 2008) presumably 
because of its higher binding affinity  to IgE than that of IgE to its FcεRI receptor, > KA 
= 1010 M-1. The side effect of these therapeutics is the development of serum sickness 
(Dreyfus and Randolph, 2006) because residual mouse antigens still persist in the 
humanized mAbs (mouse antibodies). These two drugs were developed by 
immunization with whole IgE antibody molecules and selecting mouse antibodies that 
inhibit the binding of IgE to its FcεRI receptor, noting that these antibodies are used 
only for passive immunization, therefore the patients needs to constantly  take them. 
This causes a disadvantage as it is very expensive for patients and insurance companies, 
since each dose consists of 300 - 400mg of anti IgE antibody, and needs to be taken 
every  2 - 4 weeks. A paper by (Takahashi, et al., 1999) discussed another passive 
immunisation concept which uses the binding peptide from the variable region of an 
IgG anti self IgE antibody to bind to serum IgE and thus prevent it from binding to its 
FcεRI receptor. Their findings were successful in which the peptide did bind to IgE, but 
the measured binding affinity was around KA = ~104-5 M-1, which is not high enough 
to remove receptor bound IgE nor prevent serum IgE from binding to its FcεRI receptor.
A way around this is to develop an allergy “therapeutic vaccine”, an immunogen 
that immunizes an organism against  its own self IgE, thus by administering this 
immunogen, the body  would produce IgG anti self IgE which will remove the IgE from 
serum throughout the rest of the organism’s life. This active immunization would reduce 
the serum sickness side effect, as well as the cost of the drug, as it only needs to be 
administered several times, in low quantities, to develop  life long immunity. By solving 
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these two problems this drug can be widely adopted, by passing the side effects and 
costs which are preventing Omalizumab and mAb12 from gaining world wide use.
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Table 3: Anti IgE antibodies:
This table shows previous anti IgE antibodies developed in our 
lab.
Host Antibody Isotype Target KA (M) Reference

























Rabbit Antibody Polyclonal Human Cε2-3 loop 7.1x106
Ian Sayers, PhD 
Thesis, University 
of Sheffield, 1997
Our lab has produced several anti IgE antibodies (Table 3). Serum containing 
antibodies against human IgE Cε2-3 linker was developed in the PhD thesis by (Mark 
Street, PhD Thesis, The University of Sheffield, 2010) where an allergy therapeutic 
vaccine using the structure based peptide approach was researched. Here an immunogen 
with the protein sequence of the human IgE’s Cε2-3 linker (350-363), (the synthetic 
peptide we made is called here 2Fcε2-3) Figure 49, was used. This residue is involved in 
binding of the IgE to the FcεRI receptor, it was used to stimulate the synthesis of natural 
anti self IgE antibodies that are non-anaphylactic, and capable of binding and removing 
serum self IgE, and hopefully remove self IgE already bound to its FcεRI receptor. The 
PRGV amino acid sequence, from IgE’s both Cε2-3 linker heavy chains, actually  bind 
to the FcεRI receptor. The thesis by (Mark Street, PhD Thesis, The University of 
Sheffield, 2010) employed a new (disulphide linked dimer) design for the 2Fcε2-3 where 
the Cys 328 amino acid in both chains were bonded together by a disulphide bridge, and 
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the NH2 terminal of the peptide was bonded to the adjuvant thyroglobulin to restrict its 
flexibility, while the COOH terminal was left flexible, this was in an attempt to mimic 
the conformation of the human self IgE molecule. This idea came about where previous 
studies showed that unconstrained/circularized peptides did not result in IgG antibodies 
that bound to the 2Fcε2-3 strong enough. The 2Fcε2-3 protein’s COOH end also had the 
sequence (PRGV) which is part of the self IgE’s Cε2-3 linker and that  binds to the 
FcεRI receptor (Figure 50), and it was realized that this exact sequence is shared 
between the human, mouse, rat, canine and equine IgEs (Table 4), therefore developing 
a polyclonal anti 2Fcε2-3 response has the potential to cure the human, canine and 
equine allergies simultaneously. The insoluble thyroglobulin (670kDa) was used as an 
adjuvant in this study as the peptide itself (~3kDa) was not large enough to trigger an 
effective immune response. Effective immunogens should have epitopes that can bind to 
the B cell receptors, and also can cause physical association between B cell and Th0 
cells. Adjuvants that could have been used were bovine serum albumin, ovalbumin, and 
Keyhole Limpit  Hemocyanin, but thyroglobulin was finally chosen as its coupling to 
the 2Fcε2-3 protein was efficient. The 2Fcε2-3 protein was synthesized, bound to 
thyroglobulin and used to immunized rabbits with three rounds of subcutaneous and 
intradermal injections, this was effective as previous studies showed that subcutaneous 
and peritoneal injections resulted in anaphylaxis of 75% of the vaccinated population 
(Athanassios Vratimos, PhD Thesis, University of Sheffield, 2003). The rabbits 
developed a polyclonal IgG anti 2Fcε2-3, and the result  of that project showed that the 
polyclonal IgG antibodies produced by the rabbits successfully bound to human and 
canine self IgEs. They also did not cause any receptor cross linking on the cell surface, 
thus did not cause anaphylaxis. This was because the 2Fcε2-3 protein caused IgG 
antibodies to target its self IgE epitopes, which are buried into the FcεRI receptor when 
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the self IgE binds to it, therefore the polyclonal IgG antibodies cannot reach it. But the 
project showed that these antibodies were still not capable of preventing self IgE from 
binding to its FcεRI receptor. This was because anti IgG antibodies bound to the self 
IgE much weaker than the self IgE binds its FcεRI receptor. The self IgE binds to its 
FcεRI receptor at KD= ~10-10 M, the polyclonal IgGs bound to the self IgE at 
KD=~10-5-10-6 M (therefore the IgG would dissociate more readily from the IgE than the 
FcεRI receptor). Thus free floating self IgE would still dissociate from the IgG anti self 
IgE antibody and bind to its FcεRI receptor.
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Figure 49: Structure of the 2Fcε2-3 protein, the HHoH and 
HDH antibodies:















Figure 50: The position of the Cε2-3 linker:
This figure shows the position of the Cε2-3 linker when the IgE 
binds to its FcεRI receptor. Figure was taken from (Garman, et 
al., 2000).
Table 4: Sequence of the Cε2-3 linker in different species:
This table shows the homology of the Cε2-3 linker between 
different organisms. Note that  all organisms have the same 
PRGV sequence.
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The structure based peptide approach, which was just discussed, had a main 
limitation which was it developed polyclonal IgG antibodies that bound weakly  to the 
self IgE’s Cε3 domain, this was because a small peptide, single or circularized, is still 
quite different from the actual three dimensional structure of the original protein (Ledin, 
et al., 2006). (Wang, et al., 2003) explains that this approach was successful in several 
organisms when the immunogen peptide (self IgE amino acids between 288 and 315 at 
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the end of the Cε3 domain) was complex with T helper epitopes adjuvants derived from 
measles virus (UBITh®A), therefore the adjuvants can increase the immunogenicity of 
the immunogen.
While anti-peptide antibodies commonly  are of low affinity  when assessed for 
binding to the integral protein from where the peptide was derived, (Johansson and 
Hellman, 2007) also argued that vaccinating self antigens is difficult due to the 
maturation of both B and T cells that are selected not to react  against self antigens. 
Therefore a new concept of therapeutic vaccine design (called here the self/non-self 
approach) is researched in an attempt to increase the immunogenicity  of self IgE. It uses 
chimeric self and non-self IgE constructs that could induce natural IgG anti self IgE 
antibodies (Hunter, et al., 2008; Ledin, et al., 2006; Johansson and Hellman, 2007). This 
has the added advantage over the previous method as having a full IgE antibody as an 
immunogen allowing the non-self Cε2 and Cε4 domains to maintain the correct three 
dimensional folding structure of the self Cε3 domain (Hunter, et al., 2008). The use of 
non-self Cε2 and Cε4 domains is likely to increase the immunogenicity of the final 
chimeric antibody, which means that the organism’s body will most likely develop 
antibodies against its own self Cε3 domain. This immunogenicity can be further 
increased if the chimeric antibody was administered several times as boosts to the initial 
immunization. (Johansson and Hellman, 2007) also argue that immunogenicity  can be 
increased by the use of correct potent adjuvants; such as mineral oil based adjuvants, the 
vaccine immunogen has to be soluble, properly folded and contain repetitive epitopes, 
and dimerizing the immunogen increases the immunogenicity  by  4 - 8 folds. The self/
non-self concept was shown in the paper by  (Ledin, et al., 2006) to be successful in 
producing antibodies anti self canine Cε3 domain. This was done by inserting the canine 
Cε3 domain in an opossum IgE heavy chain to make an opossum-dog-opossum 
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chimeric (ODO) protein, noting this was not a full IgE, rather only a three domain 
heavy  chain construct. The (Ledin, et al., 2006) research, though successful, did not test 
whether the immunization with a chimeric antibody  encompassing the canine Ce3 is 
likely to give rise to an immune response against epitopes that are not engaged in 
receptor binding, this might lead the antibodies to binding to receptor bound IgE, cross-
linking them and thus initiating mediator secretion. In other words, they  did not test if 
the serum causes anaphylactic. Although the research group did not report such adverse 
reaction when immunizing dogs with the ODO chimera, this should have been assessed 
at the molecular level. The generation of our RBL-2H3.1 FcεRIα transfected cell lines 
(Chapter 4 and from previous colleagues) provide an excellent means to safely  test these 
immune response at the molecular level.
Therefore the current thesis will take this concept of an allergy  therapeutic 
vaccine using the self/non-self approach further to develop active vaccination instead of 
passive immunization. Instead of immunizing organisms with the 2Fcε2-3 protein alone, 
they  will be primed with it at first, followed by  boost immunizations with a full 
chimeric antibody, where this antibody will have self Cε3 domain in between non-self 
Cε2 and Cε4 domains.
The concept of original antigenic sin (Chapter 1.8) will be used here where the 
immune system would be first  primed by the cyclised 2Fcε2-3 peptide, then boosted 
using the full 3D Cε3 structure presented to it in the form of a IgE chimera, where the 
Cε3 domain of the target species is inserted between the Cε1, Cε2 and Cε4 of a distant 
phylogenic mammal. This should lead the immune system to target the same epitopes in 
the Cε3 domain and, since the epitopes are now presented in a 3D configuration, the 
immune system should develop stronger antibodies against them through somatic 
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hypermutation, thus allow the development of stronger polyclonal antibodies against the 
self IgE Cε3 domain. It is believed that this immunization protocol would increase the 
immunogenicity  of the self IgE’s Cε3 domain and therefore would cause the organism 
to develop stronger immunity  to its own self IgE, where polyclonal antibodies would 
bind to the self IgE much stronger that the self IgE binds to its FcεRI receptor. The 
Summary of the immunization protocol is:
1. Subcutaneous and intradermal injections of all immungens.
2. First immunization is by 2Fcε2-3 protein alone.
3. This is followed by three boosts by the chimeric antibody. Where the Cε3 
domain of the IgE is replaced by the organism's own self Cε3 domain protein 
sequence, and the non-self Cε1, Cε2 and Cε4 domains of a distant phylogenic 
mammal, which are only there to maintain the correct three dimensional structure of 
the self Cε3 domain.
The project will be investigating a possible allergy therapeutic vaccine for horses, 
therefore it started by the synthesis of the human-horse-human (HHoH) IgE anti NIP-
HSA chimera antibody, but later used the HDH IgE anti NIP-HSA chimera antibody 
(Figure 49) due to financial reasons. The human non-self Cε1, Cε2 and Cε4 were used 
as scaffold with the horse self Cε3 as the human IgE sequence is phylogenically distant 
than the horse IgE sequence. The human IgE heavy chain wild type sequence (Nishida, 
et al., 1982) was obtained from the GenBank sequence database (part of the United 
States’ National Center for Biotechnology Information, NCBI). The gene was not 
optimized and the physical gene was obtained from another colleague in the laboratory. 
Each domain was amplified, through PCR, with its introns, along with the horse Cε3 
domain, and they  were constructed to make the full HHoH gene. The HHoH gene was 
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then cloned into the pSV-VNP plasmid downstream of a gene sequence that codes for a 
mouse antibody  variable region that recognizes and binds to the antigen 4-hydroxy-5-
iodo-3-nitrophenylacetic acid (NIP), therefore when expressed the protein would be a 
full HHoH IgE antibody with a mouse variable region that binds to NIP (HHoH IgE anti 
NIP). The final plasmid (pSV-VNPHHoH) was transfected into mouse B (J558L) cells, 
that after selection of the cloned cells, a J558L cell line that  expressed HHoH IgE anti 
NIP-HSA was developed. The protocol for transfection, expression and purification was 
run exactly as in Chapter 3. The human-dog-human (HDH) IgE chimeric antibody 
(Figure 49) was used to continue this research as the HHoH was not expressed in 
enough quantities to allow for vaccination.
7.2 - Results:
7.2.1 - Getting The Human And The Equine IgE Heavy Chain Genes:
The human heavy chain sequence was taken from (Nishida, et al., 1982) while the 
actual gene was in the lab isolated by a previous colleague (Hongtu Ye, PhD Thesis, The 
University  of Sheffield, 2010). The human gene did not need any optimization nor 
modification, fist  because the introns in the gene are used to insert restriction site where 
the different domains can be clones, second this gene was already proven to 
successfully  express in J558L cells. The equine heavy chain gene was the same gene 
from chapter 3.
7.2.2 - Constructing the HHoH Heavy Chain Gene:
The approach to the synthesis of the HHoH gene was through PCR. Each domain 
was amplified separately and cloned into a separate pUC18 plasmid. That enabled each 
domain to be sequenced and confirmed that no fatal mutations occurred from the PCR 
step. The different domains where then put together in a series of clonings and 
transformations (Chapters 2.2.2 - 2.2.12 and 2.2.16), until the full HHoH gene was 
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constructed. The final HHoH gene was then cloned into the pSV-VNP plasmid to make 
pSV-VNP HHoH. Noting that a parallel experiment was run where a GFP gene was 
inserted downstream of the HHoH to give the plasmid of pSV-VNP HHoHGFP as a 
means of shortcutting the J558L selection process (discussed later in chapter 7.3). The 
DNA and protein sequences of the human, equine and the final HHoH IgEs are found in 













All forward primers had a HindIII restriction site following three adenine 
nucleotides. And all reverse primers had an EcoRI restriction site following three 
thymine nucleotides. This configuration was to allow all PCR products to be cloned into 
the pUC18 plasmid for ease of handling and where they can be used for sequencing to 
confirm no mutations have occurred. All forward primers had another unique restriction 
site immediately  following the HindIII restriction site, and all reverse primers had 
another unique restriction site following the EcoRI restriction site. These strategically 
placed restriction sites allowed the different PCR amplified domains to be added 





















































Figure 51: HHoH domain construction concept:
This figure shows the PCR products formed by the above 
primers and how they were cloned together using the 
strategically  placed restriction sites to make up the full HHoH 
gene, a copy of this gene had a GFP gene added below it, as an 
attempt to shortcut the selection period.
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             1kb DNA    pUC18-       pUC18-     pUC18-    pUC18-

























Figure 52: HHoH domain PCR amplifications and cloning 
into pUC18:
A. shows the PCR product of each domain. B. shows the 
successful cloning of all the PCR products into separate pUC18 
plasmids, these plasmids were sent for sequencing to confirm no 
fatal mutations developed from the PCR step.
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All the domains were amplified by PCR as in chapter 2.2.6 where the human Cε1, 
Cε2 and Cε4 domains where amplified along with the equine Cε3 domain. They  were 
all then cloned into separate pUC18 plasmids and transformed into bacteria. Figure 
52A shows the result of the PCR, and Figure 52B shows the result of all the domains 
successfully cloned into pUC18 plasmids.
Several samples of each plasmid (pUC18-Cε1Cε2, pUC18-Cε3 and pUC18-Cε4) 
were sent  for sequencing, where the results are found in the Appendix, and the plasmids 
with genes that contained no fatal mutations (silent mutations that either appeared in 
introns or caused no change in amino acid sequence) were chosen to construct the 
HHoH gene.
             1kb DNA   pUC18-      pUC18-    pUC18-
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             Ladder    Cε1        Cε1       Cε1        Cε1
                            Cε2        Cε2       Cε2        Cε2








Figure 53: Constructing the HHoH gene:
A. shows the the results of the restriction digest for the addition 
of Cε3 domain to the Cε1Cε2 domains and B. shows the 
confirmation results of the successful addition to make pUC18-
Cε1Cε2Cε3. C. shows the restriction digest for the addition of 
Cε4 domain to the Cε1Cε2Cε3 domains and D. shows the 
confirmation results of the successful addition to make the final 
HHoH gene represented as pUC18-Cε1Cε2Cε3Cε4 (HHoH).
The domains where then constructed by adding one domain to the other to make 
the final HHoH gene (Figure 53). The Cε3 domain was added to Cε1Cε2 domains to 
make a final plasmid of pUC18-Cε1Cε2Cε3 (Figure 53A). The plasmid was 
198
transformed into bacteria, grown, harvested and checked for the successful cloning 
(Figure 53B). Then the Cε4 domain was added to the Cε1Cε2Cε3 to make the plasmid 
pUC18-Cε1Cε2Cε3Cε4 ,can also be referred to as pUC18-HHoH, (Figure 53C). The 
plasmid was transformed into bacteria, grown harvested and checked for the successful 
cloning (Figure 53D).
7.2.3 - Cloning The HHoH IgE Heavy Chain Gene Into Plasmid:
             1kb DNA    pUC18-  pSV-VNP












    pSV-VNP     pSV-VNP   pSV-VNP  DNA      pSV-VNP  pSV-VNP   pSV-VNP








Figure 54: Transferring the HHoH gene from pUC18 
plasmid to pSV-VNP plasmid:
A. shows the restriction digest of the HHoH from the pUC18 
plasmid. B. on the right, shows the successful ligation of the 
HHoH into the pSV-VNP plasmid, and on the left, shows the 
orientation tests run to confirm the gene is in the right 
orientation in the pSV-VNP plasmid, as the gene was digested by 
the same restriction enzyme from both ends.
The final pUC18-HHoH plasmid was digested with BamHI restriction enzyme, 
de-phosphorylated and cloned into the pSV-VNP plasmid (Figure 54A). The plasmid was 
also tested for the successful ligation and orientation of the gene, selecting the plasmid 
that had the gene in the correct orientation (Figure 54B) as the HHoH gene was digested 
by the same restriction enzyme from both ends.
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Figure 55: Cloning the GFP gene into pUC18:
A. shows the PCR amplification of the GFP gene . B. shows  the 
successful ligation of the GFP gene into the pUC18 plasmid.
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Figure 56: Cloning the GFP gene into the pSV-VNPHHoH 
plasmid:
A. shows the restriction digest  of the GFP gene using MluI and 
NotI restriction enzymes. B. shows the successful ligation of the 
GFP gene into the pSV-VNPHHoH to make pSV-VNPHHoHGFP.
Some of the pSV-VNPHHoH plasmid was used to clone the GFP gene downstream 
of the HHoH in an attempt to shortcut the J558L selection (Chapter 7.3). The GFP gene 
was amplified by PCR (Figure 55A) and cloned into the pUC18 plasmid (Figure 55B) 
then it  was sent  for sequencing to confirm no fatal mutations occurred in the PCR step, 
the Appendix contains the sequence and of GFP gene along with the sequencing results. 
Once a pUC18-GFP plasmid was identified with the gene containing no fatal mutations, 
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the GFP gene was digested (Figure 56A) and ligated to the pSV-VNPHHoH plasmid to 
make pSV-VNPHHoHGFP (Figure 56B).
               1kb DNA  pSV-VNP        pSV-VNP
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Figure 57: Confirmation of the presence of HHoH and 
HHoHGFP in their pSV-VNP plasmids:
A. shows a confirmation of the presence of the HHoH and 
HHoHGFP genes in their pSV-VNP plasmids, HHoH being 
1876bp and HHoHGFP being 2619bp. B. shows bacterial 
chromosome impurity test of the final purified pSV-VNPHHoH 
and pSV-VNPHHoHGFP plasmids, there were no bacterial 
chromosome impurities.
The final pSV-VNPHHoH and pSV-VNPHHoHGFP plasmid were midi prepped as 
in chapter 2.2.13 to collect large quantities of the DNA, and then the DNA was 
concentrated as in chapter 2.2.15 and re-diluted to the required concentration for 
mammalian cell transfection. They  were then run on an electrophoresis gel as a final 
confirmation for the presence of the correct genes (Figure 57A) and that there is no 
bacterial chromosome impurity  (Figure 57B), which will interfere with the cell selection 
step as bacterial chromosomes would cause mammalian cells to undergo apoptosis.
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7.2.4 - Transfecting And Selecting HHoH IgE Anti NIP-HSA Expressing J558L Cells:
J558L cells were transfected with the pSV-VNPHHoH plasmid as in chapter 2.3.5. 
Similar selection problems were faced as in Chapter 3 and they are discussed in chapter 
3.3. and several attempts, and 6 weeks of selection, the colonies were tested using SPR 






















































































































































































































































































































































































































































































Dilution Curve Bradford Assay























0.480 0.419 0.449 0.572 0 0.480 0.8408 0.4763
0.541 0.516 0.496 0.610 0.1 0.541
0.607 0.550 0.629 0.642 0.2 0.607
0.694 0.681 0.710 0.692 0.3 0.694
0.833 0.836 0.876 0.786 0.4 0.833
1.002 0.895 1.031 1.079 0.5 1.002
0.920 0.943 0.945 0.871 0.6 0.920
1.099 1.118 1.271 0.907 0.7 1.099
1.265 1.082 1.505 1.207 0.8 1.265
1.182 1.131 1.259 1.155 0.9 1.182
1.243 1.248 1.256 1.226 1.0 1.243
1x Dilution 2x Dilution 13.3x Dilution
0.249 0.686 0.403 0.622 0.756 0.802 0.389 0.542
0.430 0.838 0.705 0.602 0.793 0.486 0.425 0.705
0.457 0.489 0.682 0.498 0.564 0.470 0.502 0.456
HDH Concentration





















0.331 0.321 0.337 0.335 0 0.331 0.7338 0.4217
0.474 0.459 0.483 0.481 0.1 0.474
0.571 0.550 0.596 0.566 0.2 0.571
0.667 0.633 0.675 0.692 0.3 0.667
0.759 0.739 0.774 0.763 0.4 0.759
0.823 0.736 0.854 0.878 0.5 0.823
0.928 0.788 1.056 0.939 0.6 0.928
1.002 0.954 1.035 1.018 0.7 1.002
1.040 0.939 1.076 1.105 0.8 1.040
1.025 0.925 1.046 1.105 0.9 1.025
1.055 0.916 1.098 1.151 1.0 1.055
x By Dilution Factor Final Concentration
100x Dilution 0.402 0.409 0.422 0.411 41.1 55.44
10x Dilution 1.049 0.858 1.108 1.005 12.177 56.01
5x Dilution 1.248 1.099 1.306 1.22 6.088 56.01
5.6  μg μl-1
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Figure 58: SPR results of J558L selection for HHoH IgE anti 
NIP-HSA expression:
This figure shows the SPR result of the transfected and selected 
J558L cell medias from each well. Each bar represents the 
quantity  of HHoH IgE anti NIP-HSA, therefore well 
AD1 ,marked with the red arrows, was selected as the well 
expressing the most IgE, therefore the cells of this well were 
collected and grown separately  where the J558L cell line 
expressing HHoH IgE anti NIP-HSA was developed. Values for 
this graph are n th  Appendix.
The wells labeled A-B where transfected as in chapter 2.3.5 by electroporation, 
the wells labeled in L are cells transfected using a liposome (FuGENE® From Roche), 
and here it can be seen that there is comparable results between the two. Yet the 
selection process still did not  go as excepted, compared to results in Figure 17 (Chapter 
3.2.4), mainly due to the weak selection process that did not kill enough of the non-
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transfected cells, and thus results in colonies that do not have enough expressing cells. 
This can be determined from the graph where all the bar peaks are close to each other, 
including the negative control (non-transfected parental cells). Non the less the 
experiment had to be carried on due to financial reasons, and the AD1 colony was 
isolated.
7.2.5 - Collecting And Purifying The HHoH IgE Anti NIP-HSA:
A density of 5x105 cells ml-1 of the J558L cells expressing the HHoH IgE anti 
NIP-HSA was plated on a 100mm2 petri dish with 20ml of selective media, then 
incubated for 5 days at 37°C + 5% CO2 + 90% relative humidity as in chapter 2.4.3. 
This was found to be the optimal cell density and length of time for expression, where 
the expressed protein accumulated enough in the media, but not left long enough for it 
to start degrading.
1200ml of media with expressed HHoH IgE anti NIP-HSA was collected and 
centrifuged at 180xg for 3 minutes to remove the cells, then the media was filter 
sterilized through a 0.45µm filter to remove all cell and prevent dead cell proteases from 
degrading the IgE. Due to the large volume of the media, it was concentrated using a 
3kDa molecular filter to reduce the volume. The concentrated media was purified 
through a chromatography column as in chapter 2.4.5.
7.2.6 - Checking HHoH IgE Anti NIP-HSA Viability And Purity:
The purified HHoH IgE anti NIP-HSA was concentrated down to ~200µl, using a 
3kDa molecular filter, and its concentration was determined as in chapter 2.4.6 (Figure 
40 from chapter 5.2.4). In this case the HHoH concentration was 0.43 mg ml-1 as its 
OD625 = 0.838 and the equation used was y = 0.8408x + 0.4763. The concentration of 
the HDH IgE anti NIP-HSA was also tested (Figure 59) and came out to be 5.4 mg ml-1 
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as its OD625 = 0.411 at 100x dilution. Later in the discussion section of this chapter 
(Chapter 7.3) there is an explanation for the reasons behind the use of HDH IgE anti 























































































































































































































































































































































































































































































Dilution Curve Bradford Assay























0.480 0.419 0.449 0.572 0 0.480 0.8408 0.4763
0.541 0.516 0.496 0.610 0.1 0.541
0.607 0.550 0.629 0.642 0.2 0.607
0.694 0.681 0.710 0.692 0.3 0.694
0.833 0.836 0.876 0.786 0.4 0.833
1.002 0.895 1.031 1.079 0.5 1.002
0.920 0.943 0.945 0.871 0.6 0.920
1.099 1.118 1.271 0.907 0.7 1.099
1.265 1.082 1.505 1.207 0.8 1.265
1.182 1.131 1.259 1.155 0.9 1.182
1.243 1.248 1.256 1.226 1.0 1.243
1x Dilution 2x Dilution 13.3x Dilution
0.249 0.686 0.403 0.622 0.756 0.802 0.389 0.542
0.430 0.838 0.705 0.602 0.793 0.486 0.425 0.705
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0.331 0.321 0.337 0.335 0 0.331 0.7338 0.4217
0.474 0.459 0.483 0.481 0.1 0.474
0.571 0.550 0.596 0.566 0.2 0.571
0.667 0.633 0.675 0.692 0.3 0.667
0.759 0.739 0.774 0.763 0.4 0.759
0.823 0.736 0.854 0.878 0.5 0.823
0.928 0.788 1.056 0.939 0.6 0.928
1.002 0.954 1.035 1.018 0.7 1.002
1.040 0.939 1.076 1.105 0.8 1.040
1.025 0.925 1.046 1.105 0.9 1.025
1.055 0.916 1.098 1.151 1.0 1.055
x By Dilution Factor Final Concentration
100x Dilution 0.402 0.409 0.422 0.411 41.1 55.44
10x Dilution 1.049 0.858 1.108 1.005 12.177 56.01
5x Dilution 1.248 1.099 1.306 1.22 6.088 56.01
5.6  μg μl-1
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Figure 59: The protein purification graph used to calculate 
the concentration of the purified HDH IgE anti NIP-HSA:
This figure shows the concentration curve of bovine albumin 
solutions. At the bottom right of the graph is the equation for the 
line of best fit, from this equation the concentration of the 
HHoH IgE anti NIP-HSA was determined. Values for this graph 
are in the Appendix.
The HHoH IgE anti NIP-HSA was then tested on an SDS-PAGE for its purity 
(Figure 60A). The SDS-PAGE result showed that the non-reduced IgE had a single 
strong back band above the level of the ladder as the IgE size was ~192kDa, it  also 
showed very little IgE degradation by  the very  faint lines under the IgE band, and minor 
albumin impurity, which is shown by a band at 65kDa. The HHoH IgE was also 
reduced, using β-mercaptoethanol, to break the disulphide bridges between the two 
heavy  chains and between the heavy chain and the light chain, and this resulted should 
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give two bands at ~70kDa for the heavy chain, and ~25kDa for the light chain, but only 
the heavy chain band appeared. This was not expected, and the reason for this was not 
investigated thoroughly. The HDH IgE anti NIP-HSA was also tested in an SDS-PAGE 
for its purity (Figure 60B) and the results came out as expected.
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Figure 60: SDS-PAGE of the HHoH and HDH IgEs anti 
NIP-HSA:
A. is the SDS-PAGE result  of the HHoH IgE anti NIP-HSA, on 
the left  is the non-reduced IgE showing a single strong band 
above the ladder as the IgE size is ~192kDa, the result also show 
a lot of IgE degradation by the smear of lines under the IgE 
band, but  shows almost no albumin impurity, which would show 
a band at 65kDa. On the right is the reduced HHoH IgE anti 
NIP-HSA, by β-mercaptoethanol, therefore the disulphide 
bridges between the two heavy chains and between the heavy 
chain and the light chain are broken. The top band shows the 
heavy  chain as predicted at ~70kDa, but no bottom chain is 
visible, which would show a band at ~25kDa. The reason for 
this was not investigated thoroughly. B. is the is the SDS-PAGE 
result of the HDH IgE anti NIP-HSA that was prepared by 
(Hongtu Ye, PhD Thesis, The University of Sheffield, 2010) 
showing good strong bands at the predicted places, with minor 





















Figure 61: HHoH and HDH IgEs anti NIP-HSA viability 
test: 
A. shows the SPR curve of the HHoH IgE anti NIP-HSA, noting 
the small curve confirming that the antibody is functional and 
successfully  binds to NIP-HSA. This small curve, compared to 
the high concentration of the protein in the solution shows that 
very little of the antibody is functional. B. shows the HDH IgE 
anti NIP-HSA antibody curve to be large as the antibody binds 
to NIP-HSA as expected. C. shows the equine sFcεRIαD1&2 
protein binding to the HHoH, the curve are very small therefore 
due to the small quantities of functional HHoH.
The HHoH and HDH IgEs anti NIP-HSA antibodies were then tested for viability 
using SPR, (Figure 61) shows the result of the test for HHoH has a small curve (Figure 
61A) confirming that the antibody is functional and successfully  binds to NIP-HSA. 
This small curve, compared to the high concentration of the protein in the solution 
shows that very  little of the antibody is functional. The HDH curve (Figure 61B) was 
normally large as expected. The HHoH IgE anti NIP-HSA was then tested for binding to 
the sFcεRIαD1&2 protein (Figure 61C), the result shows successful binding as 
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expected, but the curves were very  small due to the low concentrations of functional the 
HHoH.
7.3 - Discussion:
To take a shortcut, the plasmid pSV-VNPHHoHGFP was synthesized where a GFP 
gene (Submission by Watkins and Campbell, 1995) was inserted downstream of the 
HHoH gene, without a linker amino acid region, this was in an attempt to synthesis both 
IgE outside the cell, and GFP inside the cell, which could have potentially allowed for 
the cells that express the antibody to be sorted by FACS. This protocol failed as can be 
seen in Figure 62 because the linker region between the HHoH and the GFP did not 




Figure 62: J558L cells cloned with the pSV-VNPHHoHGFP 
plasmid:
This figure shows the failure of the protocol where GFP was 
attempted to be expressed inside the J558L cells, along with the 
HHoH outside the cells, as a mean to allow only expressing cells 
to be sorted, and hence shorten the selection period. A. shows 
non-transfected cells in white light and B. in blue light to allow 
the GFP to fluoresce C. shows the transfected cells in white light 
and in D. in blue light to allow the GFP to fluoresce, noting the 
green spots here are autofluorescence from dead cell debris and 
are not an indication of cells expressing GFP.
Digesting the Cε3 domain after the plasmid pUC18-Cε3 was harvested from 
E.coli XL-1 Blue by the restriction enzymes XhoI and BclI did not work, only  a single 
site a was and not the other. The PCR protocol was revised, the gene sequence was 
analyzed and the restriction digests were optimized (as the BclI enzymes cuts DNA at 
50°C while XhoI at 37°C), and still the digestion did not go through completion. 
Therefore a series of restriction digests revealed the problem (Figure 63).
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Figure 63: Cε3 restriction digestion investigation:
This figure shows different restriction digests which revealed 
that only the BclI restriction site is not cutting, when the BclI 
enzymes was studied further it was revealed that in E.coli the 
BclI restriction site is methylated, there this problem was solved 
by transforming the pUC18-Cε3 plasmid into E.coli JM110 
strain, deficient  in the Dam and Dcm genes, therefore it does not 
methylate DNA at the BclI restriction site.
While all restriction enzymes cut the DNA, once or twice, the BclI restriction site 
was not being cut at all (the figure shows that the BclI sample is identical to the non-cut 
control sample). When the BclI restriction enzyme was studied further, it  was revealed 
that E.coli bacteria naturally methylate the BclI site through the Dam gene (which codes 
for the Dam methylase), thus the methylated DNA prevents the restriction enzyme from 
cutting it. This problem was solved by transforming pPUC18-Cε3 plasmid into JM110 
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E.coli strain which has the Dam and Dcm genes missing, and thus do not methylate 
DNA at the BclI position.
In conclusion, the HHoH IgE anti NIP-HSA experiment was not a total success. 
Up to the construction of the gene and the transfection of the J558L cells everything 
went well, but during the selection process the cells were not selected properly, the 
protocol was repeated 4 times and each time the negative control cells would not die, 
and completely survive in the selection media, this indicates that all the wells with the 
transfected cells had a large cell impurity with non-transfected cells. That is the reason 
very few of the HHoH IgE anti NIP-HSA antibody were collected. The protocol was 
repeated every time with a freshly  thawed batch of cells, but the selection process was 
not strong enough. From Figure 9 in chapter 2.2.4, it can be seen that the selection 
process greatly depends on hypoxanthine to saturate the hypoxanthine-guanine 
phosphoribosyltransferase so it will not  convert guanine to GMP. If the hypoxanthine is 
not in large enough quantity in the media, or has degraded or is being metabolized by 
the cells very fast, the hypoxanthine-guanine phosphoribosyltransferase enzyme will no 
longer be saturated with hypoxanthine and thus start converting guanine into GMP, and 
bypassing the selection process. This is the reason why this selection process was 
sometime low efficient, and an alternative protocol was discussed in chapter 5.3 which 
uses CHO (Chinese Hamster Ovary) cells to express large quantities of proteins 
(including antibodies) with a very efficient selection process.
Therefore to continue the next step  of the experiment the HHoH IgE anti NIP-
HSA, which was supposed to be used to immunize rats, was replaced by the HDH IgE 
anti NIP-HSA, which should test the exact same allergy vaccine concept and the 
original antigenic sin hypothesis, but in the canine system. Which if successful can be 
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said to be relevant for the equine and human systems since all these systems’ IgE-
mediated responses are almost identical.
212
Chapter 8 - Development of An Allergy 
Vaccine:
8.1 - Introduction:
This chapter tested the concept of developing a polyclonal antibody serum against 
an organism’s native IgE that binds at  a high enough affinity  to remove all non-bound 
serum IgEs as well as knock off the bound IgE from its FcεRI receptor. A peptide called 
2Fcε2-3 was synthesized which includes part of the amino acid sequence within the IgE 
antibody’s Cε3 domain that binds the IgE to its FcεRI receptor (Chapter 7.1 for 
explanation). This peptide contains a conserved sequence found in human, canine and 
equine IgEs. The novel concept is using this peptide to immunize the host organisms 
which are humans, canines and equines, so they can develop IgG antibodies that 
recognize this sequence, but since the sequence is in a peptide form, even though it is a 
disulphide linked dimer, will develop IgG antibodies that bind to it  at a lower affinity 
than the IgE binds to its FcεRI receptor. Therefore to increase this affinity, a chimeric 
antibody, where the native organism’s IgE’s Cε3 domain is inserted between the 
Cε1Cε2 and Cε4 domains of a distant evolutionary organism’s IgE domains, to make a 
full IgE chimeric antibody. The organism is given a vaccine boost with this chimera 
where the immune system, using the Original Antigenic Sin Hypothesis (Chapter 1.8), 
would target only the sequence, form the 2Fcε2-3 peptide, in the Cε3 domain and 
develop antibodies with higher affinities to it through somatic hypermutations. If the 
concept works it  will lead to a development of an allergy vaccine where the host 
organism would remove all serum and bound IgE and thus permanently cure allergy.
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8.2 - Results:
8.2.1 - Antibody Titer Analysis By ELISA:
As discussed in the Chapter 7.3, due to limited funds and equipment, the 
immunization protocols (Chapter 2.5.1) were run on rats using the HDH IgE anti NIP-
HSA antibody  chimera instead of the HHoH anti NIP-HSA. Therefore rats 1 and 2 were 
immunized with the 2Fcε2-3 peptide followed by two boosts with the same peptide. Rats 
3 and 4 where also initially  immunized with the 2Fcε2-3 peptide, but followed by  two 
boosts with the HDH IgE anti NIP-HSA antibody chimera (Table 5).
Table 5: Rat immunization strategy:





Bleed 1 Bleed 2 Bleed 3






Immunised with the 2Fcε2-3 peptide Boosted 1 with the 2Fcε2-3 peptide Boosted 2 with the 2Fcε2-3 peptide
Immunised with the 2Fcε2-3 peptide Boosted 1 with the 2Fcε2-3 peptide Boosted 2 with the 2Fcε2-3 peptide
Immunised with the 2Fcε2-3 peptide Boosted 1 with HDH IgE Boosted 2 with HDH IgE
Immunised with the 2Fcε2-3 peptide Boosted 1 with HDH IgE Boosted 2 with HDH IgE
The rat bleeds were initially  tested using ELISA (Chapter 2.5.2) for binding to the 
2Fcε2-3 peptide (Figure 64A). The results on Figure 65 shows that all rats were 
successfully  developed an immune response to the 2Fcε2-3 peptide, and the pre 
immunization bleed confirms this. Noting great variability  between rats of the sample 
and control group, which is expected since each individual rat would develop an 
immune response on its own pace depending its health and environment, though these 












Rat IgE + HRP
Yellow Colour
Native IgE
A                                      B
Figure 64: Bleed test using ELISA assay:
This figure shows the two different ELISA assay  construction 
used to test the rat bleeds. A. assay tested the difference between 
the first and second rat bleeds and their antibody titer that bound 
to the 2Fcε2-3 peptide. B. assay tested the difference, in of the 
second bleed, between the control rats, immunized only with the 
2Fcε2-3 peptide, and the test rats, immunized with the chimeric 
HDH anti NIP-HSA antibody.
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1:200 9.999 0.000 0.871 0.030 0.532 0.006 2.915 0.040 0.136 0.016
1:400 9.999 0.000 0.395 0.028 0.239 0.014 1.747 0.005 0.089 0.001
1:800 2.845 0.069 0.185 0.012 0.140 0.004 0.902 0.071 0.070 0.006
1:1,600 1.878 0.178 0.108 0.000 0.091 0.003 0.357 0.003 0.062 0.002
1:3,200 0.877 0.100 0.078 0.002 0.067 0.002 0.163 0.011 0.054 0.002
1:6,400 0.369 0.055 0.067 0.001 0.053 0.001 0.094 0.005 0.052 0.004
1:12,800 0.188 0.016 0.052 0.000 0.052 0.001 0.061 0.002 0.050 0.002
1:25,600 0.079 0.050 0.046 0.000 0.050 0.001 0.054 0.001 0.051 0.003
1:51,200 0.072 0.004 0.048 0.000 0.043 0.000 0.051 0.001
1:102,400 0.059 0.001 0.050 0.003 0.047 0.001 0.053 0.001









9.999 9.999 0.069 0.074 0.052 0.052 0.065 0.068 0.952 0.851 0.125 0.147
9.999 9.999 0.059 0.058 0.046 0.046 0.054 0.052 0.355 0.359 0.089 0.088
2.796 2.893 0.850 0.892 0.048 0.048 0.052 0.051 0.171 0.155 0.066 0.074
1.752 2.004 0.375 0.415 0.052 0.048 0.050 0.049 0.097 0.090 0.060 0.063
0.806 0.947 0.193 0.176 0.536 0.527 0.043 0.043 0.062 0.059 0.052 0.055
0.330 0.408 0.108 0.108 0.229 0.249 0.046 0.047 0.053 0.055 0.049 0.055
0.177 0.199 0.079 0.076 0.137 0.143 2.943 2.886 0.050 0.051 0.048 0.051
0.043 0.114 0.068 0.066 0.089 0.093 1.750 1.743 0.052 0.053 0.049 0.053




1:200 9.999 0.000 2.708 0.000 1.918 0.074 9.999 0.000 0.151 0.011
1:400 9.999 0.000 1.640 0.010 0.955 0.072 6.487 4.967 0.099 0.004
1:800 9.999 0.000 0.677 0.001 0.437 0.022 2.269 0.167 0.080 0.008
1:1,600 9.999 0.000 0.284 0.021 0.209 0.027 0.999 0.096 0.077 0.008
1:3,200 2.211 0.100 0.142 0.001 0.114 0.002 0.464 0.054 0.067 0.014
1:6,400 1.105 0.064 0.096 0.003 0.070 0.006 0.202 0.017 0.060 0.001
1:12,800 0.538 0.030 0.076 0.001 0.066 0.001 0.103 0.005 0.067 0.011
1:25,600 0.284 0.005 0.117 0.078 0.074 0.004 0.085 0.001 0.072 0.007
1:51,200 0.155 0.002 0.060 0.001 0.057 0.006 0.069 0.001
1:102,400 0.101 0.008 0.066 0.006 0.060 0.000 0.072 0.001









9.999 9.999 0.156 0.153 0.075 0.076 0.115 0.112 2.387 2.151 0.143 0.158
9.999 9.999 0.106 0.095 0.172 0.062 0.066 0.074 1.067 0.931 0.096 0.101
9.999 9.999 2.708 2.708 0.059 0.060 0.065 0.067 0.502 0.425 0.074 0.085
9.999 9.999 1.633 1.647 0.062 0.070 0.076 0.071 0.214 0.190 0.071 0.082
2.140 2.281 0.677 0.676 1.865 1.970 0.061 0.053 0.106 0.099 0.057 0.077
1.150 1.060 0.269 0.298 1.006 0.904 0.060 0.060 0.086 0.084 0.059 0.061
0.516 0.559 0.142 0.141 0.421 0.452 9.999 9.999 0.070 0.068 0.059 0.075
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216
Figure 65: ELISA test of each rat’s bleed for binding to the 
2Fcε2-3:
This figure shows the results of all rats’ 1st and 2nd bleeds tested 
by ELISA for binding to the 2Fcε2-3 peptide as in Figure 64A. 
Noting that rats 1 and 2 were immunized with the 2Fcε2-3 
peptide and also boosted with it, wile rats 3 and 4 were 
immunized with the 2Fcε2-3 peptide but boosted with the HDH 
anti NIP-HSA chimeric IgE antibody. The pre immunization 
serum shows no antibodies binding to the 2Fcε2-3 peptide as 
expected. Noting that  variations in antibody titer (quantity of 
antibodies) is expected between rats since each individual rats 
reacts differently to the immunization protocol.
Since this initial ELISA test was successful, a further ELISA test was preformed 
to test whether the rat  serum binds and recognizes the native (human, canine, equine) 
IgE anti NIP-HSA antibody’s Cε3 domain (Figure 64B). The results were successful as 
shown in Figure 66, where rats 1 and 2, that were boosted with the same 2Fcε2-3 
peptide, had a very low antibody titer that  recognizes the native IgE anti NIP-HSA 
antibody’s Cε3 domain, but rats 3 and 4, that were boosted with the HDH IgE anti NIP-
HSA antibody  chimera, have a higher antibody serum titer that recognize the native IgE 
anti NIP-HSA antibody’s Cε3 domain.
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1:200 0.233 0.008 0.354 0.021 1.986 0.045 2.043 0.009 0.127 0.004 0.941 0.120
1:400 0.132 0.011 0.195 0.001 1.874 0.019 2.081 0.043 0.108 0.002
1:800 0.114 0.006 0.123 0.000 1.737 0.049 1.841 0.159 0.107 0.004
1:1,600 0.104 0.002 0.102 0.003 1.535 0.028 1.714 0.076 0.103 0.003
1:3,200 0.093 0.004 0.094 0.001 1.143 0.019 1.393 0.032 0.096 0.004
1:6,400 0.093 0.004 0.101 0.001 0.756 0.063 1.034 0.043 0.108 0.008
1:12,800 0.097 0.003 0.094 0.001 0.461 0.006 0.670 0.021 0.102 0.013
1:25,600 0.100 0.006 0.092 0.002 0.278 0.004 0.424 0.007
1:51,200 0.092 0.001 0.096 0.002 0.182 0.010 0.271 0.014
1:102,400 0.094 0.000 0.092 0.002 0.147 0.005 0.218 0.001









0.238 0.227 0.091 0.093 0.093 0.095 1.129 1.156 1.728 1.953 0.124 0.130
0.139 0.124 0.094 0.094 0.090 0.093 0.711 0.800 1.768 1.660 0.109 0.106
0.118 0.109 0.339 0.369 0.094 0.097 0.465 0.457 1.370 1.415 0.104 0.109
0.105 0.102 0.194 0.196 0.093 0.090 0.275 0.281 1.003 1.064 0.101 0.105
0.095 0.090 0.123 0.123 1.954 2.017 0.175 0.189 0.655 0.685 0.093 0.098
0.096 0.090 0.100 0.104 1.887 1.860 0.143 0.150 0.419 0.429 0.113 0.102
0.095 0.099 0.094 0.093 1.771 1.702 2.049 2.036 0.261 0.281 0.092 0.111
0.104 0.096 0.101 0.100 1.555 1.515 2.050 2.111 0.218 0.217 0.941 0.120








1:200 1.102 0.009 0.881 0.009 1.907 0.050 2.326 0.030 0.114 0.003 1.276 0.085
1:400 0.622 0.012 0.463 0.027 1.832 0.004 2.243 0.058 0.091 0.007
1:800 0.368 0.013 0.260 0.003 1.721 0.047 1.998 0.109 0.081 0.004
1:1,600 0.232 0.019 0.174 0.001 1.555 0.023 1.704 0.037 0.076 0.004
1:3,200 0.142 0.018 0.128 0.004 1.123 0.011 1.280 0.011 0.066 0.003
1:6,400 0.112 0.016 0.108 0.006 0.694 0.043 0.826 0.000 0.070 0.004
1:12,800 0.093 0.013 0.083 0.003 0.421 0.018 0.469 0.015 0.071 0.002
1:25,600 0.109 0.009 0.070 0.002 0.245 0.008 0.304 0.001
1:51,200 0.075 0.004 0.068 0.001 0.157 0.023 0.195 0.006
1:102,400 0.064 0.001 0.065 0.001 0.114 0.001 0.138 0.007









1.095 1.108 0.077 0.072 0.081 0.085 1.130 1.115 1.921 2.075 0.112 0.116
0.630 0.613 0.063 0.064 0.071 0.068 0.663 0.724 1.678 1.730 0.086 0.096
0.377 0.358 0.874 0.887 0.068 0.067 0.434 0.408 1.272 1.288 0.078 0.084
0.245 0.218 0.482 0.444 0.065 0.064 0.250 0.239 0.826 0.826 0.073 0.079
0.155 0.129 0.258 0.262 1.871 1.942 0.173 0.141 0.479 0.458 0.064 0.068
0.123 0.101 0.173 0.175 1.829 1.834 0.113 0.115 0.304 0.303 0.067 0.072
0.102 0.084 0.125 0.130 1.754 1.687 2.347 2.305 0.190 0.199 0.069 0.072
0.115 0.102 0.112 0.103 1.571 1.539 2.202 2.284 0.143 0.133 1.276 0.085








1:200 1.397 0.112 1.014 0.071 2.288 0.146 2.696 0.076 0.148 0.010 0.560 0.123
1:400 0.810 0.049 0.591 0.037 2.265 0.054 2.716 0.076 0.119 0.001
1:800 0.500 0.008 0.337 0.025 2.170 0.095 2.349 0.198 0.110 0.006
1:1,600 0.293 0.021 0.218 0.006 1.835 0.127 2.094 0.062 0.103 0.000
1:3,200 0.186 0.013 0.154 0.004 1.511 0.000 1.475 0.068 0.095 0.001
1:6,400 0.138 0.010 0.136 0.004 0.854 0.001 0.973 0.013 0.095 0.001
1:12,800 0.121 0.018 0.117 0.005 0.507 0.023 0.533 0.023 0.103 0.002
1:25,600 0.135 0.025 0.099 0.000 0.296 0.003 0.333 0.021
1:51,200 0.105 0.002 0.094 0.001 0.189 0.004 0.212 0.002
1:102,400 0.091 0.002 0.094 0.001 0.142 0.000 0.163 0.011









1.318 1.476 0.106 0.103 0.113 0.120 1.511 1.511 2.209 2.489 0.141 0.155
0.845 0.775 0.089 0.092 0.099 0.099 0.853 0.855 2.050 2.138 0.119 0.118
0.506 0.494 0.964 1.064 0.093 0.094 0.523 0.491 1.427 1.523 0.105 0.114
0.308 0.278 0.565 0.617 0.093 0.094 0.294 0.298 0.964 0.982 0.103 0.103
0.195 0.176 0.319 0.355 2.184 2.391 0.192 0.186 0.516 0.549 0.095 0.094
0.145 0.131 0.214 0.222 2.226 2.303 0.142 0.142 0.318 0.347 0.094 0.096
0.133 0.108 0.151 0.156 2.102 2.237 2.642 2.750 0.210 0.213 0.101 0.104
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Figure 66: ELISA test of bleed to of all rats for binding to 
the native IgE antibodies:
This figure shows the ELISA test  of all rats’ 2nd bleed for 
binding to the native antibodies (human, equine and canine 
IgEs), as in Figure 64B. From the figure it  can be determined 
that the rats (3 and 4) that were boosted with the HDH anti NIP-
HSA chimeric IgE antibody had a much higher antibody titer 
than specific to the native IgEs than the rats (1 and 2) that  were 
boosted with the 2Fcε2-3 peptide.
This was expected since displaying epitopes in its native 3D structure would 
cause the immune system to better target them. The negative pre immunization bleed 
and no IgE control, along with the positive, rabbit anti human IgE AB helix from 
chapter 6.3.2, control have verified these results.
8.2.2 -Anaphylactic Shock Test By β-hexosaminidase Release Assays:
So far the immunization protocol looked promising, immunizing rats with the 
2Fcε2-3 peptide followed by a boost with the HDH IgE anti NIP-HSA antibody chimera 
resulted is large serum antibodies that target the desired epitopes. In this experiment the 
original antigenic sin hypothesis was tested whether or not it worked and the immune 
system had only targeted the PRGV sequence in the 2Fcε2-3 peptide and not other 
epitopes in the HDH IgE anti NIP-HSA antibody chimera. We used the β-
hexosaminidase release assays (Chapter 2.4.9) that we developed to test whether or not 
the rat serum causes RBL-2H3.1 cells to release mediators due to the anti IgE antibodies 
cross linking FcεRI receptor bound native IgE on the cell’s surface and thus aggregate 
the receptor. In this test the antigen (NIP-HSA or DNP-HSA) serial dilution was 















































1.43 1.41 1.32 1.39 1.61 1.29 0.18 0.21 0.19 0.18 0.11 0.12
1.32 1.32 1.32 1.28 1.68 1.37 0.11 0.12 0.11 0.13 0.17 0.17
1.39 1.39 1.42 1.34 1.65 1.41 0.16 0.18 0.17 0.18 0.18 0.18
1.41 1.45 1.48 1.36 1.63 1.41 0.17 0.18 0.19 0.21 0.17 0.19
1.40 1.48 1.41 1.27 1.65 1.43 0.16 0.16 0.17 0.22 0.20 0.21
1.37 1.39 1.31 1.24 1.66 1.36 0.16 0.18 0.23 0.27 0.19 0.20
1.29 1.37 1.26 1.22 1.69 1.35 0.15 0.16 0.23 0.25 0.14 0.14
1.22 1.36 1.23 1.17 1.76 1.39 0.10 0.12 0.17 0.22 0.21 0.22
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       	 
   	
       	    
% of Total In Cell
x2 because (I used 50 µl instead of the 
100) + Supernatant Value
To Find Original Total In Cell
20.47 22.87 22.63 20.84 12.31 15.58 
 
 	 	 
 
14.73 15.28 14.62 16.99 16.58 19.41      	
18.52 20.21 19.04 20.90 18.07 19.89 	 	 	   	




18.60 17.69 19.61 25.64 19.59 23.04 	 
 	 	  

19.22 20.75 25.74 30.26 18.23 22.73 	 	 	 	
  	
18.46 18.93 26.40 29.23 13.95 16.67 
  	 	  
14.45 15.21 21.46 27.15 19.04 23.79   	  	 

16.43 15.09 15.34 17.75 15.81 14.88  
 
   
20.90 22.40 22.32 22.22 22.59 23.28  
    
24.08 25.49 25.20 26.12 24.19 25.48   
   	
23.60 21.08 25.21 24.83 24.16 25.35 	     
25.56 25.55 27.92 32.05 26.30 25.13     	 

23.23 24.58 28.29 33.38 25.64 23.35 	     	
18.41 19.38 27.04 31.67 19.92 18.72      
24.87 26.56 33.17 36.42 21.72 28.66    	 
 	
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1.84 1.90 1.81 1.79 1.63 1.80 0.17 0.19 0.21 0.18 0.11 0.09
1.74 1.77 1.60 1.58 1.69 1.66 0.11 0.10 0.17 0.19 0.17 0.16
1.77 1.78 1.44 1.42 1.60 1.70 0.15 0.16 0.36 0.35 0.18 0.15
1.72 1.75 1.24 1.20 1.61 1.78 0.18 0.19 0.50 0.51 0.17 0.18
1.73 1.74 1.08 1.06 1.61 1.25 0.14 0.16 0.54 0.56 0.19 0.44
1.74 1.79 1.05 1.03 1.62 1.14 0.17 0.16 0.59 0.61 0.17 0.53
1.79 1.79 1.04 1.01 1.61 1.24 0.15 0.16 0.62 0.56 0.12 0.41
1.75 1.80 1.08 1.06 1.73 1.20 0.11 0.09 0.55 0.43 0.20 0.54
		 
 	 	 	 
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   	  	 	    
	 
	   
    
   
% of Total In Cell
x2 because (I used 50 µl instead of the 
100) + Supernatant Value
To Find Original Total In Cell
15.83 16.89 18.76 16.90 11.41 9.44     
 
11.04 9.96 17.53 19.06 16.34 15.82  	    	
14.66 14.83 33.46 32.83 18.03 15.25 	     
17.55 17.69 44.49 45.80 17.52 16.59      
14.02 15.37 49.86 51.47 19.10 41.20    
  
16.10 15.33 52.96 54.02 17.18 48.04 	     
14.60 15.09 54.19 52.72 13.16 39.69   	  
 
10.90 9.54 50.41 44.68 18.63 47.32   
   

11.59 12.81 12.65 13.56 11.82 13.17  
    
16.42 16.82 21.79 20.75 18.98 18.60   
   
18.02 18.08 35.73 31.74 18.57 17.54      
16.18 16.18 40.04 43.07 19.06 21.22  
  	  
19.15 18.81 47.80 49.71 19.53 30.90      	
17.98 17.77 47.28 51.63 18.78 35.92   
 	  





19.16 19.26 47.28 49.51 19.28 38.83   
   
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1.27 1.26 1.28 1.28 1.39 1.11 0.18 0.20 0.19 0.16 0.11 0.11
1.18 1.23 1.19 1.24 1.49 1.16 0.12 0.12 0.13 0.12 0.16 0.15
1.23 1.23 1.22 1.22 1.46 1.18 0.15 0.16 0.18 0.20 0.16 0.17
1.26 1.25 1.19 1.15 1.45 1.20 0.18 0.17 0.22 0.23 0.17 0.16
1.18 1.23 1.13 1.08 1.47 1.19 0.14 0.15 0.21 0.22 0.19 0.20
1.26 1.26 1.13 1.11 1.51 1.17 0.15 0.15 0.20 0.22 0.17 0.19
1.24 1.24 1.14 1.12 1.45 1.16 0.13 0.15 0.21 0.22 0.13 0.15
1.19 1.18 1.09 1.08 1.57 1.24 0.09 0.09 0.15 0.16 0.19 0.21
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 	      
 
 
 	  	 
 
 
    
% of Total In Cell
x2 because (I used 50 µl instead of the 
100) + Supernatant Value
To Find Original Total In Cell
21.60 24.10 22.89 19.60 14.09 16.04      
16.90 16.44 17.70 16.55 17.41 20.87  	   
 	
20.03 20.95 22.49 24.60 18.34 21.85   	  	 
21.93 21.78 26.99 28.66 18.63 20.63     	
 
19.51 19.92 27.00 29.13 20.63 24.68 	    
 

19.64 19.02 26.53 28.29 18.38 24.90 	    
 
17.44 19.48 26.55 28.30 14.91 20.22     	 
13.24 13.62 21.13 22.41 19.57 25.39 	 	 
   
12.16 12.77 10.96 13.79 13.47 17.23   
   
20.42 22.46 20.57 22.88 22.69 24.03    
  
21.16 23.27 21.56 23.85 23.41 25.51 
  	   

21.29 20.58 21.59 24.47 20.23 22.63  	   	 
21.20 22.61 25.12 27.98 23.08 25.00 
  	   	
24.07 23.32 26.36 31.01 23.80 27.36    
  
16.79 18.05 20.88 24.84 15.67 19.35 
   	  
23.23 25.41 24.49 27.12 22.77 25.49  	 
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Bleed Dilution FactorRat 1 Bleed 2
Rat 2 Bleed 2
Rat 3 Bleed 2
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Rat 1 Bleed 2
Rat 2 Bleed 2
Rat 3 Bleed 2
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Rat 1 Bleed 2
Rat 2 Bleed 2
Rat 3 Bleed 2

































1.19 1.19 1.96 2.17 1.71 1.71 0.09 0.0925 0.094 0.101 0.093 0.095
1.23 1.18 1.95 2.12 1.7 1.72 0.148 0.164 0.165 0.174 0.161 0.169
1.23 1.14 1.93 1.94 1.72 1.69 0.164 0.184 0.19 0.201 0.184 0.177
1.16 1.17 1.66 1.71 1.68 1.66 0.16 0.178 0.363 0.363 0.18 0.191
1.08 1.14 1.34 1.4 1.59 1.61 0.236 0.275 0.655 0.723 0.273 0.274
1.14 1.11 1.22 1.19 1.64 1.63 0.205 0.235 0.615 0.647 0.249 0.267
1.18 1.12 1.2 1.26 1.61 1.67 0.131 0.15 0.62 0.518 0.176 0.191
1.24 1.24 1.3 1.44 1.67 1.69 0.178 0.222 0.7 0.685 0.262 0.263
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NIP-HSA Antigen Concentration (ng ml   )
RBL-2H3.1 Expressing Human FcεRIα + Human IgE + NIP-HSA
RBL-2H3.1 Expressing Equine FcεRIα + Equine IgE + NIP-HSA
RBL-2H3.1 Expressing Canine FcεRIα + Canine IgE + NIP-HSA
RBL-2H3.1 Expressing Human FcεRIα No IgE + NIP-HSA
RBL-2H3.1 Expressing Human FcεRIα No IgE + NIP-HSA





























1.39 1.42 2.26 2.35 1.62 1.68 0.127 0.118 0.097 0.11 0.107 0.119
1.61 1.45 2.32 2.16 1.65 1.76 0.128 0.125 0.114 0.105 0.101 0.117
1.41 1.43 2.19 2.38 1.7 1.63 0.138 0.129 0.114 0.128 0.105 0.115
1.61 1.44 2.19 2.11 1.6 1.63 0.136 0.14 0.123 0.119 0.115 0.12
1.61 1.4 2.12 2.39 1.58 1.65 0.125 0.123 0.114 0.119 0.124 0.104
1.61 1.4 2.18 2.12 1.61 1.63 0.131 0.151 0.117 0.134 0.12 0.125
1.43 1.37 2.24 2.42 1.63 1.65 0.139 0.136 0.12 0.139 0.118 0.131
1.41 1.34 2.16 2.16 1.65 1.65 0.15 0.147 0.134 0.142 0.139 0.128
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Figure 67: Release assays of bleed 2 from all rats:
A. this figure shows the release assays of the RBL-2H3.1 cells 
that were expressing human, equine or canine FcεRIα receptors. 
All cells were sensitized with their corresponding native IgE; 
RBL-2H3.1 cells expressing human FcεRIα receptor were 
sensitized with human IgE, ect. The cells were tested for release 
with the addition of an increasing concentration of all rat’s 
serum from the 2nd bleed, this was to test  whether or not the 
polyclonal antibodies raised against  self IgE would bind to 
receptor bound IgE, aggregating, it  and causing an anaphylactic 
shock which is a body wide cell mediator release. The positive 
control used NIP-HSA to cause the cells to release, while the 
negative control used pre-immunization serum. The results show 
that the rat serum does cross link FcεRI receptor bound IgE and 
causes mediator release, i.e will cause an anaphylactic shock. B. 
this figure shows a positive and negative control assay to test the 
mediator release health of the cell lines. In the positive control 
the cells were sensitized with their corresponding native IgE anti 
NIP-HSA and challenged with increasing concentration of NIP-
HSA, while in the negative control the cells were not  sensitized 
with their corresponding native IgE anti NIP-HSA but still 
challenged with increasing concentration of NIP-HSA.
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The results on Figure 67 have revealed that the original antigenic sin hypothesis 
did not work as expected and the immune system did target  other epitopes in the HDH 
IgE anti NIP-HSA antibody chimera, which causes the serum antibodies to bind to 
different sites in the native IgE on the RBL-2H3.1 cell’s surface and cause them to 
release mediators. This is a fatal phenomena, since if this immunization technique was 














Figure 68: Concept behind immunization leading to massive 
anaphylactic shock.
This figure shows the concept behind aggregation of FcεRI 
receptor bound native IgE on the cell’s surface and causing 
mediator release. This proves that if this immunization 
technique was used it will cause the host organism to undergo a 
massive anaphylactic shock.
The fact that the RBL-2H3.1 cells expressing the human FcεRIα released 
mediators when they were sensitized with human IgE and challenged with the rat serum 
indicate, which the rat  immune system targeted epitopes in the Cε1, Cε2 and Cε4 
domains of the HDH IgE anti NIP-HSA antibody chimera, is why they cause receptor 
aggregation of the cell surface. The fact that the RBL-2H3.1 cells expressing the canine 
FcεRIα released mediators when they were sensitized with canine IgE and challenged 
with the rat serum indicate that the rat immune system targeted epitopes, different to 
that from the desired PRGV epitope displayed by the 2Fcε2-3 peptide, in the Cε3 domain 
of the HDH IgE anti NIP-HSA antibody chimera, which is why they caused receptor 
aggregation on the cell surface. The fact that the RBL-2H3.1 cells expressing the equine 
FcεRIα released mediators when they were sensitized with equine IgE and challenged 
with the rat serum indicate that the rat immune system that targeted the canine Cε3 
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domain also targeted the equine Cε3 domain since the two domains are 68% identical 
(Figure 69).
Figure 69: Equine and Canine IgE Cε3 domain sequence:
This figure shows the BLAST sequence between the Equine and 
Canine IgE Cε3 domain. The result  shows 68% sequence 
identity.
8.3 - Discussion:
All the tests were run on bleeds two as the main objective was to identify if the 
original antigenic sin hypothesis works and the immune system only targets the required 
PRGV IgE Cε3 epitope. Bleed three was supposed to identify if an extra second boost 
would increase the immune system antibody’s affinity to its self IgE up to the level 
where FcεRI receptor bound IgE can be knocked off the mast  and basophil cell’s 
surface. But since the original antigenic sin hypothesis proved not to work, and the 
organism would suffer a massive anaphylactic shock if it  was immunized using this 
strategy, testing bleed 3 was abandoned.
The immunization protocol has revealed important information regarding 
vaccinations; first of all, displaying epitopes in their native 3D structure is the best way 
to achieve good serum antibody titer against them, much better than a single or a 
cyclised peptide. Second, the original antigenic sin hypothesis does not work in this 
immunization and the immune system will recognize the initial epitope from the 
vaccine peptide, along with other epitopes in the full vaccine boost chimeric antibody 
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molecule, which will lead to cross linking of FcεRI receptor bound IgE, just like an 
antigen does, and the cells will respond by releasing mediators that will cause the 
organism to experience organ wide inflammation, which is basically  a massive 
anaphylactic shock. This is counters the observations in the paper by  (Ledin, et al., 
2006), where they did not test a potential anaphylactic shock occurring.
But a point to mention is that, at  a dilution of 1:200 the mediator release started to 
fall, this raises the question whether full serum would polarize the basophil cells, though 
receptor capping, enough to stop them completely  from releasing any mediators? This 
might be the reason why  the dogs in the (Ledin, et al., 2006) paper did not die? Immune 
complexes are theorized not to occur, since the quantity  of IgE is considerably lower 
than that of IgG even in atopic patients.
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Chapter 9 - Discussion:
9.1 - General Project Discussion:
In order to study equine allergy, this project developed some essential reagents, all 
of which allowed these experiments to be preformed. These reagents may also have 
commercial potential for the assessment of the safety  of anti-allergic drugs. The 
development of an RBL-2H3.1 cell line that expresses equine FcεRIα receptor onto its 
surface, and an equine IgE anti NIP-HSA, allowed the measurement of the quantity of 
mediator release when equine IgE binds to its FcεRI receptor (36.68%). It also showed 
that canine IgE can bind to the equine FcεRI receptor and cause mediator release (32%), 
while the equine IgE does not recognize the canine FcεRI receptor. 
The project also developed a soluble form of the equine FcεRI receptor 
(sFcεRIαD1&2) which allowed the measurement of the binding between it and the 
equine IgE (KD = 1.58x10-10M  after calibrating the measured data on the EvilFit 
Distribution Model). This was taken further and the binding between the canine IgE and 
the equine sFcεRIαD1&2 was measured (KD = 5.43x10-10M), this binding affinity is 
comparable to that between the equine IgE and the equine sFcεRIαD1&2, which 
explains why  the canine IgE causes mediator release in RBL-2H3.1 cells expressing 
equine FcεRIα. 
Since the binding between the equine IgE and its FcεRI receptor was confirmed, 
and previous members of this laboratory demonstrated the binding of the human IgE/
FcεRI receptor and the canine IgE/FcεRI, this project used this information and tested a 
hypothesis that attempts to develop a vaccine, where an organism’s body  would develop 
antibodies against its own self IgE antibody targeting the complementary sites of 
interaction between IgE and FcεRI receptor, with the expectation that the binding has a 
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strong enough affinity to allow the removal of serum IgE and FcεRI receptor bound IgE 
without aggregating the FcεRI receptor bound IgEs on mast and basophil cell surfaces 
causing an anaphylactic shock. This hypothesis implements a protocol where rats were 
initially immunized with an immungen (2Fcε2-3 peptide) that caused the organism’s 
immune response to target an essential part of the self IgE antibody, followed by boosts 
with a full chimeric IgE antibody that displayed the same peptide epitope but in a 3D 
structure to allow that immune system to develop higher affinity  antibodies against it 
through somatic hypermutations as claimed by other investigators (Ledin, et al., 2006). 
The hypothesis also useed the concept of original antigenic sin as a basis for a potential 
immunization strategy, where the immune system is thought to preferentially target, on 
second exposure, only the epitope displayed by the 2Fcε2-3 peptide even if it was 
displayed in the chimeric IgE antibody, without targeting other epitopes.
The results of this, potential allergy vaccine, was negative. The results showed 
excellent antibody titers against  the target, i.e. the chimeric IgE antibody after the first 
boost with it, indicating that displaying the 2Fcε2-3 peptide epitopes in a 3D structure 
allows the rat immune system to target them better. But when the rat serum was tested 
for IgE aggregation on the basophil cell surface, it  showed that it  does cause the cells to 
release mediators. This showed that the original antigenic sin hypothesis did not work in 
this protocol, as hoped, and the rat immune system did target other epitopes in the 
chimeric IgE antibody which resulted in its cell surface aggregation, i,e: can potentially 
cause the organism to experience an anaphylactic shock. These results indicate that an 
anti-allergy vaccine might be possible by targeting sites like the Cε3 interdomain 
region, which is highly  conserved between human, canine and equine, but the challenge 
is to raise antibodies of a high enough affinity  for the receptor binding regions in IgE to 
inhibit the binding between IgE and FcεR1 receptor.
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9.2 - Future Work:
The immunization protocol for the, potential allergy vaccine, caused FcεRI 
receptor bound IgE aggregation on mast and basophil cell surface resulting in an 
anaphylactic anti-IgE antibody response. A way around this that can be further 
researched is to boost  the immune system with a chimeric IgE antibody that has the 
same 2Fcε2-3 peptide epitope but within a Cε3 domain of an even further remote 
phylogenic mammal, with an amino acid sequence less than 60%. This might allow that 
elimination of the dependence on the original antigenic sin hypothesis for the immune 
system to target only the desired epitope, therefore it  would only target this epitope and 
other in the IgE’s Cε3 domain but of different epitopes, ones that are not found in the 
organism’s self IgE antibody. Therefore the final immune response would target only 
the self IgE antibody epitope without causing FcεRI receptor bound IgE aggregation on 
mast and basophil cell surface.
The project targeted a sequence called the Cε2-3 linker (amino acids 350-363). 
The future work can also be to apply these protocols to target other loops: BC loop 
(362-365), DE loop (393-396), and Omalizumab’s suggested target  of the FG loop 
(424-427) “within the HPL loop  (424-436)” (Figure 70). All these loops are masked 
when the IgE binds to its FcεRI receptor. This characteristic makes these loops a good 
target because, first  they interact with the FcεRI receptor, therefore disrupting them will 
interfere with the IgE binding. Second, they are masked during the IgE binding, thus 
antibodies that targets them will have no chance of causing degranulation since they 
will not be able to cross link IgE occupied receptors.
Another loop  that can be tested further is the AB helix (343-353) (Figure 70), 
which is not involved in the IgE/FcεRI receptor binding, but is essential in maintaing 
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Figure 70: Locations of potentially immogenic sequences to 
raise non-anaphylactic anti self IgE antibodies:
This figure shows the location of the different essential loops in 
the full IgE molecule, and their sequences in the equine, human 
and canine organisms. Noting all these loops are within, or close 
to, the Cε3 domain.
Since the immunization protocol was not successful in developing a strategy for 
the development of non-anaphylactogenic anti self IgE antibodies as therapeutic 
immunogen, further investigations are essential to develop immunization schedules to 
allow the organism’s body to develop non-anaphylactic antibodies against its own self 
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IgE. One possibility  would be to have the vaccine peptide made up of several repeated 
epitopes encompassing sequences involved in IgE/FcεRI in tandem to further direct the 
immune system to mount an antibody response against these sequences instead of others 
within the full IgE antibody, and thus eliminate the possibility of eliciting antibodies 
that induce IgE/FcεRI receptor aggregation on the cell’s surface that results in an 
anaphylactic shock.
The observed effect, where the mediator release started to decline after the rat 
serum was at  a dilution of 1:200 might be investigated further to see if high enough 
antibody serum titer would polarize basophil cells and cause them not to release 
mediators. This might be risky as an organism’s response to vaccination cannot be 
accurately predicted, and might develop only a small antibody titer, not  enough to 
polarize the mast and basophil cells, which would cause the cells to release mediators.
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Appendix:
Rattus norvegicus codon usage table:
First three letters are the codons in the mRNA. The numbers 
next to them are the frequencies of each codon were 1.00 = 
100%, the frequency per thousand and the actual number of the 
codons in the genome. Taken from: http://www.kazusa.or.jp/
codon/
UUU F 0.42 16.5 
(115498)  
UCU S 0.19 14.8 
(103148)  
UAU Y 0.40 11.6 
( 80999)  
UGU C 0.45  9.8 
( 68418)
UUC F 0.58 23.1 
(161568)  
UCC S 0.23 17.8 
(124290)  
UAC Y 0.60 17.1 
(119192)  
UGC C 0.55 11.9 
( 82751)
UUA L 0.06  5.9 
( 41454)  
UCA S 0.14 10.9 
( 76435)  
UAA * 0.28  0.6 
(  4473)  
UGA * 0.50  1.2 
(  8137)
UUG L 0.13 12.8 
( 89203)  
UCG S 0.06  4.4 
( 30458)  
UAG * 0.22  0.5 
(  3637)  
UGG W 1.00 13.2 
( 91958)
CUU L 0.12 12.5 
( 87332)  
CCU P 0.30 17.4 
(121358)  
CAU H 0.39  9.5 
( 66664)  
CGU R 0.09  5.0 
( 34788)
CUC L 0.20 20.4 
(142093)  
CCC P 0.31 18.0 
(125645)  
CAC H 0.61 14.9 
(104027)  
CGC R 0.18  9.8 
( 68486)
CUA L 0.08  7.6 
( 52955)  
CCA P 0.28 16.1 
(112364)  
CAA Q 0.25 11.1 
( 77366)  
CGA R 0.12  6.8 
( 47207)
CUG L 0.41 41.1 
(286626)  
CCG P 0.11  6.3 
( 43713)  
CAG Q 0.75 33.8 
(235764)  
CGG R 0.20 10.9 
( 76123)
AUU I 0.33 15.3 
(106736)  
ACU T 0.24 12.9 
( 90372)  
AAU N 0.41 15.1 
(105212)  
AGU S 0.15 11.8 
( 82659)
AUC I 0.52 24.4 
(170096)  
ACC T 0.36 19.7 
(137673)  
AAC N 0.59 21.7 
(151564)  
AGC S 0.24 19.2 
(133954)
AUA I 0.15  6.9 
( 48257)  
ACA T 0.28 15.3 
(106544)  
AAA K 0.38 21.5 
(150018)  
AGA R 0.20 11.2 
( 77965)
AUG M 1.00 23.1 
(161552)  
ACG T 0.11  6.2 
( 43237)  
AAG K 0.62 35.1 
(245259)  
AGG R 0.21 11.8 
( 82391)
GUU V 0.16 10.4 
( 72270)  
GCU A 0.28 19.7 
(137491)  
GAU D 0.43 20.9 
(146211)  
GGU G 0.17 11.4 
( 79443)
GUC V 0.25 16.2 
(113143)  
GCC A 0.39 27.1 
(189524)  
GAC D 0.57 28.0 
(195508)  
GGC G 0.33 21.9 
(152582)
GUA V 0.11  7.2 
( 50048)  
GCA A 0.23 15.6 
(109203)  
GAA E 0.39 26.9 
(187810)  
GGA G 0.25 16.6 
(115968)
GUG V 0.47 30.0 
(209458)  
GCG A 0.10  6.9 
( 47869)  
GAG E 0.61 41.3 
(288345)  
GGG G 0.24 15.6 
(108657)
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Mus musculus codon usage table:
First three letters are the codons in the mRNA. The numbers 
next to them are the frequencies of each codon were 1.00 = 
100%, the frequency per thousand and the actual number of the 
codons in the genome. Taken from: http://www.kazusa.or.jp/
codon/
UUU F 0.44 17.2 
(422153)  
UCU S 0.20 16.2 
(398250)  
UAU Y 0.43 12.2 
(298518)  
UGU C 0.48 11.4 
(279729)
UUC F 0.56 21.8 
(535439)  
UCC S 0.22 18.1 
(444041)  
UAC Y 0.57 16.1 
(394074)  
UGC C 0.52 12.3 
(301384)
UUA L 0.07  6.7 
(165150)  
UCA S 0.14 11.8 
(289799)  
UAA * 0.28  1.0 
( 23403)  
UGA * 0.49  1.6 
( 40148)
UUG L 0.13 13.4 
(329668)  
UCG S 0.05  4.2 
(103815)  
UAG * 0.23  0.8 
( 19126)  
UGG W 1.00 12.5 
(306619)
CUU L 0.13 13.4 
(329757)  
CCU P 0.31 18.4 
(450637)  
CAU H 0.41 10.6 
(260637)  
CGU R 0.08  4.7 
(114854)
CUC L 0.20 20.2 
(495018)  
CCC P 0.30 18.2 
(446868)  
CAC H 0.59 15.3 
(375626)  
CGC R 0.17  9.4 
(229758)
CUA L 0.08  8.1 
(198032)  
CCA P 0.29 17.3 
(423707)  
CAA Q 0.26 12.0 
(293318)  
CGA R 0.12  6.6 
(161412)
CUG L 0.39 39.5 
(969515)  
CCG P 0.10  6.2 
(151521)  
CAG Q 0.74 34.1 
(836320)  
CGG R 0.19 10.2 
(250836)
AUU I 0.34 15.4 
(377698)  
ACU T 0.25 13.7 
(335039)  
AAU N 0.43 15.6 
(382284)  
AGU S 0.15 12.7 
(311331)
AUC I 0.50 22.5 
(552184)  
ACC T 0.35 19.0 
(465115)  
AAC N 0.57 20.3 
(499149)  
AGC S 0.24 19.7 
(483013)
AUA I 0.16  7.4 
(180467)  
ACA T 0.29 16.0 
(391437)  
AAA K 0.39 21.9 
(537723)  
AGA R 0.22 12.1 
(297135)
AUG M 1.00 22.8 
(559953)  
ACG T 0.10  5.6 
(138180)  
AAG K 0.61 33.6 
(825270)  
AGG R 0.22 12.2 
(299472)
GUU V 0.17 10.7 
(262535)  
GCU A 0.29 20.0 
(491093)  
GAU D 0.45 21.0 
(515049)  
GGU G 0.18 11.4 
(280522)
GUC V 0.25 15.4 
(377902)  
GCC A 0.38 26.0 
(637878)  
GAC D 0.55 26.0 
(638504)  
GGC G 0.33 21.2 
(520069)
GUA V 0.12  7.4 
(182733)  
GCA A 0.23 15.8 
(388723)  
GAA E 0.41 27.0 
(661498)  
GGA G 0.26 16.8 
(411344)
GUG V 0.46 28.4 
(696158)  
GCG A 0.09  6.4 
(157124)  
GAG E 0.59 39.4 
(965963)  
GGG G 0.23 15.2 
(372099)
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Pichia pastoris codon usage table:
First three letters are the codons in the mRNA. The numbers 
next to them are the frequencies of each codon were 1.00 = 
100%, the frequency per thousand and the actual number of the 
codons in the genome. Taken from: http://www.kazusa.or.jp/
codon
UUU F 0.54 24.1 
(  1963)  
UCU S 0.29 24.4 
(  1983)  
UAU Y 0.47 16.0 
(  1300)  
UGU C 0.64  7.7 
(   626)
UUC F 0.46 20.6 
(  1675)  
UCC S 0.20 16.5 
(  1344)  
UAC Y 0.53 18.1 
(  1473)  
UGC C 0.36  4.4 
(   356)
UUA L 0.16 15.6 
(  1265)  
UCA S 0.18 15.2 
(  1234)  
UAA * 0.51  0.8 
(    69)  
UGA * 0.20  0.3 
(    27)
UUG L 0.33 31.5 
(  2562)  
UCG S 0.09  7.4 
(   598)  
UAG * 0.29  0.5 
(    40)  
UGG W 1.00 10.3 
(   834)
CUU L 0.16 15.9 
(  1289)  
CCU P 0.35 15.8 
(  1282)  
CAU H 0.57 11.8 
(   960)  
CGU R 0.17  6.9 
(   564)
CUC L 0.08  7.6 
(   620)  
CCC P 0.15  6.8 
(   553)  
CAC H 0.43  9.1 
(   737)  
CGC R 0.05  2.2 
(   175)
CUA L 0.11 10.7 
(   873)  
CCA P 0.42 18.9 
(  1540)  
CAA Q 0.61 25.4 
(  2069)  
CGA R 0.10  4.2 
(   340)
CUG L 0.16 14.9 
(  1215)  
CCG P 0.09  3.9 
(   320)  
CAG Q 0.39 16.3 
(  1323)  
CGG R 0.05  1.9 
(   158)
AUU I 0.50 31.1 
(  2532)  
ACU T 0.40 22.4 
(  1820)  
AAU N 0.48 25.1 
(  2038)  
AGU S 0.15 12.5 
(  1020)
AUC I 0.31 19.4 
(  1580)  
ACC T 0.26 14.5 
(  1175)  
AAC N 0.52 26.7 
(  2168)  
AGC S 0.09  7.6 
(   621)
AUA I 0.18 11.1 
(   906)  
ACA T 0.24 13.8 
(  1118)  
AAA K 0.47 29.9 
(  2433)  
AGA R 0.48 20.1 
(  1634)
AUG M 1.00 18.7 
(  1517)  
ACG T 0.11  6.0 
(   491)  
AAG K 0.53 33.8 
(  2748)  
AGG R 0.16  6.6 
(   539)
GUU V 0.42 26.9 
(  2188)  
GCU A 0.45 28.9 
(  2351)  
GAU D 0.58 35.7 
(  2899)  
GGU G 0.44 25.5 
(  2075)
GUC V 0.23 14.9 
(  1210)  
GCC A 0.26 16.6 
(  1348)  
GAC D 0.42 25.9 
(  2103)  
GGC G 0.14  8.1 
(   655)
GUA V 0.15  9.9 
(   804)  
GCA A 0.23 15.1 
(  1228)  
GAA E 0.56 37.4 
(  3043)  
GGA G 0.33 19.1 
(  1550)
GUG V 0.19 12.3 
(   998)  
GCG A 0.06  3.9 
(   314)  
GAG E 0.44 29.0 
(  2360)  
GGG G 0.10  5.8 
(   468)
Values for Figure 17:










































































































































































Values for Figure 19:























Values for Figure 20:



















Equine IgE Protein Sequence:
This was the equine IgE heavy chain sequence used in this 
project, noting there is no methionine (M) at the start of the gene 
as this sequence is only for the 4 heavy chain domains and not 
including the variable region. Blue represents: Cε1, red: Cε2, 
green: Cε3 and purple: Cε4.
   1  GGATCC CTGCCACGGGGTCCCCAGCTCCCCCATCCAGGCCCCCCAGGCTGATGGGCGCTGGCCTGAGGCTGGCACTGACTAGGTTCTGTCCTCACA GTG AGC AAG CAG GCC CCT CTG ATC CTG CCT CTG GCC GCC TGC TGC  
       BamH1                                              Human Intron                                   V   S   K   Q   A   P   L   I   L   P   L   A   A   C   C  
 145  AAG GAC ACC AAG ACC ACC AAC ATC ACC CTG GGC TGC CTG GTG AAG GGC TAC TTC CCT GAG CCT GTG ACC GTG ACC TGG GAC GCC GGC AGC CTG AAC AGG AGC ACC ATG ACC TTC CCT GCC GTG TTC GAC CAG ACC AGC GGC CTG  
       K   D   T   K   T   T   N   I   T   L   G   C   L   V   K   G   Y   F   P   E   P   V   T   V   T   W   D   A   G   S   L   N   R   S   T   M   T   F   P   A   V   F   D   Q   T   S   G   L  
 289  TAC ACC ACC ATC AGC AGG GTG GTG GCC AGC GGC AAG TGG GCC AAG CAG AAG TTC ACC TGC AAC GTG GTG CAC AGC CAG GAG ACC TTC AAC AAG ACC TTC AAC GCC TGC ATC GTG ACC TTC ACC CCT CCT ACC GTG AAG CTG TTC  
       Y   T   T   I   S   R   V   V   A   S   G   K   W   A   K   Q   K   F   T   C   N   V   V   H   S   Q   E   T   F   N   K   T   F   N   A   C   I   V   T   F   T   P   P   T   V   K   L   F  
 433  CAC AGC AGC TGC GAC CCT GGC GGC GAC AGC CAC ACC ACC ATC CAG CTG CTG TGC CTG ATC AGC GAC TAC ACC CCT GGC GAC ATC GAC ATC GTG TGG CTG ATC GAC GGC CAG AAG GTG GAC GAG CAG TTC CCT CAG CAC GGC CTG  
       H   S   S   C   D   P   G   G   D   S   H   T   T   I   Q   L   L   C   L   I   S   D   Y   T   P   G   D   I   D   I   V   W   L   I   D   G   Q   K   V   D   E   Q   F   P   Q   H   G   L  
 577  GTG AAG CAG GAG GGC AAG CTG GCC AGC ACC CAC AGC GAG CTG AAC ATC ACC CAG GGC CAG TGG GCC AGC GAG AAC ACC TAC ACC TGC CAG GTG ACC TAC AAG GAC ATG ATC TTC AAG GAC CAG GCC AGG AAG TGC ACC GAG AGC  
       V   K   Q   E   G   K   L   A   S   T   H   S   E   L   N   I   T   Q   G   Q   W   A   S   E   N   T   Y   T   C   Q   V   T   Y   K   D   M   I   F   K   D   Q   A   R   K   C   T   E   S  
 721  GAC CCT AGG GGC GTG AGC GTG TAC CTG AGC CCT CCT AGC CCT CTG GAC CTG TAC GTG AGC AAG AGC CCT AAG ATC ACC TGC CTG GTG GTG GAC CTG GCC AAC GTG CAG GGC CTG AGC CTG AAC TGG AGC AGG GAG AGC GGC GAG  
       D   P   R   G   V   S   V   Y   L   S   P   P   S   P   L   D   L   Y   V   S   K   S   P   K   I   T   C   L   V   V   D   L   A   N   V   Q   G   L   S   L   N   W   S   R   E   S   G   E  
 865  CCT CTG CAG AAG CAC ACC CTG GCC ACC AGC GAG CAG TTC AAC AAG ACC TTC AGC GTG ACC AGC ACC CTG CCT GTG GAC ACC ACC GAC TGG ATC GAG GGC GAG ACC TAC AAG TGC ACC GTG AGC CAC CCT GAC CTG CCT AGG GAG  
       P   L   Q   K   H   T   L   A   T   S   E   Q   F   N   K   T   F   S   V   T   S   T   L   P   V   D   T   T   D   W   I   E   G   E   T   Y   K   C   T   V   S   H   P   D   L   P   R   E  
1009  GTG GTG AGG AGC ATC GCC AAG GCC CCT GGC AAG AGG CTG AGC CCT GAG GTG TAC GTG TTC CTG CCT CCT GAG GAG GAC CAG AGC AGC AAG GAC AAG GTG ACC CTG ACC TGC CTG ATC CAG AAC TTC TTC CCT GCC GAC ATC AGC  
       V   V   R   S   I   A   K   A   P   G   K   R   L   S   P   E   V   Y   V   F   L   P   P   E   E   D   Q   S   S   K   D   K   V   T   L   T   C   L   I   Q   N   F   F   P   A   D   I   S  
1153  GTG CAG TGG CTG AGG AAC AAC GTG CTG ATC CAG ACC GAC CAG CAG GCC ACC ACC AGG CCT CAG AAG GCC AAC GGC CCT AAC CCT GCC TTC TTC GTG TTC AGC AGG CTG GAG GTG AGC AGG GCC GAG TGG GAG CAG AAG AAC AAG  
       V   Q   W   L   R   N   N   V   L   I   Q   T   D   Q   Q   A   T   T   R   P   Q   K   A   N   G   P   N   P   A   F   F   V   F   S   R   L   E   V   S   R   A   E   W   E   Q   K   N   K  
1297  TTC GCC TGC AAG GTG GTG CAC GAG GCC CTG AGC CAG AGG ACC CTG CAG AAG GAG GTG AGC AAG GAC CCT GGC AAG TGA AGATCT AGCTGCAGT GGATCC  
       F   A   C   K   V   V   H   E   A   L   S   Q   R   T   L   Q   K   E   V   S   K   D   P   G   K   -   BglII            BamH1  
Optimized Equine IgE DNA Sequence:
This is the final optimized DNA sequence used, noting the 
addition of a TAA ending sequence, the restriction sites at the 
ends of the sequence to allow for cloning, and half a human 







Equine FcεRIα Protein Sequence:
This was the equine FcεRIα sequence used in this project. 
Purple represents: the Signal Peptide, green: Domain 1, red: 






Equine sFcεRIαD1&2 Protein Sequence:
This was the equine FcεRIα sequence used in this project. 
Purple represents: the Signal Peptide, green: Domain 1, red: 
Domain 2.
AAGCTT 1 ATG CCA GCT CCA ATG GGT TCT CCA GCT CTG CTG TGG ATT ACT TTT CTG CTG TTT TCT CTG GAT GGT GTC CCA GCT GCT ATT AGA AAG TCT ACT GTC TCT CTG AAC CCA CCA TGG AAC AGA ATT TTT AGA GGT GAA AAC GTC ACT CTG  
HindIII   M   P   A   P   M   G   S   P   A   L   L   W   I   T   F   L   L   F   S   L   D   G   V   P   A   A   I   R   K   S   T   V   S   L   N   P   P   W   N   R   I   F   R   G   E   N   V   T   L  
148  ACT TGT AAC AAG AAC AAG CCA CTG AAG GGT AAC TCT ACT GAA TGG ACT TAC AAC AAC ACT ACT CTG GAA GTC ACT ACT TCT TCT CTG AAC ATT ACT AAC GCT TCT CAT AGA TCT TCT GGT GAA TAC AGA TGT AGA AAC AAC GAT CTG  
      T   C   N   K   N   K   P   L   K   G   N   S   T   E   W   T   Y   N   N   T   T   L   E   V   T   T   S   S   L   N   I   T   N   A   S   H   R   S   S   G   E   Y   R   C   R   N   N   D   L  
295  AAC CTG TCT GAA GCT GTC CAT CTG GAA GTC TTT TCT GAT TGG CTG CTG CTG CAG GCT TCT GCT GAA GAA GTC ATT GAA GGT AAG GCT CTG GTC CTG AGA TGT AGA GGT TGG AAG GAT TGG GAT GTC TTT AAG GTC ATT TAC TAC AAG  
      N   L   S   E   A   V   H   L   E   V   F   S   D   W   L   L   L   Q   A   S   A   E   E   V   I   E   G   K   A   L   V   L   R   C   R   G   W   K   D   W   D   V   F   K   V   I   Y   Y   K  
442  GAT GGT AAG CCA CTG GAA TAC TGG TAC GAA AAC AAG AAC ATT TCT ATT GAA TCT GCT ACT ACT GAA AAC TCT GGT ACT TAC TAC TGT GAA GGT GCT TTT AAC TTT AAG AGA ACT TCT GAA AGA TAC ACT TCT GAT TAC CTG AAC ATT  
      D   G   K   P   L   E   Y   W   Y   E   N   K   N   I   S   I   E   S   A   T   T   E   N   S   G   T   Y   Y   C   E   G   A   F   N   F   K   R   T   S   E   R   Y   T   S   D   Y   L   N   I  
589  ACT GTC AAG AAG GCT GAA CAG TCT AAG AGA TAC TGG CTG CAG TTT ATT ATT CCA CTG CTG GTC GTC ATT CTG TTT GCT GTC GAT ACT GGT CTG TTT GTC TCT ACT CAG CAG CAG CTG ACT TTT CTG CTG AAG ATT AAG AGA ACT AGA  
      T   V   K   K   A   E   Q   S   K   R   Y   W   L   Q   F   I   I   P   L   L   V   V   I   L   F   A   V   D   T   G   L   F   V   S   T   Q   Q   Q   L   T   F   L   L   K   I   K   R   T   R  
736  AGA GGT AGA AAG CTG ATG GAT CCA CAT CCA TAA GAATTC
      R   G   R   K   L   M   D   P   H   P   -  Ecor1
Optimized FcRIα Receptor DNA Sequence:
This is the final optimized DNA sequence used, noting the 
addition of a TAA ending sequence and the restriction sites at 







































































The pEE6 plasmid sold by CellTech (in defunct UK company 
since 2004). It integrates into a mammalian cell’s chromosome 
and therefore was designed for mammalian protein expression.
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RBL-Non-Transfected Cells Bound With Human IgE
1 2 3 4 5 6 7 8 9 10 11 12
1.633 1.749 1.787 1.773 1.830 1.858 0.074 0.078 0.088 0.124 0.100 0.102
1.709 1.896 1.909 1.887 1.920 1.868 0.070 0.072 0.069 0.101 0.091 0.084
1.737 1.865 1.891 1.904 1.989 1.966 0.076 0.077 0.072 0.073 0.076 0.080
1.809 1.897 1.927 1.993 1.984 1.963 0.065 0.064 0.066 0.070 0.079 0.073
1.793 2.020 2.023 2.005 1.953 2.107 0.085 0.086 0.083 0.088 0.086 0.086
1.719 1.910 1.967 2.028 1.952 2.010 0.089 0.080 0.085 0.081 0.080 0.086
1.736 1.854 1.963 1.994 1.994 1.970 0.088 0.096 0.092 0.091 0.098 0.096
0.542 0.688 0.642 0.723 0.742 0.907 0.941 1.220 0.747 1.247 1.207 0.819
x2 because (I used 50 μl instead of the 100) + Supernatant Value % of Total In Cell
To Find Original Total In Cell
1.781 1.905 1.963 2.021 2.03 2.062 8.310 8.189 8.966 12.271 9.852 9.893
1.849 2.04 2.047 2.089 2.102 2.036 7.572 7.059 6.742 9.670 8.658 8.251
1.889 2.019 2.035 2.05 2.141 2.126 8.047 7.628 7.076 7.122 7.099 7.526
1.939 2.025 2.059 2.133 2.142 2.109 6.704 6.321 6.411 6.564 7.376 6.923
1.963 2.192 2.189 2.181 2.125 2.279 8.660 7.847 7.583 8.070 8.094 7.547
1.897 2.07 2.137 2.19 2.112 2.182 9.383 7.729 7.955 7.397 7.576 7.883
1.912 2.046 2.147 2.176 2.19 2.162 9.205 9.384 8.570 8.364 8.950 8.881



































RBL-pEE6 Cells Bound With Human IgE
1 2 3 4 5 6 7 8 9 10 11 12
1.558 1.607 1.635 1.633 1.530 1.566 0.081 0.089 0.093 0.088 0.085 0.089
1.538 1.668 1.661 1.829 1.563 1.637 0.068 0.067 0.067 0.070 0.068 0.070
1.549 1.720 1.748 1.749 1.629 0.992 0.073 0.072 0.075 0.071 0.070 0.078
1.741 1.656 1.748 1.843 1.824 1.869 0.066 0.064 0.066 0.065 0.071 0.065
1.742 1.798 1.776 1.870 1.754 1.760 0.087 0.086 0.087 0.086 0.086 0.089
1.766 1.832 1.762 1.758 1.766 1.796 0.083 0.078 0.087 0.079 0.080 0.077
1.722 1.780 1.711 1.794 1.738 1.799 0.100 0.084 0.090 0.091 0.093 0.090
0.391 0.365 0.290 0.656 0.436 0.615 1.072 0.812 1.109 0.881 0.996 0.623
x2 because (I used 50 μl instead of the 100) + Supernatant Value % of Total In Cell
To Find Original Total In Cell
1.72 1.785 1.821 1.809 1.7 1.744 9.419 9.972 10.214 9.729 10.000 10.206
1.674 1.802 1.795 1.969 1.699 1.777 8.124 7.436 7.465 7.110 8.005 7.878
1.695 1.864 1.898 1.891 1.769 1.148 8.614 7.725 7.903 7.509 7.914 13.589
1.873 1.784 1.88 1.973 1.966 1.999 7.048 7.175 7.021 6.589 7.223 6.503
1.916 1.97 1.95 2.042 1.926 1.938 9.081 8.731 8.923 8.423 8.930 9.185
1.932 1.988 1.936 1.916 1.926 1.95 8.592 7.847 8.988 8.246 8.307 7.897
1.922 1.948 1.891 1.976 1.924 1.979 10.406 8.624 9.519 9.211 9.667 9.096




















































































RBL-Non-Transfected Cells Bound With Mouse IgE
1 2 3 4 5 6 7 8 9 10 11 12
1.803 1.779 1.797 1.959 1.730 1.239 0.036 0.064 0.044 0.048 0.054 0.018
1.910 1.851 1.874 1.936 1.804 1.682 0.032 0.041 0.036 0.043 0.038 0.019
1.641 1.733 1.789 1.842 1.744 1.555 0.131 0.157 0.178 0.160 0.185 0.124
1.275 1.361 1.350 1.367 1.307 1.175 0.314 0.428 0.554 0.551 0.609 0.510
1.349 1.236 1.166 1.080 1.025 0.936 0.433 0.537 0.726 0.704 0.707 0.517
1.173 1.236 1.192 1.156 1.081 1.374 0.385 0.669 0.695 0.716 0.584 0.517
1.284 1.189 1.277 1.492 1.113 1.177 0.414 0.652 0.472 0.574 0.323 0.324
1.094 0.964 0.888 0.969 1.037 0.933 0.351 0.413 0.463 0.517 0.494 0.410
2.165 2.283 2.206 2.189 2.244 2.257 0.039 0.037 0.050 0.036 0.036 0.028
2.215 2.233 2.221 2.218 2.169 2.265 0.053 0.048 0.051 0.045 0.054 0.033
2.133 2.170 2.114 2.049 1.909 1.983 0.168 0.166 0.142 0.161 0.148 0.153
1.651 1.693 1.743 1.722 1.747 1.713 0.680 0.586 0.469 0.514 0.435 0.513
1.296 1.260 1.356 1.303 1.301 1.283 0.906 0.689 0.699 0.710 0.767 0.774
1.288 1.306 1.285 1.334 1.248 1.285 0.779 0.553 0.672 0.992 0.718 0.545
1.336 1.296 1.459 1.332 1.392 1.416 0.842 0.433 0.641 0.727 0.552 0.697
0.636 0.653 0.603 0.668 0.658 0.422 1.060 0.713 0.966 0.858 0.680 0.397
2.730 2.660 2.686 2.649 2.646 2.674 0.036 0.052 0.044 0.038 0.037 0.038
2.790 2.668 2.708 2.829 2.667 2.623 0.074 0.063 0.066 0.060 0.056 0.064
2.696 2.719 2.698 2.565 2.611 2.540 0.175 0.165 0.168 0.167 0.123 0.162
2.339 2.392 2.264 2.295 2.247 2.281 0.653 0.596 0.598 0.585 0.542 0.530
1.902 1.917 1.858 1.890 1.824 1.883 0.947 0.849 0.888 0.874 0.870 0.823
2.099 2.062 1.920 1.938 1.911 1.881 0.902 0.879 0.916 0.821 0.793 0.804
2.052 2.091 1.934 2.049 1.856 1.958 0.830 0.777 0.894 0.849 0.784 0.806
0.356 0.141 0.182 0.173 0.207 0.158 1.940 1.679 1.847 1.482 1.300 1.689
2.458 2.438 2.560 2.387 2.265 2.278 0.062 0.045 0.046 0.032 0.047 0.033
2.584 2.681 2.702 2.686 2.249 2.587 0.076 0.058 0.071 0.043 0.065 0.051
2.591 2.600 2.544 2.543 2.434 2.263 0.255 0.212 0.287 0.257 0.208 0.214
2.187 2.159 2.254 2.154 1.940 1.915 0.737 0.747 0.713 0.613 0.582 0.529
1.875 1.704 1.772 1.839 1.519 1.505 1.024 1.195 1.154 0.745 0.906 0.791
1.929 1.686 1.742 1.720 1.590 1.804 1.001 1.019 1.152 0.791 0.835 0.714
1.936 1.795 1.756 1.768 1.411 1.713 1.036 1.045 1.096 0.871 0.884 0.710
1.170 0.300 0.250 0.247 0.237 0.198 0.981 1.384 1.601 1.321 1.385 1.538
x2 because (I used 50 μl instead of the 100) + Supernatant Value % of Total In Cell
To Find Original Total In Cell
1.875 1.907 1.885 2.055 1.838 1.275 3.840 6.712 4.668 4.672 5.876 2.824
1.974 1.933 1.946 2.022 1.88 1.72 3.242 4.242 3.700 4.253 4.043 2.209
1.903 2.047 2.145 2.162 2.114 1.803 13.768 15.340 16.597 14.801 17.502 13.755
1.903 2.217 2.458 2.469 2.525 2.195 33.001 38.611 45.077 44.633 48.238 46.469
2.215 2.31 2.618 2.488 2.439 1.97 39.097 46.494 55.462 56.592 57.975 52.487
1.943 2.574 2.582 2.588 2.249 2.408 39.629 51.981 53.834 55.332 51.934 42.940
2.112 2.493 2.221 2.64 1.759 1.825 39.205 52.306 42.503 43.485 36.725 35.507
1.796 1.79 1.814 2.003 2.025 1.753 39.087 46.145 51.047 51.623 48.790 46.777
2.243 2.357 2.306 2.261 2.316 2.313 3.477 3.140 4.337 3.184 3.109 2.421
2.321 2.329 2.323 2.308 2.277 2.331 4.567 4.122 4.391 3.899 4.743 2.831
2.469 2.502 2.398 2.371 2.205 2.289 13.609 13.269 11.843 13.581 13.424 13.368
3.011 2.865 2.681 2.75 2.617 2.739 45.168 40.908 34.987 37.382 33.244 37.459
3.108 2.638 2.754 2.723 2.835 2.831 58.301 52.237 50.763 52.148 54.109 54.680
2.846 2.412 2.629 3.318 2.684 2.375 54.743 45.854 51.122 59.795 53.502 45.895
3.02 2.162 2.741 2.786 2.496 2.81 55.762 40.056 46.771 52.190 44.231 49.609
2.756 2.079 2.535 2.384 2.018 1.216 76.923 68.591 76.213 71.980 67.393 65.296
2.802 2.764 2.774 2.725 2.72 2.75 2.570 3.763 3.172 2.789 2.721 2.764
2.938 2.794 2.84 2.949 2.779 2.751 5.037 4.510 4.648 4.069 4.030 4.653
3.046 3.049 3.034 2.899 2.857 2.864 11.490 10.823 11.074 11.521 8.610 11.313
3.645 3.584 3.46 3.465 3.331 3.341 35.830 33.259 34.566 33.766 32.543 31.727
3.796 3.615 3.634 3.638 3.564 3.529 49.895 46.971 48.872 48.048 48.822 46.642
3.903 3.82 3.752 3.58 3.497 3.489 46.221 46.021 48.827 45.866 45.353 46.088
3.712 3.645 3.722 3.747 3.424 3.57 44.720 42.634 48.039 45.316 45.794 45.154
4.236 3.499 3.876 3.137 2.807 3.536 91.596 95.970 95.304 94.485 92.626 95.532
2.582 2.528 2.652 2.451 2.359 2.344 4.802 3.560 3.469 2.611 3.985 2.816
2.736 2.797 2.844 2.772 2.379 2.689 5.556 4.147 4.993 3.102 5.464 3.793
3.101 3.024 3.118 3.057 2.85 2.691 16.446 14.021 18.409 16.814 14.596 15.905
3.661 3.653 3.68 3.38 3.104 2.973 40.262 40.898 38.750 36.272 37.500 35.587
3.923 4.094 4.08 3.329 3.331 3.087 52.205 58.378 56.569 44.758 54.398 51.247
3.931 3.724 4.046 3.302 3.26 3.232 50.929 54.726 56.945 47.910 51.227 44.183
4.008 3.885 3.948 3.51 3.179 3.133 51.697 53.797 55.522 49.630 55.615 45.324




































































RBL-pEE6 Cells Bound With Mouse IgE
1 2 3 4 5 6 7 8 9 10 11 12
2.143 2.239 2.136 2.131 2.056 2.069 0.015 0.016 0.011 0.015 0.015 0.009
2.124 2.222 2.143 2.179 2.147 2.093 0.029 0.021 0.028 0.022 0.019 0.027
2.119 2.219 2.166 2.208 2.168 2.095 0.096 0.058 0.077 0.061 0.091 0.088
1.730 1.943 1.821 1.913 1.869 1.777 0.453 0.260 0.362 0.228 0.394 0.383
1.368 1.518 1.508 1.538 1.492 1.417 0.730 0.510 0.692 0.488 0.765 0.778
1.514 1.680 1.551 1.682 1.552 1.519 0.697 0.504 0.635 0.362 0.661 0.396
1.515 1.597 1.566 1.357 1.583 1.564 0.575 0.475 0.577 0.485 0.647 0.609
0.075 0.278 0.216 0.259 0.255 0.244 1.323 1.628 1.392 1.108 1.451 1.686
2.050 2.132 2.115 2.131 2.145 2.138 0.021 0.023 0.011 0.008 0.010 0.036
2.052 2.201 2.241 2.245 2.201 2.123 0.028 0.038 0.041 0.023 0.003 0.030
1.967 2.173 2.201 2.252 2.177 2.091 0.121 0.093 0.106 0.114 0.156 0.175
1.592 1.898 1.873 1.856 1.896 1.716 0.398 0.268 0.314 0.469 0.435 0.547
1.387 1.525 1.521 1.498 1.508 1.399 0.605 0.374 0.487 0.743 0.765 0.799
1.479 1.606 1.594 1.583 1.629 1.543 0.572 0.303 0.354 0.619 0.435 0.679
1.467 1.622 1.591 1.570 1.638 1.539 0.507 0.283 0.360 0.485 0.462 0.582
0.455 0.336 0.445 0.430 0.350 0.225 1.443 0.925 0.711 1.188 0.787 0.930
2.032 2.082 2.010 2.123 2.078 2.081 0.016 0.020 0.014 0.025 0.022 0.013
2.048 2.152 2.124 2.210 2.116 2.058 0.038 0.037 0.029 0.032 0.022 0.037
2.010 2.180 2.194 2.158 2.175 2.079 0.094 0.052 0.061 0.056 0.062 0.083
1.807 1.919 1.947 2.008 2.021 1.893 0.310 0.228 0.306 0.259 0.261 0.293
1.301 1.454 1.438 1.427 1.413 1.433 0.629 0.454 0.654 0.592 0.593 0.664
1.361 1.469 1.455 1.454 1.525 1.487 0.598 0.475 0.593 0.600 0.570 0.538
1.429 1.520 1.529 1.510 1.582 1.531 0.496 0.371 0.618 0.481 0.397 0.538
0.080 0.940 0.116 0.096 0.185 0.186 1.419 1.351 1.714 1.532 0.905 0.806
x2 because (I used 50 μl instead of the 100) + Supernatant Value % of Total In Cell
To Find Original Total In Cell
2.173 2.271 2.158 2.161 2.086 2.087 1.381 1.409 1.019 1.388 1.438 0.862
2.182 2.264 2.199 2.223 2.185 2.147 2.658 1.855 2.547 1.979 1.739 2.515
2.311 2.335 2.32 2.33 2.35 2.271 8.308 4.968 6.638 5.236 7.745 7.750
2.636 2.463 2.545 2.369 2.657 2.543 34.370 21.112 28.448 19.249 29.658 30.122
2.828 2.538 2.892 2.514 3.022 2.973 51.627 40.189 47.856 38.823 50.629 52.338
2.908 2.688 2.821 2.406 2.874 2.311 47.937 37.500 45.019 30.091 45.999 34.271
2.665 2.547 2.72 2.327 2.877 2.782 43.152 37.299 42.426 41.685 44.977 43.781
2.721 3.534 3 2.475 3.157 3.616 97.244 92.134 92.800 89.535 91.923 93.252
2.092 2.178 2.137 2.147 2.165 2.21 2.008 2.112 1.029 0.745 0.924 3.258
2.108 2.277 2.323 2.291 2.207 2.183 2.657 3.338 3.530 2.008 0.272 2.749
2.209 2.359 2.413 2.48 2.489 2.441 10.955 7.885 8.786 9.194 12.535 14.338
2.388 2.434 2.501 2.794 2.766 2.81 33.333 22.021 25.110 33.572 31.453 38.932
2.597 2.273 2.495 2.984 3.038 2.997 46.592 32.908 39.038 49.799 50.362 53.320
2.623 2.212 2.302 2.821 2.499 2.901 43.614 27.396 30.756 43.885 34.814 46.811
2.481 2.188 2.311 2.54 2.562 2.703 40.871 25.868 31.155 38.189 36.066 43.063
3.341 2.186 1.867 2.806 1.924 2.085 86.381 84.629 76.165 84.676 81.809 89.209
2.064 2.122 2.038 2.173 2.122 2.107 1.550 1.885 1.374 2.301 2.074 1.234
2.124 2.226 2.182 2.274 2.16 2.132 3.578 3.324 2.658 2.814 2.037 3.471
2.198 2.284 2.316 2.27 2.299 2.245 8.553 4.553 5.268 4.934 5.394 7.394
2.427 2.375 2.559 2.526 2.543 2.479 25.546 19.200 23.916 20.507 20.527 23.639
2.559 2.362 2.746 2.611 2.599 2.761 49.160 38.442 47.633 45.347 45.633 48.099
2.557 2.419 2.641 2.654 2.665 2.563 46.774 39.272 44.907 45.215 42.777 41.982
2.421 2.262 2.765 2.472 2.376 2.607 40.975 32.803 44.702 38.916 33.418 41.273


































RBL-Non-Transfected Cells Bound With Dog IgE
1 2 3 4 5 6 7 8 9 10 11 12
1.165 1.115 1.113 1.14 1.132 1.153 0.079 0.074 0.082 0.073 0.073 0.072
1.149 1.106 1.16 1.149 1.177 1.12 0.073 0.082 0.07 0.078 0.083 0.09
1.178 1.178 1.196 1.176 1.176 1.257 0.07 0.069 0.065 0.069 0.07 0.068
1.191 1.154 1.201 1.199 1.19 1.188 0.066 0.063 0.06 0.066 0.067 0.069
1.167 1.16 1.203 1.239 1.169 1.16 0.076 0.074 0.073 0.08 0.077 0.081
1.177 1.203 1.242 1.236 1.245 1.167 0.077 0.073 0.077 0.081 0.077 0.08
1.171 1.142 1.205 1.189 1.162 1.094 0.078 0.079 0.069 0.081 0.079 0.089
x2 because (I used 50 μl instead of the 100) + Supernatant Value % of Total In Cell
To Find Original Total In Cell
1.323 1.263 1.277 1.286 1.278 1.297 11.943 11.718 12.843 11.353 11.424 11.103
1.295 1.27 1.3 1.305 1.343 1.3 11.274 12.913 10.769 11.954 12.360 13.846
1.318 1.316 1.326 1.314 1.316 1.393 10.622 10.486 9.804 10.502 10.638 9.763
1.323 1.28 1.321 1.331 1.324 1.326 9.977 9.844 9.084 9.917 10.121 10.407
1.319 1.308 1.349 1.399 1.323 1.322 11.524 11.315 10.823 11.437 11.640 12.254
1.331 1.349 1.396 1.398 1.399 1.327 11.570 10.823 11.032 11.588 11.008 12.057




































































RBL-pEE6 Cells Bound With Dog IgE
1 2 3 4 5 6 7 8 9 10 11 12
2.022 2.211 2.063 2.021 2.043 2.018 0.012 0.015 0.015 0.012 0.017 0.017
2.064 2.197 2.147 2.055 2.002 1.951 0.040 0.021 0.040 0.022 0.033 0.048
1.978 2.176 2.055 2.092 2.129 2.058 0.110 0.075 0.082 0.059 0.094 0.096
1.697 1.839 1.832 1.799 1.846 1.678 0.382 0.145 0.369 0.248 0.268 0.377
1.581 1.811 1.661 1.749 1.711 1.699 0.382 0.229 0.316 0.268 0.391 0.409
1.659 1.876 1.738 1.733 1.776 1.733 0.259 0.148 0.364 0.245 0.332 0.416
1.624 1.761 1.693 1.675 1.802 1.614 0.244 0.123 0.305 0.244 0.424 0.391
0.680 0.560 0.709 0.674 0.657 0.639 1.130 0.500 0.806 0.628 0.907 0.828
1.903 1.950 0.194 1.925 2.039 1.963 0.012 0.013 0.011 0.013 0.010 0.013
1.889 1.930 1.948 1.890 1.875 1.921 0.034 0.035 0.042 0.032 0.038 0.033
1.739 1.828 1.876 1.879 1.902 1.920 0.159 0.126 0.129 0.159 0.159 0.157
1.464 1.548 1.583 1.640 1.650 1.639 0.422 0.406 0.376 0.404 0.363 0.320
1.412 1.461 1.502 1.421 1.527 1.482 0.355 0.267 0.283 0.443 0.507 0.461
1.472 1.493 1.673 1.469 1.553 1.491 0.344 0.260 0.352 0.421 0.457 0.447
1.432 1.409 1.470 1.406 1.505 1.448 0.327 0.325 0.340 0.334 0.442 0.474
0.347 0.315 0.375 0.324 0.279 0.365 1.208 1.045 1.180 1.106 1.023 1.028
1.987 2.134 2.167 2.127 2.052 2.016 0.022 0.020 0.019 0.023 0.022 0.017
2.073 2.170 2.175 2.192 2.114 2.058 0.043 0.028 0.033 0.032 0.021 0.047
2.066 2.142 2.147 2.190 2.180 2.147 0.110 0.085 0.081 0.082 0.086 0.105
1.632 1.753 1.746 1.779 1.784 1.700 0.431 0.310 0.426 0.506 0.488 0.447
1.660 1.639 1.651 1.637 1.688 1.528 0.422 0.317 0.351 0.455 0.542 0.464
1.524 1.638 1.664 1.676 1.750 1.577 0.431 0.357 0.289 0.504 0.510 0.505
1.529 1.620 1.649 1.606 1.674 1.454 0.445 0.350 0.403 0.373 0.467 0.465
0.383 0.701 0.507 0.469 0.530 0.507 1.269 1.391 1.412 1.061 1.253 1.180
x2 because (I used 50 μl instead of the 100) + Supernatant Value % of Total In Cell
To Find Original Total In Cell
2.046 2.241 2.093 2.045 2.077 2.052 1.173 1.339 1.433 1.174 1.637 1.657
2.144 2.239 2.227 2.099 2.068 2.047 3.731 1.876 3.592 2.096 3.191 4.690
2.198 2.326 2.219 2.21 2.317 2.25 10.009 6.449 7.391 5.339 8.114 8.533
2.461 2.129 2.57 2.295 2.382 2.432 31.044 13.621 28.716 21.612 22.502 31.003
2.345 2.269 2.293 2.285 2.493 2.517 32.580 20.185 27.562 23.457 31.368 32.499
2.177 2.172 2.466 2.223 2.44 2.565 23.794 13.628 29.521 22.042 27.213 32.437
2.112 2.007 2.303 2.163 2.65 2.396 23.106 12.257 26.487 22.561 32.000 32.638
2.94 1.56 2.321 1.93 2.471 2.295 76.871 64.103 69.453 65.078 73.412 72.157
1.927 1.976 0.216 1.951 2.059 1.989 1.245 1.316 10.185 1.333 0.971 1.307
1.957 2 2.032 1.954 1.951 1.987 3.475 3.500 4.134 3.275 3.895 3.322
2.057 2.08 2.134 2.197 2.22 2.234 15.459 12.115 12.090 14.474 14.324 14.056
2.308 2.36 2.335 2.448 2.376 2.279 36.568 34.407 32.206 33.007 30.556 28.082
2.122 1.995 2.068 2.307 2.541 2.404 33.459 26.767 27.369 38.405 39.906 38.353
2.16 2.013 2.377 2.311 2.467 2.385 31.852 25.832 29.617 36.434 37.049 37.484
2.086 2.059 2.15 2.074 2.389 2.396 31.352 31.569 31.628 32.208 37.003 39.566
2.763 2.405 2.735 2.536 2.325 2.421 87.441 86.902 86.289 87.224 88.000 84.924
2.031 2.174 2.205 2.173 2.096 2.05 2.166 1.840 1.723 2.117 2.099 1.659
2.159 2.226 2.241 2.256 2.156 2.152 3.983 2.516 2.945 2.837 1.948 4.368
2.286 2.312 2.309 2.354 2.352 2.357 9.624 7.353 7.016 6.967 7.313 8.910
2.494 2.373 2.598 2.791 2.76 2.594 34.563 26.127 32.794 36.259 35.362 34.464
2.504 2.273 2.353 2.547 2.772 2.456 33.706 27.893 29.834 35.728 39.105 37.785
2.386 2.352 2.242 2.684 2.77 2.587 36.127 30.357 25.781 37.556 36.823 39.041
2.419 2.32 2.455 2.352 2.608 2.384 36.792 30.172 32.831 31.718 35.813 39.010




































RBL-Non-Transfected Cells Bound With Horse IgE
1 2 3 4 5 6 7 8 9 10 11 12
1.229 1.183 1.196 1.178 1.143 1.103 0.088 0.074 0.076 0.076 0.069 0.084
1.206 1.207 1.209 1.189 1.173 1.12 0.083 0.082 0.079 0.08 0.073 0.08
1.234 1.232 1.248 1.228 1.201 1.151 0.068 0.068 0.069 0.071 0.068 0.07
1.228 1.252 1.242 1.171 1.218 1.141 0.065 0.071 0.068 0.074 0.067 0.069
1.24 1.252 1.274 1.155 1.248 1.19 0.076 0.078 0.083 0.09 0.08 0.085
1.153 1.329 1.278 1.254 1.3 1.191 0.075 0.076 0.075 0.082 0.077 0.074
1.245 1.273 1.252 1.211 1.237 1.236 0.073 0.079 0.079 0.088 0.078 0.075
0.215 0.204 0.233 0.233 0.284 0.222 0.473 0.74 0.693 0.689 0.535 0.474
x2 because (I used 50 μl instead of the 100) + Supernatant Value % of Total In Cell
To Find Original Total In Cell
1.405 1.331 1.348 1.33 1.281 1.271 12.527 11.119 11.276 11.429 10.773 13.218
1.372 1.371 1.367 1.349 1.319 1.28 12.099 11.962 11.558 11.861 11.069 12.500
1.37 1.368 1.386 1.37 1.337 1.291 9.927 9.942 9.957 10.365 10.172 10.844
1.358 1.394 1.378 1.319 1.352 1.279 9.573 10.187 9.869 11.221 9.911 10.790
1.392 1.408 1.44 1.335 1.408 1.36 10.920 11.080 11.528 13.483 11.364 12.500
1.303 1.481 1.428 1.418 1.454 1.339 11.512 10.263 10.504 11.566 10.591 11.053
1.391 1.431 1.41 1.387 1.393 1.386 10.496 11.041 11.206 12.689 11.199 10.823




















































































RBL-pEE6 Cells Bound With Horse IgE
1 2 3 4 5 6 7 8 9 10 11 12
1.734 1.65 1.614 1.587 1.616 1.564 0.068 0.077 0.051 0.068 0.063 0.067
1.767 1.739 1.695 1.632 1.663 1.556 0.066 0.065 0.07 0.069 0.069 0.074
1.733 1.713 1.697 1.617 1.663 1.523 0.088 0.087 0.086 0.087 0.089 0.106
1.441 1.441 1.429 1.401 1.411 1.272 0.245 0.292 0.305 0.35 0.401 0.404
1.438 1.426 1.392 1.364 1.364 1.304 0.26 0.337 0.376 0.434 0.405 0.488
1.433 1.457 1.43 1.393 1.379 1.302 0.256 0.346 0.401 0.413 0.454 0.466
1.442 1.411 1.389 1.34 1.35 1.237 0.293 0.346 0.393 0.399 0.452 0.428
0.696 0.675 0.666 0.6 0.687 0.594 0.761 0.763 0.886 0.738 0.769 0.776
1.747 1.781 1.722 1.662 1.632 1.484 0.07 0.069 0.071 0.073 0.076 0.073
1.69 1.763 1.746 1.66 1.543 1.599 0.072 0.082 0.069 0.07 0.083 0.082
1.693 1.72 1.694 1.7 1.641 1.613 0.101 0.097 0.096 0.095 0.097 0.107
1.477 1.454 1.471 1.425 1.401 1.295 0.355 0.327 0.407 0.386 0.415 0.447
1.391 1.374 1.357 1.357 1.326 1.266 0.367 0.45 0.486 0.462 0.534 0.548
1.408 1.396 1.374 1.302 1.335 1.325 0.381 0.402 0.475 0.416 0.5 0.502
1.413 1.357 1.371 1.335 1.375 1.311 0.416 0.421 0.465 0.432 0.541 0.578
0.672 0.627 0.601 0.63 0.55 0.57 0.877 0.763 0.79 0.504 0.652 0.752
1.682 1.719 1.653 1.674 1.684 1.915 0.063 0.062 0.063 0.063 0.061 0.064
1.725 1.737 1.701 1.658 1.696 1.577 0.061 0.061 0.059 0.057 0.058 0.059
1.712 1.704 1.695 1.679 1.707 1.597 0.075 0.079 0.079 0.069 0.066 0.088
1.369 1.371 1.455 1.377 1.392 1.357 0.215 0.231 0.338 0.271 0.268 0.335
1.349 1.36 1.364 1.317 1.317 1.382 0.32 0.34 0.418 0.319 0.377 0.478
1.321 1.345 1.365 1.334 1.277 1.214 0.303 0.334 0.458 0.334 0.369 0.458
1.316 1.288 1.333 1.218 1.206 1.161 0.353 0.304 0.351 0.303 0.332 0.475
0.596 0.695 0.607 0.628 0.563 0.651 0.611 0.391 0.675 0.329 0.489 0.542
1.696 1.696 1.688 1.69 1.662 1.622 0.063 0.067 0.067 0.067 0.066 0.064
1.659 1.665 1.643 1.618 1.662 1.585 0.063 0.063 0.061 0.069 0.066 0.068
1.675 1.695 1.657 1.614 1.654 1.57 0.075 0.073 0.071 0.079 0.084 0.08
1.402 1.465 1.409 1.354 1.567 1.301 0.295 0.287 0.296 0.308 0.361 0.327
1.351 1.379 1.369 1.349 1.39 1.269 0.309 0.321 0.296 0.401 0.442 0.377
1.4 1.401 1.419 1.362 1.418 1.463 0.261 0.308 0.305 0.373 0.436 0.394
1.355 1.362 1.349 1.319 1.357 1.223 0.291 0.364 0.336 0.421 0.45 0.443
0.589 0.639 0.568 0.582 0.665 0.577 0.607 0.672 0.708 0.795 0.71 0.787
x2 because (I used 50 μl instead of the 100) + Supernatant Value % of Total In Cell
To Find Original Total In Cell
1.87 1.804 1.716 1.723 1.742 1.698 7.273 8.537 5.944 7.893 7.233 7.892
1.899 1.869 1.835 1.77 1.801 1.704 6.951 6.956 7.629 7.797 7.662 8.685
1.909 1.887 1.869 1.791 1.841 1.735 9.219 9.221 9.203 9.715 9.669 12.219
1.931 2.025 2.039 2.101 2.213 2.08 25.375 28.840 29.917 33.317 36.240 38.846
1.958 2.1 2.144 2.232 2.174 2.28 26.558 32.095 35.075 38.889 37.259 42.807
1.945 2.149 2.232 2.219 2.287 2.234 26.324 32.201 35.932 37.224 39.703 41.719
2.028 2.103 2.175 2.138 2.254 2.093 28.895 32.905 36.138 37.325 40.106 40.898
2.218 2.201 2.438 2.076 2.225 2.146 68.620 69.332 72.683 71.098 69.124 72.321
1.887 1.919 1.864 1.808 1.784 1.63 7.419 7.191 7.618 8.075 8.520 8.957
1.834 1.927 1.884 1.8 1.709 1.763 7.852 8.511 7.325 7.778 9.713 9.302
1.895 1.914 1.886 1.89 1.835 1.827 10.660 10.136 10.180 10.053 10.572 11.713
2.187 2.108 2.285 2.197 2.231 2.189 32.465 31.025 35.624 35.139 37.203 40.841
2.125 2.274 2.329 2.281 2.394 2.362 34.541 39.578 41.735 40.509 44.612 46.401
2.17 2.2 2.324 2.134 2.335 2.329 35.115 36.545 40.878 38.988 42.827 43.109
2.245 2.199 2.301 2.199 2.457 2.467 37.060 38.290 40.417 39.291 44.037 46.859
2.426 2.153 2.181 1.638 1.854 2.074 72.300 70.878 72.444 61.538 70.334 72.517
1.808 1.843 1.779 1.8 1.806 2.043 6.969 6.728 7.083 7.000 6.755 6.265
1.847 1.859 1.819 1.772 1.812 1.695 6.605 6.563 6.487 6.433 6.402 6.962
1.862 1.862 1.853 1.817 1.839 1.773 8.056 8.485 8.527 7.595 7.178 9.927
1.799 1.833 2.131 1.919 1.928 2.027 23.902 25.205 31.722 28.244 27.801 33.054
1.989 2.04 2.2 1.955 2.071 2.338 32.177 33.333 38.000 32.634 36.408 40.890
1.927 2.013 2.281 2.002 2.015 2.13 31.448 33.184 40.158 33.367 36.625 43.005
2.022 1.896 2.035 1.824 1.87 2.111 34.916 32.068 34.496 33.224 35.508 45.002
1.818 1.477 1.957 1.286 1.541 1.735 67.217 52.945 68.983 51.166 63.465 62.478
1.822 1.83 1.822 1.824 1.794 1.75 6.915 7.322 7.355 7.346 7.358 7.314
1.785 1.791 1.765 1.756 1.794 1.721 7.059 7.035 6.912 7.859 7.358 7.902
1.825 1.841 1.799 1.772 1.822 1.73 8.219 7.930 7.893 8.916 9.221 9.249
1.992 2.039 2.001 1.97 2.289 1.955 29.618 28.151 29.585 31.269 31.542 33.453
1.969 2.021 1.961 2.151 2.274 2.023 31.386 31.766 30.189 37.285 38.874 37.271
1.922 2.017 2.029 2.108 2.29 2.251 27.159 30.540 30.064 35.389 38.079 35.007
1.937 2.09 2.021 2.161 2.257 2.109 30.046 34.833 33.251 38.963 39.876 42.010





































































RBL-pEE6 Expressing Dog α Chain Cells Bound With Horse IgE For 0.5 Hours
1 2 3 4 5 6 7 8 9 10 11 12
2.013 2.052 2.049 2.04 2.048 2 0.09 0.102 0.096 0.094 0.095 0.092
2.092 2.092 2.013 2.068 2.046 2.036 0.088 0.094 0.092 0.092 0.093 0.097
2.06 2.027 1.991 2.056 1.998 1.979 0.136 0.134 0.133 0.143 0.146 0.17
1.976 1.988 1.956 1.914 1.914 1.884 0.207 0.163 0.182 0.216 0.206 0.242
1.92 1.913 1.974 1.893 1.906 1.893 0.201 0.158 0.183 0.185 0.208 0.227
1.967 1.974 1.964 1.955 1.896 1.886 0.132 0.123 0.142 0.138 0.14 0.164
2.042 2.038 2.021 1.994 2.002 1.955 0.093 0.092 0.092 0.092 0.093 0.088
0.838 0.896 0.9 0.845 0.861 0.805 0.876 0.918 0.954 0.887 0.926 0.832
1.693 1.807 1.804 1.812 1.809 1.833 0.091 0.091 0.088 0.085 0.087 0.078
1.744 1.779 1.801 1.744 1.772 1.789 0.091 0.096 0.096 0.09 0.091 0.085
1.707 1.793 1.803 1.774 1.793 1.783 0.111 0.124 0.121 0.12 0.123 0.112
1.721 1.719 1.737 1.752 1.796 1.747 0.094 0.086 0.092 0.091 0.087 0.08
1.695 1.762 1.772 1.774 1.796 1.801 0.097 0.095 0.093 0.094 0.092 0.087
1.677 1.636 1.713 1.737 1.695 1.728 0.105 0.105 0.107 0.119 0.116 0.126
1.739 1.746 1.777 1.795 1.756 1.786 0.093 0.091 0.092 0.094 0.091 0.085
0.753 0.826 0.842 0.808 0.814 0.781 0.748 0.774 0.804 0.715 0.603 0.791
1.631 1.553 1.46 1.58 1.674 1.838 0.086 0.094 0.084 0.085 0.084 0.086
1.485 1.651 1.623 1.738 1.74 1.848 0.086 0.089 0.088 0.088 0.089 0.089
1.609 1.57 1.609 1.736 1.772 1.774 0.104 0.118 0.106 0.108 0.113 0.124
1.557 1.654 1.725 1.843 1.727 1.756 0.083 0.081 0.082 0.086 0.086 0.084
1.578 1.673 1.68 1.626 1.645 1.657 0.145 0.137 0.149 0.155 0.172 0.189
1.654 1.595 1.603 1.603 1.625 1.629 0.137 0.129 0.137 0.141 0.152 0.159
1.684 1.696 1.605 1.698 1.716 1.718 0.091 0.093 0.094 0.092 0.092 0.089
0.816 0.707 0.857 0.844 0.748 0.865 0.746 0.639 0.695 0.694 0.733 0.805
x2 because (I used 50 μl instead of the 100) + Supernatant Value % of Total In Cell
To Find Original Total In Cell
2.193 2.256 2.241 2.228 2.238 2.184 8.208 9.043 8.568 8.438 8.490 8.425
2.268 2.28 2.197 2.252 2.232 2.23 7.760 8.246 8.375 8.171 8.333 8.700
2.332 2.295 2.257 2.342 2.29 2.319 11.664 11.678 11.786 12.212 12.751 14.661
2.39 2.314 2.32 2.346 2.326 2.368 17.322 14.088 15.690 18.414 17.713 20.439
2.322 2.229 2.34 2.263 2.322 2.347 17.313 14.177 15.641 16.350 17.916 19.344
2.231 2.22 2.248 2.231 2.176 2.214 11.833 11.081 12.633 12.371 12.868 14.815
2.228 2.222 2.205 2.178 2.188 2.131 8.348 8.281 8.345 8.448 8.501 8.259
2.59 2.732 2.808 2.619 2.713 2.469 67.645 67.204 67.949 67.736 68.264 67.396
1.875 1.989 1.98 1.982 1.983 1.989 9.707 9.150 8.889 8.577 8.775 7.843
1.926 1.971 1.993 1.924 1.954 1.959 9.450 9.741 9.634 9.356 9.314 8.678
1.929 2.041 2.045 2.014 2.039 2.007 11.509 12.151 11.834 11.917 12.065 11.161
1.909 1.891 1.921 1.934 1.97 1.907 9.848 9.096 9.578 9.411 8.832 8.390
1.889 1.952 1.958 1.962 1.98 1.975 10.270 9.734 9.499 9.582 9.293 8.810
1.887 1.846 1.927 1.975 1.927 1.98 11.129 11.376 11.105 12.051 12.039 12.727
1.925 1.928 1.961 1.983 1.938 1.956 9.662 9.440 9.383 9.481 9.391 8.691
2.249 2.374 2.45 2.238 2.02 2.363 66.518 65.206 65.633 63.896 59.703 66.949
1.803 1.741 1.628 1.75 1.842 2.01 9.540 10.798 10.319 9.714 9.121 8.557
1.657 1.829 1.799 1.914 1.918 2.026 10.380 9.732 9.783 9.195 9.281 8.786
1.817 1.806 1.821 1.952 1.998 2.022 11.447 13.068 11.642 11.066 11.311 12.265
1.723 1.816 1.889 2.015 1.899 1.924 9.634 8.921 8.682 8.536 9.057 8.732
1.868 1.947 1.978 1.936 1.989 2.035 15.525 14.073 15.066 16.012 17.295 18.575
1.928 1.853 1.877 1.885 1.929 1.947 14.212 13.923 14.598 14.960 15.759 16.333
1.866 1.882 1.793 1.882 1.9 1.896 9.753 9.883 10.485 9.777 9.684 9.388




































































RBL-pEE6 Expressing Dog α Chain Cells Bound With Mouse IgE For 0.5 Hours
1 2 3 4 5 6 7 8 9 10 11 12
1.907 1.785 1.747 1.838 1.883 1.857 0.092 0.089 0.088 0.091 0.091 0.087
1.893 1.787 1.73 1.863 1.872 1.87 0.09 0.091 0.09 0.095 0.093 0.088
1.913 1.762 1.86 1.92 1.964 2.027 0.109 0.123 0.117 0.12 0.123 0.126
1.848 1.736 1.753 1.777 1.884 1.924 0.134 0.131 0.135 0.124 0.135 0.135
1.775 1.714 1.671 1.717 1.833 1.783 0.211 0.242 0.23 0.254 0.261 0.256
1.774 1.742 1.735 1.844 1.834 1.8 0.244 0.262 0.209 0.235 0.278 0.268
1.804 1.798 1.79 1.849 1.766 1.722 0.209 0.205 0.18 0.196 0.198 0.209
0.683 0.657 0.751 0.788 0.754 0.733 0.833 0.83 0.837 0.783 0.809 0.76
1.679 1.733 1.74 1.805 1.754 1.747 0.096 0.094 0.1 0.094 0.089 0.091
1.746 1.822 1.769 1.833 1.807 1.728 0.091 0.094 0.097 0.093 0.097 0.097
1.681 1.796 1.758 1.728 1.714 1.651 0.106 0.117 0.117 0.115 0.12 0.114
1.621 1.788 1.777 1.724 1.716 1.688 0.096 0.083 0.089 0.09 0.082 0.084
1.706 1.776 1.756 1.739 1.761 1.688 0.095 0.094 0.095 0.099 0.1 0.09
1.605 1.616 1.668 1.687 1.685 1.632 0.166 0.143 0.14 0.16 0.182 0.176
1.645 1.706 1.739 1.726 1.739 1.635 0.164 0.151 0.162 0.16 0.177 0.176
0.697 0.763 0.759 0.83 0.871 0.6 0.784 0.78 0.814 0.886 0.858 0.8
1.843 1.921 1.873 1.932 1.896 1.812 0.084 0.084 0.084 0.082 0.084 0.092
1.834 1.837 1.823 1.823 1.795 1.733 0.09 0.099 0.094 0.087 0.096 0.097
1.831 1.872 1.805 1.825 1.783 1.723 0.107 0.124 0.115 0.109 0.119 0.12
1.797 1.778 1.772 1.796 1.765 1.696 0.087 0.084 0.084 0.083 0.086 0.088
1.77 1.722 1.712 1.697 1.703 1.667 0.141 0.118 0.117 0.116 0.13 0.134
1.683 1.62 1.641 1.649 1.662 1.588 0.199 0.18 0.175 0.172 0.199 0.236
1.773 1.664 1.739 1.694 1.745 1.694 0.173 0.154 0.157 0.149 0.156 0.189
0.792 0.814 0.821 0.762 0.836 0.605 0.801 0.735 0.737 0.668 0.641 0.941
x2 because (I used 50 μl instead of the 100) + Supernatant Value % of Total In Cell
To Find Original Total In Cell
2.091 1.963 1.923 2.02 2.065 2.031 8.800 9.068 9.152 9.010 8.814 8.567
2.073 1.969 1.91 2.053 2.058 2.046 8.683 9.243 9.424 9.255 9.038 8.602
2.131 2.008 2.094 2.16 2.21 2.279 10.230 12.251 11.175 11.111 11.131 11.057
2.116 1.998 2.023 2.025 2.154 2.194 12.665 13.113 13.347 12.247 12.535 12.306
2.197 2.198 2.131 2.225 2.355 2.295 19.208 22.020 21.586 22.831 22.166 22.309
2.262 2.266 2.153 2.314 2.39 2.336 21.574 23.124 19.415 20.311 23.264 22.945
2.222 2.208 2.15 2.241 2.162 2.14 18.812 18.569 16.744 17.492 18.316 19.533
2.349 2.317 2.425 2.354 2.372 2.253 70.924 71.644 69.031 66.525 68.212 67.466
1.871 1.921 1.94 1.993 1.932 1.929 10.262 9.787 10.309 9.433 9.213 9.435
1.928 2.01 1.963 2.019 2.001 1.922 9.440 9.353 9.883 9.212 9.695 10.094
1.893 2.03 1.992 1.958 1.954 1.879 11.199 11.527 11.747 11.747 12.282 12.134
1.813 1.954 1.955 1.904 1.88 1.856 10.590 8.495 9.105 9.454 8.723 9.052
1.896 1.964 1.946 1.937 1.961 1.868 10.021 9.572 9.764 10.222 10.199 9.636
1.937 1.902 1.948 2.007 2.049 1.984 17.140 15.037 14.374 15.944 17.765 17.742
1.973 2.008 2.063 2.046 2.093 1.987 16.624 15.040 15.705 15.640 16.914 17.715
2.265 2.323 2.387 2.602 2.587 2.2 69.227 67.155 68.203 68.101 66.332 72.727
2.011 2.089 2.041 2.096 2.064 1.996 8.354 8.042 8.231 7.824 8.140 9.218
2.014 2.035 2.011 1.997 1.987 1.927 8.937 9.730 9.349 8.713 9.663 10.067
2.045 2.12 2.035 2.043 2.021 1.963 10.465 11.698 11.302 10.671 11.776 12.226
1.971 1.946 1.94 1.962 1.937 1.872 8.828 8.633 8.660 8.461 8.880 9.402
2.052 1.958 1.946 1.929 1.963 1.935 13.743 12.053 12.025 12.027 13.245 13.850
2.081 1.98 1.991 1.993 2.06 2.06 19.125 18.182 17.579 17.260 19.320 22.913
2.119 1.972 2.053 1.992 2.057 2.072 16.328 15.619 15.295 14.960 15.168 18.243




































































RBL-pEE6 Expressing Dog α Chain Cells Bound With Horse IgE For 1 Hours
1 2 3 4 5 6 7 8 9 10 11 12
1.932 2 1.987 2.027 2 2.018 0.102 0.104 0.1 0.099 0.098 0.099
2.076 2.114 2.097 2.081 2.092 2.092 0.098 0.097 0.098 0.092 0.091 0.088
2.056 2.056 2.071 2.08 2.051 2.066 0.121 0.123 0.118 0.12 0.117 0.128
1.937 2.006 1.999 1.998 1.991 1.956 0.176 0.145 0.158 0.182 0.179 0.206
1.975 2.041 2.022 1.995 2.002 1.951 0.201 0.15 0.173 0.189 0.195 0.206
1.955 1.987 2.009 1.939 1.974 1.93 0.135 0.121 0.118 0.13 0.136 0.151
1.994 2.018 2.026 1.963 2.056 1.991 0.096 0.096 0.093 0.108 0.092 0.092
0.885 0.885 0.942 1.028 1.016 0.863 0.964 1.036 1.087 1.031 0.954 1.009
1.712 1.839 1.818 1.868 1.818 1.79 0.097 0.086 0.086 0.086 0.088 0.086
1.959 1.86 1.827 1.883 1.904 1.807 0.091 0.09 0.09 0.087 0.091 0.093
1.932 1.887 1.887 1.863 1.833 1.798 0.107 0.113 0.11 0.107 0.117 0.122
1.816 1.809 1.809 1.832 1.814 1.76 0.089 0.082 0.087 0.089 0.093 0.079
1.666 1.747 1.715 1.738 1.728 1.709 0.173 0.136 0.142 0.164 0.186 0.162
1.662 1.711 1.702 1.783 1.746 1.7 0.164 0.137 0.134 0.141 0.164 0.16
1.703 1.795 1.731 1.79 1.812 1.8 0.099 0.094 0.091 0.095 0.092 0.086
0.807 0.88 0.964 0.933 0.978 0.919 0.718 0.807 0.693 0.775 0.729 0.713
1.793 1.854 1.818 1.781 1.854 1.783 0.093 0.098 0.088 0.096 0.086 0.099
1.839 1.86 1.84 1.821 1.86 1.805 0.089 0.097 0.098 0.091 0.093 0.095
1.771 1.783 1.746 1.842 1.853 1.75 0.109 0.127 0.121 0.116 0.125 0.133
1.874 1.879 1.849 1.865 1.862 1.798 0.085 0.081 0.085 0.085 0.081 0.09
1.881 1.863 1.843 1.81 1.857 1.81 0.096 0.091 0.089 0.089 0.09 0.096
1.801 1.794 1.777 1.803 1.803 1.745 0.112 0.113 0.114 0.111 0.127 0.124
1.807 1.841 1.776 1.783 1.788 1.742 0.097 0.097 0.099 0.092 0.094 0.1
0.743 0.8 0.822 0.824 0.824 0.716 0.846 0.782 0.789 0.673 0.707 0.79
x2 because (I used 50 μl instead of the 100) + Supernatant Value % of Total In Cell
To Find Original Total In Cell
2.136 2.208 2.187 2.225 2.196 2.216 9.551 9.420 9.145 8.899 8.925 8.935
2.272 2.308 2.293 2.265 2.274 2.268 8.627 8.406 8.548 8.124 8.004 7.760
2.298 2.302 2.307 2.32 2.285 2.322 10.531 10.686 10.230 10.345 10.241 11.025
2.289 2.296 2.315 2.362 2.349 2.368 15.378 12.631 13.650 15.411 15.241 17.399
2.377 2.341 2.368 2.373 2.392 2.363 16.912 12.815 14.611 15.929 16.304 17.435
2.225 2.229 2.245 2.199 2.246 2.232 12.135 10.857 10.512 11.824 12.110 13.530
2.186 2.21 2.212 2.179 2.24 2.175 8.783 8.688 8.409 9.913 8.214 8.460
2.813 2.957 3.116 3.09 2.924 2.881 68.539 70.071 69.769 66.731 65.253 70.045
1.906 2.011 1.99 2.04 1.994 1.962 10.178 8.553 8.643 8.431 8.826 8.767
2.141 2.04 2.007 2.057 2.086 1.993 8.501 8.824 8.969 8.459 8.725 9.333
2.146 2.113 2.107 2.077 2.067 2.042 9.972 10.696 10.441 10.303 11.321 11.949
1.994 1.973 1.983 2.01 2 1.918 8.927 8.312 8.775 8.856 9.300 8.238
2.012 2.019 1.999 2.066 2.1 2.033 17.197 13.472 14.207 15.876 17.714 15.937
1.99 1.985 1.97 2.065 2.074 2.02 16.482 13.804 13.604 13.656 15.815 15.842
1.901 1.983 1.913 1.98 1.996 1.972 10.416 9.481 9.514 9.596 9.218 8.722
2.243 2.494 2.35 2.483 2.436 2.345 64.021 64.715 58.979 62.424 59.852 60.810
1.979 2.05 1.994 1.973 2.026 1.981 9.399 9.561 8.826 9.731 8.490 9.995
2.017 2.054 2.036 2.003 2.046 1.995 8.825 9.445 9.627 9.086 9.091 9.524
1.989 2.037 1.988 2.074 2.103 2.016 10.960 12.469 12.173 11.186 11.888 13.194
2.044 2.041 2.019 2.035 2.024 1.978 8.317 7.937 8.420 8.354 8.004 9.100
2.073 2.045 2.021 1.988 2.037 2.002 9.262 8.900 8.808 8.954 8.837 9.590
2.025 2.02 2.005 2.025 2.057 1.993 11.062 11.188 11.372 10.963 12.348 12.444
2.001 2.035 1.974 1.967 1.976 1.942 9.695 9.533 10.030 9.354 9.514 10.299




































































RBL-pEE6 Expressing Dog α Chain Cells Bound With Mouse IgE For 1 Hours
1 2 3 4 5 6 7 8 9 10 11 12
1.907 1.947 1.971 1.975 1.91 1.975 0.091 0.091 0.092 0.085 0.088 0.098
2.051 1.959 2.022 2.041 1.955 1.983 0.09 0.093 0.097 0.085 0.095 0.1
2.07 2.018 2.013 2.06 1.979 1.902 0.11 0.122 0.113 0.116 0.12 0.134
1.93 1.887 1.921 1.818 1.939 1.949 0.155 0.131 0.138 0.132 0.136 0.15
1.724 1.732 1.739 1.726 1.744 1.662 0.352 0.286 0.315 0.33 0.324 0.349
1.678 1.674 1.775 1.771 1.69 1.665 0.362 0.298 0.312 0.328 0.293 0.385
1.658 1.684 1.759 1.785 1.687 1.697 0.333 0.298 0.304 0.366 0.359 0.352
0.662 0.738 0.668 0.722 0.694 0.585 1.083 0.975 0.751 1.088 0.993 0.758
1.404 1.344 1.369 1.618 1.657 1.762 0.066 0.093 0.091 0.091 0.09 0.081
1.373 1.558 1.645 1.643 1.716 1.886 0.091 0.093 0.094 0.093 0.094 0.09
1.495 1.517 1.623 1.784 1.766 1.834 0.106 0.114 0.115 0.112 0.119 0.109
1.612 1.556 1.613 1.752 1.67 1.792 0.086 0.084 0.089 0.085 0.084 0.079
1.617 1.506 1.525 1.591 1.739 1.72 0.096 0.094 0.097 0.092 0.096 0.089
1.323 1.412 1.445 1.6 1.676 1.579 0.191 0.169 0.195 0.248 0.276 0.293
1.28 1.384 1.369 1.526 1.542 1.477 0.251 0.224 0.236 0.275 0.29 0.328
0.502 0.601 0.619 0.791 0.793 0.637 0.67 0.682 0.776 0.838 0.845 0.68
1.959 1.983 1.967 1.963 1.932 1.987 0.095 0.09 0.087 0.089 0.085 0.082
1.979 1.942 1.893 1.889 1.883 1.917 0.092 0.089 0.098 0.097 0.097 0.091
1.931 1.893 1.896 1.902 1.864 1.896 0.112 0.125 0.121 0.123 0.129 0.116
1.951 1.919 1.891 1.863 1.863 1.88 0.089 0.087 0.093 0.092 0.089 0.086
1.875 1.881 1.851 1.833 1.848 1.842 0.138 0.128 0.13 0.137 0.134 0.151
1.742 1.711 1.687 1.657 1.652 1.66 0.29 0.272 0.279 0.343 0.387 0.458
1.753 1.733 1.725 1.676 1.686 1.691 0.288 0.26 0.254 0.257 0.299 0.33
0.827 0.912 0.915 0.887 0.927 0.932 0.787 0.742 0.77 0.819 0.779 0.696
x2 because (I used 50 μl instead of the 100) + Supernatant Value % of Total In Cell
To Find Original Total In Cell
2.089 2.129 2.155 2.145 2.086 2.171 8.712 8.549 8.538 7.925 8.437 9.028
2.231 2.145 2.216 2.211 2.145 2.183 8.068 8.671 8.755 7.689 8.858 9.162
2.29 2.262 2.239 2.292 2.219 2.17 9.607 10.787 10.094 10.122 10.816 12.350
2.24 2.149 2.197 2.082 2.211 2.249 13.839 12.192 12.563 12.680 12.302 13.339
2.428 2.304 2.369 2.386 2.392 2.36 28.995 24.826 26.593 27.661 27.090 29.576
2.402 2.27 2.399 2.427 2.276 2.435 30.142 26.256 26.011 27.029 25.747 31.622
2.324 2.28 2.367 2.517 2.405 2.401 28.657 26.140 25.687 29.082 29.854 29.321
2.828 2.688 2.17 2.898 2.68 2.101 76.591 72.545 69.217 75.086 74.104 72.156
1.536 1.53 1.551 1.8 1.837 1.924 8.594 12.157 11.734 10.111 9.799 8.420
1.555 1.744 1.833 1.829 1.904 2.066 11.704 10.665 10.256 10.169 9.874 8.712
1.707 1.745 1.853 2.008 2.004 2.052 12.419 13.066 12.412 11.155 11.876 10.624
1.784 1.724 1.791 1.922 1.838 1.95 9.641 9.745 9.939 8.845 9.140 8.103
1.809 1.694 1.719 1.775 1.931 1.898 10.614 11.098 11.286 10.366 9.943 9.378
1.705 1.75 1.835 2.096 2.228 2.165 22.405 19.314 21.253 23.664 24.776 27.067
1.782 1.832 1.841 2.076 2.122 2.133 28.171 24.454 25.638 26.493 27.333 30.755
1.842 1.965 2.171 2.467 2.483 1.997 72.747 69.415 71.488 67.937 68.063 68.102
2.149 2.163 2.141 2.141 2.102 2.151 8.841 8.322 8.127 8.314 8.088 7.624
2.163 2.12 2.089 2.083 2.077 2.099 8.507 8.396 9.382 9.313 9.340 8.671
2.155 2.143 2.138 2.148 2.122 2.128 10.394 11.666 11.319 11.453 12.158 10.902
2.129 2.093 2.077 2.047 2.041 2.052 8.361 8.313 8.955 8.989 8.721 8.382
2.151 2.137 2.111 2.107 2.116 2.144 12.831 11.979 12.316 13.004 12.665 14.086
2.322 2.255 2.245 2.343 2.426 2.576 24.978 24.124 24.855 29.279 31.904 35.559
2.329 2.253 2.233 2.19 2.284 2.351 24.732 23.080 22.750 23.470 26.182 28.073




































































RBL-pEE6 Expressing Dog α Chain Cells Bound With Horse IgE For 3 Hours
1 2 3 4 5 6 7 8 9 10 11 12
2.167 2.187 2.174 2.167 2.162 2.097 0.095 0.104 0.099 0.093 0.094 0.089
2.229 2.201 2.155 2.208 2.187 2.148 0.096 0.096 0.098 0.099 0.1 0.099
2.186 2.149 2.161 2.151 2.13 2.125 0.109 0.12 0.122 0.12 0.126 0.13
2.157 2.164 2.137 2.127 2.159 2.127 0.096 0.095 0.11 0.109 0.117 0.13
2.056 2.075 2.041 2.029 2.033 2.02 0.201 0.175 0.25 0.263 0.288 0.386
2.061 2.054 2.046 2.031 2.023 1.943 0.167 0.148 0.216 0.209 0.227 0.339
2.149 2.155 2.128 2.112 2.102 2.092 0.112 0.102 0.102 0.103 0.099 0.099
1.142 1.161 1.228 1.104 1.091 1.008 0.774 0.838 0.898 0.852 0.891 0.927
1.975 1.928 1.909 1.866 1.922 1.951 0.093 0.095 0.095 0.098 0.095 0.091
2.002 1.898 1.867 1.846 1.924 1.941 0.098 0.098 0.098 0.094 0.101 0.094
1.985 1.893 1.884 1.804 1.939 1.909 0.114 0.128 0.114 0.121 0.122 0.123
2.008 1.907 1.834 1.805 1.892 1.898 0.094 0.09 0.095 0.092 0.089 0.092
1.941 1.882 1.832 1.835 1.841 1.85 0.1 0.096 0.1 0.097 0.097 0.099
1.854 1.798 1.762 1.733 1.819 1.845 0.17 0.136 0.143 0.162 0.175 0.189
1.943 1.894 1.865 1.85 1.883 1.837 0.109 0.107 0.104 0.104 0.104 0.099
0.691 0.774 0.744 0.72 0.886 0.816 0.982 0.974 0.84 0.883 0.812 0.825
1.939 1.983 2.009 2.022 2.022 1.959 0.1 0.099 0.097 0.099 0.096 0.102
1.996 1.945 1.971 1.983 1.975 1.963 0.099 0.106 0.104 0.101 0.102 0.106
1.978 1.967 1.952 2.009 1.996 1.959 0.117 0.131 0.127 0.141 0.158 0.139
1.994 1.976 1.969 1.982 1.968 1.994 0.093 0.093 0.099 0.119 0.104 0.124
1.979 1.991 1.971 1.959 1.975 1.928 0.099 0.105 0.103 0.102 0.098 0.1
1.947 1.947 1.928 1.947 1.953 1.914 0.104 0.107 0.107 0.111 0.106 0.121
1.93 1.986 1.964 1.958 1.997 1.975 0.099 0.105 0.102 0.099 0.099 0.097
1.061 1.05 1.036 0.987 1.06 0.879 0.583 0.807 0.715 0.728 0.785 0.757
x2 because (I used 50 μl instead of the 100) + Supernatant Value % of Total In Cell
To Find Original Total In Cell
2.357 2.395 2.372 2.353 2.35 2.275 8.061 8.685 8.347 7.905 8.000 7.824
2.421 2.393 2.351 2.406 2.387 2.346 7.931 8.023 8.337 8.229 8.379 8.440
2.404 2.389 2.405 2.391 2.382 2.385 9.068 10.046 10.146 10.038 10.579 10.901
2.349 2.354 2.357 2.345 2.393 2.387 8.174 8.071 9.334 9.296 9.779 10.892
2.458 2.425 2.541 2.555 2.609 2.792 16.355 14.433 19.677 20.587 22.077 27.650
2.395 2.35 2.478 2.449 2.477 2.621 13.946 12.596 17.433 17.068 18.329 25.868
2.373 2.359 2.332 2.318 2.3 2.29 9.440 8.648 8.748 8.887 8.609 8.646
2.69 2.837 3.024 2.808 2.873 2.862 57.546 59.076 59.392 60.684 62.026 64.780
2.161 2.118 2.099 2.062 2.112 2.133 8.607 8.971 9.052 9.505 8.996 8.533
2.198 2.094 2.063 2.034 2.126 2.129 8.917 9.360 9.501 9.243 9.501 8.830
2.213 2.149 2.112 2.046 2.183 2.155 10.303 11.913 10.795 11.828 11.177 11.415
2.196 2.087 2.024 1.989 2.07 2.082 8.561 8.625 9.387 9.251 8.599 8.838
2.141 2.074 2.032 2.029 2.035 2.048 9.341 9.257 9.843 9.561 9.533 9.668
2.194 2.07 2.048 2.057 2.169 2.223 15.497 13.140 13.965 15.751 16.136 17.004
2.161 2.108 2.073 2.058 2.091 2.035 10.088 10.152 10.034 10.107 9.947 9.730
2.655 2.722 2.424 2.486 2.51 2.466 73.974 71.565 69.307 71.038 64.701 66.910
2.139 2.181 2.203 2.22 2.214 2.163 9.350 9.078 8.806 8.919 8.672 9.431
2.194 2.157 2.179 2.185 2.179 2.175 9.025 9.828 9.546 9.245 9.362 9.747
2.212 2.229 2.206 2.291 2.312 2.237 10.579 11.754 11.514 12.309 13.668 12.427
2.18 2.162 2.167 2.22 2.176 2.242 8.532 8.603 9.137 10.721 9.559 11.062
2.177 2.201 2.177 2.163 2.171 2.128 9.095 9.541 9.463 9.431 9.028 9.398
2.155 2.161 2.142 2.169 2.165 2.156 9.652 9.903 9.991 10.235 9.792 11.224
2.128 2.196 2.168 2.156 2.195 2.169 9.305 9.563 9.410 9.184 9.021 8.944




































































RBL-pEE6 Expressing Dog α Chain Cells Bound With Mouse IgE For 3 Hours
1 2 3 4 5 6 7 8 9 10 11 12
2.095 2.237 2.161 2.143 2.187 2.155 0.09 0.091 0.097 0.095 0.087 0.085
2.194 2.208 2.174 2.135 2.187 2.18 0.095 0.095 0.098 0.095 0.1 0.094
2.155 2.215 2.174 2.186 2.139 2.134 0.111 0.125 0.123 0.122 0.128 0.127
2.141 2.179 2.117 2.032 2.137 2.14 0.104 0.094 0.105 0.101 0.106 0.103
1.939 2.022 1.986 1.928 1.934 1.949 0.302 0.21 0.242 0.278 0.333 0.371
1.695 1.735 1.757 1.699 1.711 1.638 0.476 0.34 0.354 0.512 0.582 0.693
1.738 1.772 1.75 1.701 1.731 1.701 0.466 0.379 0.339 0.406 0.571 0.672
0.895 0.865 1.094 1.02 1.069 1.067 0.91 1.09 0.979 0.951 1.004 0.967
1.74 1.947 1.951 2.029 2.004 1.983 0.087 0.085 0.09 0.086 0.084 0.089
1.959 1.928 1.974 1.975 1.924 1.891 0.091 0.091 0.096 0.092 0.096 0.1
2.01 1.936 1.913 1.967 1.896 1.806 0.107 0.115 0.113 0.115 0.113 0.114
1.822 1.751 1.891 1.961 1.842 1.853 0.083 0.082 0.087 0.087 0.09 0.091
1.811 1.876 1.861 1.83 1.855 1.822 0.115 0.087 0.09 0.085 0.093 0.091
1.755 1.659 1.697 1.706 1.777 1.781 0.19 0.155 0.16 0.188 0.204 0.186
1.462 1.563 1.622 1.515 1.468 1.434 0.382 0.364 0.395 0.38 0.399 0.445
0.813 0.829 0.855 0.92 0.867 0.739 0.721 0.916 0.794 0.78 0.823 0.831
2.092 2.066 1.979 2.004 2.086 2.076 0.09 0.092 0.089 0.09 0.088 0.087
2.068 2.003 1.975 2.005 2.036 2.022 0.091 0.099 0.097 0.098 0.098 0.098
2.076 1.945 1.959 1.928 2.035 2.009 0.11 0.127 0.118 0.119 0.123 0.123
2.001 1.951 1.915 1.941 1.993 1.985 0.093 0.089 0.093 0.1 0.095 0.088
1.987 1.958 1.947 1.93 1.988 1.967 0.108 0.1 0.098 0.104 0.11 0.101
1.74 1.751 1.655 1.72 1.757 1.725 0.327 0.277 0.332 0.415 0.448 0.482
1.757 1.729 1.693 1.705 1.717 1.705 0.339 0.282 0.35 0.408 0.457 0.512
0.864 1.018 1.043 0.934 1.008 0.828 0.844 0.731 0.738 0.801 0.814 0.788
x2 because (I used 50 μl instead of the 100) + Supernatant Value % of Total In Cell
To Find Original Total In Cell
2.275 2.419 2.355 2.333 2.361 2.325 7.912 7.524 8.238 8.144 7.370 7.312
2.384 2.398 2.37 2.325 2.387 2.368 7.970 7.923 8.270 8.172 8.379 7.939
2.377 2.465 2.42 2.43 2.395 2.388 9.340 10.142 10.165 10.041 10.689 10.637
2.349 2.367 2.327 2.234 2.349 2.346 8.855 7.943 9.024 9.042 9.025 8.781
2.543 2.442 2.47 2.484 2.6 2.691 23.751 17.199 19.595 22.383 25.615 27.573
2.647 2.415 2.465 2.723 2.875 3.024 35.965 28.157 28.722 37.606 40.487 45.833
2.67 2.53 2.428 2.513 2.873 3.045 34.906 29.960 27.924 32.312 39.749 44.138
2.715 3.045 3.052 2.922 3.077 3.001 67.035 71.593 64.155 65.092 65.258 64.445
1.914 2.117 2.131 2.201 2.172 2.161 9.091 8.030 8.447 7.815 7.735 8.237
2.141 2.11 2.166 2.159 2.116 2.091 8.501 8.626 8.864 8.522 9.074 9.565
2.224 2.166 2.139 2.197 2.122 2.034 9.622 10.619 10.566 10.469 10.650 11.209
1.988 1.915 2.065 2.135 2.022 2.035 8.350 8.564 8.426 8.150 8.902 8.943
2.041 2.05 2.041 2 2.041 2.004 11.269 8.488 8.819 8.500 9.113 9.082
2.135 1.969 2.017 2.082 2.185 2.153 17.799 15.744 15.865 18.060 18.673 17.278
2.226 2.291 2.412 2.275 2.266 2.324 34.322 31.777 32.753 33.407 35.216 38.296
2.255 2.661 2.443 2.48 2.513 2.401 63.947 68.846 65.002 62.903 65.499 69.221
2.272 2.25 2.157 2.184 2.262 2.25 7.923 8.178 8.252 8.242 7.781 7.733
2.25 2.201 2.169 2.201 2.232 2.218 8.089 8.996 8.944 8.905 8.781 8.837
2.296 2.199 2.195 2.166 2.281 2.255 9.582 11.551 10.752 10.988 10.785 10.909
2.187 2.129 2.101 2.141 2.183 2.161 8.505 8.361 8.853 9.341 8.704 8.144
2.203 2.158 2.143 2.138 2.208 2.169 9.805 9.268 9.146 9.729 9.964 9.313
2.394 2.305 2.319 2.55 2.653 2.689 27.318 24.035 28.633 32.549 33.773 35.850
2.435 2.293 2.393 2.521 2.631 2.729 27.844 24.597 29.252 32.368 34.740 37.523




































































RBL-pEE6 Expressing Dog α Chain Cells Bound With Horse IgE For 16 Hours
1 2 3 4 5 6 7 8 9 10 11 12
1.611 1.764 1.799 1.83 1.823 1.793 0.093 0.088 0.086 0.089 0.09 0.085
1.492 1.829 1.824 1.854 1.829 1.842 0.09 0.091 0.09 0.089 0.093 0.086
1.506 1.836 1.831 1.85 1.856 1.853 0.107 0.117 0.113 0.114 0.122 0.114
1.397 1.762 1.769 1.806 1.84 1.807 0.081 0.077 0.083 0.083 0.081 0.08
1.353 1.719 1.696 1.734 1.762 1.721 0.12 0.124 0.133 0.178 0.195 0.2
1.261 1.668 1.712 1.752 1.793 1.657 0.104 0.115 0.112 0.134 0.145 0.152
1.356 1.679 1.774 1.83 1.832 1.833 0.092 0.089 0.088 0.087 0.085 0.083
0.626 0.954 0.921 0.961 1.009 0.943 0.568 0.606 0.682 0.791 0.837 0.778
1.234 1.433 1.505 1.564 1.529 1.499 0.095 0.092 0.088 0.091 0.087 0.085
1.345 1.53 1.578 1.561 1.565 1.527 0.094 0.098 0.093 0.091 0.095 0.089
1.357 1.445 1.566 1.552 1.552 1.501 0.111 0.122 0.119 0.12 0.122 0.116
1.499 1.472 1.546 1.532 1.564 1.533 0.092 0.087 0.09 0.091 0.087 0.087
1.135 1.363 1.461 1.447 1.448 1.433 0.114 0.109 0.135 0.133 0.133 0.138
1.067 1.399 1.447 1.431 1.487 1.393 0.122 0.13 0.15 0.154 0.16 0.17
1.29 1.424 1.534 1.413 1.534 1.529 0.097 0.097 0.101 0.106 0.096 0.093
0.548 0.703 0.669 0.699 0.68 0.635 0.566 0.694 0.659 0.702 0.704 0.643
2.682 2.205 2.143 2.162 2.152 2.11 0.07 0.074 0.07 0.071 0.074 0.075
2.686 2.192 2.132 2.179 2.069 2.034 0.071 0.072 0.078 0.081 0.09 0.088
2.11 2.535 2.152 2.173 2.03 2.022 0.065 0.066 0.065 0.071 0.07 0.075
2.137 2.25 2.157 2.14 2.053 2.077 0.066 0.064 0.068 0.076 0.083 0.077
2.112 2.62 2.152 2.148 2.051 2.047 0.073 0.077 0.079 0.087 0.095 0.099
2.24 2.355 2.226 2.266 2.13 2.186 0.07 0.072 0.075 0.078 0.084 0.088
2.25 2.232 2.152 2.194 2.097 2.045 0.07 0.074 0.077 0.078 0.079 0.091
0.973 1.016 0.894 0.918 0.834 1.043 0.539 0.996 1.171 1.164 1.134 1.249
x2 because (I used 50 μl instead of the 100) + Supernatant Value % of Total In Cell
To Find Original Total In Cell
1.797 1.94 1.971 2.008 2.003 1.963 10.351 9.072 8.727 8.865 8.987 8.660
1.672 2.011 2.004 2.032 2.015 2.014 10.766 9.050 8.982 8.760 9.231 8.540
1.72 2.07 2.057 2.078 2.1 2.081 12.442 11.304 10.987 10.972 11.619 10.956
1.559 1.916 1.935 1.972 2.002 1.967 10.391 8.038 8.579 8.418 8.092 8.134
1.593 1.967 1.962 2.09 2.152 2.121 15.066 12.608 13.558 17.033 18.123 18.859
1.469 1.898 1.936 2.02 2.083 1.961 14.159 12.118 11.570 13.267 13.922 15.502
1.54 1.857 1.95 2.004 2.002 1.999 11.948 9.585 9.026 8.683 8.492 8.304
1.762 2.166 2.285 2.543 2.683 2.499 64.472 55.956 59.694 62.210 62.393 62.265
1.424 1.617 1.681 1.746 1.703 1.669 13.343 11.379 10.470 10.424 10.217 10.186
1.533 1.726 1.764 1.743 1.755 1.705 12.264 11.356 10.544 10.442 10.826 10.440
1.579 1.689 1.804 1.792 1.796 1.733 14.060 14.446 13.193 13.393 13.586 13.387
1.683 1.646 1.726 1.714 1.738 1.707 10.933 10.571 10.429 10.618 10.012 10.193
1.363 1.581 1.731 1.713 1.714 1.709 16.728 13.789 15.598 15.528 15.519 16.150
1.311 1.659 1.747 1.739 1.807 1.733 18.612 15.672 17.172 17.711 17.709 19.619
1.484 1.618 1.736 1.625 1.726 1.715 13.073 11.990 11.636 13.046 11.124 10.845
1.68 2.091 1.987 2.103 2.088 1.921 67.381 66.380 66.331 66.762 67.433 66.944
2.822 2.353 2.283 2.304 2.3 2.26 4.961 6.290 6.132 6.163 6.435 6.637
2.828 2.336 2.288 2.341 2.249 2.21 5.021 6.164 6.818 6.920 8.004 7.964
2.24 2.667 2.282 2.315 2.17 2.172 5.804 4.949 5.697 6.134 6.452 6.906
2.269 2.378 2.293 2.292 2.219 2.231 5.818 5.383 5.931 6.632 7.481 6.903
2.258 2.774 2.31 2.322 2.241 2.245 6.466 5.552 6.840 7.494 8.478 8.820
2.38 2.499 2.376 2.422 2.298 2.362 5.882 5.762 6.313 6.441 7.311 7.451
2.39 2.38 2.306 2.35 2.255 2.227 5.858 6.218 6.678 6.638 7.007 8.172




































RBL-pEE6 Expressing Dog α Chain Cells Bound With Mouse IgE For 16 Hours
1 2 3 4 5 6 7 8 9 10 11 12
1.581 1.776 1.815 1.842 1.821 1.83 0.106 0.106 0.102 0.098 0.097 0.115
1.579 1.78 1.821 1.824 1.812 1.868 0.105 0.093 0.095 0.102 0.108 0.111
1.709 1.81 1.833 1.857 1.838 1.846 0.151 0.138 0.139 0.15 0.153 0.172
1.511 1.721 1.76 1.838 1.771 1.779 0.264 0.183 0.232 0.272 0.295 0.276
1.151 1.422 1.533 1.542 1.543 1.464 0.455 0.36 0.456 0.647 0.684 0.645
1.192 1.281 1.429 1.415 1.331 1.368 0.518 0.418 0.541 0.626 0.7 0.686
1.2 1.243 1.382 1.373 1.362 1.334 0.517 0.405 0.409 0.444 0.45 0.527
0.566 0.621 0.707 0.69 0.697 0.757 0.888 0.895 0.831 0.94 0.938 0.8
x2 because (I used 50 μl instead of the 100) + Supernatant Value % of Total In Cell
To Find Original Total In Cell
1.793 1.988 2.019 2.038 2.015 2.06 11.824 10.664 10.104 9.617 9.628 11.165
1.789 1.966 2.011 2.028 2.028 2.09 11.738 9.461 9.448 10.059 10.651 10.622
2.011 2.086 2.111 2.157 2.144 2.19 15.017 13.231 13.169 13.908 14.272 15.708
2.039 2.087 2.224 2.382 2.361 2.331 25.895 17.537 20.863 22.838 24.989 23.681
2.061 2.142 2.445 2.836 2.911 2.754 44.153 33.613 37.301 45.628 46.994 46.841
2.228 2.117 2.511 2.667 2.731 2.74 46.499 39.490 43.090 46.944 51.263 50.073
2.234 2.053 2.2 2.261 2.262 2.388 46.285 39.454 37.182 39.275 39.788 44.137




















































RBL-pEE6 Expressing Dog α Chain Cells Bound With Dog IgE For 16 Hours
1 2 3 4 5 6 7 8 9 10 11 12
2.565 2.893 2.495 1.992 2.228 1.839 0.068 0.073 0.072 0.073 0.068 0.074
2.471 2.602 2.565 2.068 1.893 1.731 0.115 0.098 0.092 0.094 0.11 0.118
1.726 1.749 1.698 1.67 1.671 1.531 0.395 0.338 0.381 0.464 0.524 0.472
1.881 1.461 1.463 1.399 1.307 1.254 0.587 0.447 0.591 0.771 0.875 0.765
1.502 1.509 1.434 1.35 1.353 1.185 0.693 0.488 0.61 0.822 0.952 0.657
1.484 1.56 1.472 1.428 1.418 1.204 0.623 0.542 0.713 0.791 0.837 0.607
1.982 1.479 1.393 1.369 1.4 1.219 0.642 0.52 0.707 0.786 0.896 0.706
1.312 0.751 0.753 0.781 0.823 0.807 1.024 1.062 0.938 0.986 0.922 0.843
1.632 1.713 1.812 1.764 1.698 1.654 0.096 0.094 0.096 0.105 0.095 0.111
1.684 1.8 1.835 1.756 1.738 1.724 0.102 0.1 0.097 0.103 0.102 0.107
1.661 1.693 1.776 1.776 1.779 1.74 0.179 0.174 0.164 0.17 0.185 0.227
1.272 1.471 1.521 1.538 1.546 1.481 0.319 0.265 0.332 0.439 0.447 0.47
1.271 1.399 1.477 1.451 1.473 1.396 0.368 0.307 0.321 0.465 0.534 0.552
1.183 1.43 1.506 1.444 1.543 1.426 0.32 0.313 0.337 0.344 0.475 0.531
1.132 1.376 1.443 1.42 1.443 1.398 0.352 0.334 0.374 0.365 0.398 0.544
0.548 0.748 0.838 0.78 0.896 0.799 0.651 0.75 0.919 0.875 0.867 0.858
x2 because (I used 50 μl instead of the 100) + Supernatant Value % of Total In Cell
To Find Original Total In Cell
2.701 3.039 2.639 2.138 2.364 1.987 5.035 4.804 5.457 6.829 5.753 7.448
2.701 2.798 2.749 2.256 2.113 1.967 8.515 7.005 6.693 8.333 10.412 11.998
2.516 2.425 2.46 2.598 2.719 2.475 31.399 27.876 30.976 35.720 38.544 38.141
3.055 2.355 2.645 2.941 3.057 2.784 38.429 37.962 44.688 52.431 57.246 54.957
2.888 2.485 2.654 2.994 3.257 2.499 47.992 39.276 45.968 54.910 58.459 52.581
2.73 2.644 2.898 3.01 3.092 2.418 45.641 40.998 49.206 52.558 54.140 50.207
3.266 2.519 2.807 2.941 3.192 2.631 39.314 41.286 50.374 53.451 56.140 53.668
3.36 2.875 2.629 2.753 2.667 2.493 60.952 73.878 71.358 71.631 69.141 67.629
1.824 1.901 2.004 1.974 1.888 1.876 10.526 9.890 9.581 10.638 10.064 11.834
1.888 2 2.029 1.962 1.942 1.938 10.805 10.000 9.561 10.499 10.505 11.042
2.019 2.041 2.104 2.116 2.149 2.194 17.732 17.050 15.589 16.068 17.217 20.693
1.91 2.001 2.185 2.416 2.44 2.421 33.403 26.487 30.389 36.341 36.639 38.827
2.007 2.013 2.119 2.381 2.541 2.5 36.672 30.502 30.297 39.059 42.031 44.160
1.823 2.056 2.18 2.132 2.493 2.488 35.107 30.447 30.917 32.270 38.107 42.685
1.836 2.044 2.191 2.15 2.239 2.486 38.344 32.681 34.140 33.953 35.552 43.765










Values for Figure 35:
These are the SPR values for the equine sFcεRIαD1&2 
expression test.

























51.1 22.55 45.3 0
61.3 23.35 56.9 0
60.85 22.75 61.4 1
54.65 14.65 61.2 1
53.15 11.35 61.5 2
53.15 10.5 60.2 2
63.1 11.85 55.5 3
63.5 12.4 53.8 3
65.35 13.1 53.8 4
68 44.7 52.5 4
69.25 15.5 53.8 5
71.4 18.85 52.5 5
63 6
63.2 6
Standard Deviation 63.8 7
8.20 0.35 63.2 7
0.14 0.07 65.7 8
0.92 0.49 65 8
1.20 0.35 68.5 9
0.92 0.21 67.5 9
0.92 0.14 69.3 10
0.14 0.35 69.2 10
0.42 0.14 71.5 11
0.49 0.00 71.3 11
0.71 0.00 22.3 P0
0.07 1.98 22.8 P0























Values for Figure 36:
These are the SPR values for the equine sFcεRIαD1&2 
expression test at day 6.
Expressing Yeast Parental Yeast
Day 6 68 24.7 67.3 Sample
Standard Deviation 68.7 Sample
0.99 1.84 26 Parent
23.4 Parent
Values for Figure 37:
These are the SPR values for the equine sFcεRIαD1&2 media 
concentration test.







Values for Figure 40:
Dilution curve Bradford assay for equine sFcεRIαD1&2 and 
HHoH IgE anti NIP-HSA.
μg ml-1 Dilution Curve 
Average












0.480 0.419 0.449 0.572
0.541 0.516 0.496 0.610
0.607 0.550 0.629 0.642
0.694 0.681 0.710 0.692
0.833 0.836 0.876 0.786
1.002 0.895 1.031 1.079
0.920 0.943 0.945 0.871
1.099 1.118 1.271 0.907
1.265 1.082 1.505 1.207
1.182 1.131 1.259 1.155
1.243 1.248 1.256 1.226
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Chapter 6.3.2 Supplementary Table: EvilFit Discrete One 
Site Model:
This table shows the Discrete One Site Model values calculated 
in the EVIFIT software, note the large Root Mean Square 
Deviation indicating that the results do not fit this model and 
deviate from it.
EvilFit Discrete One Site




Horse IgE - Horse 
sFcεRIαD1&2 1.09x10
-9 1.51x10-4 166.8 1.66
Horse IgE - Human 
sFcεRIαD1&2 5.77x10
-9 2.24x10-4 6.4 0.60
Horse IgE - Dog 
sFcεRIαD1&2 6.89x10
-9 3.50x10-4 14.8 0.64
Dog IgE - Horse 
sFcεRIαD1&2 1.37x10
-9 1.22x10-4 168.3 0.90
Chapter 6.3.2 Supplementary Table: Original Fit Using One 
Site Model:
This table shows the original fit  using the Discrete One Site 
Model values, note the extremely large Root Mean Square 
Deviation indicating that the results do not fit this model and 
greatly deviate from it.
Original Fit Using One Site Model




Horse IgE - Horse 
sFcεRIαD1&2 1.70x10
-10 3.80x10-4 159 5.11 
Horse IgE - Human 
sFcεRIαD1&2 5.26x10
-7 1.30x10-5 3 0.75 
Horse IgE - Dog 
sFcεRIαD1&2 4.03x10
-6 1.60x10-3 999 0.94 
Dog IgE - Horse 
sFcεRIαD1&2 1.20x10
-10 1.90x10-4 176 1.90 
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Chapter 6.3.2 Supplementary Table: Conformational 
Change Model values:
This table shows the original fit using the Conformational 
Change Model values , note the small conformational rate 
constants (kcc) indicating that the results do not fit this model 
and the binding between the two molecules does not result in co 
conformational change.











Horse IgE - Horse 











Horse IgE - Human 









Horse IgE - Dog 









Dog IgE - Horse 









One Data Set of 7.5µg/mL Removed
Equine IgE
Equine sFcεRIαD1&2
Distribution Model Distribution Model
Discrete One Site Model Conformational-Change Model
One Data Set of 7.5µg/mL Removed One Data Set of 7.5µg/mL Removed
Chapter 6.3.2 Supplementary Figure: Diagram representing 
the three models applied to the binding between the equine 
IgE and the equine sFcεRIαD1&2:
This figure shows at the top the plot of Resonance Units against 
Time of the actual equine IgE binding to the equine 
sFcεRIαD1&2 binding analysis, the red lines indicate the 
predicted best-fit trace of model’s fit. The lines in this plot have 
the start  of the association and dissociation lines cut off as there 
was great deviation in the measurements, this was due to buffer 
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shifts during the injections, these buffer shifts can be seen in the 
red lines of Figure 45. The figure also shows at the bottom the 
EVILFIT analysis of the equine IgE binding to the equine 
sFcεRIαD1&2 and applied it to the three models. The best 
model to fit the data is the Distribution Model after the values 
for the 7µg ml-1 concentration was removed. At the right bottom 
of the window of the Distribution Model there can be seen the 
KD and kd values of the main peak, which is circled in red. The 
kinetic properties, thermodynamic properties and binding 
capacity of each of the small peaks in the log10 kd against log10 
KD distribution plot of the Distribution Model is labeled in the 
grey boxes. The final Root Mean Square Deviation is marked 
inside the red rectangle. The dots indicate the grid points for the 
calculated parameter. The grid spacing is selected 
logarithmically in both kd and KD directions, so that lines of 
constant ka are diagonal. The height of the peak values can be 
read from the colour bar at the right. The vertical grey lines are 
the experimental sFcεRIαD1&2 receptor concentrations. The 
horizontal grey  line is the inverse of the longest time constant 
for which the data would permit observing a (e-1)-fold decay.
Equine IgE
Human sFcεRIαD1&2Distribution Model Discrete One Site Model
Conformational-Change Model
Chapter 6.3.2 Supplementary Figure: Diagram representing 
the three models applied to the binding between the equine 
IgE and the human sFcεRIαD1&2:
This figure shows at the top the plot of Resonance Units against 
Time of the actual equine IgE binding to the human 
sFcεRIαD1&2 binding analysis, the red lines indicate the 
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predicted best-fit trace of model’s fit. The lines in this plot have 
the start  of the association and dissociation lines cut off as there 
was great deviation in the measurements, this was due to buffer 
shifts during the injections, these buffer shifts can be seen in the 
red lines of Figure 45. The figure also shows at the bottom the 
EVILFIT analysis of the equine IgE binding to the human 
sFcεRIαD1&2 and applied it to the three models. The best 
model to fit the data is the Distribution Model after the values 
for the 7µg ml-1 concentration was removed. At the right bottom 
of the window of the Distribution Model there can be seen the 
KD and kd values of the main peak, which is circled in red. The 
kinetic properties, thermodynamic properties and binding 
capacity of each of the small peaks in the log10 kd against log10 
KD distribution plot of the Distribution Model is labeled in the 
grey boxes. The final Root Mean Square Deviation is marked 
inside the red rectangle. The height of the peak values can be 
read from the colour bar at the right. The vertical grey lines are 
the experimental sFcεRIαD1&2 receptor concentrations. The 
horizontal grey  line is the inverse of the longest time constant 
for which the data would permit observing a (e-1)-fold decay.




Chapter 6.3.2 Supplementary Figure: Diagram representing 
the three models applied to the binding between the equine 
IgE and the canine sFcεRIαD1&2:
This figure shows at the top the plot of Resonance Units against 
Time of the actual equine IgE binding to the canine 
sFcεRIαD1&2 binding analysis, the red lines indicate the 
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predicted best-fit trace of model’s fit. The lines in this plot have 
the start  of the association and dissociation lines cut off as there 
was great deviation in the measurements, this was due to buffer 
shifts during the injections, these buffer shifts can be seen in the 
red lines of Figure 45. The figure also shows at the bottom the 
EVILFIT analysis of the equine IgE binding to the canine 
sFcεRIαD1&2 and applied it to the three models. The best 
model to fit the data is the Distribution Model after the values 
for the 7µg ml-1 concentration was removed. At the right bottom 
of the window of the Distribution Model there can be seen the 
KD and kd values of the main peak, which is circled in red. The 
kinetic properties, thermodynamic properties and binding 
capacity of each of the small peaks in the log10 kd against log10 
KD distribution plot of the Distribution Model is labeled in the 
grey boxes. The final Root Mean Square Deviation is marked 
inside the red rectangle. The height of the peak values can be 
read from the colour bar at the right. The vertical grey lines are 
the experimental sFcεRIαD1&2 receptor concentrations. The 
horizontal grey  line is the inverse of the longest time constant 
for which the data would permit observing a (e-1)-fold decay.
Canine IgE
Equine sFcεRIαD1&2Distribution Model Discrete One Site Model
Conformational-Change Model
Chapter 6.3.2 Supplementary Figure: Diagram representing 
the three models applied to the binding between the canine 
IgE and the equine sFcεRIαD1&2:
This figure shows at the top the plot of Resonance Units against 
Time of the actual canine IgE binding to the equine 
sFcεRIαD1&2 binding analysis, the red lines indicate the 
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predicted best-fit trace of model’s fit. The lines in this plot have 
the start  of the association and dissociation lines cut off as there 
was great deviation in the measurements, this was due to buffer 
shifts during the injections, these buffer shifts can be seen in the 
red lines of Figure 45. The figure also shows at the bottom the 
EVILFIT analysis of the canine IgE binding to the equine 
sFcεRIαD1&2 and applied it to the three models. The best 
model to fit the data is the Distribution Model after the values 
for the 7µg ml-1 concentration was removed. At the right bottom 
of the window of the Distribution Model there can be seen the 
KD and kd values of the main peak, which is circled in red. The 
kinetic properties, thermodynamic properties and binding 
capacity of each of the small peaks in the log10 kd against log10 
KD distribution plot of the Distribution Model is labeled in the 
grey boxes. The final Root Mean Square Deviation is marked 
inside the red rectangle. The height of the peak values can be 
read from the colour bar at the right. The vertical grey lines are 
the experimental sFcεRIαD1&2 receptor concentrations. The 
horizontal grey  line is the inverse of the longest time constant 
for which the data would permit observing a (e-1)-fold decay.
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HHoH domain amplifications, top sequences are the 


























































































































Values for Figure 58:
These are the figures from the SPR analysis of the J558L cell 
selection expressing HHoH.


































































































































































































































Values for Figure 59:
Dilution curve Bradford assay for HDH IgE anti NIP-HSA.
μg ml-1 Dilution Curve 
Average












0.331 0.321 0.337 0.335
0.474 0.459 0.483 0.481
0.571 0.550 0.596 0.566
0.667 0.633 0.675 0.692
0.759 0.739 0.774 0.763
0.823 0.736 0.854 0.878
0.928 0.788 1.056 0.939
1.002 0.954 1.035 1.018
1.040 0.939 1.076 1.105
1.025 0.925 1.046 1.105
1.055 0.916 1.098 1.151
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Values for Figure 65:













1:200 9.999 0.000 0.871 0.030 0.532 0.006 2.915 0.040 0.136 0.016
1:400 9.999 0.000 0.395 0.028 0.239 0.014 1.747 0.005 0.089 0.001
1:800 2.845 0.069 0.185 0.012 0.140 0.004 0.902 0.071 0.070 0.006
1:1,600 1.878 0.178 0.108 0.000 0.091 0.003 0.357 0.003 0.062 0.002
1:3,200 0.877 0.100 0.078 0.002 0.067 0.002 0.163 0.011 0.054 0.002
1:6,400 0.369 0.055 0.067 0.001 0.053 0.001 0.094 0.005 0.052 0.004
1:12,800 0.188 0.016 0.052 0.000 0.052 0.001 0.061 0.002 0.050 0.002
1:25,600 0.079 0.050 0.046 0.000 0.050 0.001 0.054 0.001 0.051 0.003
1:51,200 0.072 0.004 0.048 0.000 0.043 0.000 0.051 0.001













1:200 9.999 0.000 2.708 0.000 1.918 0.074 9.999 0.000 0.151 0.011
1:400 9.999 0.000 1.640 0.010 0.955 0.072 6.487 4.967 0.099 0.004
1:800 9.999 0.000 0.677 0.001 0.437 0.022 2.269 0.167 0.080 0.008
1:1,600 9.999 0.000 0.284 0.021 0.209 0.027 0.999 0.096 0.077 0.008
1:3,200 2.211 0.100 0.142 0.001 0.114 0.002 0.464 0.054 0.067 0.014
1:6,400 1.105 0.064 0.096 0.003 0.070 0.006 0.202 0.017 0.060 0.001
1:12,800 0.538 0.030 0.076 0.001 0.066 0.001 0.103 0.005 0.067 0.011
1:25,600 0.284 0.005 0.117 0.078 0.074 0.004 0.085 0.001 0.072 0.007
1:51,200 0.155 0.002 0.060 0.001 0.057 0.006 0.069 0.001
1:102,400 0.101 0.008 0.066 0.006 0.060 0.000 0.072 0.001
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Values for Figure 67:
ELISA test of bleed to of all rats for binding to the native IgE 
antibodies.
Human IgE test









1:200 0.233 0.008 0.354 0.021 1.986 0.045 2.043 0.009 0.127 0.004 0.941 0.120
1:400 0.132 0.011 0.195 0.001 1.874 0.019 2.081 0.043 0.108 0.002
1:800 0.114 0.006 0.123 0.000 1.737 0.049 1.841 0.159 0.107 0.004
1:1,600 0.104 0.002 0.102 0.003 1.535 0.028 1.714 0.076 0.103 0.003
1:3,200 0.093 0.004 0.094 0.001 1.143 0.019 1.393 0.032 0.096 0.004
1:6,400 0.093 0.004 0.101 0.001 0.756 0.063 1.034 0.043 0.108 0.008
1:12,800 0.097 0.003 0.094 0.001 0.461 0.006 0.670 0.021 0.102 0.013
1:25,600 0.100 0.006 0.092 0.002 0.278 0.004 0.424 0.007
1:51,200 0.092 0.001 0.096 0.002 0.182 0.010 0.271 0.014
1:102,40
0 0.094 0.000 0.092 0.002 0.147 0.005 0.218 0.001
Canine IgE test









1:200 1.102 0.009 0.881 0.009 1.907 0.050 2.326 0.030 0.114 0.003 1.276 0.085
1:400 0.622 0.012 0.463 0.027 1.832 0.004 2.243 0.058 0.091 0.007
1:800 0.368 0.013 0.260 0.003 1.721 0.047 1.998 0.109 0.081 0.004
1:1,600 0.232 0.019 0.174 0.001 1.555 0.023 1.704 0.037 0.076 0.004
1:3,200 0.142 0.018 0.128 0.004 1.123 0.011 1.280 0.011 0.066 0.003
1:6,400 0.112 0.016 0.108 0.006 0.694 0.043 0.826 0.000 0.070 0.004
1:12,800 0.093 0.013 0.083 0.003 0.421 0.018 0.469 0.015 0.071 0.002
1:25,600 0.109 0.009 0.070 0.002 0.245 0.008 0.304 0.001
1:51,200 0.075 0.004 0.068 0.001 0.157 0.023 0.195 0.006
1:102,40
0 0.064 0.001 0.065 0.001 0.114 0.001 0.138 0.007
Equine IgE test









1:200 1.397 0.112 1.014 0.071 2.288 0.146 2.696 0.076 0.148 0.010 0.560 0.123
1:400 0.810 0.049 0.591 0.037 2.265 0.054 2.716 0.076 0.119 0.001
1:800 0.500 0.008 0.337 0.025 2.170 0.095 2.349 0.198 0.110 0.006
1:1,600 0.293 0.021 0.218 0.006 1.835 0.127 2.094 0.062 0.103 0.000
1:3,200 0.186 0.013 0.154 0.004 1.511 0.000 1.475 0.068 0.095 0.001
1:6,400 0.138 0.010 0.136 0.004 0.854 0.001 0.973 0.013 0.095 0.001
1:12,800 0.121 0.018 0.117 0.005 0.507 0.023 0.533 0.023 0.103 0.002
1:25,600 0.135 0.025 0.099 0.000 0.296 0.003 0.333 0.021
1:51,200 0.105 0.002 0.094 0.001 0.189 0.004 0.212 0.002
1:102,40
0 0.091 0.002 0.094 0.001 0.142 0.000 0.163 0.011
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Values for Figure 71:
Release assays of Bleed 2 from all rats, along with the positive 




























































1.43 1.41 1.32 1.39 1.61 1.29 0.18 0.21 0.19 0.18 0.11 0.12
1.32 1.32 1.32 1.28 1.68 1.37 0.11 0.12 0.11 0.13 0.17 0.17
1.39 1.39 1.42 1.34 1.65 1.41 0.16 0.18 0.17 0.18 0.18 0.18
1.41 1.45 1.48 1.36 1.63 1.41 0.17 0.18 0.19 0.21 0.17 0.19
1.40 1.48 1.41 1.27 1.65 1.43 0.16 0.16 0.17 0.22 0.20 0.21
1.37 1.39 1.31 1.24 1.66 1.36 0.16 0.18 0.23 0.27 0.19 0.20
1.29 1.37 1.26 1.22 1.69 1.35 0.15 0.16 0.23 0.25 0.14 0.14
1.22 1.36 1.23 1.17 1.76 1.39 0.10 0.12 0.17 0.22 0.21 0.22
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   	     
     
      
     
 	     
           
           
% of Total In Cell
x2 because (I used 50 µl instead of 
the 100) + Supernatant Value
To Find Original Total In Cell
20.47 22.87 22.63 20.84 12.31 15.58

 
 	 	 
 
14.73 15.28 14.62 16.99 16.58 19.41
     	
18.52 20.21 19.04 20.90 18.07 19.89 	 	 	   	




18.60 17.69 19.61 25.64 19.59 23.04 	 
 	 	  

19.22 20.75 25.74 30.26 18.23 22.73 	 	 	 	
  	
18.46 18.93 26.40 29.23 13.95 16.67 
  	 	  
14.45 15.21 21.46 27.15 19.04 23.79   	  	 

16.43 15.09 15.34 17.75 15.81 14.88
 
 
   
20.90 22.40 22.32 22.22 22.59 23.28
 
    
24.08 25.49 25.20 26.12 24.19 25.48   
   	
23.60 21.08 25.21 24.83 24.16 25.35 	     
25.56 25.55 27.92 32.05 26.30 25.13     	 

23.23 24.58 28.29 33.38 25.64 23.35 	     	
18.41 19.38 27.04 31.67 19.92 18.72      
24.87 26.56 33.17 36.42 21.72 28.66    	 
 	
Rat 1 Bleed 
2
Rat 2 Bleed 
2
Rat 3 Bleed 
2
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   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    
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
    	 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 	    

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
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 
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1.84 1.90 1.81 1.79 1.63 1.80 0.17 0.19 0.21 0.18 0.11 0.09
1.74 1.77 1.60 1.58 1.69 1.66 0.11 0.10 0.17 0.19 0.17 0.16
1.77 1.78 1.44 1.42 1.60 1.70 0.15 0.16 0.36 0.35 0.18 0.15
1.72 1.75 1.24 1.20 1.61 1.78 0.18 0.19 0.50 0.51 0.17 0.18
1.73 1.74 1.08 1.06 1.61 1.25 0.14 0.16 0.54 0.56 0.19 0.44
1.74 1.79 1.05 1.03 1.62 1.14 0.17 0.16 0.59 0.61 0.17 0.53
1.79 1.79 1.04 1.01 1.61 1.24 0.15 0.16 0.62 0.56 0.12 0.41
1.75 1.80 1.08 1.06 1.73 1.20 0.11 0.09 0.55 0.43 0.20 0.54
		 
 	 	 	 
      
	 	  
 	 	 	     
	 	   	 	      
	 	 	  	 	 	     
	 
   	
 	      
		 
   	 	      
	 
   	  
     
	 
	   
       
% of Total In Cell
x2 because (I used 50 µl instead of 
the 100) + Supernatant Value
To Find Original Total In Cell
15.83 16.89 18.76 16.90 11.41 9.44
    
 
11.04 9.96 17.53 19.06 16.34 15.82
 	    	
14.66 14.83 33.46 32.83 18.03 15.25 	     
17.55 17.69 44.49 45.80 17.52 16.59      
14.02 15.37 49.86 51.47 19.10 41.20    
  
16.10 15.33 52.96 54.02 17.18 48.04 	     
14.60 15.09 54.19 52.72 13.16 39.69   	  
 
10.90 9.54 50.41 44.68 18.63 47.32   
   

11.59 12.81 12.65 13.56 11.82 13.17
 
    
16.42 16.82 21.79 20.75 18.98 18.60
  
   
18.02 18.08 35.73 31.74 18.57 17.54      
16.18 16.18 40.04 43.07 19.06 21.22  
  	  
19.15 18.81 47.80 49.71 19.53 30.90      	
17.98 17.77 47.28 51.63 18.78 35.92   
 	  





19.16 19.26 47.28 49.51 19.28 38.83   
   
Rat 1 Bleed 
2
Rat 2 Bleed 
2
Rat 3 Bleed 
2
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1.27 1.26 1.28 1.28 1.39 1.11 0.18 0.20 0.19 0.16 0.11 0.11
1.18 1.23 1.19 1.24 1.49 1.16 0.12 0.12 0.13 0.12 0.16 0.15
1.23 1.23 1.22 1.22 1.46 1.18 0.15 0.16 0.18 0.20 0.16 0.17
1.26 1.25 1.19 1.15 1.45 1.20 0.18 0.17 0.22 0.23 0.17 0.16
1.18 1.23 1.13 1.08 1.47 1.19 0.14 0.15 0.21 0.22 0.19 0.20
1.26 1.26 1.13 1.11 1.51 1.17 0.15 0.15 0.20 0.22 0.17 0.19
1.24 1.24 1.14 1.12 1.45 1.16 0.13 0.15 0.21 0.22 0.13 0.15
1.19 1.18 1.09 1.08 1.57 1.24 0.09 0.09 0.15 0.16 0.19 0.21
        
   
     	   	  
 
	     
   	   
    
  	  	  
 
 
 	         
      	     
 
  
 	       
 
 	  	 
 
     
% of Total In Cell
x2 because (I used 50 µl instead of 
the 100) + Supernatant Value
To Find Original Total In Cell
21.60 24.10 22.89 19.60 14.09 16.04
     
16.90 16.44 17.70 16.55 17.41 20.87
 	   
 	
20.03 20.95 22.49 24.60 18.34 21.85   	  	 
21.93 21.78 26.99 28.66 18.63 20.63     	
 
19.51 19.92 27.00 29.13 20.63 24.68 	    
 

19.64 19.02 26.53 28.29 18.38 24.90 	    
 
17.44 19.48 26.55 28.30 14.91 20.22     	 
13.24 13.62 21.13 22.41 19.57 25.39 	 	 
   
12.16 12.77 10.96 13.79 13.47 17.23
  
   
20.42 22.46 20.57 22.88 22.69 24.03
   
  
21.16 23.27 21.56 23.85 23.41 25.51 
  	   

21.29 20.58 21.59 24.47 20.23 22.63  	   	 
21.20 22.61 25.12 27.98 23.08 25.00 
  	   	
24.07 23.32 26.36 31.01 23.80 27.36    
  
16.79 18.05 20.88 24.84 15.67 19.35 
   	  
23.23 25.41 24.49 27.12 22.77 25.49  	 
 		 		 	
Rat 1 Bleed 
2
Rat 2 Bleed 
2
Rat 3 Bleed 
2
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1.19 1.19 1.96 2.17 1.71 1.71 0.09 0.1 0.09 0 0.09 0.09
1.23 1.18 1.95 2.12 1.7 1.72 0.15 0.2 0.17 0 0.16 0.17
1.23 1.14 1.93 1.94 1.72 1.69 0.16 0.2 0.19 0 0.18 0.18
1.16 1.17 1.66 1.71 1.68 1.66 0.16 0.2 0.36 0 0.18 0.19
1.08 1.14 1.34 1.4 1.59 1.61 0.24 0.3 0.66 1 0.27 0.27
1.14 1.11 1.22 1.19 1.64 1.63 0.21 0.2 0.62 1 0.25 0.27
1.18 1.12 1.2 1.26 1.61 1.67 0.13 0.2 0.62 1 0.18 0.19
1.24 1.24 1.3 1.44 1.67 1.69 0.18 0.2 0.7 1 0.26 0.26
x2 because (I used 50 µl instead of the 100) + Supernatant Value
% of Total In Cell
To Find Original Total In Cell
  
	 
 	  	     
 	 	      
   
   	 	 	      
   
 	 
	 
     
   
    	    
 	    
      

	  
  	 


























































1.39 1.42 2.26 2.35 1.62 1.68 0.13 0.12 0.1 0.11 0.11 0.1
1.61 1.45 2.32 2.16 1.65 1.76 0.13 0.13 0.11 0.11 0.1 0.1
1.41 1.43 2.19 2.38 1.7 1.63 0.14 0.13 0.11 0.13 0.11 0.1
1.61 1.44 2.19 2.11 1.6 1.63 0.14 0.14 0.12 0.12 0.12 0.1
1.61 1.4 2.12 2.39 1.58 1.65 0.13 0.12 0.11 0.12 0.12 0.1
1.61 1.4 2.18 2.12 1.61 1.63 0.13 0.15 0.12 0.13 0.12 0.1
1.43 1.37 2.24 2.42 1.63 1.65 0.14 0.14 0.12 0.14 0.12 0.1
1.41 1.34 2.16 2.16 1.65 1.65 0.15 0.15 0.13 0.14 0.14 0.1
x2 because (I used 50 µl instead of the 100) + Supernatant Value
% of Total In Cell
To Find Original Total In Cell
  	 
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   	 	  
 	 
	 
	 	     	     
Human Canine Equine

 8.25 
 8.90 

 9.57 

	 10.12 	
 9.38 


	 10.46 
 9.99 

			 11.33 
295
